{
    "url": "https://www.roche.com/solutions/pipeline",
    "statusCode": 200,
    "browserHtml": "<!DOCTYPE html><html lang=\"en\" dir=\"ltr\" class=\"theme--page\" data-cache-buster=\"?version=1762520514253\"><head><style class=\"vjs-styles-defaults\">\n      .video-js {\n        width: 300px;\n        height: 150px;\n      }\n\n      .vjs-fluid:not(.vjs-audio-only-mode) {\n        padding-top: 56.25%\n      }\n    </style><meta charset=\"utf-8\"><meta name=\"viewport\" content=\"width=device-width,initial-scale=1\"><meta name=\"theme-color\" content=\"#fff\"><meta name=\"generator\" content=\"Gatsby 5.13.7\"><meta name=\"title\" content=\"Roche | Product Development Portfolio\" data-gatsby-head=\"true\"><meta name=\"description\" content=\"Discover our pipeline of Pharmaceutical and Diagnostics developments\" data-gatsby-head=\"true\"><meta property=\"og:image\" content=\"https://assets.roche.com/f/176343/432x432/1d0cc8c746/pipeline-teaser.jpg\" data-gatsby-head=\"true\"><meta property=\"og:title\" content=\"Roche | Product Development Portfolio\" data-gatsby-head=\"true\"><meta property=\"og:description\" content=\"Discover our pipeline of Pharmaceutical and Diagnostics developments\" data-gatsby-head=\"true\"><meta property=\"og:type\" content=\"website\" data-gatsby-head=\"true\"><meta property=\"og:url\" content=\"https://www.roche.com/solutions/pipeline/\" data-gatsby-head=\"true\"><meta name=\"twitter:image\" content=\"https://assets.roche.com/f/176343/432x432/1d0cc8c746/pipeline-teaser.jpg\" data-gatsby-head=\"true\"><meta name=\"twitter:card\" content=\"summary\" data-gatsby-head=\"true\"><meta name=\"twitter:creator\" content=\"@roche\" data-gatsby-head=\"true\"><meta name=\"twitter:title\" content=\"Roche | Product Development Portfolio\" data-gatsby-head=\"true\"><meta name=\"twitter:description\" content=\"Discover our pipeline of Pharmaceutical and Diagnostics developments\" data-gatsby-head=\"true\"><meta name=\"private\" content=\"no\" data-gatsby-head=\"true\"><meta name=\"content-type\" content=\"pages\" data-gatsby-head=\"true\"><meta name=\"story-type\" content=\"none\" data-gatsby-head=\"true\"><meta name=\"published-date\" content=\"2021-10-20T12:48:56.000Z\" data-gatsby-head=\"true\"><meta name=\"teaser-image\" content=\"https://assets.roche.com/f/176343/432x432/1d0cc8c746/pipeline-teaser.jpg\" data-gatsby-head=\"true\"><meta name=\"teaser-title\" content=\"Product Development Portfolio\" data-gatsby-head=\"true\"><meta name=\"teaser-description\" content=\"Discover our pipeline of Pharmaceutical and Diagnostics developments\" data-gatsby-head=\"true\"><style data-href=\"/styles.e87449c8601c32bc2ea8.css\" data-identity=\"gatsby-global-css\">/*! modern-normalize v3.0.1 | MIT License | https://github.com/sindresorhus/modern-normalize */*,:after,:before{box-sizing:border-box}html{-webkit-text-size-adjust:100%;font-family:system-ui,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji;line-height:1.15;tab-size:4}body{margin:0}b,strong{font-weight:bolder}code,kbd,pre,samp{font-family:ui-monospace,SFMono-Regular,Consolas,Liberation Mono,Menlo,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}table{border-color:currentcolor}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}legend{padding:0}progress{vertical-align:baseline}::-webkit-inner-spin-button,::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}summary{display:list-item}@font-face{font-family:roche-sans;font-style:normal;font-weight:800;src:url(https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSans-Bold.woff2) format(\"woff2\")}@font-face{font-family:roche-sans;font-style:normal;font-weight:600;src:url(https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSans-Medium.woff2) format(\"woff2\")}@font-face{font-family:roche-sans;font-style:normal;font-weight:400;src:url(https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSans-Regular.woff2) format(\"woff2\")}@font-face{font-family:roche-sans;font-style:normal;font-weight:200;src:url(https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSans-Light.woff2) format(\"woff2\")}@font-face{font-family:roche-serif;font-style:normal;font-weight:400;src:url(https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSerif-Regular.woff2) format(\"woff2\")}@font-face{font-family:roche-serif;font-style:normal;font-weight:200;src:url(https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSerif-Light.woff2) format(\"woff2\")}html a{text-decoration:none}html a,html button{color:inherit;cursor:pointer}html button{-webkit-tap-highlight-color:transparent;background-color:transparent;border-width:0;padding:0}html blockquote,html figure,html h1,html h2,html h3,html h4,html h5,html h6,html p{font-weight:inherit;margin:0}html li{list-style-type:none}html li,html ol,html ul{margin:0;padding:0}html .headline--1+.story-teaser.story-teaser--variant-c{margin-top:1rem}@media (min-width:64rem){html .headline--1+.story-teaser.story-teaser--variant-c{margin-top:1.5rem}}html .headline--2+.story-teaser.story-teaser--variant-c{margin-top:3rem}@media (min-width:90rem){html .headline--2+.story-teaser.story-teaser--variant-c{margin-top:4.5rem}}html .tabs__panel>.headline,html .tabs__panel>.side-by-side{margin-top:3rem}@media (min-width:90rem){html .tabs__panel>.headline,html .tabs__panel>.side-by-side{margin-top:4.5rem}}html roche-on-load-notice .rich-text{margin-top:0}html .overline+.headline{margin-top:0}html roche-slider-item>.teaser:only-child{height:100%}html .image+.headline{margin-top:1rem}html .headline+.image{margin-top:2rem}@media (min-width:48rem){html .headline+.image{margin-top:0}}html .side-by-side>.headline,html .side-by-side>.rich-text{margin-top:3rem}html .magnet~.side-by-side:has(.accordion){margin-top:5.5rem!important}@media (min-width:64rem){html .magnet~.side-by-side:has(.accordion){margin-top:7.625rem!important}}html:root{font-size:100%}body{-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;color:var(--color-text-primary);font-family:roche-sans;font-size:var(--body-font-size-small-up);font-style:normal;font-weight:200;line-height:1.8125rem}@media (min-width:64rem){body{font-size:var(--body-font-size-xlarge-up);line-height:2rem}}:root{--body-font-size-xlarge-up:1.25rem;--body-font-size-medium-up:1.125rem;--body-font-size-small-up:1.125rem;--body-small-font-size-xlarge-up:1.125rem;--body-small-font-size-medium-up:1.125rem;--body-small-font-size-small-up:1rem;--body-link-font-size-xlarge-up:1.25rem;--body-link-font-size-medium-up:1.125rem;--body-link-font-size-small-up:1.125rem;--button-font-size-xlarge-up:1.125rem;--button-font-size-medium-up:1.125rem;--button-font-size-small-up:1.125rem;--caption-font-size-xlarge-up:1rem;--caption-font-size-medium-up:1rem;--caption-font-size-small-up:.875rem;--label-font-size-xlarge-up:1rem;--label-font-size-medium-up:1rem;--label-font-size-small-up:.875rem;--footnotes-font-size-xlarge-up:.875rem;--footnotes-font-size-medium-up:.875rem;--footnotes-font-size-small-up:.875rem;--color-dark-blue-900:#022366;--color-shadow-blue-800:#072b89;--color-shadow-blue-700:#0936ab;--color-roche-blue-600:#0b41cd;--color-shadow-blue-500:#3461d5;--color-shadow-blue-400:#5c80de;--color-shadow-blue-300:#85a0e6;--color-shadow-blue-200:#aec0ee;--color-shadow-blue-100:#d7e0f7;--color-light-blue:#1482fa;--color-extra-light-blue:#bde3ff;--color-extra-dark-red:#8c0000;--color-dark-red:#c40000;--color-red:#ff1f26;--color-light-red:#ff8782;--color-extra-dark-orange:#b22b0d;--color-dark-orange:#ed4a0d;--color-orange:#ff7d29;--color-light-orange:#ffbd69;--color-extra-dark-purple:#7d0096;--color-dark-purple:#bc36f0;--color-purple:#e085fc;--color-light-purple:#f2d4ff;--color-grey-900:#21201f;--color-grey-800:#312f2e;--color-roche-grey-700:#544f4f;--color-roche-grey-600:#706b69;--color-grey-500:#9d948e;--color-roche-grey-400:#c2bab5;--color-roche-grey-300:#dbd6d1;--color-grey-200:#eae8e5;--color-roche-grey-100:#f5f5f2;--color-roche-grey-0:#fbfbfa;--color-success:#00b458;--color-success-light:#ccf0de;--color-warning:#fbdd7a;--color-warning-light:#fff7ce;--color-error:#ff1f26;--color-error-light:#ffd2d4;--color-text-primary:#000;--color-text-secondary:#c2bab5;--color-white:#fff;--color-black-000:transparent;--color-black-100:rgba(0,0,0,.1);--color-black-200:rgba(0,0,0,.2);--color-black-800:#1e1e1e;--color-black-900-a07:rgba(0,0,0,.7);--color-black-900-a08:rgba(0,0,0,.8);--color-black-900-a09:rgba(0,0,0,.9);--color-black-900-a01:rgba(0,0,0,.1);--color-black-900:#000;--color-white-100:#fff;--color-white-300:hsla(0,0%,100%,.7);--color-white-500:hsla(0,0%,100%,.5);--color-white-600:hsla(0,0%,100%,.4);--color-white-800:hsla(0,0%,100%,.2);--color-neutral-100:#fff7f5;--color-neutral-200:#ffe8de;--color-neutral-300:#fad6c7;--color-neutral-400:#fac9b5;--color-neutral-500:#e7b198;--color-neutral-600:#d2ad90;--color-neutral-700:#c28d70;--color-neutral-800:#a26d51;--color-neutral-900:#664533}[dir=rtl]{--body-font-size-xlarge-up:1.375rem;--body-font-size-medium-up:1.25rem;--body-font-size-small-up:1.25rem;--body-small-font-size-xlarge-up:1.25rem;--body-small-font-size-medium-up:1.25rem;--body-small-font-size-small-up:1.125rem;--body-link-font-size-xlarge-up:1.375rem;--body-link-font-size-medium-up:1.25rem;--body-link-font-size-small-up:1.25rem;--button-font-size-xlarge-up:1.25rem;--button-font-size-medium-up:1.25rem;--button-font-size-small-up:1.25rem;--caption-font-size-xlarge-up:1.125rem;--caption-font-size-medium-up:1.125rem;--caption-font-size-small-up:1rem;--label-font-size-xlarge-up:1.125rem;--label-font-size-medium-up:1.125rem;--label-font-size-small-up:1rem;--footnotes-font-size-xlarge-up:1rem;--footnotes-font-size-medium-up:1rem}.icon-container{display:flex;justify-content:flex-start}.icon-container .icon{fill:var(--custom-icon-color,currentcolor)}.icon-container .icon.icon--rtl{transform:rotateY(180deg)}.icon-container.icon-container--inline{display:inline-flex}.accordion{display:flex;flex-direction:column;margin-top:3rem;padding:0;width:100%}@media (min-width:90rem){.accordion{margin-top:4.5rem}}.magnet~.accordion{margin-top:5.5rem}@media (min-width:90rem){.magnet~.accordion{margin-top:7.625rem}}.accordion .accordion__header{align-items:center;color:var(--color-roche-grey-700);cursor:pointer;display:flex;font-size:1.125rem;font-weight:400;justify-content:space-between;line-height:1.6875rem;padding:.75rem 0;text-align:left;transition:border-color .2s ease-in-out,color .2s ease-in-out;white-space:nowrap;width:100%}@media (min-width:48rem){.accordion .accordion__header{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.accordion .accordion__header{font-size:1.25rem;line-height:1.875rem}}@media (min-width:48rem){.accordion .accordion__header{padding:1rem 0}}.accordion .accordion__header:focus-visible:focus,.accordion .accordion__header:focus-visible:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.accordion .accordion__header:focus-visible:focus:not(:focus-visible){outline:0}.accordion .accordion__header-text{text-wrap:wrap;text-align:start}.accordion .accordion__icon{color:var(--color-roche-grey-700);margin-inline-start:1rem;transition:color .2s ease-in-out}.accordion .accordion__panel{max-height:0;opacity:0;overflow:hidden;padding:0;transition-duration:.4s;transition-property:max-height,opacity,padding;transition-timing-function:cubic-bezier(.4,0,.2,1);visibility:hidden}@media (prefers-reduced-motion:reduce){.accordion .accordion__panel{transition:none}}.accordion .accordion__panel:focus-visible:focus,.accordion .accordion__panel:focus-visible:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.accordion .accordion__panel:focus-visible:focus:not(:focus-visible){outline:0}.accordion .accordion__panel.accordion__panel>:first-child{margin-top:0}.accordion .accordion__item{border-bottom:1px solid var(--color-roche-grey-400);transition:padding .4s cubic-bezier(.4,0,.2,1)}@media (prefers-reduced-motion:reduce){.accordion .accordion__item{transition:none}}.accordion .accordion__item:first-child{border-top:1px solid var(--color-roche-grey-400)}.accordion .accordion__item.accordion__item--active .accordion__header,.accordion .accordion__item.accordion__item--active .accordion__icon,.accordion .accordion__item.accordion__item--closing .accordion__header,.accordion .accordion__item.accordion__item--closing .accordion__icon{color:var(--color-dark-blue-900)}.accordion .accordion__item:not(.accordion__item--active,.accordion__item--closing) .accordion__header:hover{border-bottom:2px solid var(--color-dark-blue-900);color:var(--color-dark-blue-900);margin-bottom:-2px}.accordion .accordion__item:not(.accordion__item--active,.accordion__item--closing) .accordion__header:hover .accordion__icon{color:var(--color-dark-blue-900)}.accordion .accordion__item.accordion__item--active{padding-bottom:1rem}@media (min-width:48rem){.accordion .accordion__item.accordion__item--active{padding-bottom:1.5rem}}.accordion .accordion__item.accordion__item--active .accordion__panel{opacity:1;visibility:visible}.roche-add-to-calendar{display:flex;flex-direction:column;gap:1.5rem;padding:0 2rem 3rem;width:20rem}.roche-add-to-calendar .roche-add-to-calendar__headline{font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.roche-add-to-calendar .roche-add-to-calendar__headline{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.roche-add-to-calendar .roche-add-to-calendar__headline{font-size:1.25rem;line-height:1.875rem}}.button{align-items:center;cursor:pointer;display:flex;font-family:roche-sans;font-size:var(--button-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;gap:.75rem;justify-content:center;line-height:1.3125rem;min-height:3.5rem;padding:1rem 1.5rem;position:relative;text-align:center;transition-duration:.22s;transition-property:background,border-color,box-shadow,color;transition-timing-function:ease-in;-webkit-user-select:none;user-select:none;width:100%}@media (min-width:48rem){.button{font-size:var(--button-font-size-medium-up);line-height:1.4375rem;min-width:6rem}}.button .button__icon-container{fill:currentcolor;align-items:center;display:flex;height:1.5rem;pointer-events:none;position:relative;width:1.5rem}.button .button__text{pointer-events:none}.button.button--left-aligned{justify-content:start}.button.button--primary{background:var(--color-roche-blue-600);color:var(--color-white-100)}.button.button--primary:focus,.button.button--primary:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.button.button--primary:focus:not(:focus-visible){outline:0}.button.button--primary:hover{background:var(--color-dark-blue-900);box-shadow:0 .75rem 1.5rem #2121213d}.button.button--primary:active{background:var(--color-shadow-blue-400)}.button.button--primary.button--disabled{background:var(--color-grey-200);border-color:transparent;color:var(--color-text-secondary);cursor:default}.button.button--primary.button--disabled:hover{box-shadow:none}.button.button--secondary{background:0 0;border:1px solid var(--color-roche-blue-600);color:var(--color-roche-blue-600)}.button.button--secondary:focus,.button.button--secondary:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.button.button--secondary:focus:not(:focus-visible){outline:0}.button.button--secondary:focus,.button.button--secondary:focus-visible{border:1px solid transparent;color:var(--color-roche-blue-600)}.button.button--secondary:hover{border:1px solid var(--color-dark-blue-900);color:var(--color-dark-blue-900)}.button.button--secondary:active{border:1px solid var(--color-roche-blue-600);color:var(--color-roche-blue-600)}.button.button--secondary:focus:not(:focus-visible){border:1px solid var(--color-roche-blue-600);color:var(--color-roche-blue-600)}.button.button--secondary:focus:hover{border:1px solid var(--color-dark-blue-900);color:var(--color-dark-blue-900)}.button.button--secondary:focus:active{border:1px solid var(--color-roche-blue-600);color:var(--color-roche-blue-600)}.button.button--secondary.button--disabled{background:0 0;border-color:var(--color-text-secondary);color:var(--color-text-secondary);cursor:default}.button.button--secondary.button--disabled:hover{box-shadow:none}.button.button--tertiary{background:0 0;color:var(--color-roche-blue-600)}@media (min-width:48rem){.button.button--tertiary{min-width:100%}}.button.button--tertiary:focus,.button.button--tertiary:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.button.button--tertiary:focus:not(:focus-visible){outline:0}.button.button--tertiary:hover{background:var(--color-shadow-blue-100);color:var(--color-dark-blue-900)}.button.button--tertiary:active{background:0 0}.button.button--tertiary.button--disabled{background:0 0;border-color:transparent;color:var(--color-text-secondary);cursor:default}.button.button--tertiary.button--disabled:hover{box-shadow:none}.button.button--success{background:var(--color-success)}.button.button--error,.button.button--success{color:var(--color-white-100);cursor:default;pointer-events:none}.button.button--error{background-color:var(--color-error)}.button.button--bottom-fixed{background-color:var(--color-white-100);border-radius:.9375rem .9375rem 0 0;bottom:0;box-shadow:0 -.1875rem .5rem #00000040;color:var(--color-roche-blue-600);cursor:pointer;height:4rem;justify-content:center;left:0;position:fixed;z-index:50}.button.button--bottom-fixed .button__icon-container{color:var(--color-black-900)}.button-wrapper{margin-top:2rem}@media (min-width:48rem){.button-wrapper{display:inline-block}}.button-wrapper.button-wrapper--no-margin{margin:0!important}.button-wrapper~.button-wrapper{margin-top:.5rem}@media (min-width:48rem){.button-wrapper~.button-wrapper{margin-left:.5rem;margin-top:2rem}}@media (min-width:48rem){[dir=rtl] .button-wrapper~.button-wrapper{margin-left:0;margin-right:.5rem}}.animated-words{line-height:1rem;margin-bottom:0;margin-top:3rem}@media (min-width:48rem){.animated-words{margin-top:4rem}}@media (min-width:90rem){.animated-words{margin-top:6rem}}.animated-words .animated-words__headline{display:inline-block;font-size:2.5rem;line-height:3rem;margin:0;width:100%}@media (min-width:48rem){.animated-words .animated-words__headline{font-size:3rem;line-height:3.375rem}}@media (min-width:90rem){.animated-words .animated-words__headline{font-size:3.8125rem;line-height:4.375rem}}@media (min-width:48rem){.animated-words .animated-words__headline{font-size:3.5rem;line-height:4.1875rem}}@media (min-width:48rem) and (min-width:48rem){.animated-words .animated-words__headline{font-size:4rem;line-height:4.5625rem}}@media (min-width:48rem) and (min-width:90rem){.animated-words .animated-words__headline{font-size:5.5rem;line-height:6.3125rem}}.animated-words .animated-words__text-container{display:inline-block;max-width:100%;overflow:hidden;position:relative}.animated-words .animated-words__words-container{overflow:hidden;position:relative}.animated-words .animated-words__word{display:none;font-size:2.5rem;font-weight:400;line-height:3rem;transform:translateY(100%);transition:transform .5s;transition-timing-function:cubic-bezier(.25,.46,.45,.94);width:100%}@media (min-width:48rem){.animated-words .animated-words__word{font-size:3rem;line-height:3.375rem}}@media (min-width:90rem){.animated-words .animated-words__word{font-size:3.8125rem;line-height:4.375rem}}@media (prefers-reduced-motion:reduce){.animated-words .animated-words__word{transition:none}}@media (min-width:48rem){.animated-words .animated-words__word{font-size:3.5rem;font-weight:400;line-height:4.1875rem}}@media (min-width:48rem) and (min-width:48rem){.animated-words .animated-words__word{font-size:4rem;line-height:4.5625rem}}@media (min-width:48rem) and (min-width:90rem){.animated-words .animated-words__word{font-size:5.5rem;line-height:6.3125rem}}.animated-words .animated-words__word.animated-words__word--active{display:block;transform:translateY(0)}.animated-words .animated-words__word.animated-words__word--previous{display:block;transform:translateY(-100%)}.animated-words .animated-words__word.animated-words__word--next{display:block}.animated-words .animated-words__word.animated-words__word--red{color:var(--color-extra-dark-red)}.animated-words .animated-words__word.animated-words__word--orange{color:var(--color-extra-dark-orange)}.animated-words .animated-words__word.animated-words__word--purple{color:var(--color-extra-dark-purple)}.animated-words .animated-words__word.animated-words__word--brand{color:var(--color-light-blue)}.animated-words .animated-words__word.animated-words__word--effect{color:var(--color-roche-blue-600)}.animated-words.animated-words--animated .animated-words__text-container{display:block;height:3rem}@media (min-width:48rem){.animated-words.animated-words--animated .animated-words__text-container{height:4.5625rem}}@media (min-width:90rem){.animated-words.animated-words--animated .animated-words__text-container{height:6.3125rem}}.animated-words.animated-words--animated .animated-words__word{position:absolute}.avatar{aspect-ratio:1/1;border-radius:50%;display:inline-block;height:100%;overflow:hidden;width:100%}.avatar .avatar__fallback{align-items:center;background:var(--color-roche-grey-100);display:flex;height:100%;justify-content:center;width:100%}.avatar .avatar__icon{height:62.5%;width:62.5%}.avatar>.image{margin:0}.overline{display:block}.overline .overline__text{color:var(--color-roche-grey-600);font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.overline .overline__text{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.overline .overline__text{font-size:1.25rem;line-height:1.875rem}}.text-link{display:flex;min-height:1.8125rem}@media (min-width:64rem){.text-link{min-height:2rem}}.text-link .text-link__link{align-items:baseline;color:var(--color-roche-blue-600);display:inline-flex;font-family:roche-sans;font-size:var(--button-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;gap:.5rem;line-height:1.3125rem;text-align:inherit}@media (min-width:48rem){.text-link .text-link__link{font-size:var(--button-font-size-medium-up);line-height:1.4375rem}}.text-link .text-link__link:visited{color:revert}.text-link .text-link__link:hover{color:var(--color-dark-blue-900)}.text-link .text-link__link:focus-visible:focus,.text-link .text-link__link:focus-visible:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.text-link .text-link__link:focus-visible:focus:not(:focus-visible){outline:0}.text-link .text-link__icon-container{fill:currentcolor;align-self:center;display:inline-flex;place-items:center}.text-link .text-link__icon-container:first-child{padding-left:.25rem}.text-link .text-link__icon-container:last-child{padding-right:.25rem}[dir=rtl] .text-link .text-link__link .text-link__icon-container:last-child{padding-left:.25rem;padding-right:0}.text-link .text-link__text{align-items:center;display:inline-flex;height:100%}.text-link.text-link--footnote .text-link__link{gap:.2rem}.text-link.text-link--footnote .text-link__link .text-link__icon-container{padding-right:0}.text-link.text-link--contact-person .text-link__link{font-size:1rem}.text-link.text-link--contact-person .text-link__link .text-link__icon-container{align-self:start;height:1.8125rem;padding-left:0}@media (min-width:90rem){.text-link.text-link--contact-person .text-link__link .text-link__icon-container{height:2rem}}.text-link.text-link--footer-social{display:inline-block;min-height:2.5rem;min-width:2.5rem;text-align:center}.text-link.text-link--footer-social .text-link__link{vertical-align:middle}.text-link.text-link--footer-social .text-link__link .text-link__icon-container{margin-right:.25rem;padding:0}.text-link.text-link--footer-social .text-link__link .text-link__text{display:none}.text-link.text-link--footer-column{display:block;margin-top:1rem}.text-link.text-link--footer-column .text-link__text{font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.text-link.text-link--footer-column .text-link__text{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.text-link.text-link--footer-column .text-link__text{font-size:1.25rem;line-height:1.875rem}}[dir=rtl] .text-link.text-link--footer-column{margin:1rem 0 0 1rem}.text-link.text-link--footer-quick{display:inline-block;margin-top:2rem;width:100%}.text-link.text-link--footer-quick .text-link__link{border-bottom:1px solid;display:flex;justify-content:space-between;padding-bottom:1rem}.text-link.text-link--footer-quick .text-link__link .text-link__icon-container{padding-right:0}.text-link.text-link--footer-quick .text-link__text{font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.text-link.text-link--footer-quick .text-link__text{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.text-link.text-link--footer-quick .text-link__text{font-size:1.25rem;line-height:1.875rem}}.text-link.text-link--footer-service{display:inline-block;margin-inline-end:1.5rem;width:100%}@media (min-width:48rem){.text-link.text-link--footer-service{display:inline;width:auto}}@media (min-width:90rem){.text-link.text-link--footer-service{margin-inline-end:2.5rem}}@media (min-width:48rem){[dir=rtl] .text-link.text-link--footer-service{margin-inline-end:1rem}}.text-link.text-link--footer-service .text-link__text{font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem}@media (min-width:48rem){.text-link.text-link--footer-service .text-link__text{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.text-link.text-link--breadcrumbs{min-height:unset}.text-link.text-link--breadcrumbs .text-link__link{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--label-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem;white-space:nowrap}@media (min-width:48rem){.text-link.text-link--breadcrumbs .text-link__link{font-size:var(--label-font-size-medium-up);line-height:1.3125rem}}.text-link.text-link--news-page{margin-top:1rem}.text-link.text-link--news-page .text-link__link{display:inline-flex;font-family:roche-sans;font-size:var(--body-small-font-size-small-up);font-style:normal;font-weight:200;gap:.5rem;line-height:1.625rem}@media (min-width:48rem){.text-link.text-link--news-page .text-link__link{font-size:var(--body-small-font-size-medium-up);line-height:1.8125rem}}.text-link.text-link--news-page .text-link__text{display:inline}.text-link.text-link--news-page .text-link__icon-container{align-self:flex-start;display:inline-flex;padding-left:0;position:relative;top:.5rem}.text-link.text-link--news-page .text-link__icon-container .icon-container{display:inline-flex}.text-link.text-link--footer-column .text-link__link,.text-link.text-link--footer-quick .text-link__link,.text-link.text-link--footer-service .text-link__link,.text-link.text-link--footer-social .text-link__link{color:var(--color-roche-grey-700)}.text-link.text-link--footer-column .text-link__link:hover,.text-link.text-link--footer-quick .text-link__link:hover,.text-link.text-link--footer-service .text-link__link:hover,.text-link.text-link--footer-social .text-link__link:hover{color:var(--color-roche-blue-600)}.text-link.text-link--breadcrumbs .text-link__link:hover{color:var(--color-dark-blue-900)}.roche-back-to-branch{border-top:1px solid var(--color-roche-grey-400);display:flex;flex-direction:column;margin-top:3rem;row-gap:1rem}@media (min-width:90rem){.roche-back-to-branch{margin-top:4.5rem}}.roche-back-to-branch .roche-back-to-branch__content{margin-top:1rem}.headline{color:var(--color-text-primary);display:block;font-family:inherit;font-size:inherit;font-weight:inherit}.headline:not(:first-child){margin-top:3rem}@media (min-width:90rem){.headline:not(:first-child){margin-top:4.5rem}}.headline.headline--1.headline--1{font-size:2.5rem;line-height:3rem}@media (min-width:48rem){.headline.headline--1.headline--1{font-size:3rem;line-height:3.375rem}}@media (min-width:90rem){.headline.headline--1.headline--1{font-size:3.8125rem;line-height:4.375rem}}.headline.headline--1.headline--1+*{margin-top:1rem}@media (min-width:64rem){.headline.headline--1.headline--1+*{margin-top:1.5rem}}.headline.headline--2.headline--2{font-size:1.875rem;line-height:2.25rem}@media (min-width:48rem){.headline.headline--2.headline--2{font-size:2.5rem;line-height:3rem}}@media (min-width:90rem){.headline.headline--2.headline--2{font-size:3rem;line-height:3.625rem}}.headline.headline--2.headline--2+*{margin-top:.75rem}@media (min-width:48rem){.headline.headline--2.headline--2+*{margin-top:1rem}}.headline.headline--3.headline--3{font-size:1.75rem;line-height:2.125rem}@media (min-width:48rem){.headline.headline--3.headline--3{font-size:1.875rem;line-height:2.4375rem}}@media (min-width:90rem){.headline.headline--3.headline--3{font-size:2.5rem;line-height:3.125rem}}.headline.headline--3.headline--3+*{margin-top:.75rem}@media (min-width:64rem){.headline.headline--3.headline--3+*{margin-top:1rem}}.headline.headline--4.headline--4{font-size:1.5rem;font-weight:400;line-height:1.9375rem}@media (min-width:48rem){.headline.headline--4.headline--4{font-size:1.5rem;line-height:2.125rem}}@media (min-width:90rem){.headline.headline--4.headline--4{font-size:1.875rem;line-height:2.5625rem}}.headline.headline--4.headline--4+*{margin-top:.75rem}@media (min-width:64rem){.headline.headline--4.headline--4+*{margin-top:.5rem}}.headline.headline--5.headline--5{font-size:1.25rem;font-weight:400;line-height:1.625rem}@media (min-width:48rem){.headline.headline--5.headline--5{font-size:1.25rem;line-height:1.875rem}}@media (min-width:90rem){.headline.headline--5.headline--5{font-size:1.5rem;line-height:2.125rem}}.headline.headline--5.headline--5+*{margin-top:.5rem}.headline.headline--6.headline--6{font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.headline.headline--6.headline--6{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.headline.headline--6.headline--6{font-size:1.25rem;line-height:1.875rem}}.headline.headline--6.headline--6+*{margin-top:.5rem}.headline.headline--pipeline{border-bottom:1px solid var(--color-grey-200);margin:1rem 0 0}.breadcrumbs{align-items:flex-end;display:flex;height:5rem;-webkit-mask-image:linear-gradient(270deg,transparent 0,#000 2rem);mask-image:linear-gradient(270deg,transparent 0,#000 2rem);overflow:auto hidden;padding-bottom:1rem;position:relative}@media (min-width:48rem){.breadcrumbs{height:6rem;overflow:hidden;padding-bottom:1.5rem}}@media (min-width:90rem){.breadcrumbs{height:8rem;padding-bottom:2rem}}@media print{.breadcrumbs{opacity:0}}[dir=rtl] .breadcrumbs{-webkit-mask-image:linear-gradient(90deg,transparent 0,#000 2rem);mask-image:linear-gradient(90deg,transparent 0,#000 2rem)}.breadcrumbs .breadcrumbs__item-list{align-items:center;display:flex;flex-wrap:nowrap}.breadcrumbs .breadcrumbs__item{margin-inline-end:.3125rem}.breadcrumbs .breadcrumbs__text{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--label-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem;white-space:nowrap}@media (min-width:48rem){.breadcrumbs .breadcrumbs__text{font-size:var(--label-font-size-medium-up);line-height:1.3125rem}}.breadcrumbs .breadcrumbs__icon{color:var(--color-roche-grey-400);margin:auto .5rem}@media (min-width:48rem){.breadcrumbs .breadcrumbs__icon{margin:auto .75rem}}@media (min-width:90rem){.breadcrumbs .breadcrumbs__icon{margin:auto 1rem}}.contact-person{display:flex;flex-direction:column;margin-top:3rem}.contact-person .contact-person__avatar{height:8rem;margin-bottom:2rem;width:8rem}.contact-person .contact-person__name{font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.contact-person .contact-person__name{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.contact-person .contact-person__name{font-size:1.25rem;line-height:1.875rem}}.contact-person .contact-person__job-title{font-family:roche-sans;font-size:var(--body-small-font-size-small-up);font-style:normal;font-weight:200;line-height:1.625rem;margin-top:.25rem}@media (min-width:48rem){.contact-person .contact-person__job-title{font-size:var(--body-small-font-size-medium-up);line-height:1.8125rem}}.contact-person .contact-person__email-address,.contact-person .contact-person__phone-number{display:flex}@keyframes brand-gradient-animation{0%{background-color:#0b41cd}33%{background-color:#fac9b5}66%{background-color:#ff7d29}to{background-color:#0b41cd}}.container{display:block;margin-left:1.25rem;margin-right:1.25rem;max-width:calc(100% - 40px);position:relative}@media (min-width:48rem){.container{margin-left:2rem;margin-right:2rem;max-width:calc(100% - 64px)}}@media (min-width:64rem){.container{margin-left:4rem;margin-right:4rem;max-width:calc(100% - 128px)}}@media (min-width:90rem){.container{margin-left:6rem;margin-right:6rem;max-width:calc(100% - 192px)}}@media (min-width:104.5rem){.container{margin-left:auto;margin-right:auto;width:1552px}}.container.container--full-width{max-width:none}@media (min-width:104.5rem){.container.container--full-width{width:auto}}.container.container--colored:before{content:\"\";height:calc(100% + 96px);left:50%;margin:0 -50vw;position:absolute;right:50%;top:-48px;width:100vw;z-index:-100}@media (min-width:90rem){.container.container--colored:before{height:calc(100% + 120px);top:-60px}}.container.container--theme-aware:before{background-color:var(--color-roche-grey-100)}.container.container--aware-gradient-top-left:before{background:linear-gradient(140.87deg,var(--color-extra-light-blue) -68.64%,#fff 52.89%)}.container.container--aware-gradient-bottom-right:before{background:linear-gradient(319deg,var(--color-extra-light-blue) -68%,#fff 52%)}.container.container--neutral-gradient-top-left:before{background:linear-gradient(140.87deg,#fac9b5 -68.64%,#fff 52.89%)}.container.container--blue-gradient-top-left:before{background:linear-gradient(140.87deg,#bde3ff -68.64%,#fff 52.89%)}.container.container--blue-gradient-bottom-right:before{background:linear-gradient(319deg,#bde3ff -68%,#fff 52%)}.container.container--neutral-gradient-bottom-right:before{background:linear-gradient(319deg,#fac9b5 -68%,#fff 52%)}.container.container--neutral-gradient-neutral-100-neutral-400:before{background:linear-gradient(144.84deg,#fff7f5 54.87%,#fac9b5 227.96%)}.container.container--neutral-100:before{background-color:var(--color-neutral-100)}.container.container--neutral-200:before{background-color:var(--color-neutral-200)}.container.container--grey-50:before{background-color:var(--color-roche-grey-0)}.container.container--grey-100:before{background-color:var(--color-roche-grey-100)}.container.container--grey-300:before{background-color:var(--color-roche-grey-300)}.container.container--white:before{background-color:var(--color-white)}.container.container--split-gradient-radial:before{background:linear-gradient(150deg,#fffcfa00 50%,#f5f5f2)}@media (min-width:48rem){.container.container--split-gradient-radial .container__gradient-helper{display:block}}.container.container--split-gradient-linear:before{background:linear-gradient(148.3deg,#fff 54.06%,#c2bab5 146.91%)}.container.container--brand-gradient:before{animation:brand-gradient-animation 45s linear infinite;background-image:linear-gradient(148.8deg,#fff 29.38%,#fad6c7 69.97%,transparent 141.56%)}.container.container__gradient-helper{aspect-ratio:8/4.5;clip-path:polygon(50% 0,0 100%,100% 55%);display:none;height:calc(100% + 6rem);left:48%;position:absolute;top:-3rem;transform:translate(-50%);z-index:-50}.container.container__gradient-helper:before{background:radial-gradient(circle at 20% 32%,#dbd6d1b3,#f5f5f221 38%);content:\"\";display:block;height:100%;width:100%}.container.container--extended-background:before{height:calc(100% + 64px);top:-64px}@media (min-width:48rem){.container.container--extended-background:before{height:calc(100% + 88px);top:-88px}}@media (min-width:64rem){.container.container--extended-background:before{height:calc(100% + 160px);top:-160px}}.container.container--full-width{margin-left:0;margin-right:0}[dir=rtl] .container.container--split-gradient-radial:before{transform:scaleX(-1)}[dir=rtl] .container.container__gradient-helper{left:auto;right:48%;transform:scaleX(-1) translate(-50%)}.container.container--full-height:before{height:100%;margin-top:3rem;top:0}@media (min-width:48rem){.container.container--full-height:before{margin-top:3.75rem}}@media (min-width:64rem){.container.container--full-height:before{height:calc(100% + 96px);margin-top:0;top:-48px}}@media (min-width:90rem){.container.container--full-height:before{height:calc(100% + 120px);top:-60px}}.roche-dropdown:not(:first-child){margin-top:32px}.roche-dropdown .roche-dropdown__label-wrapper{display:flex;gap:10px;position:relative}.roche-dropdown .roche-dropdown__label{color:var(--color-roche-grey-700);display:block;font-family:roche-sans;font-size:var(--label-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem;margin-bottom:.5rem;pointer-events:none}@media (min-width:48rem){.roche-dropdown .roche-dropdown__label{font-size:var(--label-font-size-medium-up);line-height:1.3125rem}}.roche-dropdown .roche-dropdown__select{-webkit-appearance:none;appearance:none;background-color:transparent;border-bottom:1px solid var(--color-roche-grey-400);border:1px solid var(--color-roche-grey-400);border-bottom-color:var(--color-text-primary);border-radius:0;cursor:pointer;font-family:roche-sans;font-size:var(--body-small-font-size-small-up);font-style:normal;font-weight:200;line-height:1.625rem;margin:0;padding:.75rem 2.875rem .75rem 1rem;width:100%}@media (min-width:48rem){.roche-dropdown .roche-dropdown__select{font-size:var(--body-small-font-size-medium-up);line-height:1.8125rem}}.roche-dropdown .roche-dropdown__select:focus,.roche-dropdown .roche-dropdown__select:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.roche-dropdown .roche-dropdown__select:focus:not(:focus-visible){outline:0}.roche-dropdown .roche-dropdown__select:active,.roche-dropdown .roche-dropdown__select:focus{border-color:var(--color-interactive--primary-idle)}.roche-dropdown .roche-dropdown__select:active{outline:0}.roche-dropdown .roche-dropdown__select::-ms-expand{display:none}.roche-dropdown .roche-dropdown__select.roche-dropdown__select--placeholder{color:var(--color-roche-grey-600)}.roche-dropdown .roche-dropdown__select:hover{border-bottom-color:var(--color-interactive--primary-idle)}.roche-dropdown .roche-dropdown__container{position:relative}.roche-dropdown .roche-dropdown__container .roche-dropdown__icon{color:var(--color-roche-grey-600);pointer-events:none;position:absolute;right:1rem;top:50%;transform:translateY(-50%)}.roche-dropdown.roche-dropdown--disabled .roche-dropdown__container{cursor:not-allowed}.roche-dropdown.roche-dropdown--disabled .roche-dropdown__container:before{background-color:var(--color-black-900);content:\"\";height:100%;left:0;opacity:.05;position:absolute;top:0;width:100%}.roche-dropdown.roche-dropdown--disabled .roche-dropdown__label{color:var(--color-interactive--disabled)}.roche-dropdown.roche-dropdown--disabled .roche-dropdown__select{border-color:transparent;color:var(--color-interactive--disabled)}.roche-dropdown.roche-dropdown--disabled .roche-dropdown__icon{fill:var(--color-interactive--disabled)}.roche-dropdown .roche-dropdown__error{align-items:center;color:var(--color-status--error);display:flex;gap:.25rem;margin-top:4px}.roche-dropdown.roche-dropdown--error .roche-dropdown__select{border-color:var(--color-status--error)}.roche-dropdown.roche-dropdown--error .roche-dropdown__select:hover{border-bottom-color:var(--color-status--error)}.roche-dropdown.roche-dropdown--error .roche-dropdown__select:active,.roche-dropdown.roche-dropdown--error .roche-dropdown__select:focus{border-color:var(--color-status--error)}.roche-dropdown.roche-dropdown--error .roche-dropdown__error-text{font-family:roche-sans;font-size:var(--label-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem}@media (min-width:48rem){.roche-dropdown.roche-dropdown--error .roche-dropdown__error-text{font-size:var(--label-font-size-medium-up);line-height:1.3125rem}}[dir=rtl] .roche-dropdown .roche-dropdown__select{padding:.75rem 1rem .75rem 2.875rem}[dir=rtl] .roche-dropdown .roche-dropdown__container .roche-dropdown__icon{left:1rem;right:auto}.tooltip{display:inline-block;font-family:roche-sans;font-size:.875rem;font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem;position:relative}@media (min-width:48rem){.tooltip{font-size:1rem;line-height:1.3125rem}}.tooltip .tooltip__icon{align-items:center;background:0 0;border:none;color:var(--color-interactive--primary-idle);cursor:pointer;display:inline-flex;justify-content:center;padding:0}.tooltip .tooltip__icon:focus,.tooltip .tooltip__icon:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.tooltip .tooltip__icon:focus:not(:focus-visible){outline:0}.tooltip .tooltip__icon:focus,.tooltip .tooltip__icon:hover{color:var(--color-interactive--primary-hover)}.tooltip .tooltip__icon .tooltip__icon--active{color:var(--color-interactive--primary-hover)}.tooltip .tooltip__content{max-width:20rem;width:max-content;block-size:max-content;opacity:0;transition-duration:.2s;transition-property:opacity,visibility;transition-timing-function:ease-in;visibility:hidden;z-index:50}.tooltip .tooltip__content[data-popper-placement^=top] .tooltip__arrow{border-bottom:none;border-left:.375rem solid transparent;border-right:.375rem solid transparent;border-top:.375rem solid var(--color-roche-grey-600);left:50%;top:100%;transform:translate(-50%)}.tooltip .tooltip__content[data-popper-placement^=bottom] .tooltip__arrow{border-bottom:.375rem solid var(--color-roche-grey-600);border-left:.375rem solid transparent;border-right:.375rem solid transparent;border-top:none;bottom:100%;left:50%;transform:translate(-50%)}.tooltip .tooltip__content--open{opacity:1;visibility:visible}.tooltip .tooltip__text{background-color:var(--color-roche-grey-600);color:var(--color-white);direction:inherit;padding:.5rem;text-align:start}.tooltip .tooltip__arrow{height:0;position:absolute;width:0}:root{--bulma-control-radius:var(--bulma-radius);--bulma-control-radius-small:var(--bulma-radius-small);--bulma-control-border-width:1px;--bulma-control-height:2.5em;--bulma-control-line-height:1.5;--bulma-control-padding-vertical:calc(0.5em - 1px);--bulma-control-padding-horizontal:calc(0.75em - 1px);--bulma-control-size:var(--bulma-size-normal);--bulma-control-focus-shadow-l:50%}:root{--bulma-column-gap:.75rem}.column{display:block;flex-basis:0;flex-grow:1;flex-shrink:1;padding:var(--bulma-column-gap)}.columns.is-mobile>.column.is-narrow{flex:none;width:unset}.columns.is-mobile>.column.is-full{flex:none;width:100%}.columns.is-mobile>.column.is-three-quarters{flex:none;width:75%}.columns.is-mobile>.column.is-two-thirds{flex:none;width:66.6666%}.columns.is-mobile>.column.is-half{flex:none;width:50%}.columns.is-mobile>.column.is-one-third{flex:none;width:33.3333%}.columns.is-mobile>.column.is-one-quarter{flex:none;width:25%}.columns.is-mobile>.column.is-one-fifth{flex:none;width:20%}.columns.is-mobile>.column.is-two-fifths{flex:none;width:40%}.columns.is-mobile>.column.is-three-fifths{flex:none;width:60%}.columns.is-mobile>.column.is-four-fifths{flex:none;width:80%}.columns.is-mobile>.column.is-offset-three-quarters{margin-inline-start:75%}.columns.is-mobile>.column.is-offset-two-thirds{margin-inline-start:66.6666%}.columns.is-mobile>.column.is-offset-half{margin-inline-start:50%}.columns.is-mobile>.column.is-offset-one-third{margin-inline-start:.3333%}.columns.is-mobile>.column.is-offset-one-quarter{margin-inline-start:25%}.columns.is-mobile>.column.is-offset-one-fifth{margin-inline-start:20%}.columns.is-mobile>.column.is-offset-two-fifths{margin-inline-start:40%}.columns.is-mobile>.column.is-offset-three-fifths{margin-inline-start:60%}.columns.is-mobile>.column.is-offset-four-fifths{margin-inline-start:80%}.columns.is-mobile>.column.is-0{flex:none;width:0}.columns.is-mobile>.column.is-offset-0{margin-inline-start:0}.columns.is-mobile>.column.is-1{flex:none;width:8.3333333333%}.columns.is-mobile>.column.is-offset-1{margin-inline-start:8.3333333333%}.columns.is-mobile>.column.is-2{flex:none;width:16.6666666667%}.columns.is-mobile>.column.is-offset-2{margin-inline-start:16.6666666667%}.columns.is-mobile>.column.is-3{flex:none;width:25%}.columns.is-mobile>.column.is-offset-3{margin-inline-start:25%}.columns.is-mobile>.column.is-4{flex:none;width:33.3333333333%}.columns.is-mobile>.column.is-offset-4{margin-inline-start:33.3333333333%}.columns.is-mobile>.column.is-5{flex:none;width:41.6666666667%}.columns.is-mobile>.column.is-offset-5{margin-inline-start:41.6666666667%}.columns.is-mobile>.column.is-6{flex:none;width:50%}.columns.is-mobile>.column.is-offset-6{margin-inline-start:50%}.columns.is-mobile>.column.is-7{flex:none;width:58.3333333333%}.columns.is-mobile>.column.is-offset-7{margin-inline-start:58.3333333333%}.columns.is-mobile>.column.is-8{flex:none;width:66.6666666667%}.columns.is-mobile>.column.is-offset-8{margin-inline-start:66.6666666667%}.columns.is-mobile>.column.is-9{flex:none;width:75%}.columns.is-mobile>.column.is-offset-9{margin-inline-start:75%}.columns.is-mobile>.column.is-10{flex:none;width:83.3333333333%}.columns.is-mobile>.column.is-offset-10{margin-inline-start:83.3333333333%}.columns.is-mobile>.column.is-11{flex:none;width:91.6666666667%}.columns.is-mobile>.column.is-offset-11{margin-inline-start:91.6666666667%}.columns.is-mobile>.column.is-12{flex:none;width:100%}.columns.is-mobile>.column.is-offset-12{margin-inline-start:100%}@media screen and (max-width:768px){.column.is-narrow-mobile{flex:none;width:unset}.column.is-full-mobile{flex:none;width:100%}.column.is-three-quarters-mobile{flex:none;width:75%}.column.is-two-thirds-mobile{flex:none;width:66.6666%}.column.is-half-mobile{flex:none;width:50%}.column.is-one-third-mobile{flex:none;width:33.3333%}.column.is-one-quarter-mobile{flex:none;width:25%}.column.is-one-fifth-mobile{flex:none;width:20%}.column.is-two-fifths-mobile{flex:none;width:40%}.column.is-three-fifths-mobile{flex:none;width:60%}.column.is-four-fifths-mobile{flex:none;width:80%}.column.is-offset-three-quarters-mobile{margin-inline-start:75%}.column.is-offset-two-thirds-mobile{margin-inline-start:66.6666%}.column.is-offset-half-mobile{margin-inline-start:50%}.column.is-offset-one-third-mobile{margin-inline-start:.3333%}.column.is-offset-one-quarter-mobile{margin-inline-start:25%}.column.is-offset-one-fifth-mobile{margin-inline-start:20%}.column.is-offset-two-fifths-mobile{margin-inline-start:40%}.column.is-offset-three-fifths-mobile{margin-inline-start:60%}.column.is-offset-four-fifths-mobile{margin-inline-start:80%}.column.is-0-mobile{flex:none;width:0}.column.is-offset-0-mobile{margin-inline-start:0}.column.is-1-mobile{flex:none;width:8.3333333333%}.column.is-offset-1-mobile{margin-inline-start:8.3333333333%}.column.is-2-mobile{flex:none;width:16.6666666667%}.column.is-offset-2-mobile{margin-inline-start:16.6666666667%}.column.is-3-mobile{flex:none;width:25%}.column.is-offset-3-mobile{margin-inline-start:25%}.column.is-4-mobile{flex:none;width:33.3333333333%}.column.is-offset-4-mobile{margin-inline-start:33.3333333333%}.column.is-5-mobile{flex:none;width:41.6666666667%}.column.is-offset-5-mobile{margin-inline-start:41.6666666667%}.column.is-6-mobile{flex:none;width:50%}.column.is-offset-6-mobile{margin-inline-start:50%}.column.is-7-mobile{flex:none;width:58.3333333333%}.column.is-offset-7-mobile{margin-inline-start:58.3333333333%}.column.is-8-mobile{flex:none;width:66.6666666667%}.column.is-offset-8-mobile{margin-inline-start:66.6666666667%}.column.is-9-mobile{flex:none;width:75%}.column.is-offset-9-mobile{margin-inline-start:75%}.column.is-10-mobile{flex:none;width:83.3333333333%}.column.is-offset-10-mobile{margin-inline-start:83.3333333333%}.column.is-11-mobile{flex:none;width:91.6666666667%}.column.is-offset-11-mobile{margin-inline-start:91.6666666667%}.column.is-12-mobile{flex:none;width:100%}.column.is-offset-12-mobile{margin-inline-start:100%}}@media print,screen and (min-width:769px){.column.is-narrow,.column.is-narrow-tablet{flex:none;width:unset}.column.is-full,.column.is-full-tablet{flex:none;width:100%}.column.is-three-quarters,.column.is-three-quarters-tablet{flex:none;width:75%}.column.is-two-thirds,.column.is-two-thirds-tablet{flex:none;width:66.6666%}.column.is-half,.column.is-half-tablet{flex:none;width:50%}.column.is-one-third,.column.is-one-third-tablet{flex:none;width:33.3333%}.column.is-one-quarter,.column.is-one-quarter-tablet{flex:none;width:25%}.column.is-one-fifth,.column.is-one-fifth-tablet{flex:none;width:20%}.column.is-two-fifths,.column.is-two-fifths-tablet{flex:none;width:40%}.column.is-three-fifths,.column.is-three-fifths-tablet{flex:none;width:60%}.column.is-four-fifths,.column.is-four-fifths-tablet{flex:none;width:80%}.column.is-offset-three-quarters,.column.is-offset-three-quarters-tablet{margin-inline-start:75%}.column.is-offset-two-thirds,.column.is-offset-two-thirds-tablet{margin-inline-start:66.6666%}.column.is-offset-half,.column.is-offset-half-tablet{margin-inline-start:50%}.column.is-offset-one-third,.column.is-offset-one-third-tablet{margin-inline-start:.3333%}.column.is-offset-one-quarter,.column.is-offset-one-quarter-tablet{margin-inline-start:25%}.column.is-offset-one-fifth,.column.is-offset-one-fifth-tablet{margin-inline-start:20%}.column.is-offset-two-fifths,.column.is-offset-two-fifths-tablet{margin-inline-start:40%}.column.is-offset-three-fifths,.column.is-offset-three-fifths-tablet{margin-inline-start:60%}.column.is-offset-four-fifths,.column.is-offset-four-fifths-tablet{margin-inline-start:80%}.column.is-0,.column.is-0-tablet{flex:none;width:0}.column.is-offset-0,.column.is-offset-0-tablet{margin-inline-start:0}.column.is-1,.column.is-1-tablet{flex:none;width:8.3333333333%}.column.is-offset-1,.column.is-offset-1-tablet{margin-inline-start:8.3333333333%}.column.is-2,.column.is-2-tablet{flex:none;width:16.6666666667%}.column.is-offset-2,.column.is-offset-2-tablet{margin-inline-start:16.6666666667%}.column.is-3,.column.is-3-tablet{flex:none;width:25%}.column.is-offset-3,.column.is-offset-3-tablet{margin-inline-start:25%}.column.is-4,.column.is-4-tablet{flex:none;width:33.3333333333%}.column.is-offset-4,.column.is-offset-4-tablet{margin-inline-start:33.3333333333%}.column.is-5,.column.is-5-tablet{flex:none;width:41.6666666667%}.column.is-offset-5,.column.is-offset-5-tablet{margin-inline-start:41.6666666667%}.column.is-6,.column.is-6-tablet{flex:none;width:50%}.column.is-offset-6,.column.is-offset-6-tablet{margin-inline-start:50%}.column.is-7,.column.is-7-tablet{flex:none;width:58.3333333333%}.column.is-offset-7,.column.is-offset-7-tablet{margin-inline-start:58.3333333333%}.column.is-8,.column.is-8-tablet{flex:none;width:66.6666666667%}.column.is-offset-8,.column.is-offset-8-tablet{margin-inline-start:66.6666666667%}.column.is-9,.column.is-9-tablet{flex:none;width:75%}.column.is-offset-9,.column.is-offset-9-tablet{margin-inline-start:75%}.column.is-10,.column.is-10-tablet{flex:none;width:83.3333333333%}.column.is-offset-10,.column.is-offset-10-tablet{margin-inline-start:83.3333333333%}.column.is-11,.column.is-11-tablet{flex:none;width:91.6666666667%}.column.is-offset-11,.column.is-offset-11-tablet{margin-inline-start:91.6666666667%}.column.is-12,.column.is-12-tablet{flex:none;width:100%}.column.is-offset-12,.column.is-offset-12-tablet{margin-inline-start:100%}}@media screen and (max-width:1023px){.column.is-narrow-touch{flex:none;width:unset}.column.is-full-touch{flex:none;width:100%}.column.is-three-quarters-touch{flex:none;width:75%}.column.is-two-thirds-touch{flex:none;width:66.6666%}.column.is-half-touch{flex:none;width:50%}.column.is-one-third-touch{flex:none;width:33.3333%}.column.is-one-quarter-touch{flex:none;width:25%}.column.is-one-fifth-touch{flex:none;width:20%}.column.is-two-fifths-touch{flex:none;width:40%}.column.is-three-fifths-touch{flex:none;width:60%}.column.is-four-fifths-touch{flex:none;width:80%}.column.is-offset-three-quarters-touch{margin-inline-start:75%}.column.is-offset-two-thirds-touch{margin-inline-start:66.6666%}.column.is-offset-half-touch{margin-inline-start:50%}.column.is-offset-one-third-touch{margin-inline-start:.3333%}.column.is-offset-one-quarter-touch{margin-inline-start:25%}.column.is-offset-one-fifth-touch{margin-inline-start:20%}.column.is-offset-two-fifths-touch{margin-inline-start:40%}.column.is-offset-three-fifths-touch{margin-inline-start:60%}.column.is-offset-four-fifths-touch{margin-inline-start:80%}.column.is-0-touch{flex:none;width:0}.column.is-offset-0-touch{margin-inline-start:0}.column.is-1-touch{flex:none;width:8.3333333333%}.column.is-offset-1-touch{margin-inline-start:8.3333333333%}.column.is-2-touch{flex:none;width:16.6666666667%}.column.is-offset-2-touch{margin-inline-start:16.6666666667%}.column.is-3-touch{flex:none;width:25%}.column.is-offset-3-touch{margin-inline-start:25%}.column.is-4-touch{flex:none;width:33.3333333333%}.column.is-offset-4-touch{margin-inline-start:33.3333333333%}.column.is-5-touch{flex:none;width:41.6666666667%}.column.is-offset-5-touch{margin-inline-start:41.6666666667%}.column.is-6-touch{flex:none;width:50%}.column.is-offset-6-touch{margin-inline-start:50%}.column.is-7-touch{flex:none;width:58.3333333333%}.column.is-offset-7-touch{margin-inline-start:58.3333333333%}.column.is-8-touch{flex:none;width:66.6666666667%}.column.is-offset-8-touch{margin-inline-start:66.6666666667%}.column.is-9-touch{flex:none;width:75%}.column.is-offset-9-touch{margin-inline-start:75%}.column.is-10-touch{flex:none;width:83.3333333333%}.column.is-offset-10-touch{margin-inline-start:83.3333333333%}.column.is-11-touch{flex:none;width:91.6666666667%}.column.is-offset-11-touch{margin-inline-start:91.6666666667%}.column.is-12-touch{flex:none;width:100%}.column.is-offset-12-touch{margin-inline-start:100%}}@media screen and (min-width:1024px){.column.is-narrow-desktop{flex:none;width:unset}.column.is-full-desktop{flex:none;width:100%}.column.is-three-quarters-desktop{flex:none;width:75%}.column.is-two-thirds-desktop{flex:none;width:66.6666%}.column.is-half-desktop{flex:none;width:50%}.column.is-one-third-desktop{flex:none;width:33.3333%}.column.is-one-quarter-desktop{flex:none;width:25%}.column.is-one-fifth-desktop{flex:none;width:20%}.column.is-two-fifths-desktop{flex:none;width:40%}.column.is-three-fifths-desktop{flex:none;width:60%}.column.is-four-fifths-desktop{flex:none;width:80%}.column.is-offset-three-quarters-desktop{margin-inline-start:75%}.column.is-offset-two-thirds-desktop{margin-inline-start:66.6666%}.column.is-offset-half-desktop{margin-inline-start:50%}.column.is-offset-one-third-desktop{margin-inline-start:.3333%}.column.is-offset-one-quarter-desktop{margin-inline-start:25%}.column.is-offset-one-fifth-desktop{margin-inline-start:20%}.column.is-offset-two-fifths-desktop{margin-inline-start:40%}.column.is-offset-three-fifths-desktop{margin-inline-start:60%}.column.is-offset-four-fifths-desktop{margin-inline-start:80%}.column.is-0-desktop{flex:none;width:0}.column.is-offset-0-desktop{margin-inline-start:0}.column.is-1-desktop{flex:none;width:8.3333333333%}.column.is-offset-1-desktop{margin-inline-start:8.3333333333%}.column.is-2-desktop{flex:none;width:16.6666666667%}.column.is-offset-2-desktop{margin-inline-start:16.6666666667%}.column.is-3-desktop{flex:none;width:25%}.column.is-offset-3-desktop{margin-inline-start:25%}.column.is-4-desktop{flex:none;width:33.3333333333%}.column.is-offset-4-desktop{margin-inline-start:33.3333333333%}.column.is-5-desktop{flex:none;width:41.6666666667%}.column.is-offset-5-desktop{margin-inline-start:41.6666666667%}.column.is-6-desktop{flex:none;width:50%}.column.is-offset-6-desktop{margin-inline-start:50%}.column.is-7-desktop{flex:none;width:58.3333333333%}.column.is-offset-7-desktop{margin-inline-start:58.3333333333%}.column.is-8-desktop{flex:none;width:66.6666666667%}.column.is-offset-8-desktop{margin-inline-start:66.6666666667%}.column.is-9-desktop{flex:none;width:75%}.column.is-offset-9-desktop{margin-inline-start:75%}.column.is-10-desktop{flex:none;width:83.3333333333%}.column.is-offset-10-desktop{margin-inline-start:83.3333333333%}.column.is-11-desktop{flex:none;width:91.6666666667%}.column.is-offset-11-desktop{margin-inline-start:91.6666666667%}.column.is-12-desktop{flex:none;width:100%}.column.is-offset-12-desktop{margin-inline-start:100%}}@media screen and (min-width:1216px){.column.is-narrow-widescreen{flex:none;width:unset}.column.is-full-widescreen{flex:none;width:100%}.column.is-three-quarters-widescreen{flex:none;width:75%}.column.is-two-thirds-widescreen{flex:none;width:66.6666%}.column.is-half-widescreen{flex:none;width:50%}.column.is-one-third-widescreen{flex:none;width:33.3333%}.column.is-one-quarter-widescreen{flex:none;width:25%}.column.is-one-fifth-widescreen{flex:none;width:20%}.column.is-two-fifths-widescreen{flex:none;width:40%}.column.is-three-fifths-widescreen{flex:none;width:60%}.column.is-four-fifths-widescreen{flex:none;width:80%}.column.is-offset-three-quarters-widescreen{margin-inline-start:75%}.column.is-offset-two-thirds-widescreen{margin-inline-start:66.6666%}.column.is-offset-half-widescreen{margin-inline-start:50%}.column.is-offset-one-third-widescreen{margin-inline-start:.3333%}.column.is-offset-one-quarter-widescreen{margin-inline-start:25%}.column.is-offset-one-fifth-widescreen{margin-inline-start:20%}.column.is-offset-two-fifths-widescreen{margin-inline-start:40%}.column.is-offset-three-fifths-widescreen{margin-inline-start:60%}.column.is-offset-four-fifths-widescreen{margin-inline-start:80%}.column.is-0-widescreen{flex:none;width:0}.column.is-offset-0-widescreen{margin-inline-start:0}.column.is-1-widescreen{flex:none;width:8.3333333333%}.column.is-offset-1-widescreen{margin-inline-start:8.3333333333%}.column.is-2-widescreen{flex:none;width:16.6666666667%}.column.is-offset-2-widescreen{margin-inline-start:16.6666666667%}.column.is-3-widescreen{flex:none;width:25%}.column.is-offset-3-widescreen{margin-inline-start:25%}.column.is-4-widescreen{flex:none;width:33.3333333333%}.column.is-offset-4-widescreen{margin-inline-start:33.3333333333%}.column.is-5-widescreen{flex:none;width:41.6666666667%}.column.is-offset-5-widescreen{margin-inline-start:41.6666666667%}.column.is-6-widescreen{flex:none;width:50%}.column.is-offset-6-widescreen{margin-inline-start:50%}.column.is-7-widescreen{flex:none;width:58.3333333333%}.column.is-offset-7-widescreen{margin-inline-start:58.3333333333%}.column.is-8-widescreen{flex:none;width:66.6666666667%}.column.is-offset-8-widescreen{margin-inline-start:66.6666666667%}.column.is-9-widescreen{flex:none;width:75%}.column.is-offset-9-widescreen{margin-inline-start:75%}.column.is-10-widescreen{flex:none;width:83.3333333333%}.column.is-offset-10-widescreen{margin-inline-start:83.3333333333%}.column.is-11-widescreen{flex:none;width:91.6666666667%}.column.is-offset-11-widescreen{margin-inline-start:91.6666666667%}.column.is-12-widescreen{flex:none;width:100%}.column.is-offset-12-widescreen{margin-inline-start:100%}}@media screen and (min-width:1408px){.column.is-narrow-fullhd{flex:none;width:unset}.column.is-full-fullhd{flex:none;width:100%}.column.is-three-quarters-fullhd{flex:none;width:75%}.column.is-two-thirds-fullhd{flex:none;width:66.6666%}.column.is-half-fullhd{flex:none;width:50%}.column.is-one-third-fullhd{flex:none;width:33.3333%}.column.is-one-quarter-fullhd{flex:none;width:25%}.column.is-one-fifth-fullhd{flex:none;width:20%}.column.is-two-fifths-fullhd{flex:none;width:40%}.column.is-three-fifths-fullhd{flex:none;width:60%}.column.is-four-fifths-fullhd{flex:none;width:80%}.column.is-offset-three-quarters-fullhd{margin-inline-start:75%}.column.is-offset-two-thirds-fullhd{margin-inline-start:66.6666%}.column.is-offset-half-fullhd{margin-inline-start:50%}.column.is-offset-one-third-fullhd{margin-inline-start:33.3333%}.column.is-offset-one-quarter-fullhd{margin-inline-start:25%}.column.is-offset-one-fifth-fullhd{margin-inline-start:20%}.column.is-offset-two-fifths-fullhd{margin-inline-start:40%}.column.is-offset-three-fifths-fullhd{margin-inline-start:60%}.column.is-offset-four-fifths-fullhd{margin-inline-start:80%}.column.is-0-fullhd{flex:none;width:0}.column.is-offset-0-fullhd{margin-inline-start:0}.column.is-1-fullhd{flex:none;width:8.3333333333%}.column.is-offset-1-fullhd{margin-inline-start:8.3333333333%}.column.is-2-fullhd{flex:none;width:16.6666666667%}.column.is-offset-2-fullhd{margin-inline-start:16.6666666667%}.column.is-3-fullhd{flex:none;width:25%}.column.is-offset-3-fullhd{margin-inline-start:25%}.column.is-4-fullhd{flex:none;width:33.3333333333%}.column.is-offset-4-fullhd{margin-inline-start:33.3333333333%}.column.is-5-fullhd{flex:none;width:41.6666666667%}.column.is-offset-5-fullhd{margin-inline-start:41.6666666667%}.column.is-6-fullhd{flex:none;width:50%}.column.is-offset-6-fullhd{margin-inline-start:50%}.column.is-7-fullhd{flex:none;width:58.3333333333%}.column.is-offset-7-fullhd{margin-inline-start:58.3333333333%}.column.is-8-fullhd{flex:none;width:66.6666666667%}.column.is-offset-8-fullhd{margin-inline-start:66.6666666667%}.column.is-9-fullhd{flex:none;width:75%}.column.is-offset-9-fullhd{margin-inline-start:75%}.column.is-10-fullhd{flex:none;width:83.3333333333%}.column.is-offset-10-fullhd{margin-inline-start:83.3333333333%}.column.is-11-fullhd{flex:none;width:91.6666666667%}.column.is-offset-11-fullhd{margin-inline-start:91.6666666667%}.column.is-12-fullhd{flex:none;width:100%}.column.is-offset-12-fullhd{margin-inline-start:100%}}.columns{margin-inline-end:calc(var(--bulma-column-gap)*-1);margin-inline-start:calc(var(--bulma-column-gap)*-1);margin-top:calc(var(--bulma-column-gap)*-1)}.columns:last-child{margin-bottom:calc(var(--bulma-column-gap)*-1)}.columns:not(:last-child){margin-bottom:calc(var(--bulma-block-spacing) - var(--bulma-column-gap))}.columns.is-centered{justify-content:center}.columns.is-gapless{margin-inline-end:0;margin-inline-start:0;margin-top:0}.columns.is-gapless>.column{margin:0;padding:0!important}.columns.is-gapless:not(:last-child){margin-bottom:1.5rem}.columns.is-gapless:last-child{margin-bottom:0}.columns.is-mobile{display:flex}.columns.is-multiline{flex-wrap:wrap}.columns.is-vcentered{align-items:center}@media print,screen and (min-width:769px){.columns:not(.is-desktop){display:flex}}@media screen and (min-width:1024px){.columns.is-desktop{display:flex}}.columns.is-0{--bulma-column-gap:0rem}@media screen and (max-width:768px){.columns.is-0-mobile{--bulma-column-gap:0rem}}@media print,screen and (min-width:769px){.columns.is-0-tablet{--bulma-column-gap:0rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-0-tablet-only{--bulma-column-gap:0rem}}@media screen and (max-width:1023px){.columns.is-0-touch{--bulma-column-gap:0rem}}@media screen and (min-width:1024px){.columns.is-0-desktop{--bulma-column-gap:0rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-0-desktop-only{--bulma-column-gap:0rem}}@media screen and (min-width:1216px){.columns.is-0-widescreen{--bulma-column-gap:0rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-0-widescreen-only{--bulma-column-gap:0rem}}@media screen and (min-width:1408px){.columns.is-0-fullhd{--bulma-column-gap:0rem}}.columns.is-1{--bulma-column-gap:.25rem}@media screen and (max-width:768px){.columns.is-1-mobile{--bulma-column-gap:.25rem}}@media print,screen and (min-width:769px){.columns.is-1-tablet{--bulma-column-gap:.25rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-1-tablet-only{--bulma-column-gap:.25rem}}@media screen and (max-width:1023px){.columns.is-1-touch{--bulma-column-gap:.25rem}}@media screen and (min-width:1024px){.columns.is-1-desktop{--bulma-column-gap:.25rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-1-desktop-only{--bulma-column-gap:.25rem}}@media screen and (min-width:1216px){.columns.is-1-widescreen{--bulma-column-gap:.25rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-1-widescreen-only{--bulma-column-gap:.25rem}}@media screen and (min-width:1408px){.columns.is-1-fullhd{--bulma-column-gap:.25rem}}.columns.is-2{--bulma-column-gap:.5rem}@media screen and (max-width:768px){.columns.is-2-mobile{--bulma-column-gap:.5rem}}@media print,screen and (min-width:769px){.columns.is-2-tablet{--bulma-column-gap:.5rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-2-tablet-only{--bulma-column-gap:.5rem}}@media screen and (max-width:1023px){.columns.is-2-touch{--bulma-column-gap:.5rem}}@media screen and (min-width:1024px){.columns.is-2-desktop{--bulma-column-gap:.5rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-2-desktop-only{--bulma-column-gap:.5rem}}@media screen and (min-width:1216px){.columns.is-2-widescreen{--bulma-column-gap:.5rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-2-widescreen-only{--bulma-column-gap:.5rem}}@media screen and (min-width:1408px){.columns.is-2-fullhd{--bulma-column-gap:.5rem}}.columns.is-3{--bulma-column-gap:.75rem}@media screen and (max-width:768px){.columns.is-3-mobile{--bulma-column-gap:.75rem}}@media print,screen and (min-width:769px){.columns.is-3-tablet{--bulma-column-gap:.75rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-3-tablet-only{--bulma-column-gap:.75rem}}@media screen and (max-width:1023px){.columns.is-3-touch{--bulma-column-gap:.75rem}}@media screen and (min-width:1024px){.columns.is-3-desktop{--bulma-column-gap:.75rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-3-desktop-only{--bulma-column-gap:.75rem}}@media screen and (min-width:1216px){.columns.is-3-widescreen{--bulma-column-gap:.75rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-3-widescreen-only{--bulma-column-gap:.75rem}}@media screen and (min-width:1408px){.columns.is-3-fullhd{--bulma-column-gap:.75rem}}.columns.is-4{--bulma-column-gap:1rem}@media screen and (max-width:768px){.columns.is-4-mobile{--bulma-column-gap:1rem}}@media print,screen and (min-width:769px){.columns.is-4-tablet{--bulma-column-gap:1rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-4-tablet-only{--bulma-column-gap:1rem}}@media screen and (max-width:1023px){.columns.is-4-touch{--bulma-column-gap:1rem}}@media screen and (min-width:1024px){.columns.is-4-desktop{--bulma-column-gap:1rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-4-desktop-only{--bulma-column-gap:1rem}}@media screen and (min-width:1216px){.columns.is-4-widescreen{--bulma-column-gap:1rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-4-widescreen-only{--bulma-column-gap:1rem}}@media screen and (min-width:1408px){.columns.is-4-fullhd{--bulma-column-gap:1rem}}.columns.is-5{--bulma-column-gap:1.25rem}@media screen and (max-width:768px){.columns.is-5-mobile{--bulma-column-gap:1.25rem}}@media print,screen and (min-width:769px){.columns.is-5-tablet{--bulma-column-gap:1.25rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-5-tablet-only{--bulma-column-gap:1.25rem}}@media screen and (max-width:1023px){.columns.is-5-touch{--bulma-column-gap:1.25rem}}@media screen and (min-width:1024px){.columns.is-5-desktop{--bulma-column-gap:1.25rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-5-desktop-only{--bulma-column-gap:1.25rem}}@media screen and (min-width:1216px){.columns.is-5-widescreen{--bulma-column-gap:1.25rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-5-widescreen-only{--bulma-column-gap:1.25rem}}@media screen and (min-width:1408px){.columns.is-5-fullhd{--bulma-column-gap:1.25rem}}.columns.is-6{--bulma-column-gap:1.5rem}@media screen and (max-width:768px){.columns.is-6-mobile{--bulma-column-gap:1.5rem}}@media print,screen and (min-width:769px){.columns.is-6-tablet{--bulma-column-gap:1.5rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-6-tablet-only{--bulma-column-gap:1.5rem}}@media screen and (max-width:1023px){.columns.is-6-touch{--bulma-column-gap:1.5rem}}@media screen and (min-width:1024px){.columns.is-6-desktop{--bulma-column-gap:1.5rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-6-desktop-only{--bulma-column-gap:1.5rem}}@media screen and (min-width:1216px){.columns.is-6-widescreen{--bulma-column-gap:1.5rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-6-widescreen-only{--bulma-column-gap:1.5rem}}@media screen and (min-width:1408px){.columns.is-6-fullhd{--bulma-column-gap:1.5rem}}.columns.is-7{--bulma-column-gap:1.75rem}@media screen and (max-width:768px){.columns.is-7-mobile{--bulma-column-gap:1.75rem}}@media print,screen and (min-width:769px){.columns.is-7-tablet{--bulma-column-gap:1.75rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-7-tablet-only{--bulma-column-gap:1.75rem}}@media screen and (max-width:1023px){.columns.is-7-touch{--bulma-column-gap:1.75rem}}@media screen and (min-width:1024px){.columns.is-7-desktop{--bulma-column-gap:1.75rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-7-desktop-only{--bulma-column-gap:1.75rem}}@media screen and (min-width:1216px){.columns.is-7-widescreen{--bulma-column-gap:1.75rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-7-widescreen-only{--bulma-column-gap:1.75rem}}@media screen and (min-width:1408px){.columns.is-7-fullhd{--bulma-column-gap:1.75rem}}.columns.is-8{--bulma-column-gap:2rem}@media screen and (max-width:768px){.columns.is-8-mobile{--bulma-column-gap:2rem}}@media print,screen and (min-width:769px){.columns.is-8-tablet{--bulma-column-gap:2rem}}@media screen and (min-width:769px) and (max-width:1023px){.columns.is-8-tablet-only{--bulma-column-gap:2rem}}@media screen and (max-width:1023px){.columns.is-8-touch{--bulma-column-gap:2rem}}@media screen and (min-width:1024px){.columns.is-8-desktop{--bulma-column-gap:2rem}}@media screen and (min-width:1024px) and (max-width:1215px){.columns.is-8-desktop-only{--bulma-column-gap:2rem}}@media screen and (min-width:1216px){.columns.is-8-widescreen{--bulma-column-gap:2rem}}@media screen and (min-width:1216px) and (max-width:1407px){.columns.is-8-widescreen-only{--bulma-column-gap:2rem}}@media screen and (min-width:1408px){.columns.is-8-fullhd{--bulma-column-gap:2rem}}.grid{display:block;max-width:100%;overflow:hidden;padding:3rem 0}@media (min-width:90rem){.grid{padding:3.75rem 0}}@media print{.grid.grid--hide-in-print-view{display:none}}.grid.grid--no-padding{padding:0}.grid.grid--extend-background-to-top{margin-top:-4rem;padding-top:4rem}@media (min-width:48rem){.grid.grid--extend-background-to-top{margin-top:-5.5rem;padding-top:5.5rem}}@media (min-width:64rem){.grid.grid--extend-background-to-top{margin-top:-10rem;padding-top:10rem}}.grid.grid--has-breadcrumbs+.grid.grid--has-staging-hero{margin-top:-5rem;padding-top:0;position:relative}@media (min-width:48rem){.grid.grid--has-breadcrumbs+.grid.grid--has-staging-hero{margin-top:-6rem}}@media (min-width:90rem){.grid.grid--has-breadcrumbs+.grid.grid--has-staging-hero{margin-top:-8rem}}.grid.grid--has-breadcrumbs+.grid.grid--has-staging-hero.grid--move-to-back{z-index:-1}.grid.grid--overflow-visible{overflow:hidden auto}.grid.grid--equal-columns .grid__column>.teaser:only-child{height:100%}@media (min-width:48rem){.grid .grid__columns.columns.is-variable{margin:0 -.75rem}.grid .grid__columns.columns.is-variable .grid__column.column{padding:0 .75rem}}.grid .grid__columns.grid__columns--multiple-rows{flex-wrap:wrap}.grid .grid__column:first-child>:first-child{margin-top:0}@media (min-width:48rem){.grid .grid__column>:first-child{margin-top:0}}.grid .grid__column:first-child>.contact-person:first-child{margin-top:0}.grid .grid__column:first-child>.contact-person:not(:first-child){margin-top:2rem}.grid .grid__column>.image:first-child{margin-top:0}.grid .grid__column+.grid__column>.headline:first-child{margin-top:3rem}@media (min-width:48rem){.grid .grid__column+.grid__column>.headline:first-child{margin-top:0}}.grid .grid__column:has(.headline.headline--1)+.grid__column>.image:first-child{margin-top:2rem}@media (min-width:48rem){.grid .grid__column:has(.headline.headline--1)+.grid__column>.image:first-child{margin-top:0}}.grid .grid__column:has(.headline.headline--1:only-child)+.grid__column>:first-child{margin-top:1rem}@media (min-width:48rem){.grid .grid__column:has(.headline.headline--1:only-child)+.grid__column>:first-child{margin-top:0}}.grid .grid__column:has(.headline.headline--2:only-child)+.grid__column>:first-child,.grid .grid__column:has(.headline.headline--3:only-child)+.grid__column>:first-child{margin-top:.75rem}@media (min-width:48rem){.grid .grid__column:has(.headline.headline--2:only-child)+.grid__column>:first-child,.grid .grid__column:has(.headline.headline--3:only-child)+.grid__column>:first-child{margin-top:0}}.grid .grid__column:has(.headline.headline--4:only-child)+.grid__column>:first-child{margin-top:.75rem}@media (min-width:48rem){.grid .grid__column:has(.headline.headline--4:only-child)+.grid__column>:first-child{margin-top:0}}.grid .grid__column:has(.headline.headline--5:only-child)+.grid__column>:first-child,.grid .grid__column:has(.headline.headline--6:only-child)+.grid__column>:first-child{margin-top:.5rem}@media (min-width:48rem){.grid .grid__column:has(.headline.headline--5:only-child)+.grid__column>:first-child,.grid .grid__column:has(.headline.headline--6:only-child)+.grid__column>:first-child{margin-top:0}}[dir=rtl] .grid>:first-child{margin-top:2rem}@media (min-width:48rem){[dir=rtl] .grid>:first-child{margin-top:0}}[dir=rtl] .grid .grid__column:has(.headline.headline--2:only-child)+.grid__column>:first-child,[dir=rtl] .grid .grid__column:has(.headline.headline--3:only-child)+.grid__column>:first-child{margin-top:2rem}@media (min-width:48rem){[dir=rtl] .grid .grid__column:has(.headline.headline--2:only-child)+.grid__column>:first-child,[dir=rtl] .grid .grid__column:has(.headline.headline--3:only-child)+.grid__column>:first-child{margin-top:0}}[dir=rtl] .grid>:last-child{margin-top:0}[dir=rtl] .grid .grid__columns.columns.disable-rtl{display:flex;flex-direction:column-reverse}@media (min-width:48rem){[dir=rtl] .grid .grid__columns.columns.disable-rtl{flex-direction:row-reverse}}.footer{--color-text--primary:var(--color-roche-grey-700);--color-interactive--primary-hover:var(--color-roche-blue-600);--footer-border-color:var(--color-dark-blue-900);--background-aware-gradient-bottom-right:linear-gradient(136.47deg,#fff 35.41%,#fff7f5 58%,#bde3ff 128.14%);background:var(--background-aware-gradient-bottom-right);border-top:.125rem solid var(--footer-border-color);color:var(--color-text-primary);display:block;margin-top:0;padding-bottom:3rem}.theme--story .footer{--footer-border-color:var(--color-extra-dark-orange);--background-aware-gradient-bottom-right:linear-gradient(319deg,#fac9b5 -68%,#fff 52%)}[dir=rtl].theme--story .footer{background:linear-gradient(49deg,#fac9b5 -68%,#fff 52%)}@media print{.footer{display:none}}@media (min-width:90rem){.footer{margin-top:0;padding-bottom:4rem}}[dir=rtl] .footer{--background-aware-gradient-bottom-left:linear-gradient(224.18deg,#fff 35.41%,#fff7f5 58%,#bde3ff 128.14%);background:var(--background-aware-gradient-bottom-left)}.footer .footer__first-row>.grid{border-bottom:1px solid var(--color-roche-grey-400);margin-top:4rem;padding:0 0 4rem}.footer .footer__columns-container .grid{padding:0}.footer .footer__second-row>.grid,.footer .footer__third-row>.grid{margin-top:4rem;padding:0}.footer .footer__quick-links{margin-top:-1.5rem}@media (min-width:48rem){.footer .footer__quick-links{margin-top:-2rem}}.footer .footer__column-title{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem;margin-top:2.5rem}@media (min-width:48rem){.footer .footer__column-title{font-size:var(--caption-font-size-medium-up);line-height:1.375rem;margin-top:0}}.footer .footer__stock-price{margin-top:2.5rem}@media (min-width:48rem){.footer .footer__stock-price{margin-top:0}}[dir=rtl] .footer .footer__copyright,[dir=rtl] .footer .footer__quick-links-nav,[dir=rtl] .footer .footer__social-links-nav{margin-top:0}.footer .footer__social-links{display:flex;flex-wrap:wrap;gap:0 1rem}.footer .footer__service-links{margin-top:3rem}@media (min-width:48rem){.footer .footer__service-links{display:inline-flex;flex-wrap:wrap;margin-top:0}}.footer .footer__copyright{color:var(--color-roche-grey-700);display:inline-block;font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem}@media (min-width:48rem){.footer .footer__copyright{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.footer .footer__legal-text{margin-top:1rem}@media (min-width:48rem){.footer .footer__legal-text{margin-top:0}}.footer.footer--with-extra-columns .footer__first-row>.grid .is-3{width:100%}@media (min-width:48rem){.footer.footer--with-extra-columns .footer__first-row>.grid .is-3{width:25%}}@media (min-width:64rem){.footer.footer--with-extra-columns .footer__first-row>.grid .is-3{width:25%}}.footer.footer--with-extra-columns .footer__first-row>.grid .is-8{width:100%}@media (min-width:48rem){.footer.footer--with-extra-columns .footer__first-row>.grid .is-8{width:75%}}@media (min-width:64rem){.footer.footer--with-extra-columns .footer__first-row>.grid .is-8{width:66.6666666667%}}.footer.footer--with-extra-columns .footer__first-row>.grid .is-3~.grid__column.is-1{padding:0;width:0}@media (min-width:64rem){.footer.footer--with-extra-columns .footer__first-row>.grid .is-3~.grid__column.is-1{padding:0 .75rem;width:8.3333333333%}}.footer.footer--with-extra-columns .footer__second-row>.grid .is-3-tablet,.footer.footer--with-extra-columns .footer__second-row>.grid .is-4-desktop,.footer.footer--with-extra-columns .footer__third-row>.grid .is-3-tablet,.footer.footer--with-extra-columns .footer__third-row>.grid .is-4-desktop{flex-wrap:wrap;gap:1rem;justify-content:flex-start}@media (min-width:64rem){.footer.footer--with-extra-columns .footer__second-row>.grid .is-3-tablet,.footer.footer--with-extra-columns .footer__second-row>.grid .is-4-desktop,.footer.footer--with-extra-columns .footer__third-row>.grid .is-3-tablet,.footer.footer--with-extra-columns .footer__third-row>.grid .is-4-desktop{flex-wrap:nowrap;gap:inherit}}.footer.footer--with-extra-columns .footer__second-row>.grid .is-3,.footer.footer--with-extra-columns .footer__second-row>.grid .is-4,.footer.footer--with-extra-columns .footer__second-row>.grid .is-8,.footer.footer--with-extra-columns .footer__third-row>.grid .is-3,.footer.footer--with-extra-columns .footer__third-row>.grid .is-4,.footer.footer--with-extra-columns .footer__third-row>.grid .is-8{min-width:100%}@media (min-width:64rem){.footer.footer--with-extra-columns .footer__second-row>.grid .is-3,.footer.footer--with-extra-columns .footer__second-row>.grid .is-4,.footer.footer--with-extra-columns .footer__second-row>.grid .is-8,.footer.footer--with-extra-columns .footer__third-row>.grid .is-3,.footer.footer--with-extra-columns .footer__third-row>.grid .is-4,.footer.footer--with-extra-columns .footer__third-row>.grid .is-8{min-width:unset}}.mobile-navigation{bottom:0;pointer-events:none;will-change:opacity,transform;z-index:350}.mobile-navigation,.mobile-navigation .mobile-navigation__overlay{display:block;left:0;position:fixed;right:0;top:0;transition:opacity .3s ease-out,transform .4s cubic-bezier(.16,1,.3,1)}.mobile-navigation .mobile-navigation__overlay{background-color:var(--color-white-100);border:none;height:100%;margin:0;max-width:100%;min-height:100%;opacity:0;overflow:auto;overflow-x:hidden;padding:0;touch-action:pan-y;transform:translateY(-25%);width:100%}@media (prefers-reduced-motion:reduce){.mobile-navigation .mobile-navigation__overlay{transition:none}}.mobile-navigation .mobile-navigation__overlay::backdrop{background-color:transparent}.mobile-navigation .mobile-navigation__overlay.mobile-navigation__overlay--open[open]{background-color:var(--color-white-100);opacity:1;pointer-events:auto;transform:translateY(0);transition:opacity .4s cubic-bezier(.65,0,.35,1),transform .3s cubic-bezier(0,0,0,1);width:100%}@media (prefers-reduced-motion:reduce){.mobile-navigation .mobile-navigation__overlay.mobile-navigation__overlay--open[open]{transition:none}}.mobile-navigation .mobile-navigation__overlay.mobile-navigation__overlay--closing{opacity:0;pointer-events:none;transform:translateY(-25%);transition:opacity .3s ease-out,transform .5s cubic-bezier(.23,0,.56,.99)}.mobile-navigation .mobile-navigation__header{align-items:center;border-bottom:1px solid var(--color-roche-grey-300);display:flex;flex-direction:row;justify-content:space-between;padding:1rem 1.25rem}.mobile-navigation .mobile-navigation__worldwide-link{fill:var(--color-roche-grey-700);align-items:center;color:var(--color-roche-grey-700);display:flex;font-family:roche-sans;font-size:var(--body-small-font-size-small-up);font-style:normal;font-weight:200;gap:.875rem;line-height:1.625rem}.mobile-navigation .mobile-navigation__worldwide-link:focus,.mobile-navigation .mobile-navigation__worldwide-link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:4px}.mobile-navigation .mobile-navigation__worldwide-link:focus:not(:focus-visible){outline:0}@media (min-width:48rem){.mobile-navigation .mobile-navigation__worldwide-link{font-size:var(--body-small-font-size-medium-up);line-height:1.8125rem}}.mobile-navigation .mobile-navigation__header-link{align-items:center;display:flex;font-family:roche-sans;font-size:var(--body-small-font-size-small-up);font-style:normal;font-weight:200;justify-content:flex-start;line-height:1.625rem}@media (min-width:48rem){.mobile-navigation .mobile-navigation__header-link{font-size:var(--body-small-font-size-medium-up);line-height:1.8125rem}}.mobile-navigation .mobile-navigation__close-button{fill:var(--color-roche-grey-700);color:var(--color-roche-grey-700)}.mobile-navigation .mobile-navigation__close-button:focus,.mobile-navigation .mobile-navigation__close-button:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.mobile-navigation .mobile-navigation__close-button:focus:not(:focus-visible){outline:0}.mobile-navigation .mobile-navigation__list{border-bottom:1px solid var(--color-roche-grey-300);color:var(--color-roche-grey-700);display:flex;flex-direction:column;font-size:1.5rem;font-weight:400;gap:1.5rem;line-height:1.9375rem;margin-inline:1.25rem;padding:1.5rem 0 1rem}@media (min-width:48rem){.mobile-navigation .mobile-navigation__list{font-size:1.5rem;line-height:2.125rem}}@media (min-width:90rem){.mobile-navigation .mobile-navigation__list{font-size:1.875rem;line-height:2.5625rem}}.mobile-navigation .mobile-navigation__list.mobile-navigation__list--primary{padding:2rem 0 1rem}.mobile-navigation .mobile-navigation__chevron{color:var(--color-roche-grey-700);transform:rotate(0);transition:transform .3s ease-out}@media (prefers-reduced-motion:reduce){.mobile-navigation .mobile-navigation__chevron{transition:none}}.mobile-navigation .mobile-navigation__list-item{display:flex;flex-direction:column}.mobile-navigation .mobile-navigation__list-item.mobile-navigation__list-item--open .mobile-navigation__chevron{transform:rotate(180deg)}.mobile-navigation .mobile-navigation__list-item.mobile-navigation__list-item--active{color:var(--color-roche-blue-600)}.mobile-navigation .mobile-navigation__list-item-button{align-items:center;display:flex;justify-content:space-between;line-height:inherit}.mobile-navigation .mobile-navigation__list-item-button:focus,.mobile-navigation .mobile-navigation__list-item-button:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.mobile-navigation .mobile-navigation__list-item-button:focus:not(:focus-visible){outline:0}.mobile-navigation .mobile-navigation__list-item-link{height:2.125rem}.mobile-navigation .mobile-navigation__list-item-link:focus,.mobile-navigation .mobile-navigation__list-item-link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.mobile-navigation .mobile-navigation__list-item-link:focus:not(:focus-visible){outline:0}.mobile-navigation .mobile-navigation__submenu-list{font-size:var(--body-font-size-small-up);overflow:hidden;transition:max-height .3s ease-out,opacity .3s ease-out}@media (prefers-reduced-motion:reduce){.mobile-navigation .mobile-navigation__submenu-list{transition:none}}.mobile-navigation .mobile-navigation__submenu-item{border-left:1px solid var(--color-roche-grey-300);font-size:var(--body-font-size-small-up);padding:.625rem .625rem .625rem 2rem}.mobile-navigation .mobile-navigation__submenu-item.mobile-navigation__submenu-item--active{border-color:var(--color-roche-blue-600);color:var(--color-roche-blue-600)}[dir=rtl] .mobile-navigation .mobile-navigation__submenu-item{border-left:none;border-right:1px solid var(--color-roche-grey-300);padding:.625rem 2rem .625rem 0}.mobile-navigation .mobile-navigation__submenu-item-title{color:var(--color-black-900);margin-top:1.5rem;padding-bottom:.625rem}.mobile-navigation .mobile-navigation__submenu-item-title.mobile-navigation__submenu-item-title--active,.mobile-navigation .mobile-navigation__submenu-item-title.mobile-navigation__submenu-item-title--active .mobile-navigation__submenu-item-arrow{color:var(--color-roche-blue-600)}.mobile-navigation .mobile-navigation__submenu-item-link{align-items:center;display:flex;font-size:var(--body-font-size-small-up);font-weight:400;gap:.5rem;line-height:1.8125rem;visibility:hidden}.mobile-navigation .mobile-navigation__submenu-item-link:focus,.mobile-navigation .mobile-navigation__submenu-item-link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.mobile-navigation .mobile-navigation__submenu-item-link:focus:not(:focus-visible){outline:0}@media (min-width:64rem){.mobile-navigation .mobile-navigation__submenu-item-link{font-size:var(--body-font-size-xlarge-up);line-height:2rem}}.mobile-navigation .mobile-navigation__list-item--open .mobile-navigation__submenu-item-link{visibility:visible}.mobile-navigation .mobile-navigation__meta-nav{display:flex;margin-inline:1.25rem;padding-block:1rem}.main-navigation{align-items:center;border-bottom:none;display:flex;flex-direction:row;font-size:1.125rem;font-weight:400;gap:2rem;line-height:1.6875rem;margin-top:3px;padding:0}@media (min-width:48rem){.main-navigation{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.main-navigation{font-size:1.25rem;line-height:1.875rem;margin-top:.125rem}}.main-navigation .main-navigation__submenu{background-color:var(--color-white-100);box-shadow:0 .25rem .75rem var(--color-black-900-a01);display:flex;flex-direction:column;gap:.5rem;left:-2rem;min-width:25rem;opacity:0;padding:1.5rem 1rem;pointer-events:none;position:absolute;top:2.5rem;transform:translateY(4rem);transition:opacity .15s ease-in,transform .15s ease-in;visibility:hidden;width:100%;z-index:1}@media (prefers-reduced-motion:reduce){.main-navigation .main-navigation__submenu{transition:none}}.main-navigation .main-navigation__submenu .main-navigation__submenu-item--active{color:var(--color-roche-blue-600)}.main-navigation .main-navigation__submenu:before{background-color:transparent;content:\"\";display:block;height:1rem;left:0;position:absolute;top:-1rem;width:50%}[dir=rtl] .main-navigation .main-navigation__submenu{left:auto;right:-2rem}[dir=rtl] .main-navigation .main-navigation__submenu:before{left:auto;right:0}.main-navigation .main-navigation__item{align-items:center;border:4px solid transparent;color:var(--color-roche-grey-700);display:flex;height:100%;justify-content:center;padding:0 0 .5rem;position:relative;transition:.1s ease-in}.main-navigation .main-navigation__item:focus,.main-navigation .main-navigation__item:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:4px}.main-navigation .main-navigation__item:focus:not(:focus-visible){outline:0}.main-navigation .main-navigation__item:first-child{margin-left:-4px}.main-navigation .main-navigation__item.main-navigation__item--active,.main-navigation .main-navigation__item.main-navigation__item--open,.main-navigation .main-navigation__item:hover{border-bottom-color:var(--color-roche-blue-600)}.main-navigation .main-navigation__item.main-navigation__item--open .main-navigation__submenu,.main-navigation .main-navigation__item:hover .main-navigation__submenu{display:flex;opacity:1;pointer-events:auto;transform:translateY(1rem);visibility:inherit}.main-navigation .main-navigation__item.main-navigation__item--separator{background-color:var(--color-grey-500);border:0;content:\"\";display:block;height:1.125rem;margin-bottom:.5rem;width:1px}.main-navigation .main-navigation__item-button{display:flex;justify-content:space-between;line-height:inherit;padding:0;width:100%}.main-navigation .main-navigation__item-button:focus,.main-navigation .main-navigation__item-button:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:4px}.main-navigation .main-navigation__item-button:focus:not(:focus-visible){outline:0}.main-navigation .navigation-item__link:focus,.main-navigation .navigation-item__link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:4px}.main-navigation .navigation-item__link:focus:not(:focus-visible){outline:0}.main-navigation .main-navigation__submenu-link{align-items:center;border-radius:6px;display:flex;font-size:1.125rem;font-weight:400;gap:.5rem;justify-content:flex-start;line-height:1.6875rem;padding:.5rem 1rem;transition:background-color .1s ease-in}.main-navigation .main-navigation__submenu-link:focus-visible,.main-navigation .main-navigation__submenu-link:hover{background-color:var(--color-roche-grey-100)}.main-navigation .main-navigation__submenu-link:focus,.main-navigation .main-navigation__submenu-link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:4px}.main-navigation .main-navigation__submenu-link:focus:not(:focus-visible){outline:0}@media (min-width:48rem){.main-navigation .main-navigation__submenu-link{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.main-navigation .main-navigation__submenu-link{font-size:1.25rem;line-height:1.875rem}}.main-navigation .main-navigation__submenu-link.main-navigation__submenu-link--title{color:var(--color-black-900);font-size:1.25rem;font-weight:400;line-height:1.625rem}@media (min-width:48rem){.main-navigation .main-navigation__submenu-link.main-navigation__submenu-link--title{font-size:1.25rem;line-height:1.875rem}}@media (min-width:90rem){.main-navigation .main-navigation__submenu-link.main-navigation__submenu-link--title{font-size:1.5rem;line-height:2.125rem}}.meta-navigation{display:flex;gap:1.5rem}.meta-navigation .meta-navigation__items{align-items:center;border-bottom:none;display:flex;flex-direction:row;font-size:1.125rem;font-weight:400;gap:1.5rem;line-height:1.6875rem;margin:0;padding:0}@media (min-width:48rem){.meta-navigation .meta-navigation__items{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.meta-navigation .meta-navigation__items{font-size:1.25rem;line-height:1.875rem}}.meta-navigation .meta-navigation__item-icon{color:var(--color-roche-grey-700)}.meta-navigation .meta-navigation__item{align-items:center;border:2px solid transparent;color:var(--color-roche-grey-700);display:flex;height:100%;justify-content:center;padding:0 0 .125rem;position:relative;transition:.1s ease-in}.meta-navigation .meta-navigation__item:focus,.meta-navigation .meta-navigation__item:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.meta-navigation .meta-navigation__item:focus:not(:focus-visible){outline:0}.meta-navigation .meta-navigation__item:focus-within,.meta-navigation .meta-navigation__item:hover{border-bottom-color:var(--color-roche-blue-600)}.meta-navigation .meta-navigation__item.meta-navigation__item--icon{margin-inline:.125rem}.meta-navigation .meta-navigation__item.meta-navigation__item--active{border-bottom-color:var(--color-roche-blue-600);color:var(--color-roche-blue-600)}.meta-navigation .meta-navigation__item.meta-navigation__item--active .meta-navigation__item-icon{color:var(--color-roche-blue-600)}.meta-navigation .meta-navigation__item-link:focus,.meta-navigation .meta-navigation__item-link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.meta-navigation .meta-navigation__item-link:focus:not(:focus-visible){outline:0}.meta-navigation .meta-navigation__separator{align-items:center;display:flex}.meta-navigation .meta-navigation__separator:after{background-color:var(--color-grey-500);border:0;content:\"\";height:1.125rem;width:1px}.language-switch-dropdown{box-sizing:border-box;margin-right:-.25rem;position:relative}@media (min-width:64rem){.language-switch-dropdown{margin-top:0}}.language-switch-dropdown .language-switch-dropdown__chevron-icon{fill:var(--color-roche-grey-700);color:var(--color-roche-grey-700);text-decoration:none}.language-switch-dropdown.language-switch-dropdown__open .language-switch-dropdown__list,.language-switch-dropdown:hover .language-switch-dropdown__list{opacity:1;pointer-events:auto;transform:translateY(16px)}.language-switch-dropdown.language-switch-dropdown__open .language-switch-dropdown__button,.language-switch-dropdown:hover .language-switch-dropdown__button{border-bottom-color:var(--color-roche-blue-600)}.language-switch-dropdown.language-switch-dropdown__open .language-switch-dropdown__button .language-switch-dropdown__chevron-icon,.language-switch-dropdown:hover .language-switch-dropdown__button .language-switch-dropdown__chevron-icon{transform:rotate(-180deg)}.language-switch-dropdown .language-switch-dropdown__button{align-items:center;border:2px solid transparent;color:var(--color-roche-grey-700);display:flex;flex-direction:row;font-size:1.125rem;font-weight:400;gap:.5rem;height:100%;justify-content:space-between;line-height:1.6875rem;padding:0 0 .125rem;transition:border-color .1s ease-in}@media (min-width:48rem){.language-switch-dropdown .language-switch-dropdown__button{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.language-switch-dropdown .language-switch-dropdown__button{font-size:1.25rem;line-height:1.875rem}}.language-switch-dropdown .language-switch-dropdown__button:focus,.language-switch-dropdown .language-switch-dropdown__button:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.language-switch-dropdown .language-switch-dropdown__button:focus:not(:focus-visible){outline:0}.language-switch-dropdown .language-switch-dropdown__button .language-switch-dropdown__chevron-icon{transition:opacity .15s ease-in,transform .15s ease-in}@media (prefers-reduced-motion:reduce){.language-switch-dropdown .language-switch-dropdown__button .language-switch-dropdown__chevron-icon{transition:none}}.language-switch-dropdown .language-switch-dropdown__button:focus-visible{border-bottom-color:var(--color-roche-blue-600)}.language-switch-dropdown .language-switch-dropdown__list{background-color:var(--color-white-100);box-shadow:0 .25rem .75rem #0000001a;font-size:1.125rem;font-weight:400;left:auto;line-height:1.6875rem;min-width:9.375rem;opacity:0;padding:1.5rem 1rem;pointer-events:none;position:absolute;right:0;top:40px;transform:translateY(64px);transition:opacity .15s ease-in,transform .15s ease-in}@media (min-width:48rem){.language-switch-dropdown .language-switch-dropdown__list{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.language-switch-dropdown .language-switch-dropdown__list{font-size:1.25rem;line-height:1.875rem}}@media (prefers-reduced-motion:reduce){.language-switch-dropdown .language-switch-dropdown__list{transition:none}}.language-switch-dropdown .language-switch-dropdown__list:before{background-color:transparent;content:\"\";display:block;height:16px;position:absolute;right:0;top:-16px;width:50%}.language-switch-dropdown .language-switch-dropdown__list-item{margin:.5rem 0 0}.language-switch-dropdown .language-switch-dropdown__link{align-items:center;border-radius:6px;color:var(--color-roche-grey-700);display:flex;justify-content:flex-start;padding:.5rem 1rem;transition:background-color .1s ease-in}.language-switch-dropdown .language-switch-dropdown__link:focus,.language-switch-dropdown .language-switch-dropdown__link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.language-switch-dropdown .language-switch-dropdown__link:focus:not(:focus-visible){outline:0}.language-switch-dropdown .language-switch-dropdown__link:focus,.language-switch-dropdown .language-switch-dropdown__link:hover{background-color:var(--color-roche-grey-100)}.language-switch-dropdown .language-switch-dropdown__link.language-switch-dropdown__link--selected{background-color:transparent;color:var(--color-roche-blue-600)}[dir=rtl] .language-switch-dropdown .language-switch-dropdown__button{flex-direction:row-reverse}.language-switch-inline{box-sizing:border-box;display:block;max-width:100%}.language-switch-inline .language-switch-inline__list,.language-switch-inline .language-switch-inline__list-item{list-style:none;padding:0}.language-switch-inline .language-switch-inline__list{display:flex;flex-direction:row;gap:1.5rem}.language-switch-inline .language-switch-inline__list-item{display:inline}.language-switch-inline .language-switch-inline__link{fill:var(--color-roche-grey-700);color:var(--color-roche-grey-700);font-size:var(--body-font-size-small-up);font-weight:400;line-height:1.8125rem;text-decoration:none}.language-switch-inline .language-switch-inline__link.language-switch-inline__link--selected{color:var(--color-roche-blue-600)}.language-switch-inline .language-switch-inline__link:focus,.language-switch-inline .language-switch-inline__link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.language-switch-inline .language-switch-inline__link:focus:not(:focus-visible){outline:0}@media (min-width:64rem){.language-switch-inline .language-switch-inline__link{font-size:var(--body-font-size-xlarge-up);line-height:2rem}}[dir=rtl] .language-switch-inline .language-switch-inline__list{margin:0 0 0 1rem}[dir=rtl] .language-switch-inline .language-switch-inline__list-item{display:inline;margin:0 0 0 1.5rem}.header{background-color:var(--color-white-100);position:sticky;top:0;transition-duration:.25s;transition-property:transform,background-color;transition-timing-function:cubic-bezier(.23,0,.56,.99);z-index:300}@media print{.header{position:relative}}.header .header__skip-link{background-color:var(--color-white-100);color:var(--color-roche-grey-700);display:block;font-size:1.125rem;font-weight:400;height:auto;inset-inline-start:-2000px;line-height:1.6875rem;position:absolute;top:-2000px;width:auto}.header .header__skip-link:focus,.header .header__skip-link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.header .header__skip-link:focus:not(:focus-visible){outline:0}@media (min-width:48rem){.header .header__skip-link{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.header .header__skip-link{font-size:1.25rem;line-height:1.875rem}}.header .header__skip-link:focus{inset-inline-start:.5rem;padding:.5rem;top:.5rem;z-index:1}.header .header__first-row{display:flex;justify-content:space-between;margin:0 auto;max-width:calc(100% - 40px);padding:1rem 0}@media (min-width:48rem){.header .header__first-row{max-width:calc(100% - 64px);padding:1.5rem 0}}@media (min-width:64rem){.header .header__first-row{max-width:calc(100% - 128px);padding:2.5rem 0 0}}@media (min-width:90rem){.header .header__first-row{max-width:calc(100% - 192px)}}@media (min-width:104.5rem){.header .header__first-row{max-width:1552px}}.header .header__second-row{display:none}@media (min-width:64rem){.header .header__second-row{display:flex;margin:2rem auto 0;max-width:calc(100% - 128px)}}@media (min-width:90rem){.header .header__second-row{max-width:calc(100% - 192px)}}@media (min-width:104.5rem){.header .header__second-row{max-width:1552px}}.header .header__logo{fill:var(--color-roche-blue-600);color:var(--color-roche-blue-600);display:none}@media (min-width:48rem){.header .header__logo{display:block}}.header .header__logo-mobile{fill:var(--color-roche-blue-600);color:var(--color-roche-blue-600)}@media (min-width:48rem){.header .header__logo-mobile{display:none}}.header .header__logo-link{align-items:center;display:flex;gap:1rem}.header .header__logo-link:focus,.header .header__logo-link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:4px}.header .header__logo-link:focus:not(:focus-visible){outline:0}.header .header__actions{align-items:center;display:flex;gap:1.5rem}@media (min-width:64rem){.header .header__actions{display:none}}.header .header__search:focus,.header .header__search:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.header .header__search:focus:not(:focus-visible){outline:0}@media (min-width:64rem){.header .header__search{display:none}}.header .header__search.header__search--active{fill:var(--color-roche-blue-600)}.header .header__burger:focus,.header .header__burger:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.header .header__burger:focus:not(:focus-visible){outline:0}@media (min-width:64rem){.header .header__burger{display:none}}.header .header__burger-icon,.header .header__search-icon{color:var(--color-text-primary)}@media (min-width:64rem){.header .header__mobile-nav{display:none}}.header .header__secondary-nav{display:none}@media (min-width:64rem){.header .header__secondary-nav{display:flex}}.header.header--scrolled{box-shadow:inset 0 -.0625rem 0 var(--color-roche-grey-300)}@media print{.header.header--scrolled{box-shadow:none}}.header.header--transparent{background-color:transparent}.header.header--hidden{transform:translateY(-100%);transition-duration:.3s}.hero-teaser{align-items:center;display:flex;flex-direction:column;gap:1rem}@media (min-width:48rem){.hero-teaser{flex-direction:row;gap:0;justify-content:space-between}}.hero-teaser .hero-teaser__info-container{display:flex;flex-direction:column;gap:1.5rem;width:100%}@media (min-width:48rem){.hero-teaser .hero-teaser__info-container{gap:2rem;margin-top:1rem;width:calc(50% - 12px)}}@media (min-width:90rem){.hero-teaser .hero-teaser__info-container{gap:4rem;width:41.6666666667%}}.hero-teaser .hero-teaser__text-container{display:flex;flex-direction:column;gap:1.125rem}@media (min-width:64rem){.hero-teaser .hero-teaser__text-container{gap:1.25rem}}.hero-teaser .hero-teaser__title-container{display:flex;flex-direction:column;gap:.25rem}.hero-teaser .hero-teaser__title{font-size:1.875rem;line-height:2.25rem}@media (min-width:48rem){.hero-teaser .hero-teaser__title{font-size:2.5rem;line-height:3rem}}@media (min-width:90rem){.hero-teaser .hero-teaser__title{font-size:3rem;line-height:3.625rem}}.hero-teaser .hero-teaser__overline{color:var(--color-roche-grey-600);font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.hero-teaser .hero-teaser__overline{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.hero-teaser .hero-teaser__overline{font-size:1.25rem;line-height:1.875rem}}.hero-teaser .hero-teaser__button-container{display:flex;flex-direction:column;gap:.5rem}@media (min-width:48rem){.hero-teaser .hero-teaser__button-container{flex-direction:row;gap:1rem}}.hero-teaser .hero-teaser__image-container{width:100%}@media (min-width:48rem){.hero-teaser .hero-teaser__image-container{width:calc(50% - 12px)}}.hero-teaser .hero-teaser__image-container .video-player,.hero-teaser .hero-teaser__image-container>.image{margin:0}.hero-teaser.hero-teaser--unpublished{background:#ff0000b3;border:1px dashed maroon}.image{background-repeat:no-repeat;background-size:cover;margin-top:3rem;overflow:hidden;position:relative;width:100%}.image .image__img{height:100%;object-fit:cover;width:100%}@media print{.image .image__img{height:31.25rem;object-fit:contain;opacity:1;width:18.75rem}}.image .image__container{line-height:0}.image.image--bleed,.image.image--fullscreen{margin-left:calc(50% - 50vw);width:100vw}@media (min-width:90rem){.image.image--bleed{margin-left:calc(-129.33333px - 1.66667%);width:calc(1552px + 20%)}}[dir=rtl] .image.image--bleed{margin-left:0;margin-right:calc(50% - 50vw)}@media (min-width:90rem){[dir=rtl] .image.image--bleed{margin-left:0;margin-right:calc(-129.33333px - 1.66667%)}}.image.image--original{background-size:contain;overflow:auto}.image.image--original .image__img{display:block;height:auto}.image.image--top{background-position:top}.image.image--center{background-position:50%}.image.image--bottom{background-position:bottom}.image.image--full-height,.image.image--full-height .image__container,.image.image--full-height .image__img{height:100%}.image .image__description{color:var(--color-roche-grey-100);font-family:roche-sans;font-size:.875rem;font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem;margin-top:.75rem;max-width:47rem}@media (min-width:48rem){.image .image__description{font-size:1rem;line-height:1.3125rem}}@media (min-width:64rem){.image .image__description{max-width:55rem}}@media (min-width:90rem){.image .image__description{max-width:60rem}}.image .image__caption{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--body-small-font-size-small-up);font-style:normal;font-weight:200;line-height:1.625rem}@media (min-width:48rem){.image .image__caption{font-size:var(--body-small-font-size-medium-up);line-height:1.8125rem}}.image .image__copyright{color:var(--color-grey-500);font-family:roche-sans;font-size:.875rem;font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem;margin-top:.25rem}@media (min-width:48rem){.image .image__copyright{font-size:1rem;line-height:1.3125rem}}.image .image__ratio-hd{aspect-ratio:16/9}.image .image__ratio-wide{aspect-ratio:2.39/1}.image .image__ratio-square{aspect-ratio:1/1}.image .image__ratio-vertical{aspect-ratio:4/5}.image .image__ratio-normal{aspect-ratio:4/3}.image .image__ratio-sixtofive{aspect-ratio:6/5}@media (min-width:90rem){.image{margin-top:4.5rem}}.video-player{margin-top:3rem;width:100%}@media (min-width:90rem){.video-player{margin-top:4.5rem}}.video-player .video-player__service--aws-video-js,.video-player .video-player__service--brightcove,.video-player .video-player__service--youtube{position:relative}.video-player .video-player__content--absolute{display:none;height:100%;left:0;position:absolute;top:0;width:100%}.video-player .video-player__content--absolute.video-player__content--absolute-active{align-items:center;display:flex;justify-content:center}.video-player .video-player__content--relative{aspect-ratio:1.7777777778;opacity:0;position:relative;width:100%}.video-player .video-player__content--relative.video-player__content--relative--fullscreen{aspect-ratio:2.39}.video-player .video-player__content--relative.video-player__content--relative-ready{opacity:1;transition:1s;transition-delay:1s}.video-player .video-player__overlay{align-items:center;display:flex;height:100%;justify-content:center;left:0;position:absolute;top:0;width:100%;z-index:250}.video-player .video-player__overlay .video-player__overlay-icon{background:#0003;border-radius:50%;box-shadow:0 0 5px #0000004d;color:var(--color-white-100)}.video-player .video-player__overlay .video-player__overlay-icon:hover{border-color:var(--color-white-300);color:var(--color-white-300);cursor:pointer}.video-player .video-player__overlay .video-player__overlay-icon:focus,.video-player .video-player__overlay .video-player__overlay-icon:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.video-player .video-player__overlay .video-player__overlay-icon:focus:not(:focus-visible){outline:0}.video-player .video-player__overlay.video-player__overlay-videoloop .video-player__overlay-icon{-webkit-tap-highlight-color:transparent;opacity:0;transition:opacity .3s ease-in-out}.video-player .video-player__overlay.video-player__overlay-videoloop .video-player__overlay-icon:focus{opacity:1}.video-player .video-player__overlay.video-player__overlay-videoloop:active .video-player__overlay-icon,.video-player .video-player__overlay.video-player__overlay-videoloop:hover .video-player__overlay-icon{opacity:1}.video-player .video-player__overlay.video-player__overlay--hidden{display:none}.video-player .video-player__close-button{color:var(--color-white-100);margin-right:calc(50% - 50vw);position:absolute;right:1.5rem;top:1.5rem}.video-player .video-player__close-button:hover{color:var(--color-shadow-blue-100);cursor:pointer}.video-player .video-player__close-button:focus,.video-player .video-player__close-button:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.video-player .video-player__close-button:focus:not(:focus-visible){outline:0}.video-player.video-player--fullscreen{margin-left:calc(50% - 50vw);width:100vw}.video-player .video-player__image{opacity:1}.video-player .video-player__image .image{margin:0}.video-player .video-player__image.video-player__image--hidden{opacity:0}.video-player .video-player__image.video-player__image--fullscreen{margin-left:calc(50% - 50vw);width:100vw}.video-player .video-player__image.video-player__image--fullscreen.video-player__image--fullscreen-playing{filter:brightness(30%)}.video-player .video-player__image.video-player__image--error{background-color:var(--color-black-900)}.video-player .video-player__image.video-player__image--error .image{opacity:0}.video-player__placeholder{aspect-ratio:1.7777777778;background-color:transparent;opacity:0;width:100%}.video-player__placeholder.video-player__placeholder--fullscreen{aspect-ratio:2.39}.video-player__placeholder.video-player__placeholder--hidden{display:none}.video-description{color:var(--color-roche-grey-100);font-family:roche-sans;font-size:.875rem;font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem;margin-top:.75rem;max-width:47rem}@media (min-width:48rem){.video-description{font-size:1rem;line-height:1.3125rem}}@media (min-width:64rem){.video-description{max-width:55rem}}@media (min-width:90rem){.video-description{max-width:60rem}}.video-description .video-description__caption{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--body-small-font-size-small-up);font-style:normal;font-weight:200;line-height:1.625rem}@media (min-width:48rem){.video-description .video-description__caption{font-size:var(--body-small-font-size-medium-up);line-height:1.8125rem}}.video-description .video-description__copyright{color:var(--color-grey-500);font-family:roche-sans;font-size:.875rem;font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem;margin-top:.25rem}@media (min-width:48rem){.video-description .video-description__copyright{font-size:1rem;line-height:1.3125rem}}.vjs-svg-icon{fill:currentColor;background-position:50%;background-repeat:no-repeat;display:inline-block;height:1.8em;width:1.8em}.vjs-svg-icon:before{content:none!important}.vjs-control:focus .vjs-svg-icon,.vjs-svg-icon:hover{filter:drop-shadow(0 0 .25em #fff)}.video-js .vjs-big-play-button .vjs-icon-placeholder:before,.video-js .vjs-modal-dialog,.vjs-button>.vjs-icon-placeholder:before,.vjs-modal-dialog .vjs-modal-dialog-content{height:100%;left:0;position:absolute;top:0;width:100%}.video-js .vjs-big-play-button .vjs-icon-placeholder:before,.vjs-button>.vjs-icon-placeholder:before{text-align:center}@font-face{font-family:VideoJS;font-style:normal;font-weight:400;src:url(data:application/font-woff;charset=utf-8;base64,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) format(\"woff\")}.video-js .vjs-big-play-button .vjs-icon-placeholder:before,.video-js .vjs-play-control .vjs-icon-placeholder,.vjs-icon-play{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-big-play-button .vjs-icon-placeholder:before,.video-js .vjs-play-control .vjs-icon-placeholder:before,.vjs-icon-play:before{content:\"\uf101\"}.vjs-icon-play-circle{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-play-circle:before{content:\"\uf102\"}.video-js .vjs-play-control.vjs-playing .vjs-icon-placeholder,.vjs-icon-pause{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-play-control.vjs-playing .vjs-icon-placeholder:before,.vjs-icon-pause:before{content:\"\uf103\"}.video-js .vjs-mute-control.vjs-vol-0 .vjs-icon-placeholder,.vjs-icon-volume-mute{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-mute-control.vjs-vol-0 .vjs-icon-placeholder:before,.vjs-icon-volume-mute:before{content:\"\uf104\"}.video-js .vjs-mute-control.vjs-vol-1 .vjs-icon-placeholder,.vjs-icon-volume-low{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-mute-control.vjs-vol-1 .vjs-icon-placeholder:before,.vjs-icon-volume-low:before{content:\"\uf105\"}.video-js .vjs-mute-control.vjs-vol-2 .vjs-icon-placeholder,.vjs-icon-volume-mid{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-mute-control.vjs-vol-2 .vjs-icon-placeholder:before,.vjs-icon-volume-mid:before{content:\"\uf106\"}.video-js .vjs-mute-control .vjs-icon-placeholder,.vjs-icon-volume-high{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-mute-control .vjs-icon-placeholder:before,.vjs-icon-volume-high:before{content:\"\uf107\"}.video-js .vjs-fullscreen-control .vjs-icon-placeholder,.vjs-icon-fullscreen-enter{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-fullscreen-control .vjs-icon-placeholder:before,.vjs-icon-fullscreen-enter:before{content:\"\uf108\"}.video-js.vjs-fullscreen .vjs-fullscreen-control .vjs-icon-placeholder,.vjs-icon-fullscreen-exit{font-family:VideoJS;font-style:normal;font-weight:400}.video-js.vjs-fullscreen .vjs-fullscreen-control .vjs-icon-placeholder:before,.vjs-icon-fullscreen-exit:before{content:\"\uf109\"}.vjs-icon-spinner{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-spinner:before{content:\"\uf10a\"}.video-js .vjs-subs-caps-button .vjs-icon-placeholder,.video-js .vjs-subtitles-button .vjs-icon-placeholder,.video-js.video-js:lang(en-AU) .vjs-subs-caps-button .vjs-icon-placeholder,.video-js.video-js:lang(en-GB) .vjs-subs-caps-button .vjs-icon-placeholder,.video-js.video-js:lang(en-IE) .vjs-subs-caps-button .vjs-icon-placeholder,.video-js.video-js:lang(en-NZ) .vjs-subs-caps-button .vjs-icon-placeholder,.vjs-icon-subtitles{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-subs-caps-button .vjs-icon-placeholder:before,.video-js .vjs-subtitles-button .vjs-icon-placeholder:before,.video-js.video-js:lang(en-AU) .vjs-subs-caps-button .vjs-icon-placeholder:before,.video-js.video-js:lang(en-GB) .vjs-subs-caps-button .vjs-icon-placeholder:before,.video-js.video-js:lang(en-IE) .vjs-subs-caps-button .vjs-icon-placeholder:before,.video-js.video-js:lang(en-NZ) .vjs-subs-caps-button .vjs-icon-placeholder:before,.vjs-icon-subtitles:before{content:\"\uf10b\"}.video-js .vjs-captions-button .vjs-icon-placeholder,.video-js:lang(en) .vjs-subs-caps-button .vjs-icon-placeholder,.video-js:lang(fr-CA) .vjs-subs-caps-button .vjs-icon-placeholder,.vjs-icon-captions{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-captions-button .vjs-icon-placeholder:before,.video-js:lang(en) .vjs-subs-caps-button .vjs-icon-placeholder:before,.video-js:lang(fr-CA) .vjs-subs-caps-button .vjs-icon-placeholder:before,.vjs-icon-captions:before{content:\"\uf10c\"}.vjs-icon-hd{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-hd:before{content:\"\uf10d\"}.video-js .vjs-chapters-button .vjs-icon-placeholder,.vjs-icon-chapters{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-chapters-button .vjs-icon-placeholder:before,.vjs-icon-chapters:before{content:\"\uf10e\"}.vjs-icon-downloading{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-downloading:before{content:\"\uf10f\"}.vjs-icon-file-download{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-file-download:before{content:\"\uf110\"}.vjs-icon-file-download-done{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-file-download-done:before{content:\"\uf111\"}.vjs-icon-file-download-off{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-file-download-off:before{content:\"\uf112\"}.vjs-icon-share{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-share:before{content:\"\uf113\"}.vjs-icon-cog{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-cog:before{content:\"\uf114\"}.vjs-icon-square{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-square:before{content:\"\uf115\"}.video-js .vjs-play-progress,.video-js .vjs-volume-level,.vjs-icon-circle,.vjs-seek-to-live-control .vjs-icon-placeholder{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-play-progress:before,.video-js .vjs-volume-level:before,.vjs-icon-circle:before,.vjs-seek-to-live-control .vjs-icon-placeholder:before{content:\"\uf116\"}.vjs-icon-circle-outline{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-circle-outline:before{content:\"\uf117\"}.vjs-icon-circle-inner-circle{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-circle-inner-circle:before{content:\"\uf118\"}.video-js .vjs-control.vjs-close-button .vjs-icon-placeholder,.vjs-icon-cancel{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-control.vjs-close-button .vjs-icon-placeholder:before,.vjs-icon-cancel:before{content:\"\uf119\"}.vjs-icon-repeat{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-repeat:before{content:\"\uf11a\"}.video-js .vjs-play-control.vjs-ended .vjs-icon-placeholder,.vjs-icon-replay{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-play-control.vjs-ended .vjs-icon-placeholder:before,.vjs-icon-replay:before{content:\"\uf11b\"}.video-js .vjs-skip-backward-5 .vjs-icon-placeholder,.vjs-icon-replay-5{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-skip-backward-5 .vjs-icon-placeholder:before,.vjs-icon-replay-5:before{content:\"\uf11c\"}.video-js .vjs-skip-backward-10 .vjs-icon-placeholder,.vjs-icon-replay-10{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-skip-backward-10 .vjs-icon-placeholder:before,.vjs-icon-replay-10:before{content:\"\uf11d\"}.video-js .vjs-skip-backward-30 .vjs-icon-placeholder,.vjs-icon-replay-30{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-skip-backward-30 .vjs-icon-placeholder:before,.vjs-icon-replay-30:before{content:\"\uf11e\"}.video-js .vjs-skip-forward-5 .vjs-icon-placeholder,.vjs-icon-forward-5{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-skip-forward-5 .vjs-icon-placeholder:before,.vjs-icon-forward-5:before{content:\"\uf11f\"}.video-js .vjs-skip-forward-10 .vjs-icon-placeholder,.vjs-icon-forward-10{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-skip-forward-10 .vjs-icon-placeholder:before,.vjs-icon-forward-10:before{content:\"\uf120\"}.video-js .vjs-skip-forward-30 .vjs-icon-placeholder,.vjs-icon-forward-30{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-skip-forward-30 .vjs-icon-placeholder:before,.vjs-icon-forward-30:before{content:\"\uf121\"}.video-js .vjs-audio-button .vjs-icon-placeholder,.vjs-icon-audio{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-audio-button .vjs-icon-placeholder:before,.vjs-icon-audio:before{content:\"\uf122\"}.vjs-icon-next-item{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-next-item:before{content:\"\uf123\"}.vjs-icon-previous-item{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-previous-item:before{content:\"\uf124\"}.vjs-icon-shuffle{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-shuffle:before{content:\"\uf125\"}.vjs-icon-cast{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-cast:before{content:\"\uf126\"}.video-js .vjs-picture-in-picture-control .vjs-icon-placeholder,.vjs-icon-picture-in-picture-enter{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-picture-in-picture-control .vjs-icon-placeholder:before,.vjs-icon-picture-in-picture-enter:before{content:\"\uf127\"}.video-js.vjs-picture-in-picture .vjs-picture-in-picture-control .vjs-icon-placeholder,.vjs-icon-picture-in-picture-exit{font-family:VideoJS;font-style:normal;font-weight:400}.video-js.vjs-picture-in-picture .vjs-picture-in-picture-control .vjs-icon-placeholder:before,.vjs-icon-picture-in-picture-exit:before{content:\"\uf128\"}.vjs-icon-facebook{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-facebook:before{content:\"\uf129\"}.vjs-icon-linkedin{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-linkedin:before{content:\"\uf12a\"}.vjs-icon-twitter{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-twitter:before{content:\"\uf12b\"}.vjs-icon-tumblr{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-tumblr:before{content:\"\uf12c\"}.vjs-icon-pinterest{font-family:VideoJS;font-style:normal;font-weight:400}.vjs-icon-pinterest:before{content:\"\uf12d\"}.video-js .vjs-descriptions-button .vjs-icon-placeholder,.vjs-icon-audio-description{font-family:VideoJS;font-style:normal;font-weight:400}.video-js .vjs-descriptions-button .vjs-icon-placeholder:before,.vjs-icon-audio-description:before{content:\"\uf12e\"}.video-js{background-color:#000;box-sizing:border-box;color:#fff;display:inline-block;font-family:Arial,Helvetica,sans-serif;font-size:10px;font-style:normal;font-weight:400;line-height:1;padding:0;position:relative;vertical-align:top;word-break:normal}.video-js:-moz-full-screen{position:absolute}.video-js:-webkit-full-screen{height:100%!important;width:100%!important}.video-js[tabindex=\"-1\"]{outline:0}.video-js *,.video-js :after,.video-js :before{box-sizing:inherit}.video-js ul{font-family:inherit;font-size:inherit;line-height:inherit;list-style-position:outside;margin:0}.video-js.vjs-1-1,.video-js.vjs-16-9,.video-js.vjs-4-3,.video-js.vjs-9-16,.video-js.vjs-fluid{max-width:100%;width:100%}.video-js.vjs-1-1:not(.vjs-audio-only-mode),.video-js.vjs-16-9:not(.vjs-audio-only-mode),.video-js.vjs-4-3:not(.vjs-audio-only-mode),.video-js.vjs-9-16:not(.vjs-audio-only-mode),.video-js.vjs-fluid:not(.vjs-audio-only-mode){height:0}.video-js.vjs-16-9:not(.vjs-audio-only-mode){padding-top:56.25%}.video-js.vjs-4-3:not(.vjs-audio-only-mode){padding-top:75%}.video-js.vjs-9-16:not(.vjs-audio-only-mode){padding-top:177.7777777778%}.video-js.vjs-1-1:not(.vjs-audio-only-mode){padding-top:100%}.video-js.vjs-fill:not(.vjs-audio-only-mode){height:100%;width:100%}.video-js .vjs-tech{height:100%;left:0;position:absolute;top:0;width:100%}.video-js.vjs-audio-only-mode .vjs-tech{display:none}body.vjs-full-window,body.vjs-pip-window{height:100%;margin:0;padding:0}.vjs-full-window .video-js.vjs-fullscreen,body.vjs-pip-window .video-js{bottom:0;left:0;overflow:hidden;position:fixed;right:0;top:0;z-index:1000}.video-js.vjs-fullscreen:not(.vjs-ios-native-fs),body.vjs-pip-window .video-js{display:block;height:100%!important;padding-top:0!important;width:100%!important}.video-js.vjs-fullscreen.vjs-user-inactive{cursor:none}.vjs-pip-container .vjs-pip-text{background-color:#000000b3;bottom:10%;font-size:2em;padding:.5em;position:absolute;text-align:center;width:100%}.vjs-layout-small.vjs-pip-container .vjs-pip-text,.vjs-layout-tiny.vjs-pip-container .vjs-pip-text,.vjs-layout-x-small.vjs-pip-container .vjs-pip-text{bottom:0;font-size:1.4em}.vjs-hidden{display:none!important}.vjs-disabled{cursor:default;opacity:.5}.video-js .vjs-offscreen{height:1px;left:-9999px;position:absolute;top:0;width:1px}.vjs-lock-showing{display:block!important;opacity:1!important;visibility:visible!important}.vjs-no-js{background-color:#000;color:#fff;font-family:Arial,Helvetica,sans-serif;font-size:18px;height:150px;margin:0 auto;padding:20px;text-align:center;width:300px}.vjs-no-js a,.vjs-no-js a:visited{color:#66a8cc}.video-js .vjs-big-play-button{background-color:#2b333f;background-color:#2b333fb3;border:.06666em solid #fff;border-radius:.3em;cursor:pointer;display:block;font-size:3em;height:1.63332em;left:50%;line-height:1.5em;margin-left:-1.5em;margin-top:-.81666em;opacity:1;padding:0;position:absolute;top:50%;transition:all .4s;width:3em}.vjs-big-play-button .vjs-svg-icon{height:1em;left:50%;line-height:1;position:absolute;top:50%;transform:translate(-50%,-50%);width:1em}.video-js .vjs-big-play-button:focus,.video-js:hover .vjs-big-play-button{background-color:#73859f;background-color:#73859f80;border-color:#fff;transition:all 0s}.vjs-controls-disabled .vjs-big-play-button,.vjs-error .vjs-big-play-button,.vjs-has-started .vjs-big-play-button,.vjs-using-native-controls .vjs-big-play-button{display:none}.vjs-has-started.vjs-paused.vjs-show-big-play-button-on-pause:not(.vjs-seeking,.vjs-scrubbing,.vjs-error) .vjs-big-play-button{display:block}.video-js button{-webkit-appearance:none;appearance:none;background:0 0;border:none;color:inherit;display:inline-block;font-size:inherit;line-height:inherit;text-decoration:none;text-transform:none;transition:none}.video-js.vjs-spatial-navigation-enabled .vjs-button:focus{box-shadow:none;outline:.0625em solid #fff}.vjs-control .vjs-button{height:100%;width:100%}.video-js .vjs-control.vjs-close-button{cursor:pointer;height:3em;position:absolute;right:0;top:.5em;z-index:2}.video-js .vjs-modal-dialog{background:#000c;background:linear-gradient(180deg,#000c,#fff0);overflow:auto}.video-js .vjs-modal-dialog>*{box-sizing:border-box}.vjs-modal-dialog .vjs-modal-dialog-content{font-size:1.2em;line-height:1.5;padding:20px 24px;z-index:1}.vjs-menu-button{cursor:pointer}.vjs-menu-button.vjs-disabled{cursor:default}.vjs-workinghover .vjs-menu-button.vjs-disabled:hover .vjs-menu{display:none}.vjs-menu .vjs-menu-content{display:block;font-family:Arial,Helvetica,sans-serif;margin:0;overflow:auto;padding:0}.vjs-menu .vjs-menu-content>*{box-sizing:border-box}.vjs-scrubbing .vjs-control.vjs-menu-button:hover .vjs-menu{display:none}.vjs-menu li{display:flex;font-size:1.2em;justify-content:center;line-height:1.4em;list-style:none;margin:0;padding:.2em 0;text-align:center;text-transform:lowercase}.js-focus-visible .vjs-menu li.vjs-menu-item:hover,.vjs-menu li.vjs-menu-item:focus,.vjs-menu li.vjs-menu-item:hover{background-color:#73859f;background-color:#73859f80}.js-focus-visible .vjs-menu li.vjs-selected:hover,.vjs-menu li.vjs-selected,.vjs-menu li.vjs-selected:focus,.vjs-menu li.vjs-selected:hover{background-color:#fff;color:#2b333f}.js-focus-visible .vjs-menu li.vjs-selected:hover .vjs-svg-icon,.vjs-menu li.vjs-selected .vjs-svg-icon,.vjs-menu li.vjs-selected:focus .vjs-svg-icon,.vjs-menu li.vjs-selected:hover .vjs-svg-icon{fill:#000}.js-focus-visible .vjs-menu :not(.vjs-selected):focus:not(.focus-visible),.video-js .vjs-menu :not(.vjs-selected):focus:not(:focus-visible){background:0 0}.vjs-menu li.vjs-menu-title{cursor:default;font-size:1em;font-weight:700;line-height:2em;margin:0 0 .3em;padding:0;text-align:center;text-transform:uppercase}.vjs-menu-button-popup .vjs-menu{border-top-color:#2b333fb3;bottom:0;display:none;height:0;left:-3em;margin-bottom:1.5em;position:absolute;width:10em}.vjs-pip-window .vjs-menu-button-popup .vjs-menu{left:unset;right:1em}.vjs-menu-button-popup .vjs-menu .vjs-menu-content{background-color:#2b333f;background-color:#2b333fb3;bottom:1.5em;max-height:15em;position:absolute;width:100%}.vjs-layout-tiny .vjs-menu-button-popup .vjs-menu .vjs-menu-content,.vjs-layout-x-small .vjs-menu-button-popup .vjs-menu .vjs-menu-content{max-height:5em}.vjs-layout-small .vjs-menu-button-popup .vjs-menu .vjs-menu-content{max-height:10em}.vjs-layout-medium .vjs-menu-button-popup .vjs-menu .vjs-menu-content{max-height:14em}.vjs-layout-huge .vjs-menu-button-popup .vjs-menu .vjs-menu-content,.vjs-layout-large .vjs-menu-button-popup .vjs-menu .vjs-menu-content,.vjs-layout-x-large .vjs-menu-button-popup .vjs-menu .vjs-menu-content{max-height:25em}.vjs-menu-button-popup .vjs-menu.vjs-lock-showing,.vjs-workinghover .vjs-menu-button-popup.vjs-hover .vjs-menu{display:block}.video-js .vjs-menu-button-inline{overflow:hidden;transition:all .4s}.video-js .vjs-menu-button-inline:before{width:2.222222222em}.video-js .vjs-menu-button-inline.vjs-slider-active,.video-js .vjs-menu-button-inline:focus,.video-js .vjs-menu-button-inline:hover{width:12em}.vjs-menu-button-inline .vjs-menu{height:100%;left:4em;margin:0;opacity:0;padding:0;position:absolute;top:0;transition:all .4s;width:auto}.vjs-menu-button-inline.vjs-slider-active .vjs-menu,.vjs-menu-button-inline:focus .vjs-menu,.vjs-menu-button-inline:hover .vjs-menu{display:block;opacity:1}.vjs-menu-button-inline .vjs-menu-content{height:100%;margin:0;overflow:hidden;width:auto}.video-js .vjs-control-bar{background-color:#2b333f;background-color:#2b333fb3;bottom:0;display:none;height:3em;left:0;position:absolute;right:0;width:100%}.video-js.vjs-spatial-navigation-enabled .vjs-control-bar{gap:1px}.video-js:not(.vjs-controls-disabled,.vjs-using-native-controls,.vjs-error) .vjs-control-bar.vjs-lock-showing{display:flex!important}.vjs-audio-only-mode .vjs-control-bar,.vjs-has-started .vjs-control-bar{display:flex;opacity:1;transition:visibility .1s,opacity .1s;visibility:visible}.vjs-has-started.vjs-user-inactive.vjs-playing .vjs-control-bar{opacity:0;pointer-events:none;transition:visibility 1s,opacity 1s;visibility:visible}.vjs-controls-disabled .vjs-control-bar,.vjs-error .vjs-control-bar,.vjs-using-native-controls .vjs-control-bar{display:none!important}.vjs-audio-only-mode.vjs-has-started.vjs-user-inactive.vjs-playing .vjs-control-bar,.vjs-audio.vjs-has-started.vjs-user-inactive.vjs-playing .vjs-control-bar{opacity:1;pointer-events:auto;visibility:visible}.video-js .vjs-control{flex:none;height:100%;margin:0;padding:0;position:relative;text-align:center;width:4em}.video-js .vjs-control.vjs-visible-text{padding-left:1em;padding-right:1em;width:auto}.vjs-button>.vjs-icon-placeholder:before{font-size:1.8em;line-height:1.67}.vjs-button>.vjs-icon-placeholder{display:block}.vjs-button>.vjs-svg-icon{display:inline-block}.video-js .vjs-control:focus,.video-js .vjs-control:focus:before,.video-js .vjs-control:hover:before{text-shadow:0 0 1em #fff}.video-js :not(.vjs-visible-text)>.vjs-control-text{clip:rect(0 0 0 0);border:0;height:1px;overflow:hidden;padding:0;position:absolute;width:1px}.video-js .vjs-custom-control-spacer{display:none}.video-js .vjs-progress-control{align-items:center;cursor:pointer;display:flex;flex:auto;min-width:4em;touch-action:none}.video-js .vjs-progress-control.disabled{cursor:default}.vjs-live .vjs-progress-control{display:none}.vjs-liveui .vjs-progress-control{align-items:center;display:flex}.video-js .vjs-progress-holder{flex:auto;height:.3em;transition:all .2s}.video-js .vjs-progress-control .vjs-progress-holder{margin:0 10px}.video-js .vjs-progress-control:hover .vjs-progress-holder,.video-js.vjs-scrubbing.vjs-touch-enabled .vjs-progress-control .vjs-progress-holder{font-size:1.6666666667em}.video-js .vjs-progress-control:hover .vjs-progress-holder.disabled{font-size:1em}.video-js .vjs-progress-holder .vjs-load-progress,.video-js .vjs-progress-holder .vjs-load-progress div,.video-js .vjs-progress-holder .vjs-play-progress{display:block;height:100%;margin:0;padding:0;position:absolute;width:0}.video-js .vjs-play-progress{background-color:#fff}.video-js .vjs-play-progress:before{font-size:.9em;line-height:.35em;position:absolute;right:-.5em;z-index:1}.vjs-svg-icons-enabled .vjs-play-progress:before{content:none!important}.vjs-play-progress .vjs-svg-icon{height:.9em;line-height:.15em;pointer-events:none;position:absolute;right:-.4em;top:-.35em;width:.9em;z-index:1}.video-js .vjs-load-progress{background:#73859f80}.video-js .vjs-load-progress div{background:#73859fbf}.video-js .vjs-time-tooltip{background-color:#fff;background-color:#fffc;border-radius:.3em;color:#000;float:right;font-family:Arial,Helvetica,sans-serif;font-size:1em;padding:6px 8px 8px;pointer-events:none;position:absolute;top:-3.4em;visibility:hidden;z-index:1}.video-js .vjs-progress-holder:focus .vjs-time-tooltip{display:none}.video-js .vjs-progress-control:hover .vjs-progress-holder:focus .vjs-time-tooltip,.video-js .vjs-progress-control:hover .vjs-time-tooltip,.video-js.vjs-scrubbing.vjs-touch-enabled .vjs-progress-control .vjs-time-tooltip{display:block;font-size:.6em;visibility:visible}.video-js .vjs-progress-control.disabled:hover .vjs-time-tooltip{font-size:1em}.video-js .vjs-progress-control .vjs-mouse-display{background-color:#000;display:none;height:100%;position:absolute;width:1px;z-index:1}.video-js .vjs-progress-control:hover .vjs-mouse-display,.video-js.vjs-scrubbing.vjs-touch-enabled .vjs-progress-control .vjs-mouse-display{display:block}.video-js.vjs-touch-enabled:not(.vjs-scrubbing) .vjs-progress-control .vjs-mouse-display,.video-js.vjs-user-inactive .vjs-progress-control .vjs-mouse-display{opacity:0;transition:visibility 1s,opacity 1s;visibility:hidden}.vjs-mouse-display .vjs-time-tooltip{background-color:#000;background-color:#000c;color:#fff}.video-js .vjs-slider{-webkit-touch-callout:none;background-color:#73859f;background-color:#73859f80;cursor:pointer;margin:0 .45em;padding:0;position:relative;-webkit-user-select:none;user-select:none}.video-js .vjs-slider.disabled{cursor:default}.video-js .vjs-slider:focus{box-shadow:0 0 1em #fff;text-shadow:0 0 1em #fff}.video-js.vjs-spatial-navigation-enabled .vjs-slider:focus{outline:.0625em solid #fff}.video-js .vjs-mute-control{cursor:pointer;flex:none}.video-js .vjs-volume-control{cursor:pointer;display:flex;margin-right:1em}.video-js .vjs-volume-control.vjs-volume-horizontal{width:5em}.video-js .vjs-volume-panel .vjs-volume-control{height:1px;margin-left:-1px;opacity:0;visibility:visible;width:1px}.video-js .vjs-volume-panel{transition:width 1s}.video-js .vjs-volume-panel .vjs-volume-control.vjs-slider-active,.video-js .vjs-volume-panel .vjs-volume-control:active,.video-js .vjs-volume-panel.vjs-hover .vjs-mute-control~.vjs-volume-control,.video-js .vjs-volume-panel.vjs-hover .vjs-volume-control,.video-js .vjs-volume-panel:active .vjs-volume-control,.video-js .vjs-volume-panel:focus .vjs-volume-control{opacity:1;position:relative;transition:visibility .1s,opacity .1s,height .1s,width .1s,left 0s,top 0s;visibility:visible}.video-js .vjs-volume-panel .vjs-volume-control.vjs-slider-active.vjs-volume-horizontal,.video-js .vjs-volume-panel .vjs-volume-control:active.vjs-volume-horizontal,.video-js .vjs-volume-panel.vjs-hover .vjs-mute-control~.vjs-volume-control.vjs-volume-horizontal,.video-js .vjs-volume-panel.vjs-hover .vjs-volume-control.vjs-volume-horizontal,.video-js .vjs-volume-panel:active .vjs-volume-control.vjs-volume-horizontal,.video-js .vjs-volume-panel:focus .vjs-volume-control.vjs-volume-horizontal{height:3em;margin-right:0;width:5em}.video-js .vjs-volume-panel .vjs-volume-control.vjs-slider-active.vjs-volume-vertical,.video-js .vjs-volume-panel .vjs-volume-control:active.vjs-volume-vertical,.video-js .vjs-volume-panel.vjs-hover .vjs-mute-control~.vjs-volume-control.vjs-volume-vertical,.video-js .vjs-volume-panel.vjs-hover .vjs-volume-control.vjs-volume-vertical,.video-js .vjs-volume-panel:active .vjs-volume-control.vjs-volume-vertical,.video-js .vjs-volume-panel:focus .vjs-volume-control.vjs-volume-vertical{left:-3.5em;transition:left 0s}.video-js .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-hover,.video-js .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-slider-active,.video-js .vjs-volume-panel.vjs-volume-panel-horizontal:active{transition:width .1s;width:10em}.video-js .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-mute-toggle-only{width:4em}.video-js .vjs-volume-panel .vjs-volume-control.vjs-volume-vertical{height:8em;left:-3000em;transition:visibility 1s,opacity 1s,height 1s 1s,width 1s 1s,left 1s 1s,top 1s 1s;width:3em}.video-js .vjs-volume-panel .vjs-volume-control.vjs-volume-horizontal{transition:visibility 1s,opacity 1s,height 1s 1s,width 1s,left 1s 1s,top 1s 1s}.video-js .vjs-volume-panel{display:flex}.video-js .vjs-volume-bar{margin:1.35em .45em}.vjs-volume-bar.vjs-slider-horizontal{height:.3em;width:5em}.vjs-volume-bar.vjs-slider-vertical{height:5em;margin:1.35em auto;width:.3em}.video-js .vjs-volume-level{background-color:#fff;bottom:0;left:0;position:absolute}.video-js .vjs-volume-level:before{font-size:.9em;position:absolute;z-index:1}.vjs-slider-vertical .vjs-volume-level{width:.3em}.vjs-slider-vertical .vjs-volume-level:before{left:-.3em;top:-.5em;z-index:1}.vjs-svg-icons-enabled .vjs-volume-level:before{content:none}.vjs-volume-level .vjs-svg-icon{height:.9em;pointer-events:none;position:absolute;width:.9em;z-index:1}.vjs-slider-horizontal .vjs-volume-level{height:.3em}.vjs-slider-horizontal .vjs-volume-level:before{line-height:.35em;right:-.5em}.vjs-slider-horizontal .vjs-volume-level .vjs-svg-icon{right:-.3em;transform:translateY(-50%)}.vjs-slider-vertical .vjs-volume-level .vjs-svg-icon{top:-.55em;transform:translate(-50%)}.video-js .vjs-volume-panel.vjs-volume-panel-vertical{width:4em}.vjs-volume-bar.vjs-slider-vertical .vjs-volume-level{height:100%}.vjs-volume-bar.vjs-slider-horizontal .vjs-volume-level{width:100%}.video-js .vjs-volume-vertical{background-color:#2b333f;background-color:#2b333fb3;bottom:8em;height:8em;width:3em}.video-js .vjs-volume-horizontal .vjs-menu{left:-2em}.video-js .vjs-volume-tooltip{background-color:#fff;background-color:#fffc;border-radius:.3em;color:#000;float:right;font-family:Arial,Helvetica,sans-serif;font-size:1em;padding:6px 8px 8px;pointer-events:none;position:absolute;top:-3.4em;visibility:hidden;z-index:1}.video-js .vjs-volume-control:hover .vjs-progress-holder:focus .vjs-volume-tooltip,.video-js .vjs-volume-control:hover .vjs-volume-tooltip{display:block;font-size:1em;visibility:visible}.video-js .vjs-volume-vertical:hover .vjs-progress-holder:focus .vjs-volume-tooltip,.video-js .vjs-volume-vertical:hover .vjs-volume-tooltip{left:1em;top:-12px}.video-js .vjs-volume-control.disabled:hover .vjs-volume-tooltip{font-size:1em}.video-js .vjs-volume-control .vjs-mouse-display{background-color:#000;display:none;height:1px;position:absolute;width:100%;z-index:1}.video-js .vjs-volume-horizontal .vjs-mouse-display{height:100%;width:1px}.video-js .vjs-volume-control:hover .vjs-mouse-display{display:block}.video-js.vjs-user-inactive .vjs-volume-control .vjs-mouse-display{opacity:0;transition:visibility 1s,opacity 1s;visibility:hidden}.vjs-mouse-display .vjs-volume-tooltip{background-color:#000;background-color:#000c;color:#fff}.vjs-poster{bottom:0;cursor:pointer;display:inline-block;height:100%;left:0;margin:0;padding:0;position:absolute;right:0;top:0;vertical-align:middle}.vjs-has-started .vjs-poster,.vjs-using-native-controls .vjs-poster{display:none}.vjs-audio.vjs-has-started .vjs-poster,.vjs-has-started.vjs-audio-poster-mode .vjs-poster,.vjs-pip-container.vjs-has-started .vjs-poster{display:block}.vjs-poster img{height:100%;object-fit:contain;width:100%}.video-js .vjs-live-control{align-items:flex-start;display:flex;flex:auto;font-size:1em;line-height:3em}.video-js.vjs-liveui .vjs-live-control,.video-js:not(.vjs-live) .vjs-live-control{display:none}.video-js .vjs-seek-to-live-control{align-items:center;cursor:pointer;display:inline-flex;flex:none;font-size:1em;height:100%;line-height:3em;min-width:4em;padding-left:.5em;padding-right:.5em;width:auto}.video-js.vjs-live:not(.vjs-liveui) .vjs-seek-to-live-control,.video-js:not(.vjs-live) .vjs-seek-to-live-control{display:none}.vjs-seek-to-live-control.vjs-control.vjs-at-live-edge{cursor:auto}.vjs-seek-to-live-control .vjs-icon-placeholder{color:#888;margin-right:.5em}.vjs-svg-icons-enabled .vjs-seek-to-live-control{line-height:0}.vjs-seek-to-live-control .vjs-svg-icon{fill:#888;height:1em;pointer-events:none;width:1em}.vjs-seek-to-live-control.vjs-control.vjs-at-live-edge .vjs-icon-placeholder{color:red}.vjs-seek-to-live-control.vjs-control.vjs-at-live-edge .vjs-svg-icon{fill:red}.video-js .vjs-time-control{flex:none;font-size:1em;line-height:3em;min-width:2em;padding-left:1em;padding-right:1em;width:auto}.video-js .vjs-current-time,.video-js .vjs-duration,.vjs-live .vjs-time-control,.vjs-live .vjs-time-divider{display:none}.vjs-time-divider{display:none;line-height:3em}.vjs-normalise-time-controls:not(.vjs-live) .vjs-time-control{display:flex}.video-js .vjs-play-control{cursor:pointer}.video-js .vjs-play-control .vjs-icon-placeholder{flex:none}.vjs-text-track-display{bottom:3em;left:0;pointer-events:none;position:absolute;right:0;top:0}.vjs-error .vjs-text-track-display{display:none}.video-js.vjs-controls-disabled .vjs-text-track-display,.video-js.vjs-user-inactive.vjs-playing .vjs-text-track-display{bottom:1em}.video-js .vjs-text-track{font-size:1.4em;margin-bottom:.1em;text-align:center}.vjs-subtitles{color:#fff}.vjs-captions{color:#fc6}.vjs-tt-cue{display:block}video::-webkit-media-text-track-display{transform:translateY(-3em)}.video-js.vjs-controls-disabled video::-webkit-media-text-track-display,.video-js.vjs-user-inactive.vjs-playing video::-webkit-media-text-track-display{transform:translateY(-1.5em)}.video-js.vjs-force-center-align-cues .vjs-text-track-cue{text-align:center!important;width:80%!important}@supports not (inset:10px){.video-js .vjs-text-track-display>div{bottom:0;left:0;right:0;top:0}}.video-js .vjs-picture-in-picture-control{cursor:pointer;flex:none}.video-js.vjs-audio-only-mode .vjs-picture-in-picture-control,.vjs-pip-window .vjs-picture-in-picture-control{display:none}.video-js .vjs-fullscreen-control{cursor:pointer;flex:none}.video-js.vjs-audio-only-mode .vjs-fullscreen-control,.vjs-pip-window .vjs-fullscreen-control{display:none}.vjs-playback-rate .vjs-playback-rate-value,.vjs-playback-rate>.vjs-menu-button{height:100%;left:0;position:absolute;top:0;width:100%}.vjs-playback-rate .vjs-playback-rate-value{font-size:1.5em;line-height:2;pointer-events:none;text-align:center}.vjs-playback-rate .vjs-menu{left:0;width:4em}.vjs-error .vjs-error-display .vjs-modal-dialog-content{font-size:1.4em;text-align:center}.vjs-loading-spinner{background-clip:padding-box;border:.6em solid rgba(43,51,63,.7);border-radius:50%;box-sizing:border-box;display:none;height:5em;left:50%;opacity:.85;position:absolute;text-align:left;top:50%;transform:translate(-50%,-50%);visibility:hidden;width:5em}.vjs-seeking .vjs-loading-spinner,.vjs-waiting .vjs-loading-spinner{align-items:center;animation:vjs-spinner-show 0s linear .3s forwards;display:flex;justify-content:center}.vjs-error .vjs-loading-spinner{display:none}.vjs-loading-spinner:after,.vjs-loading-spinner:before{border:inherit;border-color:#fff transparent transparent;border-radius:inherit;box-sizing:inherit;content:\"\";height:inherit;opacity:1;position:absolute;width:inherit}.vjs-seeking .vjs-loading-spinner:after,.vjs-seeking .vjs-loading-spinner:before,.vjs-waiting .vjs-loading-spinner:after,.vjs-waiting .vjs-loading-spinner:before{animation:vjs-spinner-spin 1.1s cubic-bezier(.6,.2,0,.8) infinite,vjs-spinner-fade 1.1s linear infinite}.vjs-seeking .vjs-loading-spinner:before,.vjs-waiting .vjs-loading-spinner:before{border-top-color:#fff}.vjs-seeking .vjs-loading-spinner:after,.vjs-waiting .vjs-loading-spinner:after{animation-delay:.44s;border-top-color:#fff}@keyframes vjs-spinner-show{to{visibility:visible}}@keyframes vjs-spinner-spin{to{transform:rotate(1turn)}}@keyframes vjs-spinner-fade{0%{border-top-color:#73859f}20%{border-top-color:#73859f}35%{border-top-color:#fff}60%{border-top-color:#73859f}to{border-top-color:#73859f}}.video-js.vjs-audio-only-mode .vjs-captions-button{display:none}.vjs-chapters-button .vjs-menu ul{width:24em}.video-js.vjs-audio-only-mode .vjs-descriptions-button{display:none}.vjs-subs-caps-button+.vjs-menu .vjs-captions-menu-item .vjs-svg-icon{height:1.5em;width:1.5em}.video-js .vjs-subs-caps-button+.vjs-menu .vjs-captions-menu-item .vjs-menu-item-text .vjs-icon-placeholder{display:inline-block;margin-bottom:-.1em;vertical-align:middle}.video-js .vjs-subs-caps-button+.vjs-menu .vjs-captions-menu-item .vjs-menu-item-text .vjs-icon-placeholder:before{content:\"\uf10c\";font-family:VideoJS;font-size:1.5em;line-height:inherit}.video-js.vjs-audio-only-mode .vjs-subs-caps-button{display:none}.video-js .vjs-audio-button+.vjs-menu .vjs-descriptions-menu-item .vjs-menu-item-text .vjs-icon-placeholder,.video-js .vjs-audio-button+.vjs-menu .vjs-main-desc-menu-item .vjs-menu-item-text .vjs-icon-placeholder{display:inline-block;margin-bottom:-.1em;vertical-align:middle}.video-js .vjs-audio-button+.vjs-menu .vjs-descriptions-menu-item .vjs-menu-item-text .vjs-icon-placeholder:before,.video-js .vjs-audio-button+.vjs-menu .vjs-main-desc-menu-item .vjs-menu-item-text .vjs-icon-placeholder:before{content:\" \uf12e\";font-family:VideoJS;font-size:1.5em;line-height:inherit}.video-js.vjs-layout-small .vjs-current-time,.video-js.vjs-layout-small .vjs-duration,.video-js.vjs-layout-small .vjs-playback-rate,.video-js.vjs-layout-small .vjs-remaining-time,.video-js.vjs-layout-small .vjs-time-divider,.video-js.vjs-layout-small .vjs-volume-control,.video-js.vjs-layout-tiny .vjs-current-time,.video-js.vjs-layout-tiny .vjs-duration,.video-js.vjs-layout-tiny .vjs-playback-rate,.video-js.vjs-layout-tiny .vjs-remaining-time,.video-js.vjs-layout-tiny .vjs-time-divider,.video-js.vjs-layout-tiny .vjs-volume-control,.video-js.vjs-layout-x-small .vjs-current-time,.video-js.vjs-layout-x-small .vjs-duration,.video-js.vjs-layout-x-small .vjs-playback-rate,.video-js.vjs-layout-x-small .vjs-remaining-time,.video-js.vjs-layout-x-small .vjs-time-divider,.video-js.vjs-layout-x-small .vjs-volume-control{display:none}.video-js.vjs-layout-small .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-hover,.video-js.vjs-layout-small .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-slider-active,.video-js.vjs-layout-small .vjs-volume-panel.vjs-volume-panel-horizontal:active,.video-js.vjs-layout-small .vjs-volume-panel.vjs-volume-panel-horizontal:hover,.video-js.vjs-layout-tiny .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-hover,.video-js.vjs-layout-tiny .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-slider-active,.video-js.vjs-layout-tiny .vjs-volume-panel.vjs-volume-panel-horizontal:active,.video-js.vjs-layout-tiny .vjs-volume-panel.vjs-volume-panel-horizontal:hover,.video-js.vjs-layout-x-small .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-hover,.video-js.vjs-layout-x-small .vjs-volume-panel.vjs-volume-panel-horizontal.vjs-slider-active,.video-js.vjs-layout-x-small .vjs-volume-panel.vjs-volume-panel-horizontal:active,.video-js.vjs-layout-x-small .vjs-volume-panel.vjs-volume-panel-horizontal:hover{width:auto}.video-js.vjs-layout-tiny .vjs-progress-control,.video-js.vjs-layout-x-small .vjs-progress-control{display:none}.video-js.vjs-layout-x-small .vjs-custom-control-spacer{display:block;flex:auto}.vjs-modal-dialog.vjs-text-track-settings{background-color:#2b333f;background-color:#2b333fbf;color:#fff;height:70%}.vjs-spatial-navigation-enabled .vjs-modal-dialog.vjs-text-track-settings{height:80%}.vjs-error .vjs-text-track-settings{display:none}.vjs-text-track-settings .vjs-modal-dialog-content{display:table}.vjs-text-track-settings .vjs-track-settings-colors,.vjs-text-track-settings .vjs-track-settings-controls,.vjs-text-track-settings .vjs-track-settings-font{display:table-cell}.vjs-text-track-settings .vjs-track-settings-controls{text-align:right;vertical-align:bottom}@supports (display:grid){.vjs-text-track-settings .vjs-modal-dialog-content{display:grid;grid-template-columns:1fr 1fr;grid-template-rows:1fr;padding:20px 24px 0}.vjs-track-settings-controls .vjs-default-button{margin-bottom:20px}.vjs-text-track-settings .vjs-track-settings-controls{grid-column:1/-1}.vjs-layout-small .vjs-text-track-settings .vjs-modal-dialog-content,.vjs-layout-tiny .vjs-text-track-settings .vjs-modal-dialog-content,.vjs-layout-x-small .vjs-text-track-settings .vjs-modal-dialog-content{grid-template-columns:1fr}}.vjs-text-track-settings select{font-size:inherit}.vjs-track-setting>select{margin-bottom:.5em;margin-right:1em}.vjs-text-track-settings fieldset{border:none;margin:10px}.vjs-text-track-settings fieldset span{display:inline-block;padding:0 .6em .8em}.vjs-text-track-settings fieldset span>select{max-width:7.3em}.vjs-text-track-settings legend{color:#fff;font-size:1.2em;font-weight:700}.vjs-text-track-settings .vjs-label{margin:0 .5em .5em 0}.vjs-track-settings-controls button:active,.vjs-track-settings-controls button:focus{background-image:linear-gradient(0deg,#fff 88%,#73859f);outline-style:solid;outline-width:medium}.vjs-track-settings-controls button:hover{color:#2b333fbf}.vjs-track-settings-controls button{background-color:#fff;background-image:linear-gradient(-180deg,#fff 88%,#73859f);border-radius:2px;color:#2b333f;cursor:pointer}.vjs-track-settings-controls .vjs-default-button{margin-right:1em}.vjs-title-bar{background:#000000e6;background:linear-gradient(180deg,#000000e6,#000000b3 60%,#0000);font-size:1.2em;line-height:1.5;padding:.666em 1.333em 4em;pointer-events:none;position:absolute;top:0;transition:opacity .1s;width:100%}.vjs-error .vjs-title-bar{display:none}.vjs-title-bar-description,.vjs-title-bar-title{margin:0;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}.vjs-title-bar-title{font-weight:700;margin-bottom:.333em}.vjs-playing.vjs-user-inactive .vjs-title-bar{opacity:0;transition:opacity 1s}.video-js .vjs-skip-backward-10,.video-js .vjs-skip-backward-30,.video-js .vjs-skip-backward-5,.video-js .vjs-skip-forward-10,.video-js .vjs-skip-forward-30,.video-js .vjs-skip-forward-5{cursor:pointer}.video-js .vjs-transient-button{align-items:center;background-color:#32323280;cursor:pointer;display:flex;height:3em;justify-content:center;opacity:1;position:absolute;transition:opacity 1s}.video-js:not(.vjs-has-started) .vjs-transient-button{display:none}.video-js.not-hover .vjs-transient-button:not(.force-display),.video-js.vjs-user-inactive .vjs-transient-button:not(.force-display){opacity:0}.video-js .vjs-transient-button span{padding:0 .5em}.video-js .vjs-transient-button.vjs-left{left:1em}.video-js .vjs-transient-button.vjs-right{right:1em}.video-js .vjs-transient-button.vjs-top{top:1em}.video-js .vjs-transient-button.vjs-near-top{top:4em}.video-js .vjs-transient-button.vjs-bottom{bottom:4em}.video-js .vjs-transient-button:hover{background-color:#323232e6}@media print{.video-js>:not(.vjs-tech):not(.vjs-poster){visibility:hidden}}.vjs-resize-manager{border:none;height:100%;left:0;position:absolute;top:0;width:100%;z-index:-1000}.js-focus-visible .video-js :focus:not(.focus-visible){outline:0}.video-js :focus:not(:focus-visible){outline:0}.aws-player{width:100%}.aws-player .video-js .vjs-dock-shelf,.aws-player .video-js .vjs-dock-text{display:none}.aws-player .video-js .vjs-load-progress div,.aws-player .video-js .vjs-volume-bar{background-color:var(--color-neutral-400)}.aws-player .video-js .vjs-play-progress,.aws-player .video-js .vjs-volume-level{background-color:var(--color-roche-blue-600)}.aws-player .video-js .vjs-picture-in-picture-control{display:none}.aws-player .video-js .vjs-current-time-display,.aws-player .video-js .vjs-duration-display{color:var(--color-white-100);font-size:.75rem}.aws-player .video-js .vjs-time-control{display:block}.aws-player .video-js .vjs-remaining-time{display:none}.aws-player .video-js .vjs-custom-control-spacer{display:flex;flex:auto}.aws-player .video-js .vjs-progress-control{bottom:26px;height:10px;left:0;position:absolute;right:0;width:100%}.aws-player .video-js .vjs-progress-control .vjs-progress-holder{margin:0}.aws-player .video-js .vjs-big-play-button,.aws-player .video-js .vjs-live-display{display:none}.aws-player.aws-player__controls--hidden .video-js{background-color:transparent;pointer-events:none}.aws-player.aws-player__controls--hidden .video-js .vjs-control-bar{display:none}.aws-player.aws-player__controls--hidden .video-js .vjs-loading-spinner{display:none;visibility:hidden}.aws-player.aws-player--fullscreen-videoloop{margin-left:calc(50% - 50vw);width:100vw}.aws-player.aws-player--fullscreen-videoloop .video-js{background-color:transparent;overflow:hidden;padding-top:41.841%}.aws-player.aws-player--fullscreen-videoloop .video-js .vjs-tech{object-fit:cover}.aws-player.aws-player--fullscreen{aspect-ratio:1.7777777778;height:90%;width:auto}.highlight-box{padding:2.5rem}.highlight-box.highlight-box--transparent{background:0 0}.highlight-box.highlight-box--theme-aware{background:var(--color-roche-grey-100)}.highlight-box.highlight-box--neutral{background:var(--color-neutral-400)}.highlight-box.highlight-box--neutral-100{background:var(--color-neutral-100)}.highlight-box.highlight-box--neutral-200{background:var(--color-neutral-200)}.highlight-box.highlight-box--grey{background:var(--color-roche-grey-400)}.highlight-box.highlight-box--grey-50{background:var(--color-roche-grey-0)}.highlight-box.highlight-box--grey-100{background:var(--color-roche-grey-100)}.highlight-box.highlight-box--grey-200{background:var(--color-grey-200)}.highlight-box.highlight-box--grey-300{background:var(--color-roche-grey-300)}.highlight-box.highlight-box--white{background:var(--color-white)}.horizontal-center{align-items:center;display:flex;justify-content:center;margin-top:3rem}@media (min-width:90rem){.horizontal-center{margin-top:4.5rem}}.lead-text{font-family:roche-sans;font-size:1.25rem;font-style:normal;font-weight:200;line-height:2rem;margin-bottom:1.25rem;margin-top:2rem}@media (min-width:48rem){.lead-text{font-size:1.375rem;line-height:2.1875rem}}@media (min-width:90rem){.lead-text{font-size:1.625rem;line-height:2.625rem}}@media (min-width:48rem){.lead-text{margin-bottom:1.375rem}}@media (min-width:90rem){.lead-text{margin-bottom:1.625rem;margin-top:2.5rem}}.highlight-box .lead-text:empty{margin-bottom:0;margin-top:0}.loading-spinner{align-items:center;display:flex;flex-direction:column;margin:8rem 0;min-height:100vh}.loading-spinner .loading-spinner__icon-container{align-items:center;animation:loading-spinner 2s linear infinite;color:var(--color-shadow-blue-200);display:flex;width:min-content}.loading-spinner .loading-spinner__text{color:var(--color-roche-grey-600);font-family:roche-sans;font-size:var(--label-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem;margin-top:.5rem;width:min-content}@media (min-width:48rem){.loading-spinner .loading-spinner__text{font-size:var(--label-font-size-medium-up);line-height:1.3125rem}.loading-spinner{margin:10rem 0}}[dir=rtl] .loading-spinner .loading-spinner__icon-container{animation-direction:reverse}@keyframes loading-spinner{0%{transform:rotate(0)}to{transform:rotate(1turn)}}.magnet{margin:-3rem 0}@media (min-width:64rem){.magnet{margin:-5rem 0}}.marketo .mktoForm{margin-top:.5rem!important;width:100%!important}.marketo .mktoForm *{font-family:var(--font-family-primary)!important}.marketo .mktoForm .mktoFormRow{display:flex!important;flex-wrap:wrap!important}@media (min-width:64rem){.marketo .mktoForm .mktoFormRow{padding-left:2rem!important}}.marketo .mktoForm .mktoFormRow:has(div.mktoFormCol) div.mktoFormCol{margin-bottom:3rem!important}.marketo .mktoForm .mktoFormRow:has(div.mktoFormCol):nth-last-of-type(2) div.mktoFormCol:nth-last-of-type(2){margin-bottom:2rem!important}.marketo .mktoForm .mktoFormRow div.mktoFormCol:has(#LblConsent_given_to_contact_for_Mktg_Info__c),.marketo .mktoForm .mktoFormRow div.mktoFormCol:has(#LblConsent_given_to_store_data_in_Data_Base__c),.marketo .mktoForm .mktoFormRow div.mktoFormCol:has(#LblconsentforDataTracking){margin-bottom:2rem!important}@media (min-width:64rem){.marketo .mktoForm .mktoFormRow>.mktoFormCol{margin-right:2rem!important}}.marketo .mktoForm .mktoFormCol{margin-bottom:0!important;width:100%!important}@media (min-width:64rem){.marketo .mktoForm .mktoFormCol{flex-basis:0;flex-grow:1;max-width:100%}}.marketo .mktoForm .mktoFieldWrap{box-sizing:border-box!important;width:100%!important}.marketo .mktoForm .mktoFieldWrap:has(.mktoError) input[type=date],.marketo .mktoForm .mktoFieldWrap:has(.mktoError) input[type=email],.marketo .mktoForm .mktoFieldWrap:has(.mktoError) input[type=number],.marketo .mktoForm .mktoFieldWrap:has(.mktoError) input[type=tel],.marketo .mktoForm .mktoFieldWrap:has(.mktoError) input[type=text],.marketo .mktoForm .mktoFieldWrap:has(.mktoError) input[type=url],.marketo .mktoForm .mktoFieldWrap:has(.mktoError) select,.marketo .mktoForm .mktoFieldWrap:has(.mktoError) textarea{border:1px solid var(--color-error)!important}.marketo .mktoForm .mktoFieldWrap:has(select){position:relative}.marketo .mktoForm .mktoFieldWrap:has(select):after{bottom:1.5rem;content:url(\"data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='16' height='16' viewBox='0 0 24 24'%3E%3Cpath d='m12 15.7 6-6-1.4-1.4-4.6 4.6-4.6-4.6L6 9.7l6 6z'/%3E%3C/svg%3E\");height:1rem;position:absolute;right:1rem;width:1rem}.marketo .mktoForm .mktoFieldWrap:has(select):has(.mktoError):after{bottom:3.5rem}.marketo .mktoForm .mktoFieldWrap:has(#LblConsent_given_to_contact_for_Mktg_Info__c),.marketo .mktoForm .mktoFieldWrap:has(#LblConsent_given_to_store_data_in_Data_Base__c),.marketo .mktoForm .mktoFieldWrap:has(#LblconsentforDataTracking){display:flex;flex-direction:row-reverse}.marketo .mktoForm .mktoFieldWrap:has(#LblConsent_given_to_contact_for_Mktg_Info__c+div+select),.marketo .mktoForm .mktoFieldWrap:has(#LblConsent_given_to_store_data_in_Data_Base__c+div+select),.marketo .mktoForm .mktoFieldWrap:has(#LblconsentforDataTracking+div+select){flex-direction:column}.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_contact_for_Mktg_Info__c:after,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_store_data_in_Data_Base__c:after,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblconsentforDataTracking:after{display:none!important}.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_contact_for_Mktg_Info__c>div:has(>span),.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_contact_for_Mktg_Info__c>span,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_store_data_in_Data_Base__c>div:has(>span),.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_store_data_in_Data_Base__c>span,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblconsentforDataTracking>div:has(>span),.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblconsentforDataTracking>span{display:flex;gap:.25rem;text-decoration:none!important}.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_contact_for_Mktg_Info__c>div:has(>span):last-of-type:after,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_contact_for_Mktg_Info__c>span:last-of-type:after,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_store_data_in_Data_Base__c>div:has(>span):last-of-type:after,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblConsent_given_to_store_data_in_Data_Base__c>span:last-of-type:after,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblconsentforDataTracking>div:has(>span):last-of-type:after,.marketo .mktoForm .mktoFieldWrap.mktoRequiredField #LblconsentforDataTracking>span:last-of-type:after{content:\"*\";text-decoration:none!important}.marketo .mktoForm .mktoCheckboxList{float:none!important;padding:.1em 0 0!important;width:auto!important}.marketo .mktoForm .mktoCheckboxList>label{display:block!important;margin-left:0!important}.marketo .mktoForm .mktoCheckboxList>label:hover:before{border-color:var(--color-roche-blue-600)!important}.marketo .mktoForm .mktoCheckboxList input,.marketo .mktoForm .mktoCheckboxList label{font-size:1rem!important;line-height:1.5rem!important}.marketo .mktoForm .mktoCheckboxList input{background-color:var(--color-white)!important;border:1px solid var(--color-roche-grey-400)!important;color:var(--color-text-primary)!important;font-weight:300!important;margin-bottom:.7em!important;opacity:0;position:absolute}.marketo .mktoForm .mktoCheckboxList input:focus,.marketo .mktoForm .mktoCheckboxList input:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.marketo .mktoForm .mktoCheckboxList input:focus:not(:focus-visible){outline:0}.marketo .mktoForm .mktoCheckboxList input:focus,.marketo .mktoForm .mktoCheckboxList input:focus-visible{outline:var(--color-roche-blue-600) dashed 2px!important}.marketo .mktoForm .mktoCheckboxList input:focus:not(:focus-visible){outline:0!important}.marketo .mktoForm .mktoCheckboxList input:hover+label:before{border-color:var(--color-roche-blue-600)!important}.marketo .mktoForm .mktoCheckboxList input+label:before{background-color:var(--color-white)!important;border:1px solid var(--color-roche-grey-400)!important;border-radius:0!important;box-shadow:none!important;content:\"\";display:inline-block;height:1rem!important;margin-left:0!important;margin-right:.75rem!important;position:relative!important;text-align:center;vertical-align:text-top;width:1rem!important}.marketo .mktoForm .mktoCheckboxList input:checked+label:before{border-color:var(--color-roche-blue-600)!important;color:var(--color-roche-blue-600)!important;content:url(\"data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='14' height='14' viewBox='0 0 24 24'%3E%3Cpath d='m20.5 6.4-11 11L8.1 16l-4.6-4.6L4.9 10l4.6 4.6L19.1 5l1.4 1.4z' clip-rule='evenodd'/%3E%3C/svg%3E\")!important;font-family:var(--font-family-primary);font-size:.5rem;font-weight:900;line-height:1.5rem}.marketo .mktoForm .mktoCheckboxList input,.marketo .mktoForm .mktoCheckboxList label{cursor:pointer;display:inline-block;margin:.25rem;vertical-align:middle}.marketo .mktoForm .mktoRadioList{float:none!important;padding:.1em 0 0!important;width:auto!important}.marketo .mktoForm .mktoRadioList>label{display:block!important;margin-left:0!important}.marketo .mktoForm .mktoRadioList>label:hover:before{border-color:var(--color-roche-blue-600)!important}.marketo .mktoForm .mktoRadioList input,.marketo .mktoForm .mktoRadioList label{cursor:pointer;display:inline-block;margin:.25rem;vertical-align:middle}.marketo .mktoForm .mktoRadioList label{color:var(--color-grey-800)!important;font-size:1rem!important;line-height:1.5rem!important;margin-bottom:.7em!important;position:relative}.marketo .mktoForm .mktoRadioList input{background-color:var(--color-white)!important;border:1px solid var(--color-roche-grey-400)!important;opacity:0;position:absolute}.marketo .mktoForm .mktoRadioList input:focus,.marketo .mktoForm .mktoRadioList input:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.marketo .mktoForm .mktoRadioList input:focus:not(:focus-visible){outline:0}.marketo .mktoForm .mktoRadioList input:focus+label{outline:0}.marketo .mktoForm .mktoRadioList input+label:before{background-color:var(--color-white);border:1px solid var(--color-roche-grey-400)!important;border-radius:50%;content:\"\";display:inline-block;height:1rem;line-height:1rem;margin-right:.75rem;text-align:center;vertical-align:middle;width:1rem}.marketo .mktoForm .mktoRadioList input:checked+label:before{border-color:var(--color-roche-blue-600)!important;color:var(--color-roche-blue-600)!important;content:url(\"data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' width='14' height='14' viewBox='0 0 24 24'%3E%3Cpath d='m20.5 6.4-11 11L8.1 16l-4.6-4.6L4.9 10l4.6 4.6L19.1 5l1.4 1.4z' clip-rule='evenodd'/%3E%3C/svg%3E\");font-family:var(--font-family-primary);font-size:.5rem;font-weight:900;line-height:1.5rem}.marketo .mktoForm .mktoButtonRow{padding-right:2rem!important;text-align:left!important;width:100%!important}@media (min-width:64rem){.marketo .mktoForm .mktoButtonRow{margin:0 2rem!important}}.marketo .mktoForm .mktoButtonWrap{margin:0!important}.marketo .mktoForm .mktoButtonWrap .mktoButton{background-color:var(--color-interactive--primary-idle)!important;background-image:none!important;border:1px solid var(--color-interactive--primary-idle)!important;border-radius:0!important;color:var(--color-white)!important;font-size:1rem!important;font-weight:400!important;line-height:1.5rem!important;padding:1rem 1.5rem!important;transition:background-color .3s linear,color .3s linear!important}.marketo .mktoForm .mktoButtonWrap .mktoButton:focus,.marketo .mktoForm .mktoButtonWrap .mktoButton:focus-visible{outline:var(--color-interactive--primary-idle) dashed 2px;outline-offset:unset}.marketo .mktoForm .mktoButtonWrap .mktoButton:focus:not(:focus-visible){outline:0}.marketo .mktoForm .mktoButtonWrap .mktoButton:focus,.marketo .mktoForm .mktoButtonWrap .mktoButton:focus-visible{outline:var(--color-interactive--primary-idle) dashed 2px!important}.marketo .mktoForm .mktoButtonWrap .mktoButton:focus:not(:focus-visible){outline:0!important}.marketo .mktoForm .mktoButtonWrap .mktoButton:hover{background-color:var(--color-interactive--primary-hover)!important;border:1px solid var(--color-interactive--primary-hover)!important;box-shadow:0 .75rem 1.5rem #2121213d!important;color:var(--color-white);transition-duration:.22s!important;transition-property:background-color,box-shadow,border,color;transition-timing-function:ease-in!important}.marketo .mktoForm .mktoHtmlText{font-size:1rem!important;font-weight:400!important;line-height:1.5rem!important;width:100%!important}.marketo .mktoForm .mktoDateButton{margin-left:-1.25rem!important;margin-top:-.5rem!important}.marketo .mktoForm .mktoLabel{color:var(--color-roche-grey-700)!important;float:none!important;font-size:.75rem!important;font-weight:400!important;line-height:1.5rem!important;margin-bottom:.5rem!important;padding:0!important;width:100%!important}@media (min-width:48rem){.marketo .mktoForm .mktoLabel{font-size:1rem!important}}.marketo .mktoForm .mktoLabel:not(#LblConsent_given_to_contact_for_Mktg_Info__c,#LblConsent_given_to_store_data_in_Data_Base__c,#LblconsentforDataTracking)>br{display:none}.marketo .mktoForm .mktoLabel span>br:first-child:not(:only-child){display:none}.marketo .mktoForm .mktoRequiredField:not(:has(>label:has(div.mktoAsterix:only-child))) .mktoCheckboxList>label:not(:empty):after{content:\" *\";display:inline!important}.marketo .mktoForm .mktoRequiredField:has(#LblConsent_given_to_contact_for_Mktg_Info__c)>label:after,.marketo .mktoForm .mktoRequiredField:has(#LblConsent_given_to_store_data_in_Data_Base__c)>label:after,.marketo .mktoForm .mktoRequiredField:has(#LblconsentforDataTracking)>label:after{content:\" *\";display:inline!important}.marketo .mktoForm .mktoRequiredField:has(#LblConsent_given_to_contact_for_Mktg_Info__c)>label:has(div.mktoAsterix:only-child),.marketo .mktoForm .mktoRequiredField:has(#LblConsent_given_to_store_data_in_Data_Base__c)>label:has(div.mktoAsterix:only-child),.marketo .mktoForm .mktoRequiredField:has(#LblconsentforDataTracking)>label:has(div.mktoAsterix:only-child){display:none!important}.marketo .mktoForm .mktoRequiredField:has(#LblConsent_given_to_contact_for_Mktg_Info__c) label:after,.marketo .mktoForm .mktoRequiredField:has(#LblConsent_given_to_store_data_in_Data_Base__c) label:after,.marketo .mktoForm .mktoRequiredField:has(#LblconsentforDataTracking) label:after{display:none}.marketo .mktoForm .mktoRequiredField .mktoLabel{font-weight:400!important}.marketo .mktoForm .mktoRequiredField .mktoLabel:after{content:\" *\"!important}.marketo .mktoForm .mktoRequiredField .mktoAsterix{display:none!important}.marketo .mktoForm .mktoError{color:var(--color-error)!important;display:block!important;height:auto!important;margin-top:.25rem!important;opacity:1!important;position:static!important}.marketo .mktoForm .mktoError .mktoErrorMsg{background:0 0!important;border:0 solid var(--color-error)!important;border-radius:0!important;box-shadow:none!important;color:var(--color-error)!important;display:inline-block!important;font-size:.75rem!important;font-weight:400!important;line-height:1.5rem!important;max-width:100%!important;padding:0!important;text-align:left!important;text-shadow:none!important}@media (min-width:48rem){.marketo .mktoForm .mktoError .mktoErrorMsg{font-size:1rem!important}}.marketo .mktoForm .mktoError .mktoErrorMsg .mktoErrorDetail{display:inline!important}.marketo .mktoForm .mktoError .mktoErrorArrowWrap{background:0 0!important;background-color:none!important;border:0 solid var(--color-error)!important;height:0!important;left:0!important;margin-top:.75rem!important;top:0!important;width:0!important}.marketo .mktoForm div.mktoInvalid{border:1px solid transparent!important}.marketo .mktoForm .mktoGutter,.marketo .mktoForm .mktoOffset{display:none!important;height:0!important;width:0!important}.marketo .mktoForm h1,.marketo .mktoForm h2,.marketo .mktoForm h3,.marketo .mktoForm h4,.marketo .mktoForm h5{color:var(--color-text-primary)!important;font-family:var(--font-family-primary)!important;font-size:1.25rem!important;font-style:normal!important;font-weight:var(--font-weight-regular)!important;line-height:1.5rem!important}.marketo .mktoForm a{color:var(--color-interactive--primary-idle)!important;text-decoration:none!important}.marketo .mktoForm a:focus,.marketo .mktoForm a:focus-visible{outline:var(--color-interactive--primary-idle) dashed 2px;outline-offset:unset}.marketo .mktoForm a:focus:not(:focus-visible){outline:0}.marketo .mktoForm a:hover{color:var(--color-interactive--primary-hover)!important;text-decoration:none!important}.marketo .mktoForm fieldset.mktoFormCol{width:100%!important}.marketo .mktoForm fieldset legend{margin:0 1em .5em 0!important}.marketo .mktoForm input[type=date],.marketo .mktoForm input[type=email],.marketo .mktoForm input[type=number],.marketo .mktoForm input[type=tel],.marketo .mktoForm input[type=text],.marketo .mktoForm input[type=url],.marketo .mktoForm select,.marketo .mktoForm textarea{background-color:var(--color-white)!important;border:1px solid var(--color-roche-grey-400)!important;border-bottom-color:var(--color-roche-grey-600)!important;border-radius:0!important;box-shadow:none!important;color:var(--color-text-primary)!important;font-size:1rem!important;font-weight:300!important;height:auto!important;line-height:1.5rem!important;margin:0!important;outline:0!important;padding:.75rem 1rem!important;transition:border-color .15s ease-in-out,box-shadow .15s ease-in-out;width:100%!important}.marketo .mktoForm input[type=date]:focus,.marketo .mktoForm input[type=date]:focus-visible,.marketo .mktoForm input[type=email]:focus,.marketo .mktoForm input[type=email]:focus-visible,.marketo .mktoForm input[type=number]:focus,.marketo .mktoForm input[type=number]:focus-visible,.marketo .mktoForm input[type=tel]:focus,.marketo .mktoForm input[type=tel]:focus-visible,.marketo .mktoForm input[type=text]:focus,.marketo .mktoForm input[type=text]:focus-visible,.marketo .mktoForm input[type=url]:focus,.marketo .mktoForm input[type=url]:focus-visible,.marketo .mktoForm select:focus,.marketo .mktoForm select:focus-visible,.marketo .mktoForm textarea:focus,.marketo .mktoForm textarea:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.marketo .mktoForm input[type=date]:focus:not(:focus-visible),.marketo .mktoForm input[type=email]:focus:not(:focus-visible),.marketo .mktoForm input[type=number]:focus:not(:focus-visible),.marketo .mktoForm input[type=tel]:focus:not(:focus-visible),.marketo .mktoForm input[type=text]:focus:not(:focus-visible),.marketo .mktoForm input[type=url]:focus:not(:focus-visible),.marketo .mktoForm select:focus:not(:focus-visible),.marketo .mktoForm textarea:focus:not(:focus-visible){outline:0}@media (min-width:48rem){.marketo .mktoForm input[type=date],.marketo .mktoForm input[type=email],.marketo .mktoForm input[type=number],.marketo .mktoForm input[type=tel],.marketo .mktoForm input[type=text],.marketo .mktoForm input[type=url],.marketo .mktoForm select,.marketo .mktoForm textarea{font-size:1rem!important;line-height:1.5rem!important}}.marketo .mktoForm input[type=date]:hover,.marketo .mktoForm input[type=email]:hover,.marketo .mktoForm input[type=number]:hover,.marketo .mktoForm input[type=tel]:hover,.marketo .mktoForm input[type=text]:hover,.marketo .mktoForm input[type=url]:hover,.marketo .mktoForm select:hover,.marketo .mktoForm textarea:hover{border-bottom-color:var(--color-roche-blue-600)!important}.marketo .mktoForm input[type=date]:focus,.marketo .mktoForm input[type=email]:focus,.marketo .mktoForm input[type=number]:focus,.marketo .mktoForm input[type=tel]:focus,.marketo .mktoForm input[type=text]:focus,.marketo .mktoForm input[type=url]:focus,.marketo .mktoForm select:focus,.marketo .mktoForm textarea:focus{border-color:var(--color-roche-blue-600)!important;outline:var(--color-roche-blue-600) dashed 2px!important;outline-offset:2px!important}.marketo .mktoForm input[type=date]:focus:not(:focus-visible),.marketo .mktoForm input[type=email]:focus:not(:focus-visible),.marketo .mktoForm input[type=number]:focus:not(:focus-visible),.marketo .mktoForm input[type=tel]:focus:not(:focus-visible),.marketo .mktoForm input[type=text]:focus:not(:focus-visible),.marketo .mktoForm input[type=url]:focus:not(:focus-visible),.marketo .mktoForm select:focus:not(:focus-visible),.marketo .mktoForm textarea:focus:not(:focus-visible){outline:0!important}.marketo .mktoForm textarea{height:6rem!important;padding-bottom:.5rem!important;padding-top:.5rem!important}.marketo .mktoForm select{-webkit-appearance:none!important;appearance:none!important;background:0 0!important;border-radius:0!important;font-size:1rem!important;outline:0!important;overflow:hidden!important;padding:.75rem 3rem .75rem 1rem!important;text-indent:.125rem!important;text-overflow:\"\"!important}.marketo .mktoForm select::-ms-expand{display:none}.marketo .mktoForm select[multiple]{-webkit-appearance:auto!important;appearance:auto!important;background-image:none!important;height:auto!important;outline:0!important;overflow-y:auto!important}.marketo .mktoForm select>option:first-child{color:var(--color-roche-grey-600)!important}@media only screen and (device-height <= 480px),only screen and (device-width <= 480px),only screen and (width <= 480px){.marketo .mktoForm{padding-left:0!important;padding-right:0!important}.marketo .mktoForm *{padding:0!important}}.marketo #LblConsent_given_to_contact_for_Mktg_Info__c,.marketo #LblConsent_given_to_store_data_in_Data_Base__c,.marketo #LblconsentforDataTracking{color:var(--color-text-primary)!important;font-size:1rem!important;font-weight:300!important;line-height:1.5rem!important;margin:0!important}.marketo #LblConsent_given_to_contact_for_Mktg_Info__c *,.marketo #LblConsent_given_to_store_data_in_Data_Base__c *,.marketo #LblconsentforDataTracking *{font-size:1rem!important;line-height:1.5rem!important}@media (min-width:48rem){.marketo #LblConsent_given_to_contact_for_Mktg_Info__c,.marketo #LblConsent_given_to_contact_for_Mktg_Info__c *,.marketo #LblConsent_given_to_store_data_in_Data_Base__c,.marketo #LblConsent_given_to_store_data_in_Data_Base__c *,.marketo #LblconsentforDataTracking,.marketo #LblconsentforDataTracking *{font-size:1rem!important;line-height:1.5rem!important}}.podcast.podcast--soundcloud .podcast__iframe{height:12.5rem}.podcast.podcast--spotify .podcast__iframe{height:5rem}.podcast.podcast--spotify-creators{height:6.75rem;overflow:hidden}@media (min-width:48rem){.podcast.podcast--spotify-creators{height:10.75rem}}.podcast.podcast--spotify-creators .podcast__iframe{height:18.75rem}.podcast.podcast--transistor .podcast__iframe{height:11.5625rem}.podcast .podcast__iframe{border:0}.published-date{color:var(--color-roche-grey-600);font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.published-date{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.published-date{font-size:1.25rem;line-height:1.875rem}}.roche-quote{margin-top:3rem;width:100%}@media (min-width:90rem){.roche-quote{margin-top:4.5rem}}.roche-quote .roche-quote__image{width:100%}@media (min-width:48rem){.roche-quote .roche-quote__image{margin:auto}}.roche-quote .roche-quote__image>.image{margin:0}.roche-quote .roche-quote__content{margin:auto}.roche-quote .roche-quote__text{font-family:roche-serif;font-size:2rem;font-style:normal;font-weight:200;line-height:2.875rem;margin-top:2.5rem}@media (min-width:48rem){.roche-quote .roche-quote__text{font-size:2.5rem;line-height:3.5rem}}@media (min-width:90rem){.roche-quote .roche-quote__text{font-size:3rem;line-height:4.1875rem}}@media (min-width:48rem){.roche-quote .roche-quote__text{margin:0}}.roche-quote .roche-quote__text.roche-quote__text--small{font-family:roche-serif;font-size:1.5rem;font-style:normal;font-weight:200;line-height:2.125rem}@media (min-width:48rem){.roche-quote .roche-quote__text.roche-quote__text--small{font-size:1.75rem;line-height:2.5rem}}@media (min-width:90rem){.roche-quote .roche-quote__text.roche-quote__text--small{font-size:1.875rem;line-height:2.5rem}}.roche-quote .roche-quote__subline{display:flex;flex-direction:column;gap:1rem;margin-top:1rem}@media (min-width:48rem){.roche-quote .roche-quote__subline{gap:1.5rem;margin-top:1.5rem}}@media (min-width:90rem){.roche-quote .roche-quote__subline{gap:2rem;margin-top:2rem}}.roche-quote .roche-quote__link{margin:2rem 0 0}.roche-quote.roche-quote--with-image{width:100%}@media (min-width:48rem){.roche-quote.roche-quote--with-image{display:grid;gap:calc(8.33333% + 24px);grid-template-columns:calc(41.66667% - 12px) 50%;margin-inline:auto}.roche-quote.roche-quote--equal-ratio{gap:24px;grid-template-columns:calc(50% - 12px) calc(50% - 12px)}}@media (min-width:90rem){.roche-quote.roche-quote--equal-ratio{gap:32px;grid-template-columns:calc(50% - 16px) calc(50% - 16px)}}@media print{.no-print{display:none}.print-grid-full-width .grid__column.is-8{width:100%}.print-grid-full-width .grid__column.is-1,.print-grid-full-width .grid__column.is-3{display:none}}.rich-text{margin-top:3rem}@media (min-width:90rem){.rich-text{margin-top:4.5rem}}.rich-text .gnw_colhead,.rich-text .gnw_heading,.rich-text .gnw_subhead,.rich-text .gnw_table_border_collapse td.gnw_colhead,.rich-text .gnw_table_border_collapse td.gnw_heading,.rich-text .gnw_table_border_collapse td.gnw_subhead{text-align:center;vertical-align:middle}.rich-text .gnw_colhead_uline,.rich-text .gnw_table_border_collapse td.gnw_colhead_uline{border-bottom:1pt solid #000;text-align:center;vertical-align:middle}.rich-text .gnw_colhead_dline,.rich-text .gnw_table_border_collapse td.gnw_colhead_dline{border-bottom:2.5pt double #000;text-align:center;vertical-align:middle}.rich-text .gnw_label,.rich-text .gnw_table_border_collapse td.gnw_label{text-align:left;vertical-align:middle}.rich-text .gnw_label_uline,.rich-text .gnw_table_border_collapse td.gnw_label_uline{border-bottom:1pt solid #000;text-align:left;vertical-align:middle}.rich-text .gnw_label_uline_i10,.rich-text .gnw_table_border_collapse td.gnw_label_uline_i10{border-bottom:1pt solid #000;padding-left:10px;text-align:left;vertical-align:middle}.rich-text .gnw_label_uline_i15,.rich-text .gnw_table_border_collapse td.gnw_label_uline_i15{border-bottom:1pt solid #000;padding-left:15px;text-align:left;vertical-align:middle}.rich-text .gnw_label_uline_i20,.rich-text .gnw_table_border_collapse td.gnw_label_uline_i20{border-bottom:1pt solid #000;padding-left:20px;text-align:left;vertical-align:middle}.rich-text .gnw_label_uline_i25,.rich-text .gnw_table_border_collapse td.gnw_label_uline_i25{border-bottom:1pt solid #000;padding-left:25px;text-align:left;vertical-align:middle}.rich-text .gnw_label_uline_i30,.rich-text .gnw_table_border_collapse td.gnw_label_uline_i30{border-bottom:1pt solid #000;padding-left:30px;text-align:left;vertical-align:middle}.rich-text .gnw_label_dline_i10,.rich-text .gnw_table_border_collapse td.gnw_label_dline_i10{border-bottom:2.5pt double #000;padding-left:10px;text-align:left;vertical-align:middle}.rich-text .gnw_label_dline_i15,.rich-text .gnw_table_border_collapse td.gnw_label_dline_i15{border-bottom:2.5pt double #000;padding-left:15px;text-align:left;vertical-align:middle}.rich-text .gnw_label_dline_i20,.rich-text .gnw_table_border_collapse td.gnw_label_dline_i20{border-bottom:2.5pt double #000;padding-left:20px;text-align:left;vertical-align:middle}.rich-text .gnw_label_dline_i25,.rich-text .gnw_table_border_collapse td.gnw_label_dline_i25{border-bottom:2.5pt double #000;padding-left:25px;text-align:left;vertical-align:middle}.rich-text .gnw_label_dline_i30,.rich-text .gnw_table_border_collapse td.gnw_label_dline_i30{border-bottom:2.5pt double #000;padding-left:30px;text-align:left;vertical-align:middle}.rich-text .gnw_label_ulinetop,.rich-text .gnw_table_border_collapse td.gnw_label_ulinetop{border-top:1pt solid #000;text-align:left;vertical-align:middle}.rich-text .gnw_label_dline,.rich-text .gnw_table_border_collapse td.gnw_label_dline{border-bottom:2.5pt double #000;text-align:left;vertical-align:middle}.rich-text .gnw_label_i10,.rich-text .gnw_table_border_collapse td.gnw_label_i10{padding-left:10px;text-align:left;vertical-align:middle}.rich-text .gnw_label_i15,.rich-text .gnw_table_border_collapse td.gnw_label_i15{padding-left:15px;text-align:left;vertical-align:middle}.rich-text .gnw_label_i20,.rich-text .gnw_table_border_collapse td.gnw_label_i20{padding-left:20px;text-align:left;vertical-align:middle}.rich-text .gnw_label_i25,.rich-text .gnw_table_border_collapse td.gnw_label_i25{padding-left:25px;text-align:left;vertical-align:middle}.rich-text .gnw_label_i30,.rich-text .gnw_table_border_collapse td.gnw_label_i30{padding-left:30px;text-align:left;vertical-align:middle}.rich-text .gnw_num,.rich-text .gnw_table_border_collapse td.gnw_num{text-align:right;vertical-align:middle;white-space:nowrap}.rich-text .gnw_num_uline,.rich-text .gnw_table_border_collapse td.gnw_num_uline{border-bottom:1pt solid #000;text-align:right;vertical-align:middle;white-space:nowrap}.rich-text .gnw_num_ulinetop,.rich-text .gnw_table_border_collapse td.gnw_num_ulinetop{border-top:1pt solid #000;text-align:right;vertical-align:middle;white-space:nowrap}.rich-text .gnw_num_dline,.rich-text .gnw_table_border_collapse td.gnw_num_dline{border-bottom:2.5pt double #000;text-align:right;vertical-align:middle;white-space:nowrap}.rich-text .gnw_num_dlinetop,.rich-text .gnw_table_border_collapse td.gnw_num_dlinetop{border-top:2.5pt double #000;text-align:right;vertical-align:middle;white-space:nowrap}.rich-text .gnw_data,.rich-text .gnw_table_border_collapse td.gnw_data{text-align:left;vertical-align:middle;white-space:nowrap}.rich-text .gnw_data_uline,.rich-text .gnw_table_border_collapse td.gnw_data_uline{border-bottom:1pt solid #000;text-align:left;vertical-align:middle}.rich-text .gnw_data_dline,.rich-text .gnw_table_border_collapse td.gnw_data_dline{border-bottom:2.5pt double #000;text-align:left;vertical-align:middle}.rich-text .gnw_news_media_box{border:1px solid #a9a9a9;margin:15px 6px 6px}.rich-text .gnw_media_caption,.rich-text .gnw_table_border_collapse td.gnw_media_caption{font-size:8pt}.rich-text .gnw_media_bgcolor{background-color:transparent}.rich-text .gnw_table{border-collapse:separate;border-spacing:6px}.rich-text .gnw_table_border_collapse td.gnw_videotitle,.rich-text .gnw_videotitle{color:#1d5296;font-weight:700}.rich-text .gnw_border_top_solid{border-top:1px solid #000!important}.rich-text .gnw_border_right_solid{border-right:1px solid #000!important}.rich-text .gnw_border_bottom_solid{border-bottom:1px solid #000!important}.rich-text .gnw_border_left_solid{border-left:1px solid #000!important}.rich-text .gnw_border_top_double{border-top:3px double #000!important}.rich-text .gnw_border_right_double{border-right:3px double #000!important}.rich-text .gnw_border_bottom_double{border-bottom:3px double #000!important}.rich-text .gnw_border_left_double{border-left:3px double #000!important}.rich-text .gnw_table_border_collapse{border-collapse:collapse!important}.rich-text .gnw_align_left{text-align:left!important;vertical-align:middle}.rich-text .gnw_align_center{text-align:center!important;vertical-align:middle}.rich-text .gnw_align_right{text-align:right!important;vertical-align:middle}.rich-text .gnw_align_justify{text-align:justify!important;vertical-align:middle}.rich-text .gnw_vertical_align_top{vertical-align:top!important}.rich-text .gnw_vertical_align_middle{vertical-align:middle!important}.rich-text .gnw_vertical_align_bottom{vertical-align:bottom!important}.rich-text .gnw_padding_left_none{padding-left:0!important}.rich-text .gnw_padding_right_none{padding-right:0!important}.rich-text .gnw_table_border_spacing{border-collapse:separate!important;border-spacing:0}.rich-text .gnw_release_detail_printview{font:11pt;padding:20px}.rich-text .logo-area_printview span{display:inline-block;margin-bottom:15px;margin-right:30px}.rich-text .gnw_hidden_cell{display:none}.rich-text table{color:var(--color-text-primary);display:block;font-size:1rem;font-weight:400;line-height:1.5;max-width:100%;overflow:hidden;overflow-x:auto}.rich-text table *{padding:0}@media (min-width:48rem){.rich-text table{display:table;max-width:none}}.rich-text tbody{display:block;max-width:none}@media (min-width:48rem){.rich-text tbody{display:table-row-group;min-width:none}}[dir=rtl] .rich-text ol{padding:0 1.25rem 0 0}[dir=rtl] .rich-text ol li{padding:0 .625rem 0 0}[dir=rtl] .rich-text ol li:before{left:unset;right:-1.25rem}[dir=rtl] .rich-text ol,[dir=rtl] .rich-text ul li{padding:0 1.25rem 0 0}[dir=rtl] .rich-text ul li:before{left:unset;right:0}.rich-text>div{box-sizing:border-box;margin:0;padding:0}.rich-text>div>*{margin:1.625rem 0 0;padding:0}@media (min-width:48rem){.rich-text>div>*{margin:1.75rem 0 0}}.rich-text>div>:first-child{margin:0}.rich-text br{margin:0}.rich-text ol>li,.rich-text ul>li{display:block;margin:.5rem 0 0;padding:0 0 0 1.25rem;position:relative}.rich-text ol{counter-reset:item;padding:0 0 0 1.25rem}.rich-text ol>li{counter-increment:item;padding:0 0 0 .625rem}.rich-text ol>li:before{content:counter(item) \".\";left:-1.25rem;position:absolute}.rich-text ul{counter-increment:none;list-style:none}.rich-text ul>li:before{background-color:var(--color-black-200);border-radius:50%;content:\"\";display:block;height:.4375rem;left:0;position:absolute;top:.625rem;width:.4375rem}@media (min-width:48rem){.rich-text ul>li:before{top:.65625rem}}@media (min-width:64rem){.rich-text ul>li:before{top:.7375rem}}@media (min-width:90rem){.rich-text ul>li:before{top:.775rem}}@media print{.rich-text ul>li:before{-webkit-print-color-adjust:exact;print-color-adjust:exact}}.rich-text ul>li ul li:before{background-color:transparent;border:1.5px solid var(--color-black-200);height:.3125rem;width:.3125rem}.rich-text>div>p{margin-top:1rem}.rich-text.rich-text--is-footnote{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:.875rem;font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem}@media (min-width:48rem){.rich-text.rich-text--is-footnote{font-size:1rem;line-height:1.3125rem}}.rich-text.rich-text--is-footnote ul li:before{top:.375rem}.rich-text.rich-text--is-footnote ol li{padding:0 0 0 .3125rem}.rich-text.rich-text--is-footnote .text-link{min-height:unset}.rich-text.rich-text--is-footnote .text-link .text-link__link{gap:.1875rem}.rich-text.rich-text--is-footnote .text-link .text-link__icon-container{padding:0;transform:scale(.75) translateY(-.25rem)}.rich-text.rich-text--is-footer-type{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--footnotes-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem;margin-top:0}@media (min-width:48rem){.rich-text.rich-text--is-footer-type{font-size:var(--footnotes-font-size-medium-up)}}.rich-text figure,.rich-text img{height:auto;max-width:100%}.rich-text sup.hugin{vertical-align:middle!important}.rich-text .subscript,.rich-text .superscript{font-size:80%;line-height:80%}.rich-text .superscript{vertical-align:super}.rich-text .subscript{vertical-align:sub}.rich-text .headline{margin-top:3rem}@media (min-width:90rem){.rich-text .headline{margin-top:4.5rem}}.rich-text a[href]:not(.text-link a){color:#00e;text-decoration:underline}.rich-text p>.text-link{display:inline-block}.rich-text .text-link a,.rich-text .text-link button{font-size:inherit;line-height:inherit;position:relative}.rich-text .text-link a:after,.rich-text .text-link button:after{background:currentcolor;bottom:.125rem;content:\"\";height:.0625rem;position:absolute;width:100%}.rich-text>div>.icon-container{display:block}.rich-text h1 b,.rich-text h1 strong,.rich-text h2 b,.rich-text h2 strong,.rich-text h3 b,.rich-text h3 strong,.rich-text h4 b,.rich-text h4 strong,.rich-text h5 b,.rich-text h5 strong,.rich-text h6 b,.rich-text h6 strong{font-weight:700}.side-by-side{display:block;margin-top:3rem}@media (min-width:48rem){.side-by-side{align-items:center;display:flex;justify-content:flex-start}.side-by-side.side-by-side--right{justify-content:flex-end}.side-by-side.side-by-side--space-between{justify-content:space-between}}@media (min-width:90rem){.side-by-side{margin-top:4.5rem}}.side-by-side:only-child{margin-top:0}.side-by-side.side-by-side--top{align-items:flex-start}.side-by-side.side-by-side--bottom{align-items:flex-end}.side-by-side.side-by-side--equal-ratio>*{flex:1 1}@media (min-width:48rem){.side-by-side>*{margin-top:0!important}}.side-by-side>:not(:first-child){margin-top:1rem}@media (min-width:48rem){.side-by-side>:not(:first-child){margin-top:0;margin-inline-start:24px}}@media (min-width:48rem){.side-by-side .side-by-side{align-items:flex-start;flex-direction:column;gap:1rem}.side-by-side .side-by-side>*{margin-inline-start:0}}@font-face{font-family:swiper-icons;font-style:normal;font-weight:400;src:url(data:application/font-woff;charset=utf-8;base64,\\ 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)}:root{--swiper-theme-color:#007aff}:host{display:block;margin-left:auto;margin-right:auto;position:relative;z-index:1}.swiper{display:block;list-style:none;margin-left:auto;margin-right:auto;padding:0;position:relative;z-index:1}.swiper-vertical>.swiper-wrapper{flex-direction:column}.swiper-wrapper{box-sizing:content-box;display:flex;height:100%;position:relative;transition-property:transform;transition-timing-function:var(--swiper-wrapper-transition-timing-function,initial);width:100%;z-index:1}.swiper-android .swiper-slide,.swiper-ios .swiper-slide,.swiper-wrapper{transform:translateZ(0)}.swiper-horizontal{touch-action:pan-y}.swiper-vertical{touch-action:pan-x}.swiper-slide{display:block;flex-shrink:0;height:100%;position:relative;transition-property:transform;width:100%}.swiper-slide-invisible-blank{visibility:hidden}.swiper-autoheight,.swiper-autoheight .swiper-slide{height:auto}.swiper-autoheight .swiper-wrapper{align-items:flex-start;transition-property:transform,height}.swiper-backface-hidden .swiper-slide{backface-visibility:hidden;transform:translateZ(0)}.swiper-3d.swiper-css-mode .swiper-wrapper{perspective:1200px}.swiper-3d .swiper-wrapper{transform-style:preserve-3d}.swiper-3d{perspective:1200px}.swiper-3d .swiper-cube-shadow,.swiper-3d .swiper-slide{transform-style:preserve-3d}.swiper-css-mode>.swiper-wrapper{-ms-overflow-style:none;overflow:auto;scrollbar-width:none}.swiper-css-mode>.swiper-wrapper::-webkit-scrollbar{display:none}.swiper-css-mode>.swiper-wrapper>.swiper-slide{scroll-snap-align:start start}.swiper-css-mode.swiper-horizontal>.swiper-wrapper{scroll-snap-type:x mandatory}.swiper-css-mode.swiper-vertical>.swiper-wrapper{scroll-snap-type:y mandatory}.swiper-css-mode.swiper-free-mode>.swiper-wrapper{scroll-snap-type:none}.swiper-css-mode.swiper-free-mode>.swiper-wrapper>.swiper-slide{scroll-snap-align:none}.swiper-css-mode.swiper-centered>.swiper-wrapper:before{content:\"\";flex-shrink:0;order:9999}.swiper-css-mode.swiper-centered>.swiper-wrapper>.swiper-slide{scroll-snap-align:center center;scroll-snap-stop:always}.swiper-css-mode.swiper-centered.swiper-horizontal>.swiper-wrapper>.swiper-slide:first-child{margin-inline-start:var(--swiper-centered-offset-before)}.swiper-css-mode.swiper-centered.swiper-horizontal>.swiper-wrapper:before{height:100%;min-height:1px;width:var(--swiper-centered-offset-after)}.swiper-css-mode.swiper-centered.swiper-vertical>.swiper-wrapper>.swiper-slide:first-child{margin-block-start:var(--swiper-centered-offset-before)}.swiper-css-mode.swiper-centered.swiper-vertical>.swiper-wrapper:before{height:var(--swiper-centered-offset-after);min-width:1px;width:100%}.swiper-3d .swiper-slide-shadow,.swiper-3d .swiper-slide-shadow-bottom,.swiper-3d .swiper-slide-shadow-left,.swiper-3d .swiper-slide-shadow-right,.swiper-3d .swiper-slide-shadow-top{height:100%;left:0;pointer-events:none;position:absolute;top:0;width:100%;z-index:10}.swiper-3d .swiper-slide-shadow{background:#00000026}.swiper-3d .swiper-slide-shadow-left{background-image:linear-gradient(270deg,#00000080,#0000)}.swiper-3d .swiper-slide-shadow-right{background-image:linear-gradient(90deg,#00000080,#0000)}.swiper-3d .swiper-slide-shadow-top{background-image:linear-gradient(0deg,#00000080,#0000)}.swiper-3d .swiper-slide-shadow-bottom{background-image:linear-gradient(180deg,#00000080,#0000)}.swiper-lazy-preloader{border:4px solid var(--swiper-preloader-color,var(--swiper-theme-color));border-radius:50%;border-top:4px solid transparent;box-sizing:border-box;height:42px;left:50%;margin-left:-21px;margin-top:-21px;position:absolute;top:50%;transform-origin:50%;width:42px;z-index:10}.swiper-watch-progress .swiper-slide-visible .swiper-lazy-preloader,.swiper:not(.swiper-watch-progress) .swiper-lazy-preloader{animation:swiper-preloader-spin 1s linear infinite}.swiper-lazy-preloader-white{--swiper-preloader-color:#fff}.swiper-lazy-preloader-black{--swiper-preloader-color:#000}@keyframes swiper-preloader-spin{0%{transform:rotate(0)}to{transform:rotate(1turn)}}.swiper-pagination{position:absolute;text-align:center;transform:translateZ(0);transition:opacity .3s;z-index:10}.swiper-pagination.swiper-pagination-hidden{opacity:0}.swiper-pagination-disabled>.swiper-pagination,.swiper-pagination.swiper-pagination-disabled{display:none!important}.swiper-horizontal>.swiper-pagination-bullets,.swiper-pagination-bullets.swiper-pagination-horizontal,.swiper-pagination-custom,.swiper-pagination-fraction{bottom:var(--swiper-pagination-bottom,8px);left:0;top:var(--swiper-pagination-top,auto);width:100%}.swiper-pagination-bullets-dynamic{font-size:0;overflow:hidden}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{position:relative;transform:scale(.33)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active,.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-main{transform:scale(1)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-prev{transform:scale(.66)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-prev-prev{transform:scale(.33)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-next{transform:scale(.66)}.swiper-pagination-bullets-dynamic .swiper-pagination-bullet-active-next-next{transform:scale(.33)}.swiper-pagination-bullet{background:var(--swiper-pagination-bullet-inactive-color,#000);border-radius:var(--swiper-pagination-bullet-border-radius,50%);display:inline-block;height:var(--swiper-pagination-bullet-height,var(--swiper-pagination-bullet-size,8px));opacity:var(--swiper-pagination-bullet-inactive-opacity,.2);width:var(--swiper-pagination-bullet-width,var(--swiper-pagination-bullet-size,8px))}button.swiper-pagination-bullet{-webkit-appearance:none;appearance:none;border:none;box-shadow:none;margin:0;padding:0}.swiper-pagination-clickable .swiper-pagination-bullet{cursor:pointer}.swiper-pagination-bullet:only-child{display:none!important}.swiper-pagination-bullet-active{background:var(--swiper-pagination-color,var(--swiper-theme-color));opacity:var(--swiper-pagination-bullet-opacity,1)}.swiper-pagination-vertical.swiper-pagination-bullets,.swiper-vertical>.swiper-pagination-bullets{left:var(--swiper-pagination-left,auto);right:var(--swiper-pagination-right,8px);top:50%;transform:translate3d(0,-50%,0)}.swiper-pagination-vertical.swiper-pagination-bullets .swiper-pagination-bullet,.swiper-vertical>.swiper-pagination-bullets .swiper-pagination-bullet{display:block;margin:var(--swiper-pagination-bullet-vertical-gap,6px) 0}.swiper-pagination-vertical.swiper-pagination-bullets.swiper-pagination-bullets-dynamic,.swiper-vertical>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic{top:50%;transform:translateY(-50%);width:8px}.swiper-pagination-vertical.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet,.swiper-vertical>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{display:inline-block;transition:transform .2s,top .2s}.swiper-horizontal>.swiper-pagination-bullets .swiper-pagination-bullet,.swiper-pagination-horizontal.swiper-pagination-bullets .swiper-pagination-bullet{margin:0 var(--swiper-pagination-bullet-horizontal-gap,4px)}.swiper-horizontal>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic,.swiper-pagination-horizontal.swiper-pagination-bullets.swiper-pagination-bullets-dynamic{left:50%;transform:translate(-50%);white-space:nowrap}.swiper-horizontal>.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet,.swiper-pagination-horizontal.swiper-pagination-bullets.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{transition:transform .2s,left .2s}.swiper-horizontal.swiper-rtl>.swiper-pagination-bullets-dynamic .swiper-pagination-bullet{transition:transform .2s,right .2s}.swiper-pagination-fraction{color:var(--swiper-pagination-fraction-color,inherit)}.swiper-pagination-progressbar{background:var(--swiper-pagination-progressbar-bg-color,rgba(0,0,0,.25));position:absolute}.swiper-pagination-progressbar .swiper-pagination-progressbar-fill{background:var(--swiper-pagination-color,var(--swiper-theme-color));height:100%;left:0;position:absolute;top:0;transform:scale(0);transform-origin:left top;width:100%}.swiper-rtl .swiper-pagination-progressbar .swiper-pagination-progressbar-fill{transform-origin:right top}.swiper-horizontal>.swiper-pagination-progressbar,.swiper-pagination-progressbar.swiper-pagination-horizontal,.swiper-pagination-progressbar.swiper-pagination-vertical.swiper-pagination-progressbar-opposite,.swiper-vertical>.swiper-pagination-progressbar.swiper-pagination-progressbar-opposite{height:var(--swiper-pagination-progressbar-size,4px);left:0;top:0;width:100%}.swiper-horizontal>.swiper-pagination-progressbar.swiper-pagination-progressbar-opposite,.swiper-pagination-progressbar.swiper-pagination-horizontal.swiper-pagination-progressbar-opposite,.swiper-pagination-progressbar.swiper-pagination-vertical,.swiper-vertical>.swiper-pagination-progressbar{height:100%;left:0;top:0;width:var(--swiper-pagination-progressbar-size,4px)}.swiper-pagination-lock{display:none}.swiper-fade.swiper-free-mode .swiper-slide{transition-timing-function:ease-out}.swiper-fade .swiper-slide{pointer-events:none;transition-property:opacity}.swiper-fade .swiper-slide .swiper-slide{pointer-events:none}.swiper-fade .swiper-slide-active,.swiper-fade .swiper-slide-active .swiper-slide-active{pointer-events:auto}.swiper{margin-top:1.5rem;overflow:hidden}@media (min-width:90rem){.swiper{margin-top:4.5rem}}.swiper .swiper-slide{height:auto}.swiper .swiper-slide>:first-child{margin-top:0}.swiper .swiper-slide .teaser:only-child{height:100%}.swiper .swiper-slide:focus,.swiper .swiper-slide:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.swiper .swiper-slide:focus:not(:focus-visible){outline:0}.swiper .swiper-pagination{-webkit-tap-highlight-color:transparent;padding:0 1.5rem;position:static}.swiper .swiper-pagination-current,.swiper .swiper-pagination-total{color:var(--color-roche-grey-700);font-size:var(--body-font-size-small-up);font-weight:400;line-height:1.8125rem}@media (min-width:64rem){.swiper .swiper-pagination-current,.swiper .swiper-pagination-total{font-size:var(--body-font-size-xlarge-up);line-height:2rem}}.swiper .swiper-pagination-fraction{color:var(--color-roche-grey-700);font-size:var(--body-font-size-small-up);font-weight:400;line-height:1.8125rem}@media (min-width:64rem){.swiper .swiper-pagination-fraction{font-size:var(--body-font-size-xlarge-up);line-height:2rem}}.swiper .swiper-pagination-current{margin:0 .375rem 0 0}.swiper .swiper-pagination-total{margin:0 0 0 .375rem}.swiper .swiper__button-next-custom,.swiper .swiper__button-prev-custom{align-items:center;display:flex;justify-content:center;margin:0;padding:.125rem;transition-duration:.2s;transition-property:background-color,color;transition-timing-function:ease-in}@media (min-width:48rem){.swiper .swiper__button-next-custom,.swiper .swiper__button-prev-custom{display:inline-block}}.swiper .swiper__button-next-custom .swiper__button-icon-custom,.swiper .swiper__button-prev-custom .swiper__button-icon-custom{color:var(--color-roche-grey-700);transition:color .2s ease-in}.swiper .swiper__button-next-custom.swiper__button--disabled,.swiper .swiper__button-prev-custom.swiper__button--disabled{cursor:default;opacity:.35}@media (hover:hover) and (pointer:fine){.swiper .swiper__button-next-custom:hover:not(.swiper__button--disabled),.swiper .swiper__button-prev-custom:hover:not(.swiper__button--disabled){background-color:var(--color-dark-blue-900)}.swiper .swiper__button-next-custom:hover:not(.swiper__button--disabled) .swiper__button-icon-custom,.swiper .swiper__button-prev-custom:hover:not(.swiper__button--disabled) .swiper__button-icon-custom{color:var(--color-white-100)}}.swiper .swiper__button-next-custom:focus,.swiper .swiper__button-next-custom:focus-visible,.swiper .swiper__button-prev-custom:focus,.swiper .swiper__button-prev-custom:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.swiper .swiper__button-next-custom:focus:not(:focus-visible),.swiper .swiper__button-prev-custom:focus:not(:focus-visible){outline:0}.swiper .swiper__controls{align-items:center;display:inline-flex;justify-content:center;-webkit-user-select:none;user-select:none}.swiper .swiper__controls-wrapper{display:flex;justify-content:center;margin-bottom:.0625rem;margin-top:2rem}@media (min-width:64rem){.swiper .swiper__controls-wrapper{margin-bottom:.125rem}}.swiper .swiper__controls-wrapper.swiper__controls-wrapper--navigation-hidden{margin-top:1.5625rem}@media (min-width:64rem){.swiper .swiper__controls-wrapper.swiper__controls-wrapper--navigation-hidden{margin-top:1.5rem}}.swiper .swiper__controls-wrapper.swiper__controls-wrapper--navigation-hidden .swiper__controls{display:none}.social-media{display:block;height:auto;position:relative}.social-media .social-media__overline{font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem;margin:0 0 2rem}@media (min-width:48rem){.social-media .social-media__overline{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.social-media .social-media__links-list{align-items:center;display:flex;flex-wrap:nowrap;gap:1.5rem;list-style:none;margin:0;padding:0}.social-media .social-media__icon{align-items:center;color:var(--color-roche-grey-700);display:flex;justify-content:center;transition:color .2s ease-in-out}.social-media .social-media__link-wrapper{overflow:visible;position:relative;text-align:center}.social-media .social-media__link-wrapper:hover .social-media__icon{color:var(--color-roche-blue-600)}.social-media .social-media__link{display:inline-block;height:100%;left:0;position:absolute;top:0;width:100%}.social-media .social-media__link:focus,.social-media .social-media__link:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.social-media .social-media__link:focus:not(:focus-visible){outline:0}.social-media .social-media__copy-feedback{left:50%;margin-top:1.5rem;opacity:0;pointer-events:none;position:absolute;top:60%;transform:translate(-50%);transition:opacity .2s ease-in-out,visibility .2s ease-in-out;visibility:hidden}.social-media .social-media__copy-feedback.social-media__copy-feedback--show{opacity:1;pointer-events:all;visibility:visible}.social-media .social-media__copy-feedback-content{background:var(--color-roche-grey-600);color:var(--color-white-100);font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem;padding:.5rem;position:relative;white-space:nowrap}@media (min-width:48rem){.social-media .social-media__copy-feedback-content{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.social-media .social-media__copy-feedback-arrow{border-bottom:.5625rem solid var(--color-roche-grey-600);border-left:.5625rem solid transparent;border-right:.5625rem solid transparent;bottom:100%;height:0;left:50%;position:absolute;transform:translate(-50%);width:0}.social-media.social-media--align-left .social-media__overline{text-align:left}.social-media.social-media--align-left .social-media__links-list{justify-content:left}.social-media.social-media--align-center .social-media__overline{text-align:center}.social-media.social-media--align-center .social-media__links-list{justify-content:center}.social-media.social-media--align-right .social-media__overline{text-align:right}.social-media.social-media--align-right .social-media__links-list{justify-content:right}.stage-home-teaser{display:flex;flex-direction:column;justify-content:space-between;overflow:hidden;padding:3rem 0;position:relative}@media (min-width:48rem){.stage-home-teaser{padding:4rem 0}}@media (min-width:90rem){.stage-home-teaser{padding:6rem 0}}.stage-home-teaser .stage-home-teaser__title{font-size:1.875rem;line-height:2.25rem;width:100%}@media (min-width:48rem){.stage-home-teaser .stage-home-teaser__title{font-size:2.5rem;line-height:3rem}}@media (min-width:90rem){.stage-home-teaser .stage-home-teaser__title{font-size:3rem;line-height:3.625rem}}@media (min-width:64rem){.stage-home-teaser .stage-home-teaser__title{width:83.3333333333%}}.stage-home-teaser .stage-home-teaser__description{font-family:roche-sans;font-size:var(--body-font-size-small-up);font-style:normal;font-weight:200;line-height:1.8125rem;margin:.5rem 0 2rem;width:100%}@media (min-width:64rem){.stage-home-teaser .stage-home-teaser__description{font-size:var(--body-font-size-xlarge-up);line-height:2rem;margin:1rem 0 2.5rem;width:83.3333333333%}}@media (min-width:90rem){.stage-home-teaser .stage-home-teaser__description{margin:1rem 0 3rem}}@media (min-width:48rem){.stage-home-teaser .stage-home-teaser__button-wrapper{width:fit-content}}.stage-home-teaser:after,.stage-home-teaser:before{background:var(--color-grey-500);content:\"\";display:block;height:132.5013%;inset-block-start:50%;inset-inline-end:0;opacity:0;position:absolute;transform-origin:top;transition:transform .1s ease-in;width:.0625rem}.stage-home-teaser:before{transform:rotate(-41deg) translateY(-50%) scale(0)}.stage-home-teaser:after{transform:rotate(41deg) translateY(-50%) scale(0)}@media (min-width:48rem){.stage-home-teaser:has(.stage-home-teaser__button-wrapper:hover):after,.stage-home-teaser:has(.stage-home-teaser__button-wrapper:hover):before{opacity:1;transition:transform .5s ease-in}}@media (min-width:48rem) and (prefers-reduced-motion:reduce){.stage-home-teaser:has(.stage-home-teaser__button-wrapper:hover):after,.stage-home-teaser:has(.stage-home-teaser__button-wrapper:hover):before{transition:opacity .5s ease 0s}}@media (min-width:48rem){.stage-home-teaser:has(.stage-home-teaser__button-wrapper:hover):before{transform:rotate(-41deg) translateY(-50%) scale(1)}.stage-home-teaser:has(.stage-home-teaser__button-wrapper:hover):after{transform:rotate(41deg) translateY(-50%) scale(1)}}.scale-on-scroll{display:block}.scale-on-scroll .image{transform:scale(clamp(1,var(--scale-factor),2));transform-origin:top center;transition:all .4s;transition-timing-function:cubic-bezier(0,0,0,1)}@media (prefers-reduced-motion:reduce){.scale-on-scroll .image{transform:none;transition:none}}.stage-home{display:block;margin-top:0}.stage-home .headline.headline--1{font-size:3.5rem;-webkit-hyphens:auto;hyphens:auto;line-height:4.1875rem;margin:0;opacity:0;overflow-wrap:break-word;padding:3rem 0;transform:translate3d(0,100px,0);transition:opacity .5s cubic-bezier(.25,.46,.45,.94) .2s,transform .5s cubic-bezier(.25,.46,.45,.94) .2s}@media (prefers-reduced-motion:reduce){.stage-home .headline.headline--1{transition:opacity .5s cubic-bezier(.25,.46,.45,.94) .2s}}@media (min-width:48rem){.stage-home .headline.headline--1{font-size:4rem;line-height:4.5625rem;padding:4rem calc(8.33333% + 2px) 4rem 0}}@media (min-width:64rem){.stage-home .headline.headline--1{padding:4rem calc(8.33333% + 2px) 6rem 0}}@media (min-width:90rem){.stage-home .headline.headline--1{font-size:5.5rem;line-height:6.3125rem;padding:4rem calc(8.33333% + 2.66667px) 6rem 0}}.stage-home.stage-home--heading-visible .headline.headline--1{opacity:1;transform:translateZ(0)}.stage-home.stage-home--original-branding .headline{font-size:3rem;line-height:3.625rem}@media (width >= 348px){.stage-home.stage-home--original-branding .headline{font-size:3.5rem;line-height:4.1875rem}}@media (width >= 399px){.stage-home.stage-home--original-branding .headline{max-width:22.375rem}}@media (width >= 463px){.stage-home.stage-home--original-branding .headline{max-width:42.6875rem}}@media (min-width:48rem){.stage-home.stage-home--original-branding .headline{font-size:4rem;line-height:4.5625rem;max-width:none}}@media (width >= 1000px){.stage-home.stage-home--original-branding .headline{max-width:58.75rem}}@media (min-width:90rem){.stage-home.stage-home--original-branding .headline{font-size:5.5rem;line-height:6.3125rem;max-width:none}}@media (width >= 1480px){.stage-home.stage-home--original-branding .headline{max-width:75rem}}.stage-home .image,.stage-home .scale-on-scroll.scale-on-scroll,.stage-home .video-player{margin-top:0}.stage-home .stage-home__teasers{display:grid;grid-auto-rows:1fr;grid-template-columns:1fr}@media (min-width:48rem){.stage-home .stage-home__teasers{grid-template-columns:repeat(2,1fr)}}@media (min-width:48rem){.stage-home .stage-home__teasers .stage-home-teaser:first-child{border-right:.0625rem solid var(--color-grey-500)}}@media (min-width:48rem){.stage-home .stage-home__teasers .stage-home-teaser~.stage-home-teaser{transform:translate(2rem)}}@media (min-width:64rem){.stage-home .stage-home__teasers .stage-home-teaser~.stage-home-teaser{transform:translate(4rem)}}@media (min-width:90rem){.stage-home .stage-home__teasers .stage-home-teaser~.stage-home-teaser{transform:translate(6rem)}}@media (min-width:48rem){[dir=rtl] .stage-home .stage-home__teasers .stage-home-teaser:first-child{border-left:.0625rem solid var(--color-grey-500);border-right:none}}@media (min-width:48rem){[dir=rtl] .stage-home .stage-home__teasers .stage-home-teaser~.stage-home-teaser{transform:translate(-2rem)}}@media (min-width:64rem){[dir=rtl] .stage-home .stage-home__teasers .stage-home-teaser~.stage-home-teaser{transform:translate(-4rem)}}@media (min-width:90rem){[dir=rtl] .stage-home .stage-home__teasers .stage-home-teaser~.stage-home-teaser{transform:translate(-6rem)}}[dir=rtl] .stage-home .headline{padding:3rem 0}@media (min-width:48rem){[dir=rtl] .stage-home .headline{padding:4rem 0 4rem calc(8.33333% + 2px)}}@media (min-width:64rem){[dir=rtl] .stage-home .headline{padding:4rem 0 6rem calc(8.33333% + 2px)}}@media (min-width:90rem){[dir=rtl] .stage-home .headline{padding:4rem 0 6rem calc(8.33333% + 2.66667px)}}.staging-hero{display:block;margin-top:0}.staging-hero .staging-hero__background{background:linear-gradient(121.21deg,#bde3ff -17.31%,#fff7f5 46.37%,#fff 65.87%);height:100%;left:calc(50% - 50vw);pointer-events:none;position:absolute;top:0;width:100vw}.staging-hero .staging-hero__image .image{margin-top:0}.staging-hero .staging-hero__wrapper{align-items:center;display:flex}.staging-hero .staging-hero__content{margin:0;position:relative;width:100%}.staging-hero .staging-hero__headline{font-size:3.5rem;height:100%;line-height:4.1875rem;margin:0}@media (min-width:48rem){.staging-hero .staging-hero__headline{font-size:4rem;line-height:4.5625rem}}@media (min-width:90rem){.staging-hero .staging-hero__headline{font-size:5.5rem;line-height:6.3125rem}}.staging-hero .staging-hero__text{font-family:roche-sans;font-size:1.25rem;font-style:normal;font-weight:200;line-height:2rem}@media (min-width:48rem){.staging-hero .staging-hero__text{font-size:1.375rem;line-height:2.1875rem}}@media (min-width:90rem){.staging-hero .staging-hero__text{font-size:1.625rem;line-height:2.625rem}}.staging-hero .staging-hero__divider{background-color:var(--color-roche-grey-400);bottom:0;content:\"\";height:1px;left:50%;margin:0 -50vw;position:absolute;right:50%;width:100vw}@media (min-width:48rem){.staging-hero.hero--variant-a{height:28.125rem}}@media (min-width:90rem){.staging-hero.hero--variant-a{height:37.5rem}}.staging-hero.hero--variant-a .staging-hero__image,.staging-hero.hero--variant-a .staging-hero__letter{display:none}.staging-hero.hero--variant-a .staging-hero__wrapper{padding:5rem 0 2rem}@media (min-width:48rem){.staging-hero.hero--variant-a .staging-hero__wrapper{height:100%;padding:0}}.staging-hero.hero--variant-a .staging-hero__wrapper .staging-hero__content{align-items:flex-start;display:flex;flex-direction:column}@media (min-width:48rem){.staging-hero.hero--variant-a .staging-hero__wrapper .staging-hero__content{align-items:center;flex-direction:row;height:100%;justify-content:space-between}}.staging-hero.hero--variant-a .staging-hero__headline{-webkit-hyphens:auto;hyphens:auto;overflow-wrap:break-word}@media (min-width:48rem){.staging-hero.hero--variant-a .staging-hero__headline{align-items:center;display:flex;padding-right:.75rem;width:50%}}@media (min-width:64rem){.staging-hero.hero--variant-a .staging-hero__headline{height:100%;padding-right:0;width:33.3333333333%}}.staging-hero.hero--variant-a .staging-hero__text{margin-top:1.5rem}@media (min-width:48rem){.staging-hero.hero--variant-a .staging-hero__text{align-items:center;display:flex;margin-top:0;padding-left:.75rem;width:50%}}@media (min-width:64rem){.staging-hero.hero--variant-a .staging-hero__text{border-left:1px solid var(--color-roche-grey-400);box-sizing:content-box;height:100%;padding-left:8.3333333333%;position:relative}.staging-hero.hero--variant-a .staging-hero__text:before{background-color:var(--color-roche-grey-400);bottom:11.75rem;content:\"\";height:18.5rem;left:-6.125rem;position:absolute;transform:rotate(-41deg);width:1px}.staging-hero.hero--variant-a .staging-hero__text:after{background-color:var(--color-roche-grey-400);content:\"\";height:18.5rem;left:-6.125rem;position:absolute;top:11.875rem;transform:rotate(41deg);width:1px}}@media (min-width:90rem){.staging-hero.hero--variant-a .staging-hero__text:before{bottom:15.6875rem;height:24.6875rem;left:-8.125rem}.staging-hero.hero--variant-a .staging-hero__text:after{height:24.8125rem;left:-8.1875rem;top:15.6875rem}}.staging-hero.hero--variant-b .staging-hero__wrapper{display:block;padding-bottom:2.5rem;padding-top:5rem}@media (min-width:48rem){.staging-hero.hero--variant-b .staging-hero__wrapper{padding-bottom:3rem;padding-top:6rem}}@media (min-width:90rem){.staging-hero.hero--variant-b .staging-hero__wrapper{padding-bottom:4.5rem;padding-top:8rem}}.staging-hero.hero--variant-b .staging-hero__wrapper .staging-hero__content{position:relative}.staging-hero.hero--variant-b .staging-hero__headline{font-size:2.5rem;line-height:3rem}@media (min-width:48rem){.staging-hero.hero--variant-b .staging-hero__headline{font-size:3rem;line-height:3.375rem}}@media (min-width:90rem){.staging-hero.hero--variant-b .staging-hero__headline{font-size:3.8125rem;line-height:4.375rem}}@media (min-width:64rem){.staging-hero.hero--variant-b .staging-hero__headline{width:83.3333333333%}}.staging-hero.hero--variant-b .staging-hero__divider{bottom:auto;position:relative;top:3rem}@media (min-width:90rem){.staging-hero.hero--variant-b .staging-hero__divider{top:4.5rem}}.staging-hero.hero--variant-b .staging-hero__letter{height:calc(100% + 40px + 5rem);left:-50vw;margin:0 auto;overflow:hidden;pointer-events:none;position:absolute;right:-50vw;top:-5rem;transform:translate(-2%);width:100vw}@media (min-width:48rem){.staging-hero.hero--variant-b .staging-hero__letter{height:calc(100% + 48px + 6rem);top:-6rem}}@media (min-width:64rem){.staging-hero.hero--variant-b .staging-hero__letter:before{background-color:var(--color-roche-grey-400);bottom:50%;content:\"\";height:67.5%;position:absolute;right:16px;transform:rotate(-41deg);transform-origin:center bottom;width:1px}.staging-hero.hero--variant-b .staging-hero__letter:after{background-color:var(--color-roche-grey-400);content:\"\";height:67.5%;position:absolute;right:16px;top:50%;transform:rotate(41deg);transform-origin:center top;width:1px}}@media (min-width:90rem){.staging-hero.hero--variant-b .staging-hero__letter{height:calc(100% + 12.5rem);top:-8rem}}.staging-hero.hero--variant-b .staging-hero__text{margin-top:1.5rem}@media (min-width:64rem){.staging-hero.hero--variant-b .staging-hero__text{width:66.6666666667%}}@media (min-width:48rem){[dir=rtl] .staging-hero.hero--variant-a .staging-hero__text{padding-left:0;padding-right:.75rem}}@media (min-width:64rem){[dir=rtl] .staging-hero.hero--variant-a .staging-hero__text{border-left:none;border-right:1px solid var(--color-roche-grey-400);padding-right:8.3333333333%}[dir=rtl] .staging-hero.hero--variant-a .staging-hero__text:before{left:auto;right:-6.125rem;transform:rotate(41deg)}[dir=rtl] .staging-hero.hero--variant-a .staging-hero__text:after{left:auto;right:-6.125rem;transform:rotate(-41deg);width:1px}}@media (min-width:90rem){[dir=rtl] .staging-hero.hero--variant-a .staging-hero__text:before{left:auto;right:-8.125rem}[dir=rtl] .staging-hero.hero--variant-a .staging-hero__text:after{left:auto;right:-8.1875rem}}[dir=rtl] .staging-hero.hero--variant-b .staging-hero__letter{transform:translate(2%)}@media (min-width:64rem){[dir=rtl] .staging-hero.hero--variant-b .staging-hero__letter:before{left:1rem;right:auto;transform:rotate(41deg)}[dir=rtl] .staging-hero.hero--variant-b .staging-hero__letter:after{left:1rem;right:auto;transform:rotate(-41deg)}}[dir=rtl] .staging-hero.hero--variant-b .staging-hero__image{margin-left:0;margin-right:0}@media (min-width:90rem){[dir=rtl] .staging-hero.hero--variant-b .staging-hero__image{margin-left:0;margin-right:0}}.stock-price{align-items:flex-start;display:flex;flex-direction:column;text-decoration:none}.stock-price:focus-visible:focus,.stock-price:focus-visible:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2}.stock-price:focus-visible:focus:not(:focus-visible){outline:0}.stock-price .stock-price__heading{color:var(--color-roche-grey-600);font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem;margin:0}@media (min-width:48rem){.stock-price .stock-price__heading{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.stock-price .stock-price__price{margin:.5rem 0 .25rem}.stock-price .stock-price__value{font-size:1.75rem;font-weight:400;line-height:2.125rem}@media (min-width:48rem){.stock-price .stock-price__value{font-size:1.875rem;line-height:2.4375rem}}@media (min-width:90rem){.stock-price .stock-price__value{font-size:2.5rem;line-height:3.125rem}}.stock-price .stock-price__currency{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem;margin-inline-start:.5rem}@media (min-width:48rem){.stock-price .stock-price__currency{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.stock-price .stock-price__unavailable{color:var(--color-text-primary);font-size:1.125rem;font-weight:400;line-height:1.6875rem;margin:.5rem 0 .25rem}@media (min-width:48rem){.stock-price .stock-price__unavailable{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.stock-price .stock-price__unavailable{font-size:1.25rem;line-height:1.875rem}}.stock-price .stock-price__daily-change{color:var(--color-roche-grey-700);display:flex;flex-wrap:wrap}.stock-price .stock-price__difference{white-space:nowrap}.stock-price .stock-price__relative-difference{margin-inline-end:.5rem}.stock-price .stock-price__price-difference{margin-inline-end:.25rem}.stock-price .stock-price__icon{align-items:center;display:inline-flex;justify-content:center;margin-inline-end:1rem}.stock-price .stock-price__icon.stock-price__icon--down{fill:var(--color-error);color:var(--color-error)}.stock-price .stock-price__icon.stock-price__icon--equal{fill:var(--color-roche-grey-600);color:var(--color-roche-grey-600)}.stock-price .stock-price__icon.stock-price__icon--up{fill:var(--color-success);color:var(--color-success)}.story-staging-hero{--background-aware-gradient-top-left:var(colors.$background-aware-gradient-top-left)}.theme--story .story-staging-hero{--background-aware-gradient-top-left:linear-gradient(140.87deg,#fac9b5 -68.64%,#fff 52.89%)}.story-staging-hero .story-staging-hero__background{background:var(--background-aware-gradient-top-left);height:100%;left:calc(50% - 50vw);pointer-events:none;position:absolute;top:0;width:100vw}.story-staging-hero .story-staging-hero__wrapper{align-items:center;display:flex;justify-content:center}.story-staging-hero .story-staging-hero__content{position:relative;width:100%}.story-staging-hero .story-staging-hero__header{font-size:3.5rem;line-height:4.1875rem}.story-staging-hero .story-staging-hero__header .story-staging-hero__headline{font-size:inherit;font-weight:inherit;margin:0}@media (min-width:48rem){.story-staging-hero .story-staging-hero__header{font-size:4rem;line-height:4.5625rem}}@media (min-width:90rem){.story-staging-hero .story-staging-hero__header{font-size:5.5rem;line-height:6.3125rem}}.story-staging-hero .story-staging-hero__text{font-family:roche-sans;font-size:1.25rem;font-style:normal;font-weight:200;line-height:2rem}@media (min-width:48rem){.story-staging-hero .story-staging-hero__text{font-size:1.375rem;line-height:2.1875rem}}@media (min-width:90rem){.story-staging-hero .story-staging-hero__text{font-size:1.625rem;line-height:2.625rem}}.story-staging-hero .story-staging-hero__divider{background-color:var(--color-roche-grey-400);bottom:0;content:\"\";height:1px;left:50%;margin:0 -50vw;position:absolute;right:50%;width:100vw}.story-staging-hero .story-staging-hero__story-type-wrapper{align-items:center;display:flex;margin-bottom:2.1875rem}.story-staging-hero .story-staging-hero__story-type{font-size:1.25rem;font-weight:400;line-height:1.625rem;text-transform:capitalize}@media (min-width:48rem){.story-staging-hero .story-staging-hero__story-type{font-size:1.25rem;line-height:1.875rem}}@media (min-width:90rem){.story-staging-hero .story-staging-hero__story-type{font-size:1.5rem;line-height:2.125rem}}.story-staging-hero .story-staging-hero__tag-wrapper{display:flex;flex-wrap:wrap;margin-top:2rem}.story-staging-hero.hero--variant-a{position:relative}@media (min-width:48rem){.story-staging-hero.hero--variant-a{height:25rem}}.story-staging-hero.hero--variant-a .story-staging-hero__image,.story-staging-hero.hero--variant-a .story-staging-hero__letter{display:none}.story-staging-hero.hero--variant-a .story-staging-hero__wrapper{padding:5rem 0 2rem}@media (min-width:48rem){.story-staging-hero.hero--variant-a .story-staging-hero__wrapper{height:100%;padding:0}}.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__content{align-items:flex-start;display:flex;flex-direction:column;overflow:hidden}@media (min-width:48rem){.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__content{align-items:center;flex-direction:row;height:100%;justify-content:space-between}}.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__header{-webkit-hyphens:auto;hyphens:auto;overflow-wrap:break-word}@media (min-width:48rem){.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__header{align-items:center;display:flex;padding-left:0;padding-right:.75rem;width:50%}}@media (min-width:64rem){.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__header{height:100%;padding-right:0;width:33.3333333333%}}.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text{margin-top:1.5rem}@media (min-width:48rem){.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text{align-items:center;display:flex;margin-top:0;padding-left:.75rem;width:50%}}@media (min-width:64rem){.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text{border-left:1px solid var(--color-roche-grey-400);box-sizing:content-box;height:100%;padding-left:8.3333333333%;position:relative}.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:before{background-color:var(--color-roche-grey-400);bottom:10.3125rem;content:\"\";height:18.5rem;left:-6.125rem;position:absolute;transform:rotate(-41deg);width:1px}.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:after{background-color:var(--color-roche-grey-400);content:\"\";height:18.5rem;left:-6.125rem;position:absolute;top:10.3125rem;transform:rotate(41deg);width:1px}}@media (min-width:90rem){.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:before{bottom:9.375rem;height:24.6875rem;left:-8.125rem}.story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:after{height:24.8125rem;left:-8.1875rem;top:9.375rem}}.story-staging-hero.hero--variant-b .story-staging-hero__wrapper{display:block;padding-bottom:40px;padding-top:80px}@media (min-width:48rem){.story-staging-hero.hero--variant-b .story-staging-hero__wrapper{padding-bottom:48px;padding-top:96px}}@media (min-width:90rem){.story-staging-hero.hero--variant-b .story-staging-hero__wrapper{padding-bottom:72px;padding-top:128px}}.story-staging-hero.hero--variant-b .story-staging-hero__wrapper .story-staging-hero__header{font-size:2.5rem;line-height:3rem}@media (min-width:48rem){.story-staging-hero.hero--variant-b .story-staging-hero__wrapper .story-staging-hero__header{font-size:3rem;line-height:3.375rem}}@media (min-width:90rem){.story-staging-hero.hero--variant-b .story-staging-hero__wrapper .story-staging-hero__header{font-size:3.8125rem;line-height:4.375rem}}@media (min-width:64rem){.story-staging-hero.hero--variant-b .story-staging-hero__wrapper .story-staging-hero__header{width:66.6666666667%}}.story-staging-hero.hero--variant-b .story-staging-hero__content{position:relative}.story-staging-hero.hero--variant-b .story-staging-hero__divider{bottom:auto;position:relative;top:48px}@media (min-width:90rem){.story-staging-hero.hero--variant-b .story-staging-hero__divider{top:72px}}.story-staging-hero.hero--variant-b .story-staging-hero__letter{height:calc(100% + 128px);left:-50vw;margin:0 auto;overflow:hidden;pointer-events:none;position:absolute;right:-50vw;top:-5rem;transform:translate(-2%);width:100vw}@media (min-width:48rem){.story-staging-hero.hero--variant-b .story-staging-hero__letter{height:calc(100% + 144px);top:-96px}}@media (min-width:64rem){.story-staging-hero.hero--variant-b .story-staging-hero__letter:before{background-color:var(--color-roche-grey-400);bottom:50%;content:\"\";height:67.5%;position:absolute;right:1rem;transform:rotate(-41deg);transform-origin:center bottom;width:1px}.story-staging-hero.hero--variant-b .story-staging-hero__letter:after{background-color:var(--color-roche-grey-400);content:\"\";height:67.5%;position:absolute;right:1rem;top:50%;transform:rotate(41deg);transform-origin:center top;width:1px}}@media (min-width:90rem){.story-staging-hero.hero--variant-b .story-staging-hero__letter{height:calc(100% + 12.5rem);top:-128px}}.story-staging-hero.hero--variant-b .story-staging-hero__text{margin-top:1.5rem}@media (min-width:64rem){.story-staging-hero.hero--variant-b .story-staging-hero__text{width:66.6666666667%}}.story-staging-hero .story-staging-hero__icon{height:1.5rem;margin-right:.6875rem}.story-staging-hero .story-staging-hero__image>*{margin-top:0}[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper{padding-bottom:2rem;padding-top:5rem}@media (min-width:48rem){[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper{padding:0}}@media (min-width:48rem){[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__header{padding-left:.75rem;padding-right:0}}@media (min-width:64rem){[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__header{padding:0}}@media (min-width:48rem){[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text{padding-left:0;padding-right:.75rem}}@media (min-width:64rem){[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text{border-left:none;border-right:1px solid var(--color-roche-grey-400);padding-right:8.3333333333%}[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:before{left:auto;right:-6.125rem;transform:rotate(41deg)}[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:after{left:auto;right:-6.125rem;transform:rotate(-41deg);width:1px}}@media (min-width:90rem){[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:before{left:auto;right:-8.125rem}[dir=rtl] .story-staging-hero.hero--variant-a .story-staging-hero__wrapper .story-staging-hero__text:after{left:auto;right:-8.1875rem}}[dir=rtl] .story-staging-hero.hero--variant-b .story-staging-hero__letter{transform:translate(2%)}@media (min-width:64rem){[dir=rtl] .story-staging-hero.hero--variant-b .story-staging-hero__letter:before{left:16px;right:auto;transform:rotate(41deg)}[dir=rtl] .story-staging-hero.hero--variant-b .story-staging-hero__letter:after{left:16px;right:auto;transform:rotate(-41deg)}}[dir=rtl] .story-staging-hero.hero--variant-b .story-staging-hero__text{margin-top:1rem}.date{color:var(--color-roche-grey-600);display:flex}.story-teaser{box-shadow:0 0 .625rem var(--color-black-100);display:block;overflow-y:hidden;position:relative;width:100%}.story-teaser .image{margin:0}.story-teaser .story-teaser__tag{align-items:center;display:flex;gap:.5rem}.story-teaser .story-teaser__image-container{opacity:1;transition-duration:.3s,.2s;transition-property:opacity,border-bottom-color;transition-timing-function:cubic-bezier(.33,1,.68,1)}.story-teaser .story-teaser__image-container .video-player{margin:0}.story-teaser .story-teaser__details{display:flex;flex-direction:column;gap:.75rem}.story-teaser .story-teaser__title{-webkit-box-orient:vertical;-webkit-line-clamp:3;display:-webkit-box;overflow:hidden}.story-teaser .story-teaser__description{-webkit-box-orient:vertical;-webkit-line-clamp:4;display:-webkit-box;overflow:hidden}.story-teaser .story-teaser__date{font-family:roche-sans;font-size:var(--label-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem}@media (min-width:48rem){.story-teaser .story-teaser__date{font-size:var(--label-font-size-medium-up);line-height:1.3125rem}}.story-teaser.story-teaser--variant-a{background-color:var(--color-white-100);height:100%;transition:box-shadow .3s cubic-bezier(.33,1,.68,1)}.story-teaser.story-teaser--variant-a .story-teaser__image-container{border-bottom:.125rem solid var(--color-neutral-400)}.story-teaser.story-teaser--variant-a .story-teaser__tag{fill:var(--color-grey-800);-webkit-backdrop-filter:blur(2rem);backdrop-filter:blur(2rem);background-color:var(--color-white-500);border-radius:4.25rem;color:var(--color-grey-800);font-family:roche-sans;font-size:var(--button-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;left:1.25rem;line-height:1.3125rem;padding:.5rem 1rem;position:absolute;top:1.25rem;transition-duration:.2s;transition-property:background-color,color,fill;transition-timing-function:cubic-bezier(.33,1,.68,1);z-index:50}@media (min-width:48rem){.story-teaser.story-teaser--variant-a .story-teaser__tag{font-size:var(--button-font-size-medium-up);line-height:1.4375rem}}@media (min-width:90rem){.story-teaser.story-teaser--variant-a .story-teaser__tag{left:1.5rem;top:1.5rem}}.story-teaser.story-teaser--variant-a .story-teaser__details{padding:1.890625rem 1.5rem 2rem}@media (min-width:48rem){.story-teaser.story-teaser--variant-a .story-teaser__details{padding:1.921875rem 1.5rem 2rem}}@media (min-width:64rem){.story-teaser.story-teaser--variant-a .story-teaser__details{padding:1.875rem 1.5rem 2rem}}@media (min-width:90rem){.story-teaser.story-teaser--variant-a .story-teaser__details{padding:2.375rem 2rem 2rem}}.story-teaser.story-teaser--variant-a .story-teaser__description-container{transition:transform .3s cubic-bezier(.33,1,.68,1)}@media (prefers-reduced-motion:reduce){.story-teaser.story-teaser--variant-a .story-teaser__description-container{transition:none}}.story-teaser.story-teaser--variant-a .story-teaser__title{font-size:1.25rem;font-weight:400;height:78px;line-height:1.625rem}@media (min-width:48rem){.story-teaser.story-teaser--variant-a .story-teaser__title{font-size:1.25rem;line-height:1.875rem}}@media (min-width:90rem){.story-teaser.story-teaser--variant-a .story-teaser__title{font-size:1.5rem;line-height:2.125rem}}@media (min-width:48rem){.story-teaser.story-teaser--variant-a .story-teaser__title{height:90px}}@media (min-width:90rem){.story-teaser.story-teaser--variant-a .story-teaser__title{height:102px}}.story-teaser.story-teaser--variant-a .story-teaser__description{height:0;opacity:0;visibility:hidden}.story-teaser.story-teaser--variant-b{color:var(--color-white-100);transition:box-shadow .2s cubic-bezier(.33,1,.68,1)}.story-teaser.story-teaser--variant-b .story-teaser__details{bottom:0;padding:2rem 1.5rem;position:absolute;transition:all .2s cubic-bezier(.33,1,.68,1);z-index:50}@media (prefers-reduced-motion:reduce){.story-teaser.story-teaser--variant-b .story-teaser__details{transition:none}}.story-teaser.story-teaser--variant-b .story-teaser__tag{fill:var(--color-white-100);font-size:1.125rem;font-weight:400;line-height:1.6875rem}@media (min-width:48rem){.story-teaser.story-teaser--variant-b .story-teaser__tag{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.story-teaser.story-teaser--variant-b .story-teaser__tag{font-size:1.25rem;line-height:1.875rem}}.story-teaser.story-teaser--variant-b .story-teaser__image-container:before{background:linear-gradient(34.31deg,var(--color-black-900-a08) 0,var(--color-black-000) 102.12%);content:\"\";height:100%;left:0;opacity:1;position:absolute;top:0;transition:opacity .2s cubic-bezier(.65,0,.35,1);width:100%;z-index:50}@media (min-width:90rem){.story-teaser.story-teaser--variant-b .story-teaser__image-container:before{background:linear-gradient(359.16deg,var(--color-black-900-a09) .67%,var(--color-black-000) 82.88%)}}.story-teaser.story-teaser--variant-b .story-teaser__image-container:after{background:linear-gradient(46.32deg,var(--color-black-900-a08) -8.5%,var(--color-black-000) 115.75%),var(--color-dark-blue-900);content:\"\";height:100%;left:0;opacity:0;position:absolute;top:0;transition:opacity .2s cubic-bezier(.65,0,.35,1);width:100%}.story-teaser.story-teaser--variant-b .story-teaser__title{font-size:1.75rem;line-height:2.125rem}@media (min-width:48rem){.story-teaser.story-teaser--variant-b .story-teaser__title{font-size:1.875rem;line-height:2.4375rem}}@media (min-width:90rem){.story-teaser.story-teaser--variant-b .story-teaser__title{font-size:2.5rem;line-height:3.125rem}}.story-teaser.story-teaser--variant-b .story-teaser__description{opacity:0;position:absolute;visibility:hidden}.story-teaser.story-teaser--variant-c{color:var(--color-white-100);margin-top:3rem}@media (min-width:90rem){.story-teaser.story-teaser--variant-c{margin-top:4.5rem}}.story-teaser.story-teaser--variant-c .story-teaser__image-container{height:480px}.story-teaser.story-teaser--variant-c .story-teaser__details{display:flex;flex-direction:column;gap:1.5rem;height:100%;justify-content:center;margin:0 2.5rem;position:absolute;top:0;z-index:250}@media (min-width:90rem){.story-teaser.story-teaser--variant-c .story-teaser__details{gap:2rem;margin:0 4rem}}.story-teaser.story-teaser--variant-c .story-teaser__image-container:after{background:linear-gradient(46.32deg,var(--color-black-900-a07) -8.5%,var(--color-black-000) 115.75%);content:\"\";height:100%;left:0;position:absolute;top:0;width:100%;z-index:250}.story-teaser.story-teaser--variant-c .story-teaser__tag{fill:var(--color-white-100);font-family:roche-sans;font-size:var(--label-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem}@media (min-width:48rem){.story-teaser.story-teaser--variant-c .story-teaser__tag{font-size:var(--label-font-size-medium-up);line-height:1.3125rem}}.story-teaser.story-teaser--variant-c .story-teaser__description-container{display:flex;flex-direction:column;gap:1rem}.story-teaser.story-teaser--variant-c .story-teaser__title{font-size:1.875rem;line-height:2.25rem;margin-top:1rem;max-width:30ch}@media (min-width:48rem){.story-teaser.story-teaser--variant-c .story-teaser__title{font-size:2.5rem;line-height:3rem}}@media (min-width:90rem){.story-teaser.story-teaser--variant-c .story-teaser__title{font-size:3rem;line-height:3.625rem}}.story-teaser.story-teaser--variant-c .story-teaser__description{max-width:50ch}.story-teaser.story-teaser--variant-c .button{width:max-content}.story-teaser.story-teaser--unpublished{background:#ff0000b3;border:1px dashed maroon}.story-teaser:focus-visible:not(.story-teaser--variant-c),.story-teaser:hover:not(.story-teaser--variant-c){box-shadow:0 .3125rem 1.25rem var(--color-black-200)}.story-teaser:focus-visible:not(.story-teaser--variant-c):focus,.story-teaser:focus-visible:not(.story-teaser--variant-c):focus-visible,.story-teaser:hover:not(.story-teaser--variant-c):focus,.story-teaser:hover:not(.story-teaser--variant-c):focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:2px}.story-teaser:focus-visible:not(.story-teaser--variant-c):focus:not(:focus-visible),.story-teaser:hover:not(.story-teaser--variant-c):focus:not(:focus-visible){outline:0}.story-teaser:focus-visible:not(.story-teaser--variant-c) .story-teaser__description,.story-teaser:hover:not(.story-teaser--variant-c) .story-teaser__description{height:auto;opacity:1;padding-top:1rem;visibility:visible}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__tag,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__tag{fill:var(--color-roche-grey-600);background-color:var(--color-roche-grey-100);color:var(--color-roche-grey-600)}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__image-container,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__image-container{border-bottom-color:transparent;opacity:0;transition-duration:.1s}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__description,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__description{position:absolute;transition:opacity .3s cubic-bezier(.33,1,.68,1);transition-delay:.1s}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__description-container,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-a .story-teaser__description-container{transform:translateY(-250%)}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__image-container:before,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__image-container:before{opacity:0;transition:opacity .2s cubic-bezier(.65,0,.35,1)}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__image-container:after,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__image-container:after{opacity:1;transition:opacity .2s cubic-bezier(.65,0,.35,1)}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__details,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__details{transform:translateY(calc(var(--teaser-hover-offset)*-1 - 1rem))}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__description-container,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__description-container{position:relative}.story-teaser:focus-visible:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__description,.story-teaser:hover:not(.story-teaser--variant-c).story-teaser--variant-b .story-teaser__description{opacity:1;transition:opacity .2s cubic-bezier(.33,1,.68,1)}.subline{display:flex;flex-direction:column;gap:1.5rem}.subline .subline__attribution-phrase{color:var(--color-roche-grey-600);font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem}@media (min-width:48rem){.subline .subline__attribution-phrase{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.subline .subline__author-container{display:flex;gap:1.5rem}.subline .subline__avatar{height:3rem;width:3rem}.subline .subline__author-description-container{align-self:center}.subline .subline__author{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--footnotes-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.1875rem}@media (min-width:48rem){.subline .subline__author{font-size:var(--footnotes-font-size-medium-up)}}.subline .subline__author-description{color:var(--color-roche-grey-700);font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem}@media (min-width:48rem){.subline .subline__author-description{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.subline .subline__date{font-family:roche-sans;font-size:var(--caption-font-size-small-up);font-style:normal;font-weight:200;line-height:1.1875rem;margin-top:.25rem}@media (min-width:48rem){.subline .subline__date{font-size:var(--caption-font-size-medium-up);line-height:1.375rem}}.tabs{display:flex;flex-direction:column;margin-top:3rem;padding:0}@media (min-width:90rem){.tabs{margin-top:4.5rem}}.tabs .tabs__tab{border-bottom:3px solid transparent;color:var(--color-roche-grey-700);margin-top:0;padding-bottom:.5rem;transition:border-bottom-color .2s ease-in-out}@media (min-width:48rem){.tabs .tabs__tab{padding-bottom:1rem}}@media (min-width:64rem){.tabs .tabs__tab{margin-top:.15625rem}}@media (min-width:90rem){.tabs .tabs__tab{margin-top:.0625rem}}.tabs .tabs__tab:hover{border-bottom-color:var(--color-dark-blue-900)}.tabs .tabs__tab:focus-visible{border-bottom-color:transparent}.tabs .tabs__tab:focus-visible:focus,.tabs .tabs__tab:focus-visible:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.tabs .tabs__tab:focus-visible:focus:not(:focus-visible){outline:0}.tabs .tabs__tab.tabs__tab--active{border-bottom-color:var(--color-dark-blue-900);color:var(--color-dark-blue-900)}.tabs .tabs__tab-label{font-size:1.125rem;font-weight:400;line-height:1.6875rem;white-space:nowrap}@media (min-width:48rem){.tabs .tabs__tab-label{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.tabs .tabs__tab-label{font-size:1.25rem;line-height:1.875rem}}.tabs .tabs__panel{display:none}.tabs .tabs__panel:focus-visible:focus,.tabs .tabs__panel:focus-visible:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.tabs .tabs__panel:focus-visible:focus:not(:focus-visible){outline:0}.tabs .tabs__panel.tabs__panel--active{display:block}.tabs .tabs__tab-list{align-items:center;border-bottom:1px solid var(--color-roche-grey-400);display:flex;flex-direction:row;gap:1.5rem;margin:0;overflow-x:auto;padding:0;scrollbar-width:none}@media (min-width:48rem){.tabs .tabs__tab-list{gap:2rem}}.tabs .tabs__tab-list.tabs__tab-list--blur-left{-webkit-mask-image:linear-gradient(90deg,transparent 0,#000 2rem);mask-image:linear-gradient(90deg,transparent 0,#000 2rem)}.tabs .tabs__tab-list.tabs__tab-list--blur-right{-webkit-mask-image:linear-gradient(270deg,transparent 0,#000 2rem);mask-image:linear-gradient(270deg,transparent 0,#000 2rem)}.tabs .tabs__tab-list.tabs__tab-list--blur-both{-webkit-mask-composite:source-in;mask-composite:intersect;-webkit-mask-image:linear-gradient(90deg,transparent 0,#000 2rem),linear-gradient(270deg,transparent 0,#000 2rem);mask-image:linear-gradient(90deg,transparent 0,#000 2rem),linear-gradient(270deg,transparent 0,#000 2rem)}.tabs .tabs__tab-list.tabs__tab-list--filter{border-bottom:none;gap:.75rem;margin:-2px;padding:2px}@media (min-width:64rem){.tabs .tabs__tab-list.tabs__tab-list--filter{gap:1rem}}.tabs .tabs__tab-list.tabs__tab-list--filter .tabs__tab{border:1px solid var(--color-roche-grey-300);display:inline;padding:.34375rem 1rem;transition:color .2s ease-in-out,border-color .2s ease-in-out,background-color .2s ease-in-out;white-space:nowrap}.tabs .tabs__tab-list.tabs__tab-list--filter .tabs__tab.tabs__tab--active{background-color:var(--color-dark-blue-900);border-color:var(--color-dark-blue-900);color:var(--color-white)}.tabs .tabs__tab-list.tabs__tab-list--filter .tabs__tab-label{font-size:var(--body-font-size-small-up);font-weight:400;line-height:1.8125rem}@media (min-width:64rem){.tabs .tabs__tab-list.tabs__tab-list--filter .tabs__tab-label{font-size:var(--body-font-size-xlarge-up);line-height:2rem}}@media (min-width:90rem){.tabs .tabs__tab-list.tabs__tab-list--filter .tabs__tab-label{font-size:1.125rem;line-height:1.8125rem}}.tabs .tabs__tab-list.tabs__tab-list--filter.tabs__tab-list--filter-gray .tabs__tab{border:1px solid var(--color-grey-500);color:var(--color-grey-500)}.tabs .tabs__tab-list.tabs__tab-list--filter.tabs__tab-list--filter-gray .tabs__tab.tabs__tab--active{background-color:var(--color-grey-500);border-color:var(--color-grey-500);color:var(--color-white-100)}.tabs .tabs__tab-list.tabs__tab-list--filter.tabs__tab-list--filter-gray .tabs__tab:hover{background-color:var(--color-grey-200);border-color:var(--color-grey-600);color:var(--color-roche-grey-700)}.tabs.tabs--centered .tabs__tab-list-wrapper{display:flex;justify-content:center}.tabs.tabs--centered .tabs__tab-list{display:flex;justify-content:flex-start}.tabs.tabs--centered .tabs__tab{padding-inline:1rem}roche-accordion-tabs>.tabs{flex-direction:row}.tag{background:var(--color-white-100);border:1px solid var(--color-neutral-900);border-radius:56px;color:var(--color-neutral-900);display:inline-flex;font-family:roche-sans;font-size:var(--button-font-size-small-up);font-style:normal;font-weight:200;font-weight:400;line-height:1.3125rem;margin:0 0 1rem;margin-inline-end:1rem;padding:.5rem 1rem;text-align:center;transition:background-color .2s ease,border-color .2s ease,color .2s ease}@media (min-width:48rem){.tag{font-size:var(--button-font-size-medium-up);line-height:1.4375rem}}.tag:focus,.tag:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:unset}.tag:focus:not(:focus-visible){outline:0}.tag:focus{background-color:var(--color-neutral-300)}.tag:focus-visible{background-color:var(--color-neutral-300)}.tag:hover{background:var(--color-neutral-500);border-color:var(--color-neutral-500);box-shadow:0 .375rem .75rem #2121213d}.tag:active{background:var(--color-neutral-300);border-color:var(--color-neutral-300)}@media (min-width:48rem){.tag{padding:.75rem 1.5rem}}.teaser{display:flex;flex-direction:column;margin-top:2rem;position:relative;transform:translateZ(0);z-index:1}@media (min-width:90rem){.teaser{margin-top:4.5rem}}.teaser .teaser__image-wrapper{margin-bottom:1.5rem;margin-top:0;overflow:hidden;transition:transform .6s ease}.teaser .image{margin-top:0}.teaser .teaser__link-wrapper{display:flex;flex-direction:column;height:100%}.teaser .teaser__link-wrapper:focus,.teaser .teaser__link-wrapper:focus-visible{outline:var(--color-roche-blue-600) dashed 2px;outline-offset:1px}.teaser .teaser__link-wrapper:focus:not(:focus-visible){outline:0}.teaser .teaser__image-border{border-bottom:.25rem solid var(--color-roche-grey-400);position:relative}.teaser .teaser__image-border:after{border-bottom:.25rem solid var(--color-roche-blue-600);content:\"\";display:block;left:0;opacity:0;position:absolute;transform:scaleX(0);transform-origin:left;transition:transform .4s ease,opacity .4s ease,border-color .4s ease;width:100%}@media (prefers-reduced-motion:reduce){.teaser .teaser__image-border:after{transition:opacity .4s ease 0s}}.teaser .teaser__heading{display:flex;flex-direction:column;gap:.25rem}.teaser .teaser__overline{color:var(--color-roche-grey-600);display:flex;font-size:1.125rem;font-weight:400;gap:2rem;line-height:1.6875rem;order:-1}@media (min-width:48rem){.teaser .teaser__overline{font-size:1.125rem;line-height:1.8125rem}}@media (min-width:90rem){.teaser .teaser__overline{font-size:1.25rem;line-height:1.875rem}}.teaser .teaser__overline-element{position:relative}.teaser .teaser__title{display:flex;font-size:1.5rem;font-weight:400;justify-content:space-between;line-height:1.9375rem;transition:color .2s ease;word-break:break-word}@media (min-width:48rem){.teaser .teaser__title{font-size:1.5rem;line-height:2.125rem}}@media (min-width:90rem){.teaser .teaser__title{font-size:1.875rem;line-height:2.5625rem}}.teaser .teaser__title.teaser__title--small{font-size:1.25rem;font-weight:400;line-height:1.625rem}@media (min-width:48rem){.teaser .teaser__title.teaser__title--small{font-size:1.25rem;line-height:1.875rem}}@media (min-width:90rem){.teaser .teaser__title.teaser__title--small{font-size:1.5rem;line-height:2.125rem}}.teaser .teaser__icon{color:var(--color-roche-blue-600);padding:.25rem 1rem 0}.teaser .teaser__description{flex:1 1;margin:.5rem 0 0}.teaser .teaser__author-description{font-size:var(--body-font-size-small-up);font-weight:400;line-height:1.8125rem;margin-top:.5rem}@media (min-width:64rem){.teaser .teaser__author-description{font-size:var(--body-font-size-xlarge-up);line-height:2rem}}.teaser .teaser__border{border-bottom:.125rem solid var(--color-roche-grey-400);margin-top:auto;padding-top:1.875rem;position:relative}.teaser .teaser__border:after{border-bottom:.125rem solid var(--color-roche-blue-600);content:\"\";display:block;left:0;opacity:0;position:absolute;transform:scaleX(0);transform-origin:left;transition:transform .4s ease,opacity .4s ease,border-color .4s ease;width:100%}@media (prefers-reduced-motion:reduce){.teaser .teaser__border:after{transition:opacity .4s ease 0s}}.teaser .teaser__buttons-wrapper{display:flex;flex-direction:column;gap:.5rem;margin-top:1.5rem}@media (min-width:104.5rem){.teaser .teaser__buttons-wrapper{gap:1.5rem}}.teaser .teaser__buttons-wrapper:not(.teaser__buttons-wrapper--align-left) *{margin:0;padding:0}.teaser .teaser__buttons-wrapper.teaser__buttons-wrapper--align-left{flex-direction:row;gap:0;margin-top:0}.teaser.teaser--card{border:1px solid var(--color-shadow-blue-200);justify-content:space-between;padding:1.5rem}@media (min-width:48rem){.teaser.teaser--card{padding:2rem}}.teaser.teaser--unpublished{background:#ff0000b3;border:1px dashed maroon}.teaser.teaser--in-draft{display:none}.teaser:hover .teaser__border:after,.teaser:hover .teaser__image-border:after{opacity:1;transform:scaleX(1)}.teaser:hover:not(.teaser--card) .teaser__title{color:var(--color-roche-blue-600)}.teaser:hover .teaser__image.teaser__image--loaded{transform:scale(1.1)}.teaser:hover .teaser__image.teaser__image--loaded.teaser__image--reduced-scale{transform:scale(1.03)}.teaser .teaser__video :first-child{margin-top:0}</style><style>roche-accordion-tabs{display:block;margin-top:3rem}@media (min-width: 90rem){roche-accordion-tabs{margin-top:4.5rem}}roche-accordion-tabs,roche-accordion-tabs *{box-sizing:border-box}roche-accordion-tabs[no-margin]{margin-top:0}@media (min-width: 64rem){roche-accordion-tabs[no-margin]{margin-top:0}}roche-accordion-tabs .tabs{display:flex;overflow-x:auto;padding:0;margin:0;border-bottom:1px solid #c2bab5;opacity:0;pointer-events:none;scrollbar-width:none;position:relative;z-index:50}roche-accordion-tabs .tabs::-webkit-scrollbar{display:none}roche-accordion-tabs .tabs li{display:inline-block;list-style:none}roche-accordion-tabs .tabs li+li{margin-left:1.5rem}@media (min-width: 48rem){roche-accordion-tabs .tabs li+li{margin-left:2rem}}roche-accordion-tabs .tabs--visible{height:auto;opacity:1;pointer-events:all}roche-accordion-tabs .tabs__item{all:unset;padding:0;color:var(--color-text--primary);font-family:\"roche-sans\";font-style:normal;font-weight:400;font-size:1.125rem;line-height:1.6875rem;position:relative;color:#544f4f;cursor:pointer;white-space:nowrap;padding-bottom:0.5rem;border-bottom:0.1875rem solid transparent;transition:border-color 100ms ease-in, color 100ms ease-in}roche-accordion-tabs .tabs__item strong{font-weight:600}@media (min-width: 48rem){roche-accordion-tabs .tabs__item{font-size:1.125rem;line-height:1.8125rem}}@media (min-width: 90rem){roche-accordion-tabs .tabs__item{font-size:1.25rem;line-height:1.875rem}}@media (min-width: 48rem){roche-accordion-tabs .tabs__item{padding-bottom:1rem}}roche-accordion-tabs .tabs__item:focus,roche-accordion-tabs .tabs__item:focus-visible{outline:var(--color-interactive--focus) dashed 2px;outline-offset:-2px}roche-accordion-tabs .tabs__item:focus:not(:focus-visible){outline:none}roche-accordion-tabs .tabs__item:hover{border-bottom-color:var(--color-interactive--primary-hover)}roche-accordion-tabs .tabs__item.active{border-bottom-color:var(--color-interactive--primary-hover);color:var(--color-interactive--primary-hover)}roche-accordion-tabs .tabs--centered.tabs--visible{display:table;margin-left:auto;margin-right:auto}roche-accordion-tabs .tabs--centered .tabs__item{padding-left:1rem;padding-right:1rem;text-align:center}roche-accordion-tabs[blur-ends=both] .tabs{mask-image:linear-gradient(to right, transparent 0%, black 4rem), linear-gradient(to left, transparent 0%, black 4rem);mask-composite:intersect;-webkit-mask-image:linear-gradient(to right, transparent 0%, black 4rem), linear-gradient(to left, transparent 0%, black 4rem);-webkit-mask-composite:intersect}@supports selector(::-internal-media-controls-overlay-cast-button){roche-accordion-tabs[blur-ends=both] .tabs{-webkit-mask-composite:source-in}}roche-accordion-tabs[blur-ends=left] .tabs{mask-image:linear-gradient(to right, transparent 0%, black 4rem);-webkit-mask-image:linear-gradient(to right, transparent 0%, black 4rem)}roche-accordion-tabs[blur-ends=right] .tabs{mask-image:linear-gradient(to left, transparent 0%, black 4rem);-webkit-mask-image:linear-gradient(to left, transparent 0%, black 4rem)}roche-accordion-tabs[appearance=filter] .tabs{border-bottom:none}roche-accordion-tabs[appearance=filter] .tabs__item{font-family:\"roche-sans\";font-style:normal;font-weight:200;color:var(--color-text--primary);font-size:var(--body--font-size--small-up);line-height:1.8125rem;font-weight:400;display:inline;position:relative;border:1px solid #dbd6d1;padding:0.34375rem 1rem;color:#544f4f;white-space:nowrap}@media (min-width: 64rem){roche-accordion-tabs[appearance=filter] .tabs__item{font-size:var(--body--font-size--xlarge-up);line-height:2rem}}@media (min-width: 90rem){roche-accordion-tabs[appearance=filter] .tabs__item{font-size:1.125rem;line-height:1.8125rem}}roche-accordion-tabs[appearance=filter] .tabs__item:focus,roche-accordion-tabs[appearance=filter] .tabs__item:focus-visible{outline:var(--color-interactive--focus) dashed 2px;outline-offset:unset}roche-accordion-tabs[appearance=filter] .tabs__item:focus:not(:focus-visible){outline:none}roche-accordion-tabs[appearance=filter] .tabs__item:hover,roche-accordion-tabs[appearance=filter] .tabs__item.active{background-color:var(--color-interactive--primary-hover);border-color:var(--color-interactive--primary-hover);color:#fff;transition:background-color 200ms ease, border-color 200ms ease, color 200ms ease;text-decoration:none}roche-accordion-tabs[appearance=filter] .tabs__item:hover:not(.tabs__item.active){background-color:#eae8e5;border-color:#706b69;color:#544f4f;cursor:pointer}roche-accordion-tabs[appearance=filter] .tabs li+li{margin-left:1.5rem}@media (min-width: 48rem){roche-accordion-tabs[appearance=filter] .tabs li+li{margin-left:1rem}}roche-accordion-tabs[appearance=pipeline] .tabs{border-bottom:none}roche-accordion-tabs[appearance=pipeline] .tabs__item{font-family:\"roche-sans\";font-style:normal;font-weight:200;color:var(--color-text--primary);font-size:var(--body--font-size--small-up);line-height:1.8125rem;font-weight:400;display:inline;position:relative;border:1px solid #9d948e;padding:0.34375rem 1rem;color:#9d948e;white-space:nowrap}@media (min-width: 64rem){roche-accordion-tabs[appearance=pipeline] .tabs__item{font-size:var(--body--font-size--xlarge-up);line-height:2rem}}@media (min-width: 90rem){roche-accordion-tabs[appearance=pipeline] .tabs__item{font-size:1.125rem;line-height:1.8125rem}}roche-accordion-tabs[appearance=pipeline] .tabs__item:focus,roche-accordion-tabs[appearance=pipeline] .tabs__item:focus-visible{outline:var(--color-interactive--focus) dashed 2px;outline-offset:unset}roche-accordion-tabs[appearance=pipeline] .tabs__item:focus:not(:focus-visible){outline:none}roche-accordion-tabs[appearance=pipeline] .tabs__item:hover,roche-accordion-tabs[appearance=pipeline] .tabs__item.active{background-color:#9d948e;border-color:#9d948e;color:#fff;transition:background-color 200ms ease, border-color 200ms ease, color 200ms ease;text-decoration:none}roche-accordion-tabs[appearance=pipeline] .tabs__item:hover:not(.tabs__item.active){background-color:#eae8e5;border-color:#706b69;color:#544f4f;cursor:pointer}roche-accordion-tabs[appearance=pipeline] .tabs li+li{margin-left:1.5rem}@media (min-width: 48rem){roche-accordion-tabs[appearance=pipeline] .tabs li+li{margin-left:1rem}}roche-accordion-tabs[dir=rtl] .tabs li+li{margin-right:1.5rem;margin-left:0}@media (min-width: 48rem){roche-accordion-tabs[dir=rtl] .tabs li+li{margin-right:2rem;margin-left:0}}slot-fb{display:contents}slot-fb[hidden]{display:none}</style><style>:host{display:block;margin-top:3rem;display:block}@media (min-width: 90rem){:host{margin-top:4.5rem}}:host,:host *{box-sizing:border-box}.diagnostics-caption{max-width:18.75rem;margin-top:3rem}@media (min-width: 20rem){.diagnostics-caption{margin-top:2rem}}@media (min-width: 48rem){.diagnostics-caption{margin-top:3rem}}.diagnostics-caption__item .abbreviation{font-family:\"roche-sans\";font-style:normal;font-weight:200;font-size:var(--caption--font-size--small-up);line-height:1.1875rem;font-weight:400}@media (min-width: 48rem){.diagnostics-caption__item .abbreviation{font-size:var(--caption--font-size--medium-up);line-height:1.375rem}}.diagnostics-caption__item .description{font-family:\"roche-sans\";font-style:normal;font-weight:200;font-size:var(--caption--font-size--small-up);line-height:1.1875rem}@media (min-width: 48rem){.diagnostics-caption__item .description{font-size:var(--caption--font-size--medium-up);line-height:1.375rem}}</style><style>:host{width:100%}.table>div{font-family:\"roche-sans\";width:100%;margin-top:1.5rem;overflow-x:auto;display:block}.table__header{background:transparent;position:relative;display:grid}@media (min-width: 20rem){.table__header{grid-template-columns:1fr 1fr}}@media (min-width: 48rem){.table__header{grid-template-columns:25% 20% 15% 15% 15% 10%}}.table__headline{font-family:\"roche-sans\";font-style:normal;font-weight:200;font-weight:400;font-size:var(--button--font-size--small-up);line-height:1.3125rem;vertical-align:bottom;text-transform:capitalize}@media (min-width: 48rem){.table__headline{font-size:var(--button--font-size--medium-up);line-height:1.4375rem}}.table__headline--sortable{position:relative;}.table__headline--sortable:hover roche-icon{fill:var(--color-interactive--primary-hover)}.table__headline--sortable__item{cursor:pointer}.table__headline--sortable roche-icon{position:absolute;right:0.625rem;bottom:1.4375rem;fill:var(--color-interactive--primary-idle)}.table__headline--sortable roche-icon:hover{fill:var(--color-interactive--primary-hover)}roche-table-sort-header[appearance=pipeline] .table__headline{font-family:\"roche-sans\";font-style:normal;font-weight:200;font-weight:400;font-size:var(--footnotes--font-size--small-up);line-height:1.1875rem;vertical-align:top;padding:1rem calc(1rem / 2);color:#544f4f;border-bottom:1px solid #eae8e5;}@media (min-width: 48rem){roche-table-sort-header[appearance=pipeline] .table__headline{font-size:var(--footnotes--font-size--medium-up)}}roche-table-sort-header[appearance=pipeline] .table__headline--sortable span{display:flex}roche-table-sort-header[appearance=pipeline] .table__headline--sortable__item{float:left;clear:left;white-space:pre}roche-table-sort-header[appearance=pipeline] .table__headline--sortable roche-icon{bottom:2.875rem;padding:4px 0 0 4px;position:unset}@media (min-width: 20rem){roche-table-sort-header[appearance=pipeline] .table__headline--sortable:last-of-type{display:flex;align-items:center;justify-content:flex-end;padding-right:1rem}}@media (min-width: 48rem){roche-table-sort-header[appearance=pipeline] .table__headline--sortable:last-of-type{display:block}}roche-table-sort-header[appearance=pipeline] .table__headline--sortable:first-of-type{padding:1rem 0 1rem 0}roche-table-sort-header[appearance=pipeline] .table__headline--sortable:first-of-type .table__headline--sortable__item:last-child roche-icon{bottom:1.4375rem}@media (min-width: 48rem){roche-table-sort-header[appearance=pipeline] .table__headline--sortable:nth-child(2){padding-left:1rem}}roche-table-sort-header[appearance=diagnostics] .table__header{background:transparent;position:relative;display:grid}@media (min-width: 20rem){roche-table-sort-header[appearance=diagnostics] .table__header{grid-template-columns:1fr 1fr}}@media (min-width: 64rem){roche-table-sort-header[appearance=diagnostics] .table__header{grid-template-columns:15% 15% 60% 10%}}roche-table-sort-header[appearance=diagnostics] .table__headline{font-family:\"roche-sans\";font-style:normal;font-weight:200;font-weight:400;font-size:var(--footnotes--font-size--small-up);line-height:1.1875rem;vertical-align:top;padding:1rem calc(1rem / 2) 1rem calc(1rem * 2);color:#544f4f;border-bottom:1px solid #eae8e5;}@media (min-width: 48rem){roche-table-sort-header[appearance=diagnostics] .table__headline{font-size:var(--footnotes--font-size--medium-up)}}roche-table-sort-header[appearance=diagnostics] .table__headline--sortable__item{cursor:default}@media (min-width: 20rem){roche-table-sort-header[appearance=diagnostics] .table__headline:last-of-type{display:flex;align-items:center;justify-content:flex-end}}@media (min-width: 1024px){roche-table-sort-header[appearance=diagnostics] .table__headline:last-of-type{display:block}}roche-table-sort-header[appearance=diagnostics] .table__headline:first-of-type{padding:1rem 0 1rem 0}</style><style>:host{display:block;margin-top:3rem;margin-top:0}@media (min-width: 90rem){:host{margin-top:4.5rem}}:host,:host *{box-sizing:border-box}@media (min-width: 64rem){:host{margin-top:0}}.pipeline-table{display:block;width:100%}</style><style>roche-headline{display:block;margin-top:3rem;display:block}@media (min-width: 90rem){roche-headline{margin-top:4.5rem}}roche-headline,roche-headline *{box-sizing:border-box}roche-headline [data-aos^=fade][data-aos^=fade]{opacity:0;transition-property:opacity, transform}roche-headline [data-aos^=fade][data-aos^=fade].aos-animate{opacity:1;transform:none}roche-headline [data-aos=fade-up]{transform:translate3d(0, 100px, 0)}roche-headline [data-aos=fade-down]{transform:translate3d(0, -100px, 0)}roche-headline [data-aos=fade-right]{transform:translate3d(-100px, 0, 0)}roche-headline [data-aos=fade-left]{transform:translate3d(100px, 0, 0)}roche-headline [data-aos]{pointer-events:none}roche-headline [data-aos].aos-animate{pointer-events:auto}body[data-aos-easing=linear] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=linear]{transition-timing-function:cubic-bezier(0.25, 0.25, 0.75, 0.75)}body[data-aos-easing=ease] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease]{transition-timing-function:cubic-bezier(0.25, 0.1, 0.25, 1)}body[data-aos-easing=ease-in] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in]{transition-timing-function:cubic-bezier(0.42, 0, 1, 1)}body[data-aos-easing=ease-out] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-out]{transition-timing-function:cubic-bezier(0, 0, 0.58, 1)}body[data-aos-easing=ease-in-out] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-out]{transition-timing-function:cubic-bezier(0.42, 0, 0.58, 1)}body[data-aos-easing=ease-in-back] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-back]{transition-timing-function:cubic-bezier(0.6, -0.28, 0.735, 0.045)}body[data-aos-easing=ease-out-back] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-out-back]{transition-timing-function:cubic-bezier(0.175, 0.885, 0.32, 1.275)}body[data-aos-easing=ease-in-out-back] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-out-back]{transition-timing-function:cubic-bezier(0.68, -0.55, 0.265, 1.55)}body[data-aos-easing=ease-in-sine] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-sine]{transition-timing-function:cubic-bezier(0.47, 0, 0.745, 0.715)}body[data-aos-easing=ease-out-sine] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-out-sine]{transition-timing-function:cubic-bezier(0.39, 0.575, 0.565, 1)}body[data-aos-easing=ease-in-out-sine] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-out-sine]{transition-timing-function:cubic-bezier(0.445, 0.05, 0.55, 0.95)}body[data-aos-easing=ease-in-quad] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-quad]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-quad] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-out-quad]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-quad] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-out-quad]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-easing=ease-in-cubic] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-cubic]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-cubic] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-out-cubic]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-cubic] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-out-cubic]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-easing=ease-in-quart] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-quart]{transition-timing-function:cubic-bezier(0.55, 0.085, 0.68, 0.53)}body[data-aos-easing=ease-out-quart] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-out-quart]{transition-timing-function:cubic-bezier(0.25, 0.46, 0.45, 0.94)}body[data-aos-easing=ease-in-out-quart] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-easing=ease-in-out-quart]{transition-timing-function:cubic-bezier(0.455, 0.03, 0.515, 0.955)}body[data-aos-duration=\"50\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"50\"]{transition-duration:50ms}body[data-aos-delay=\"50\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"50\"]{transition-delay:0s}body[data-aos-delay=\"50\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"50\"].aos-animate{transition-delay:50ms}body[data-aos-duration=\"100\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"100\"]{transition-duration:100ms}body[data-aos-delay=\"100\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"100\"]{transition-delay:0s}body[data-aos-delay=\"100\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"100\"].aos-animate{transition-delay:100ms}body[data-aos-duration=\"150\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"150\"]{transition-duration:150ms}body[data-aos-delay=\"150\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"150\"]{transition-delay:0s}body[data-aos-delay=\"150\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"150\"].aos-animate{transition-delay:150ms}body[data-aos-duration=\"200\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"200\"]{transition-duration:200ms}body[data-aos-delay=\"200\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"200\"]{transition-delay:0s}body[data-aos-delay=\"200\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"200\"].aos-animate{transition-delay:200ms}body[data-aos-duration=\"250\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"250\"]{transition-duration:250ms}body[data-aos-delay=\"250\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"250\"]{transition-delay:0s}body[data-aos-delay=\"250\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"250\"].aos-animate{transition-delay:250ms}body[data-aos-duration=\"300\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"300\"]{transition-duration:300ms}body[data-aos-delay=\"300\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"300\"]{transition-delay:0s}body[data-aos-delay=\"300\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"300\"].aos-animate{transition-delay:300ms}body[data-aos-duration=\"350\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"350\"]{transition-duration:350ms}body[data-aos-delay=\"350\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"350\"]{transition-delay:0s}body[data-aos-delay=\"350\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"350\"].aos-animate{transition-delay:350ms}body[data-aos-duration=\"400\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"400\"]{transition-duration:400ms}body[data-aos-delay=\"400\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"400\"]{transition-delay:0s}body[data-aos-delay=\"400\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"400\"].aos-animate{transition-delay:400ms}body[data-aos-duration=\"450\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"450\"]{transition-duration:450ms}body[data-aos-delay=\"450\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"450\"]{transition-delay:0s}body[data-aos-delay=\"450\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"450\"].aos-animate{transition-delay:450ms}body[data-aos-duration=\"500\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"500\"]{transition-duration:500ms}body[data-aos-delay=\"500\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"500\"]{transition-delay:0s}body[data-aos-delay=\"500\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"500\"].aos-animate{transition-delay:500ms}body[data-aos-duration=\"550\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"550\"]{transition-duration:550ms}body[data-aos-delay=\"550\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"550\"]{transition-delay:0s}body[data-aos-delay=\"550\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"550\"].aos-animate{transition-delay:550ms}body[data-aos-duration=\"600\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"600\"]{transition-duration:600ms}body[data-aos-delay=\"600\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"600\"]{transition-delay:0s}body[data-aos-delay=\"600\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"600\"].aos-animate{transition-delay:600ms}body[data-aos-duration=\"650\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"650\"]{transition-duration:650ms}body[data-aos-delay=\"650\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"650\"]{transition-delay:0s}body[data-aos-delay=\"650\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"650\"].aos-animate{transition-delay:650ms}body[data-aos-duration=\"700\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"700\"]{transition-duration:700ms}body[data-aos-delay=\"700\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"700\"]{transition-delay:0s}body[data-aos-delay=\"700\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"700\"].aos-animate{transition-delay:700ms}body[data-aos-duration=\"750\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"750\"]{transition-duration:750ms}body[data-aos-delay=\"750\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"750\"]{transition-delay:0s}body[data-aos-delay=\"750\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"750\"].aos-animate{transition-delay:750ms}body[data-aos-duration=\"800\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"800\"]{transition-duration:800ms}body[data-aos-delay=\"800\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"800\"]{transition-delay:0s}body[data-aos-delay=\"800\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"800\"].aos-animate{transition-delay:800ms}body[data-aos-duration=\"850\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"850\"]{transition-duration:850ms}body[data-aos-delay=\"850\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"850\"]{transition-delay:0s}body[data-aos-delay=\"850\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"850\"].aos-animate{transition-delay:850ms}body[data-aos-duration=\"900\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"900\"]{transition-duration:900ms}body[data-aos-delay=\"900\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"900\"]{transition-delay:0s}body[data-aos-delay=\"900\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"900\"].aos-animate{transition-delay:900ms}body[data-aos-duration=\"950\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"950\"]{transition-duration:950ms}body[data-aos-delay=\"950\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"950\"]{transition-delay:0s}body[data-aos-delay=\"950\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"950\"].aos-animate{transition-delay:950ms}body[data-aos-duration=\"1000\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1000\"]{transition-duration:1000ms}body[data-aos-delay=\"1000\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1000\"]{transition-delay:0s}body[data-aos-delay=\"1000\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1000\"].aos-animate{transition-delay:1000ms}body[data-aos-duration=\"1050\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1050\"]{transition-duration:1050ms}body[data-aos-delay=\"1050\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1050\"]{transition-delay:0s}body[data-aos-delay=\"1050\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1050\"].aos-animate{transition-delay:1050ms}body[data-aos-duration=\"1100\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1100\"]{transition-duration:1100ms}body[data-aos-delay=\"1100\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1100\"]{transition-delay:0s}body[data-aos-delay=\"1100\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1100\"].aos-animate{transition-delay:1100ms}body[data-aos-duration=\"1150\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1150\"]{transition-duration:1150ms}body[data-aos-delay=\"1150\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1150\"]{transition-delay:0s}body[data-aos-delay=\"1150\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1150\"].aos-animate{transition-delay:1150ms}body[data-aos-duration=\"1200\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1200\"]{transition-duration:1200ms}body[data-aos-delay=\"1200\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1200\"]{transition-delay:0s}body[data-aos-delay=\"1200\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1200\"].aos-animate{transition-delay:1200ms}body[data-aos-duration=\"1250\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1250\"]{transition-duration:1250ms}body[data-aos-delay=\"1250\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1250\"]{transition-delay:0s}body[data-aos-delay=\"1250\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1250\"].aos-animate{transition-delay:1250ms}body[data-aos-duration=\"1300\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1300\"]{transition-duration:1300ms}body[data-aos-delay=\"1300\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1300\"]{transition-delay:0s}body[data-aos-delay=\"1300\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1300\"].aos-animate{transition-delay:1300ms}body[data-aos-duration=\"1350\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1350\"]{transition-duration:1350ms}body[data-aos-delay=\"1350\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1350\"]{transition-delay:0s}body[data-aos-delay=\"1350\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1350\"].aos-animate{transition-delay:1350ms}body[data-aos-duration=\"1400\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1400\"]{transition-duration:1400ms}body[data-aos-delay=\"1400\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1400\"]{transition-delay:0s}body[data-aos-delay=\"1400\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1400\"].aos-animate{transition-delay:1400ms}body[data-aos-duration=\"1450\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1450\"]{transition-duration:1450ms}body[data-aos-delay=\"1450\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1450\"]{transition-delay:0s}body[data-aos-delay=\"1450\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1450\"].aos-animate{transition-delay:1450ms}body[data-aos-duration=\"1500\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1500\"]{transition-duration:1500ms}body[data-aos-delay=\"1500\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1500\"]{transition-delay:0s}body[data-aos-delay=\"1500\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1500\"].aos-animate{transition-delay:1500ms}body[data-aos-duration=\"1550\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1550\"]{transition-duration:1550ms}body[data-aos-delay=\"1550\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1550\"]{transition-delay:0s}body[data-aos-delay=\"1550\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1550\"].aos-animate{transition-delay:1550ms}body[data-aos-duration=\"1600\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1600\"]{transition-duration:1600ms}body[data-aos-delay=\"1600\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1600\"]{transition-delay:0s}body[data-aos-delay=\"1600\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1600\"].aos-animate{transition-delay:1600ms}body[data-aos-duration=\"1650\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1650\"]{transition-duration:1650ms}body[data-aos-delay=\"1650\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1650\"]{transition-delay:0s}body[data-aos-delay=\"1650\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1650\"].aos-animate{transition-delay:1650ms}body[data-aos-duration=\"1700\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1700\"]{transition-duration:1700ms}body[data-aos-delay=\"1700\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1700\"]{transition-delay:0s}body[data-aos-delay=\"1700\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1700\"].aos-animate{transition-delay:1700ms}body[data-aos-duration=\"1750\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1750\"]{transition-duration:1750ms}body[data-aos-delay=\"1750\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1750\"]{transition-delay:0s}body[data-aos-delay=\"1750\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1750\"].aos-animate{transition-delay:1750ms}body[data-aos-duration=\"1800\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1800\"]{transition-duration:1800ms}body[data-aos-delay=\"1800\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1800\"]{transition-delay:0s}body[data-aos-delay=\"1800\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1800\"].aos-animate{transition-delay:1800ms}body[data-aos-duration=\"1850\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1850\"]{transition-duration:1850ms}body[data-aos-delay=\"1850\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1850\"]{transition-delay:0s}body[data-aos-delay=\"1850\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1850\"].aos-animate{transition-delay:1850ms}body[data-aos-duration=\"1900\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1900\"]{transition-duration:1900ms}body[data-aos-delay=\"1900\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1900\"]{transition-delay:0s}body[data-aos-delay=\"1900\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1900\"].aos-animate{transition-delay:1900ms}body[data-aos-duration=\"1950\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"1950\"]{transition-duration:1950ms}body[data-aos-delay=\"1950\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"1950\"]{transition-delay:0s}body[data-aos-delay=\"1950\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"1950\"].aos-animate{transition-delay:1950ms}body[data-aos-duration=\"2000\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2000\"]{transition-duration:2000ms}body[data-aos-delay=\"2000\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2000\"]{transition-delay:0s}body[data-aos-delay=\"2000\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2000\"].aos-animate{transition-delay:2000ms}body[data-aos-duration=\"2050\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2050\"]{transition-duration:2050ms}body[data-aos-delay=\"2050\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2050\"]{transition-delay:0s}body[data-aos-delay=\"2050\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2050\"].aos-animate{transition-delay:2050ms}body[data-aos-duration=\"2100\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2100\"]{transition-duration:2100ms}body[data-aos-delay=\"2100\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2100\"]{transition-delay:0s}body[data-aos-delay=\"2100\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2100\"].aos-animate{transition-delay:2100ms}body[data-aos-duration=\"2150\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2150\"]{transition-duration:2150ms}body[data-aos-delay=\"2150\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2150\"]{transition-delay:0s}body[data-aos-delay=\"2150\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2150\"].aos-animate{transition-delay:2150ms}body[data-aos-duration=\"2200\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2200\"]{transition-duration:2200ms}body[data-aos-delay=\"2200\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2200\"]{transition-delay:0s}body[data-aos-delay=\"2200\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2200\"].aos-animate{transition-delay:2200ms}body[data-aos-duration=\"2250\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2250\"]{transition-duration:2250ms}body[data-aos-delay=\"2250\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2250\"]{transition-delay:0s}body[data-aos-delay=\"2250\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2250\"].aos-animate{transition-delay:2250ms}body[data-aos-duration=\"2300\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2300\"]{transition-duration:2300ms}body[data-aos-delay=\"2300\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2300\"]{transition-delay:0s}body[data-aos-delay=\"2300\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2300\"].aos-animate{transition-delay:2300ms}body[data-aos-duration=\"2350\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2350\"]{transition-duration:2350ms}body[data-aos-delay=\"2350\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2350\"]{transition-delay:0s}body[data-aos-delay=\"2350\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2350\"].aos-animate{transition-delay:2350ms}body[data-aos-duration=\"2400\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2400\"]{transition-duration:2400ms}body[data-aos-delay=\"2400\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2400\"]{transition-delay:0s}body[data-aos-delay=\"2400\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2400\"].aos-animate{transition-delay:2400ms}body[data-aos-duration=\"2450\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2450\"]{transition-duration:2450ms}body[data-aos-delay=\"2450\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2450\"]{transition-delay:0s}body[data-aos-delay=\"2450\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2450\"].aos-animate{transition-delay:2450ms}body[data-aos-duration=\"2500\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2500\"]{transition-duration:2500ms}body[data-aos-delay=\"2500\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2500\"]{transition-delay:0s}body[data-aos-delay=\"2500\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2500\"].aos-animate{transition-delay:2500ms}body[data-aos-duration=\"2550\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2550\"]{transition-duration:2550ms}body[data-aos-delay=\"2550\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2550\"]{transition-delay:0s}body[data-aos-delay=\"2550\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2550\"].aos-animate{transition-delay:2550ms}body[data-aos-duration=\"2600\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2600\"]{transition-duration:2600ms}body[data-aos-delay=\"2600\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2600\"]{transition-delay:0s}body[data-aos-delay=\"2600\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2600\"].aos-animate{transition-delay:2600ms}body[data-aos-duration=\"2650\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2650\"]{transition-duration:2650ms}body[data-aos-delay=\"2650\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2650\"]{transition-delay:0s}body[data-aos-delay=\"2650\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2650\"].aos-animate{transition-delay:2650ms}body[data-aos-duration=\"2700\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2700\"]{transition-duration:2700ms}body[data-aos-delay=\"2700\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2700\"]{transition-delay:0s}body[data-aos-delay=\"2700\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2700\"].aos-animate{transition-delay:2700ms}body[data-aos-duration=\"2750\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2750\"]{transition-duration:2750ms}body[data-aos-delay=\"2750\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2750\"]{transition-delay:0s}body[data-aos-delay=\"2750\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2750\"].aos-animate{transition-delay:2750ms}body[data-aos-duration=\"2800\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2800\"]{transition-duration:2800ms}body[data-aos-delay=\"2800\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2800\"]{transition-delay:0s}body[data-aos-delay=\"2800\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2800\"].aos-animate{transition-delay:2800ms}body[data-aos-duration=\"2850\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2850\"]{transition-duration:2850ms}body[data-aos-delay=\"2850\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2850\"]{transition-delay:0s}body[data-aos-delay=\"2850\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2850\"].aos-animate{transition-delay:2850ms}body[data-aos-duration=\"2900\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2900\"]{transition-duration:2900ms}body[data-aos-delay=\"2900\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2900\"]{transition-delay:0s}body[data-aos-delay=\"2900\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2900\"].aos-animate{transition-delay:2900ms}body[data-aos-duration=\"2950\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"2950\"]{transition-duration:2950ms}body[data-aos-delay=\"2950\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"2950\"]{transition-delay:0s}body[data-aos-delay=\"2950\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"2950\"].aos-animate{transition-delay:2950ms}body[data-aos-duration=\"3000\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-duration=\"3000\"]{transition-duration:3000ms}body[data-aos-delay=\"3000\"] roche-headline [data-aos],roche-headline [data-aos][data-aos][data-aos-delay=\"3000\"]{transition-delay:0s}body[data-aos-delay=\"3000\"] roche-headline [data-aos].aos-animate,roche-headline [data-aos][data-aos][data-aos-delay=\"3000\"].aos-animate{transition-delay:3000ms}roche-headline h1,roche-headline h2,roche-headline h3,roche-headline h4,roche-headline h5,roche-headline h6{margin:0;color:var(--color-text--primary);font-family:inherit;font-size:inherit;font-weight:inherit}roche-headline[level=\"1\"]{padding:0;color:var(--color-text--primary);font-family:\"roche-sans\";font-style:normal;font-weight:200;font-size:2.5rem;line-height:3rem}roche-headline[level=\"1\"] strong{font-weight:600}@media (min-width: 48rem){roche-headline[level=\"1\"]{font-size:3rem;line-height:3.375rem}}@media (min-width: 90rem){roche-headline[level=\"1\"]{font-size:3.8125rem;line-height:4.375rem}}roche-headline[level=\"2\"]{padding:0;color:var(--color-text--primary);font-family:\"roche-sans\";font-style:normal;font-weight:200;font-size:1.875rem;line-height:2.25rem}roche-headline[level=\"2\"] strong{font-weight:600}@media (min-width: 48rem){roche-headline[level=\"2\"]{font-size:2.5rem;line-height:3rem}}@media (min-width: 90rem){roche-headline[level=\"2\"]{font-size:3rem;line-height:3.625rem}}roche-headline[level=\"3\"]{padding:0;color:var(--color-text--primary);font-family:\"roche-sans\";font-style:normal;font-weight:200;font-size:1.75rem;line-height:2.125rem}roche-headline[level=\"3\"] strong{font-weight:600}@media (min-width: 48rem){roche-headline[level=\"3\"]{font-size:1.875rem;line-height:2.4375rem}}@media (min-width: 90rem){roche-headline[level=\"3\"]{font-size:2.5rem;line-height:3.125rem}}roche-headline[level=\"4\"]{padding:0;color:var(--color-text--primary);font-family:\"roche-sans\";font-style:normal;font-weight:400;font-size:1.5rem;line-height:1.9375rem}roche-headline[level=\"4\"] strong{font-weight:600}@media (min-width: 48rem){roche-headline[level=\"4\"]{font-size:1.5rem;line-height:2.125rem}}@media (min-width: 90rem){roche-headline[level=\"4\"]{font-size:1.875rem;line-height:2.5625rem}}roche-headline[level=\"5\"]{padding:0;color:var(--color-text--primary);font-family:\"roche-sans\";font-style:normal;font-weight:400;font-size:1.25rem;line-height:1.625rem}roche-headline[level=\"5\"] strong{font-weight:600}@media (min-width: 48rem){roche-headline[level=\"5\"]{font-size:1.25rem;line-height:1.875rem}}@media (min-width: 90rem){roche-headline[level=\"5\"]{font-size:1.5rem;line-height:2.125rem}}roche-headline[level=\"6\"]{padding:0;color:var(--color-text--primary);font-family:\"roche-sans\";font-style:normal;font-weight:400;font-size:1.125rem;line-height:1.6875rem}roche-headline[level=\"6\"] strong{font-weight:600}@media (min-width: 48rem){roche-headline[level=\"6\"]{font-size:1.125rem;line-height:1.8125rem}}@media (min-width: 90rem){roche-headline[level=\"6\"]{font-size:1.25rem;line-height:1.875rem}}roche-headline roche-icon{display:inline-block}:host([appearance=pipeline]){margin:1rem 0 0;border-bottom:1px solid #eae8e5}slot-fb{display:contents}slot-fb[hidden]{display:none}</style><link rel=\"icon\" href=\"/favicon-32x32.png?v=7f5356ff0eaba89671bed4a1828ef379\" type=\"image/png\"><link rel=\"manifest\" href=\"/manifest.webmanifest\" crossorigin=\"anonymous\"><link rel=\"apple-touch-icon\" sizes=\"192x192\" href=\"/src/resources/images/android-chrome-192x192.png?v=7f5356ff0eaba89671bed4a1828ef379\"><link rel=\"apple-touch-icon\" sizes=\"512x512\" href=\"/src/resources/images/android-chrome-512x512.png?v=7f5356ff0eaba89671bed4a1828ef379\"><link rel=\"apple-touch-icon\" sizes=\"180x180\" href=\"/src/resources/images/apple-touch-icon.png?v=7f5356ff0eaba89671bed4a1828ef379\"><link rel=\"apple-touch-icon\" sizes=\"16x16\" href=\"/src/resources/images/favicon-16x16.png?v=7f5356ff0eaba89671bed4a1828ef379\"><link rel=\"apple-touch-icon\" sizes=\"32x32\" href=\"/src/resources/images/favicon-32x32.png?v=7f5356ff0eaba89671bed4a1828ef379\"><link rel=\"apple-touch-icon\" sizes=\"48x48 32x32 16x16\" href=\"/src/resources/images/favicon.ico?v=7f5356ff0eaba89671bed4a1828ef379\"><link rel=\"apple-touch-icon\" sizes=\"150x150\" href=\"/src/resources/images/mstile-150x150.png?v=7f5356ff0eaba89671bed4a1828ef379\"><link rel=\"apple-touch-icon\" sizes=\"512x512\" href=\"/src/resources/images/safari-pinned-tab.svg?v=7f5356ff0eaba89671bed4a1828ef379\"><title data-gatsby-head=\"true\">Roche | Product Development Portfolio</title><script src=\"https://assets.adobedtm.com/extensions/EP31dbb9c60e404ba1aa6e746d49be6f29/AppMeasurement.min.js\" async=\"\"></script><link rel=\"canonical\" href=\"https://www.roche.com/solutions/pipeline\"><link rel=\"preconnect dns-prefetch\" href=\"https://component-library.roche.com/feat/monorepo\"><link rel=\"preconnect dns-prefetch\" href=\"https://cdn.cookielaw.org\"><link rel=\"preconnect dns-prefetch\" href=\"https://www.googletagmanager.com\"><link rel=\"preconnect dns-prefetch\" href=\"https://players.brightcove.net\"><script src=\"https://cdn.cookielaw.org/scripttemplates/otSDKStub.js\" type=\"text/javascript\" charset=\"UTF-8\" async=\"true\" defer=\"true\" data-domain-script=\"8831b9b2-1d9d-4efb-8a91-ddd8af0c32f4\" data-document-language=\"true\"></script><script>function OptanonWrapper(){window.OneTrust.OnConsentChanged((function(){window.dispatchEvent(new CustomEvent(\"onetrustInitialized\"))}))}</script><link rel=\"stylesheet\" href=\"https://component-library.roche.com/feat/monorepo/build/roche-component-library.css?version=1762520514253\" as=\"style\" onload=\"this.onload=null;this.rel=&quot;stylesheet&quot;\"><script>document.querySelectorAll('link[href=\"https://component-library.roche.com/feat/monorepo/build/roche-component-library.css?version=1762520514253\"]').forEach((e=>e.setAttribute(\"onload\",'this.onload=null;this.rel=\"stylesheet\"')))</script><noscript><link rel=\"stylesheet\" href=\"https://component-library.roche.com/feat/monorepo/build/roche-component-library.css?version=1762520514253\"></noscript><link rel=\"preload\" href=\"https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSans-Regular.woff2\" as=\"font\" crossorigin=\"anonymous\"><link rel=\"preload\" href=\"https://component-library.roche.com/feat/monorepo/assets/fonts/RocheSans-Light.woff2\" as=\"font\" crossorigin=\"anonymous\"><script>window.componentLibraryPath=\"https://component-library.roche.com/feat/monorepo/build\"</script><script src=\"https://component-library.roche.com/feat/monorepo/build/roche-component-library.bundle.js?version=1762520514253\"></script><style type=\"text/css\" data-gatsby-head=\"true\"></style><script src=\"https://assets.adobedtm.com/9215900255c9/17f1b4dd3439/launch-bb453ba32d52.min.js\" async=\"\" data-gatsby-head=\"true\"></script><script id=\"digital-registry\" type=\"text/plain\" class=\"optanon-category-C0002\" data-gatsby-head=\"true\">\n              !function() {\n                var e = function(e, t, n) {\n                    if (n) {\n                        var o = new Date;\n                        o.setTime(o.getTime() + 24 * n * 60 * 60 * 1e3);\n                        var a = \"; expires=\" + o.toGMTString()\n                    } else a = \"\";\n                    document.cookie = e + \"=\" + t + a + \";domain=.roche.com;path=/\"\n                };\n                var t = new Image;\n                t.addEventListener(\"error\", function() {\n                    e(\"netLocation\", \"external\")\n                }), t.addEventListener(\"load\", function() {\n                    e(\"netLocation\", \"internal\")\n                })\n                t.src = \"https://digitalregistry.roche.com/favicon.ico\"\n              }();\n            </script><script id=\"google-tag-manager\" type=\"text/plain\" class=\"optanon-category-C0002\" data-gatsby-head=\"true\">\n              (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':\n              new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],\n              j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=\n              'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);\n              })(window,document,'script','dataLayer','GTM-59ZDWVQ');\n\n              window.dataLayer = window.dataLayer || [];\n            </script><script src=\"https://cdn.cookielaw.org/scripttemplates/202508.1.0/otBannerSdk.js\" async=\"\" type=\"text/javascript\"></script><script src=\"https://assets.adobedtm.com/9215900255c9/17f1b4dd3439/6638f9da92c8/RC8845766bce2a4f948c9945d7f2e5c203-source.min.js\" async=\"\"></script><script src=\"https://assets.adobedtm.com/9215900255c9/17f1b4dd3439/6638f9da92c8/RC9ea2956572e2453db768a54544c889ce-source.min.js\" async=\"\"></script><script src=\"https://assets.adobedtm.com/9215900255c9/17f1b4dd3439/6638f9da92c8/RC1c6c2aaa575647d5aa78c3c36455a301-source.min.js\" async=\"\"></script><style id=\"onetrust-style\">#onetrust-banner-sdk .onetrust-vendors-list-handler{cursor:pointer;color:#1f96db;font-size:inherit;font-weight:bold;text-decoration:none;margin-left:5px}#onetrust-banner-sdk .onetrust-vendors-list-handler:hover{color:#1f96db}#onetrust-banner-sdk:focus{outline:2px solid #000;outline-offset:-2px}#onetrust-banner-sdk a:focus{outline:2px solid #000}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{outline-offset:1px}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{height:64px;width:64px}#onetrust-banner-sdk .ot-tcf2-vendor-count.ot-text-bold{font-weight:bold}#onetrust-banner-sdk .ot-button-order-0{order:0}#onetrust-banner-sdk .ot-button-order-1{order:1}#onetrust-banner-sdk .ot-button-order-2{order:2}#onetrust-banner-sdk #onetrust-close-btn-container svg{height:10px;width:10px;pointer-events:none}#onetrust-banner-sdk .ot-close-icon,#onetrust-pc-sdk .ot-close-icon,#ot-sync-ntfy .ot-close-icon{background-size:contain;background-repeat:no-repeat;background-position:center;height:12px;width:12px}#onetrust-banner-sdk .powered-by-logo,#onetrust-banner-sdk .ot-pc-footer-logo a,#onetrust-pc-sdk .powered-by-logo,#onetrust-pc-sdk .ot-pc-footer-logo a,#ot-sync-ntfy .powered-by-logo,#ot-sync-ntfy .ot-pc-footer-logo a{background-size:contain;background-repeat:no-repeat;background-position:center;height:25px;width:152px;display:block;text-decoration:none;font-size:.75em}#onetrust-banner-sdk .powered-by-logo:hover,#onetrust-banner-sdk .ot-pc-footer-logo a:hover,#onetrust-pc-sdk .powered-by-logo:hover,#onetrust-pc-sdk .ot-pc-footer-logo a:hover,#ot-sync-ntfy .powered-by-logo:hover,#ot-sync-ntfy .ot-pc-footer-logo a:hover{color:#565656}#onetrust-banner-sdk h3 *,#onetrust-banner-sdk h4 *,#onetrust-banner-sdk h6 *,#onetrust-banner-sdk button *,#onetrust-banner-sdk a[data-parent-id] *,#onetrust-pc-sdk h3 *,#onetrust-pc-sdk h4 *,#onetrust-pc-sdk h6 *,#onetrust-pc-sdk button *,#onetrust-pc-sdk a[data-parent-id] *,#ot-sync-ntfy h3 *,#ot-sync-ntfy h4 *,#ot-sync-ntfy h6 *,#ot-sync-ntfy button *,#ot-sync-ntfy a[data-parent-id] *{font-size:inherit;font-weight:inherit;color:inherit}#onetrust-banner-sdk .ot-hide,#onetrust-pc-sdk .ot-hide,#ot-sync-ntfy .ot-hide{display:none !important}#onetrust-banner-sdk button.ot-link-btn:hover,#onetrust-pc-sdk button.ot-link-btn:hover,#ot-sync-ntfy button.ot-link-btn:hover{text-decoration:underline;opacity:1}#onetrust-pc-sdk .ot-sdk-row .ot-sdk-column{padding:0}#onetrust-pc-sdk .ot-sdk-container{padding-right:0}#onetrust-pc-sdk .ot-sdk-row{flex-direction:initial;width:100%}#onetrust-pc-sdk [type=checkbox]:checked,#onetrust-pc-sdk [type=checkbox]:not(:checked){pointer-events:initial}#onetrust-pc-sdk [type=checkbox]:disabled+label::before,#onetrust-pc-sdk [type=checkbox]:disabled+label:after,#onetrust-pc-sdk [type=checkbox]:disabled+label{pointer-events:none;opacity:.8}#onetrust-pc-sdk #vendor-list-content{transform:translate3d(0, 0, 0)}#onetrust-pc-sdk li input[type=checkbox]{z-index:1}#onetrust-pc-sdk li .ot-checkbox label{z-index:2}#onetrust-pc-sdk li .ot-checkbox input[type=checkbox]{height:auto;width:auto}#onetrust-pc-sdk li .host-title a,#onetrust-pc-sdk li .ot-host-name a,#onetrust-pc-sdk li .accordion-text,#onetrust-pc-sdk li .ot-acc-txt{z-index:2;position:relative}#onetrust-pc-sdk input{margin:3px .1ex}#onetrust-pc-sdk .pc-logo,#onetrust-pc-sdk .ot-pc-logo{height:60px;width:180px;background-position:center;background-size:contain;background-repeat:no-repeat;display:inline-flex;justify-content:center;align-items:center}#onetrust-pc-sdk .pc-logo img,#onetrust-pc-sdk .ot-pc-logo img{max-height:100%;max-width:100%}#onetrust-pc-sdk .pc-logo svg,#onetrust-pc-sdk .ot-pc-logo svg{height:60px;width:180px}#onetrust-pc-sdk #close-pc-btn-handler>svg{margin:auto;display:block;height:12px;width:12px}#onetrust-pc-sdk .screen-reader-only,#onetrust-pc-sdk .ot-scrn-rdr,.ot-sdk-cookie-policy .screen-reader-only,.ot-sdk-cookie-policy .ot-scrn-rdr{border:0;clip:rect(0 0 0 0);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute;width:1px}#onetrust-pc-sdk.ot-fade-in,.onetrust-pc-dark-filter.ot-fade-in,#onetrust-banner-sdk.ot-fade-in{animation-name:onetrust-fade-in;animation-duration:400ms;animation-timing-function:ease-in-out}#onetrust-pc-sdk.ot-hide{display:none !important}.onetrust-pc-dark-filter.ot-hide{display:none !important}#ot-sdk-btn.ot-sdk-show-settings,#ot-sdk-btn.optanon-show-settings{color:#fff;background-color:#468254;height:auto;white-space:normal;word-wrap:break-word;padding:.8em 2em;font-size:.8em;line-height:1.2;cursor:pointer;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease}#ot-sdk-btn.ot-sdk-show-settings:hover,#ot-sdk-btn.optanon-show-settings:hover{color:#fff;background-color:#2c6415}#ot-sdk-btn.ot-sdk-show-settings:active,#ot-sdk-btn.optanon-show-settings:active{color:#fff;background-color:#2c6415;border:1px solid rgba(162,192,169,.5)}.onetrust-pc-dark-filter{background:rgba(0,0,0,.5);z-index:2147483646;width:100%;height:100%;overflow:hidden;position:fixed;top:0;bottom:0;left:0}@keyframes onetrust-fade-in{0%{opacity:0}100%{opacity:1}}.ot-cookie-label{text-decoration:underline}@media only screen and (min-width: 426px)and (max-width: 896px)and (orientation: landscape){#onetrust-pc-sdk p{font-size:.75em}}#onetrust-banner-sdk .banner-option-input:focus+label{outline:1px solid #000;outline-style:auto}.category-vendors-list-handler+a:focus,.category-vendors-list-handler+a:focus-visible{outline:2px solid #000}#onetrust-pc-sdk .ot-userid-title{margin-top:10px}#onetrust-pc-sdk .ot-userid-title>span,#onetrust-pc-sdk .ot-userid-timestamp>span{font-weight:700}#onetrust-pc-sdk .ot-userid-desc{font-style:italic}#onetrust-pc-sdk .ot-host-desc a{pointer-events:initial}#onetrust-pc-sdk .ot-ven-hdr>p a{position:relative;z-index:2;pointer-events:initial}#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info a{margin-right:auto}#onetrust-pc-sdk .ot-pc-footer-logo svg,#onetrust-pc-sdk .ot-pc-footer-logo img{width:136px;height:16px}#onetrust-pc-sdk .ot-pur-vdr-count{font-weight:400;font-size:.8em;padding-top:3px;display:block}#onetrust-banner-sdk .ot-optout-signal,#onetrust-pc-sdk .ot-optout-signal{border:1px solid #32ae88;border-radius:3px;padding:5px;margin-bottom:10px;background-color:#f9fffa;font-size:.85rem;line-height:2}#onetrust-banner-sdk .ot-optout-signal .ot-optout-icon,#onetrust-pc-sdk .ot-optout-signal .ot-optout-icon{display:inline;margin-right:5px}#onetrust-banner-sdk .ot-optout-signal svg,#onetrust-pc-sdk .ot-optout-signal svg{height:20px;width:30px}#onetrust-banner-sdk .ot-optout-signal svg.ot-source-sprite,#onetrust-pc-sdk .ot-optout-signal svg.ot-source-sprite{position:relative;bottom:-3px}#onetrust-banner-sdk .ot-optout-signal svg:not(.ot-source-sprite),#onetrust-pc-sdk .ot-optout-signal svg:not(.ot-source-sprite){transform:scale(0.5)}#onetrust-banner-sdk .ot-optout-signal svg:not(.ot-source-sprite) path,#onetrust-pc-sdk .ot-optout-signal svg:not(.ot-source-sprite) path{fill:#32ae88}#onetrust-consent-sdk .ot-general-modal{overflow:hidden;position:fixed;margin:0 auto;top:50%;left:50%;width:40%;padding:1.5rem;max-width:575px;min-width:575px;z-index:2147483647;border-radius:2.5px;transform:translate(-50%, -50%)}#onetrust-consent-sdk .ot-signature-health-group{margin-top:1rem;padding-left:1.25rem;padding-right:1.25rem;margin-bottom:.625rem;width:calc(100% - 2.5rem)}#onetrust-consent-sdk .ot-signature-health-group .ot-signature-health-form{gap:.5rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-health-form{width:70%;gap:.35rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-input{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-consent-sdk .ot-signature-health .ot-signature-subtitle{font-size:1.125rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-group-title{font-size:1.25rem;font-weight:bold}#onetrust-consent-sdk .ot-signature-health,#onetrust-consent-sdk .ot-signature-health-group{display:flex;flex-direction:column;gap:1rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-cont,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-cont{display:flex;flex-direction:column;gap:.25rem}#onetrust-consent-sdk .ot-signature-health .ot-signature-paragraph,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-paragraph{margin:0;line-height:20px;font-size:max(14px,.875rem)}#onetrust-consent-sdk .ot-signature-health .ot-health-signature-error,#onetrust-consent-sdk .ot-signature-health-group .ot-health-signature-error{color:#4d4d4d;font-size:min(12px,.75rem)}#onetrust-consent-sdk .ot-signature-health .ot-signature-buttons-cont,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-buttons-cont{margin-top:max(.75rem,2%);gap:1rem;display:flex;justify-content:flex-end}#onetrust-consent-sdk .ot-signature-health .ot-signature-button,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-button{flex:1;height:auto;color:#fff;cursor:pointer;line-height:1.2;min-width:125px;font-weight:600;font-size:.813em;border-radius:2px;padding:12px 10px;white-space:normal;word-wrap:break-word;word-break:break-word;background-color:#68b631;border:2px solid #68b631}#onetrust-consent-sdk .ot-signature-health .ot-signature-button.reject,#onetrust-consent-sdk .ot-signature-health-group .ot-signature-button.reject{background-color:#fff}#onetrust-consent-sdk .ot-input-field-cont{display:flex;flex-direction:column;gap:.5rem}#onetrust-consent-sdk .ot-input-field-cont .ot-signature-input{width:65%}#onetrust-consent-sdk .ot-signature-health-form{display:flex;flex-direction:column}#onetrust-consent-sdk .ot-signature-health-form .ot-signature-label{margin-bottom:0;line-height:20px;font-size:max(14px,.875rem)}#onetrust-consent-sdk #onetrust-sprite-svg{display:none}@media only screen and (max-width: 600px){#onetrust-consent-sdk .ot-general-modal{min-width:100%}#onetrust-consent-sdk .ot-signature-health .ot-signature-health-form{width:100%}#onetrust-consent-sdk .ot-input-field-cont .ot-signature-input{width:100%}}#onetrust-banner-sdk,#onetrust-pc-sdk,#ot-sdk-cookie-policy,#ot-sync-ntfy{font-size:16px}#onetrust-banner-sdk *,#onetrust-banner-sdk ::after,#onetrust-banner-sdk ::before,#onetrust-pc-sdk *,#onetrust-pc-sdk ::after,#onetrust-pc-sdk ::before,#ot-sdk-cookie-policy *,#ot-sdk-cookie-policy ::after,#ot-sdk-cookie-policy ::before,#ot-sync-ntfy *,#ot-sync-ntfy ::after,#ot-sync-ntfy ::before{-webkit-box-sizing:content-box;-moz-box-sizing:content-box;box-sizing:content-box}#onetrust-banner-sdk div,#onetrust-banner-sdk span,#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-banner-sdk p,#onetrust-banner-sdk img,#onetrust-banner-sdk svg,#onetrust-banner-sdk button,#onetrust-banner-sdk section,#onetrust-banner-sdk a,#onetrust-banner-sdk label,#onetrust-banner-sdk input,#onetrust-banner-sdk ul,#onetrust-banner-sdk li,#onetrust-banner-sdk nav,#onetrust-banner-sdk table,#onetrust-banner-sdk thead,#onetrust-banner-sdk tr,#onetrust-banner-sdk td,#onetrust-banner-sdk tbody,#onetrust-banner-sdk .ot-main-content,#onetrust-banner-sdk .ot-toggle,#onetrust-banner-sdk #ot-content,#onetrust-banner-sdk #ot-pc-content,#onetrust-banner-sdk .checkbox,#onetrust-pc-sdk div,#onetrust-pc-sdk span,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#onetrust-pc-sdk p,#onetrust-pc-sdk img,#onetrust-pc-sdk svg,#onetrust-pc-sdk button,#onetrust-pc-sdk section,#onetrust-pc-sdk a,#onetrust-pc-sdk label,#onetrust-pc-sdk input,#onetrust-pc-sdk ul,#onetrust-pc-sdk li,#onetrust-pc-sdk nav,#onetrust-pc-sdk table,#onetrust-pc-sdk thead,#onetrust-pc-sdk tr,#onetrust-pc-sdk td,#onetrust-pc-sdk tbody,#onetrust-pc-sdk .ot-main-content,#onetrust-pc-sdk .ot-toggle,#onetrust-pc-sdk #ot-content,#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk .checkbox,#ot-sdk-cookie-policy div,#ot-sdk-cookie-policy span,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy p,#ot-sdk-cookie-policy img,#ot-sdk-cookie-policy svg,#ot-sdk-cookie-policy button,#ot-sdk-cookie-policy section,#ot-sdk-cookie-policy a,#ot-sdk-cookie-policy label,#ot-sdk-cookie-policy input,#ot-sdk-cookie-policy ul,#ot-sdk-cookie-policy li,#ot-sdk-cookie-policy nav,#ot-sdk-cookie-policy table,#ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy tr,#ot-sdk-cookie-policy td,#ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy .ot-main-content,#ot-sdk-cookie-policy .ot-toggle,#ot-sdk-cookie-policy #ot-content,#ot-sdk-cookie-policy #ot-pc-content,#ot-sdk-cookie-policy .checkbox,#ot-sync-ntfy div,#ot-sync-ntfy span,#ot-sync-ntfy h1,#ot-sync-ntfy h2,#ot-sync-ntfy h3,#ot-sync-ntfy h4,#ot-sync-ntfy h5,#ot-sync-ntfy h6,#ot-sync-ntfy p,#ot-sync-ntfy img,#ot-sync-ntfy svg,#ot-sync-ntfy button,#ot-sync-ntfy section,#ot-sync-ntfy a,#ot-sync-ntfy label,#ot-sync-ntfy input,#ot-sync-ntfy ul,#ot-sync-ntfy li,#ot-sync-ntfy nav,#ot-sync-ntfy table,#ot-sync-ntfy thead,#ot-sync-ntfy tr,#ot-sync-ntfy td,#ot-sync-ntfy tbody,#ot-sync-ntfy .ot-main-content,#ot-sync-ntfy .ot-toggle,#ot-sync-ntfy #ot-content,#ot-sync-ntfy #ot-pc-content,#ot-sync-ntfy .checkbox{font-family:inherit;font-weight:normal;-webkit-font-smoothing:auto;letter-spacing:normal;line-height:normal;padding:0;margin:0;height:auto;min-height:0;max-height:none;width:auto;min-width:0;max-width:none;border-radius:0;border:none;clear:none;float:none;position:static;bottom:auto;left:auto;right:auto;top:auto;text-align:left;text-decoration:none;text-indent:0;text-shadow:none;text-transform:none;white-space:normal;background:none;overflow:visible;vertical-align:baseline;visibility:visible;z-index:auto;box-shadow:none}#onetrust-banner-sdk img,#onetrust-pc-sdk img,#ot-sdk-cookie-policy img,#ot-sync-ntfy img{overflow:hidden !important}#onetrust-banner-sdk label:before,#onetrust-banner-sdk label:after,#onetrust-banner-sdk .checkbox:after,#onetrust-banner-sdk .checkbox:before,#onetrust-pc-sdk label:before,#onetrust-pc-sdk label:after,#onetrust-pc-sdk .checkbox:after,#onetrust-pc-sdk .checkbox:before,#ot-sdk-cookie-policy label:before,#ot-sdk-cookie-policy label:after,#ot-sdk-cookie-policy .checkbox:after,#ot-sdk-cookie-policy .checkbox:before,#ot-sync-ntfy label:before,#ot-sync-ntfy label:after,#ot-sync-ntfy .checkbox:after,#ot-sync-ntfy .checkbox:before{content:\"\";content:none}#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{position:relative;width:100%;max-width:100%;margin:0 auto;padding:0 20px;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{width:100%;float:left;box-sizing:border-box;padding:0;display:initial}@media(min-width: 400px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:90%;padding:0}}@media(min-width: 550px){#onetrust-banner-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container,#ot-sdk-cookie-policy .ot-sdk-container{width:100%}#onetrust-banner-sdk .ot-sdk-column,#onetrust-banner-sdk .ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-column,#onetrust-pc-sdk .ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-column,#ot-sdk-cookie-policy .ot-sdk-columns{margin-left:4%}#onetrust-banner-sdk .ot-sdk-column:first-child,#onetrust-banner-sdk .ot-sdk-columns:first-child,#onetrust-pc-sdk .ot-sdk-column:first-child,#onetrust-pc-sdk .ot-sdk-columns:first-child,#ot-sdk-cookie-policy .ot-sdk-column:first-child,#ot-sdk-cookie-policy .ot-sdk-columns:first-child{margin-left:0}#onetrust-banner-sdk .ot-sdk-two.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-two.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-two.ot-sdk-columns{width:13.3333333333%}#onetrust-banner-sdk .ot-sdk-three.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-three.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-three.ot-sdk-columns{width:22%}#onetrust-banner-sdk .ot-sdk-four.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-four.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-four.ot-sdk-columns{width:30.6666666667%}#onetrust-banner-sdk .ot-sdk-eight.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eight.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eight.ot-sdk-columns{width:65.3333333333%}#onetrust-banner-sdk .ot-sdk-nine.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-nine.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-nine.ot-sdk-columns{width:74%}#onetrust-banner-sdk .ot-sdk-ten.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-ten.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-ten.ot-sdk-columns{width:82.6666666667%}#onetrust-banner-sdk .ot-sdk-eleven.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-eleven.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-eleven.ot-sdk-columns{width:91.3333333333%}#onetrust-banner-sdk .ot-sdk-twelve.ot-sdk-columns,#onetrust-pc-sdk .ot-sdk-twelve.ot-sdk-columns,#ot-sdk-cookie-policy .ot-sdk-twelve.ot-sdk-columns{width:100%;margin-left:0}}#onetrust-banner-sdk h1,#onetrust-banner-sdk h2,#onetrust-banner-sdk h3,#onetrust-banner-sdk h4,#onetrust-banner-sdk h5,#onetrust-banner-sdk h6,#onetrust-pc-sdk h1,#onetrust-pc-sdk h2,#onetrust-pc-sdk h3,#onetrust-pc-sdk h4,#onetrust-pc-sdk h5,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h1,#ot-sdk-cookie-policy h2,#ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy h5,#ot-sdk-cookie-policy h6{margin-top:0;font-weight:600;font-family:inherit}#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem;line-height:1.2}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem;line-height:1.25}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem;line-height:1.3}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem;line-height:1.35}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem;line-height:1.5}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem;line-height:1.6}@media(min-width: 550px){#onetrust-banner-sdk h1,#onetrust-pc-sdk h1,#ot-sdk-cookie-policy h1{font-size:1.5rem}#onetrust-banner-sdk h2,#onetrust-pc-sdk h2,#ot-sdk-cookie-policy h2{font-size:1.5rem}#onetrust-banner-sdk h3,#onetrust-pc-sdk h3,#ot-sdk-cookie-policy h3{font-size:1.5rem}#onetrust-banner-sdk h4,#onetrust-pc-sdk h4,#ot-sdk-cookie-policy h4{font-size:1.5rem}#onetrust-banner-sdk h5,#onetrust-pc-sdk h5,#ot-sdk-cookie-policy h5{font-size:1.5rem}#onetrust-banner-sdk h6,#onetrust-pc-sdk h6,#ot-sdk-cookie-policy h6{font-size:1.5rem}}#onetrust-banner-sdk p,#onetrust-pc-sdk p,#ot-sdk-cookie-policy p{margin:0 0 1em 0;font-family:inherit;line-height:normal}#onetrust-banner-sdk a,#onetrust-pc-sdk a,#ot-sdk-cookie-policy a{color:#565656;text-decoration:underline}#onetrust-banner-sdk a:hover,#onetrust-pc-sdk a:hover,#ot-sdk-cookie-policy a:hover{color:#565656;text-decoration:none}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-button,#onetrust-banner-sdk button,#onetrust-pc-sdk .ot-sdk-button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy .ot-sdk-button,#ot-sdk-cookie-policy button{display:inline-block;height:38px;padding:0 30px;color:#555;text-align:center;font-size:.9em;font-weight:400;line-height:38px;letter-spacing:.01em;text-decoration:none;white-space:nowrap;background-color:rgba(0,0,0,0);border-radius:2px;border:1px solid #bbb;cursor:pointer;box-sizing:border-box}#onetrust-banner-sdk .ot-sdk-button:hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#onetrust-pc-sdk .ot-sdk-button:hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus,#ot-sdk-cookie-policy .ot-sdk-button:hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):hover,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:not(.ot-link-btn):focus{color:#333;border-color:#888;opacity:.9}#onetrust-banner-sdk .ot-sdk-button:focus,#onetrust-banner-sdk :not(.ot-leg-btn-container)>button:focus,#onetrust-pc-sdk .ot-sdk-button:focus,#onetrust-pc-sdk :not(.ot-leg-btn-container)>button:focus,#ot-sdk-cookie-policy .ot-sdk-button:focus,#ot-sdk-cookie-policy :not(.ot-leg-btn-container)>button:focus{outline:2px solid #000}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-banner-sdk button.ot-sdk-button-primary,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary,#onetrust-pc-sdk button.ot-sdk-button-primary,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary,#ot-sdk-cookie-policy button.ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary{color:#fff;background-color:#33c3f0;border-color:#33c3f0}#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-banner-sdk button.ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary:hover,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary:hover,#onetrust-banner-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-banner-sdk button.ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=submit].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=reset].ot-sdk-button-primary:focus,#onetrust-banner-sdk input[type=button].ot-sdk-button-primary:focus,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:hover,#onetrust-pc-sdk button.ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary:hover,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary:hover,#onetrust-pc-sdk .ot-sdk-button.ot-sdk-button-primary:focus,#onetrust-pc-sdk button.ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=submit].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=reset].ot-sdk-button-primary:focus,#onetrust-pc-sdk input[type=button].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy button.ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary:hover,#ot-sdk-cookie-policy .ot-sdk-button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy button.ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=submit].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=reset].ot-sdk-button-primary:focus,#ot-sdk-cookie-policy input[type=button].ot-sdk-button-primary:focus{color:#fff;background-color:#1eaedb;border-color:#1eaedb}#onetrust-banner-sdk input[type=text],#onetrust-pc-sdk input[type=text],#ot-sdk-cookie-policy input[type=text]{height:38px;padding:6px 10px;background-color:#fff;border:1px solid #d1d1d1;border-radius:4px;box-shadow:none;box-sizing:border-box}#onetrust-banner-sdk input[type=text],#onetrust-pc-sdk input[type=text],#ot-sdk-cookie-policy input[type=text]{-webkit-appearance:none;-moz-appearance:none;appearance:none}#onetrust-banner-sdk input[type=text]:focus,#onetrust-pc-sdk input[type=text]:focus,#ot-sdk-cookie-policy input[type=text]:focus{border:1px solid #000;outline:0}#onetrust-banner-sdk label,#onetrust-pc-sdk label,#ot-sdk-cookie-policy label{display:block;margin-bottom:.5rem;font-weight:600}#onetrust-banner-sdk input[type=checkbox],#onetrust-pc-sdk input[type=checkbox],#ot-sdk-cookie-policy input[type=checkbox]{display:inline}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{list-style:circle inside}#onetrust-banner-sdk ul,#onetrust-pc-sdk ul,#ot-sdk-cookie-policy ul{padding-left:0;margin-top:0}#onetrust-banner-sdk ul ul,#onetrust-pc-sdk ul ul,#ot-sdk-cookie-policy ul ul{margin:1.5rem 0 1.5rem 3rem;font-size:90%}#onetrust-banner-sdk li,#onetrust-pc-sdk li,#ot-sdk-cookie-policy li{margin-bottom:1rem}#onetrust-banner-sdk th,#onetrust-banner-sdk td,#onetrust-pc-sdk th,#onetrust-pc-sdk td,#ot-sdk-cookie-policy th,#ot-sdk-cookie-policy td{padding:12px 15px;text-align:left;border-bottom:1px solid #e1e1e1}#onetrust-banner-sdk button,#onetrust-pc-sdk button,#ot-sdk-cookie-policy button{margin-bottom:1rem;font-family:inherit}#onetrust-banner-sdk .ot-sdk-container:after,#onetrust-banner-sdk .ot-sdk-row:after,#onetrust-pc-sdk .ot-sdk-container:after,#onetrust-pc-sdk .ot-sdk-row:after,#ot-sdk-cookie-policy .ot-sdk-container:after,#ot-sdk-cookie-policy .ot-sdk-row:after{content:\"\";display:table;clear:both}#onetrust-banner-sdk .ot-sdk-row,#onetrust-pc-sdk .ot-sdk-row,#ot-sdk-cookie-policy .ot-sdk-row{margin:0;max-width:none;display:block}#onetrust-banner-sdk{box-shadow:0 0 18px rgba(0,0,0,.2)}#onetrust-banner-sdk.otFlat{position:fixed;z-index:2147483645;bottom:0;right:0;left:0;background-color:#fff;max-height:90%;overflow-x:hidden;overflow-y:auto}#onetrust-banner-sdk.otFlat.top{top:0px;bottom:auto}#onetrust-banner-sdk.otRelFont{font-size:1rem}#onetrust-banner-sdk>.ot-sdk-container{overflow:hidden}#onetrust-banner-sdk::-webkit-scrollbar{width:11px}#onetrust-banner-sdk::-webkit-scrollbar-thumb{border-radius:10px;background:#c1c1c1}#onetrust-banner-sdk{scrollbar-arrow-color:#c1c1c1;scrollbar-darkshadow-color:#c1c1c1;scrollbar-face-color:#c1c1c1;scrollbar-shadow-color:#c1c1c1}#onetrust-banner-sdk #onetrust-policy{margin:1.25em 0 .625em 2em;overflow:hidden}#onetrust-banner-sdk #onetrust-policy .ot-gv-list-handler{float:left;font-size:.82em;padding:0;margin-bottom:0;border:0;line-height:normal;height:auto;width:auto}#onetrust-banner-sdk #onetrust-policy-title{font-size:1.2em;line-height:1.3;margin-bottom:10px}#onetrust-banner-sdk #onetrust-group-container{position:relative}#onetrust-banner-sdk #onetrust-policy-text{clear:both;text-align:left;font-size:.88em;line-height:1.4}#onetrust-banner-sdk #onetrust-policy-text *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk #onetrust-policy-text a{font-weight:bold}#onetrust-banner-sdk #onetrust-policy-title,#onetrust-banner-sdk #onetrust-policy-text{color:dimgray;float:left}#onetrust-banner-sdk #onetrust-button-group-parent{min-height:1px;text-align:center}#onetrust-banner-sdk #onetrust-button-group{display:inline-block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{background-color:#68b631;color:#fff;border-color:#68b631;margin-right:1em;min-width:125px;height:auto;white-space:normal;word-break:break-word;word-wrap:break-word;padding:12px 10px;line-height:1.2;font-size:.813em;font-weight:600}#onetrust-banner-sdk #onetrust-pc-btn-handler.cookie-setting-link{background-color:#fff;border:none;color:#68b631;text-decoration:underline;padding-left:0;padding-right:0}#onetrust-banner-sdk .onetrust-close-btn-ui{width:44px;height:44px;background-size:12px;border:none;position:relative;margin:auto;padding:0}#onetrust-banner-sdk .banner_logo{display:none}#onetrust-banner-sdk.ot-bnr-w-logo .ot-bnr-logo{position:absolute;top:50%;transform:translateY(-50%);left:0px;margin-right:5px}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-policy{margin-left:65px}#onetrust-banner-sdk .ot-b-addl-desc{clear:both;float:left;display:block}#onetrust-banner-sdk #banner-options{float:left;display:table;margin-right:0;margin-left:1em;width:calc(100% - 1em)}#onetrust-banner-sdk .banner-option-input{cursor:pointer;width:auto;height:auto;border:none;padding:0;padding-right:3px;margin:0 0 10px;font-size:.82em;line-height:1.4}#onetrust-banner-sdk .banner-option-input *{pointer-events:none;font-size:inherit;line-height:inherit}#onetrust-banner-sdk .banner-option-input[aria-expanded=true]~.banner-option-details{display:block;height:auto}#onetrust-banner-sdk .banner-option-input[aria-expanded=true] .ot-arrow-container{transform:rotate(90deg)}#onetrust-banner-sdk .banner-option{margin-bottom:12px;margin-left:0;border:none;float:left;padding:0}#onetrust-banner-sdk .banner-option:first-child{padding-left:2px}#onetrust-banner-sdk .banner-option:not(:first-child){padding:0;border:none}#onetrust-banner-sdk .banner-option-header{cursor:pointer;display:inline-block}#onetrust-banner-sdk .banner-option-header :first-child{color:dimgray;font-weight:bold;float:left}#onetrust-banner-sdk .banner-option-header .ot-arrow-container{display:inline-block;border-top:6px solid rgba(0,0,0,0);border-bottom:6px solid rgba(0,0,0,0);border-left:6px solid dimgray;margin-left:10px;vertical-align:middle}#onetrust-banner-sdk .banner-option-details{display:none;font-size:.83em;line-height:1.5;padding:10px 0px 5px 10px;margin-right:10px;height:0px}#onetrust-banner-sdk .banner-option-details *{font-size:inherit;line-height:inherit;color:dimgray}#onetrust-banner-sdk .ot-arrow-container,#onetrust-banner-sdk .banner-option-details{transition:all 300ms ease-in 0s;-webkit-transition:all 300ms ease-in 0s;-moz-transition:all 300ms ease-in 0s;-o-transition:all 300ms ease-in 0s}#onetrust-banner-sdk .ot-dpd-container{float:left}#onetrust-banner-sdk .ot-dpd-title{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-title,#onetrust-banner-sdk .ot-dpd-desc{font-size:.88em;line-height:1.4;color:dimgray}#onetrust-banner-sdk .ot-dpd-title *,#onetrust-banner-sdk .ot-dpd-desc *{font-size:inherit;line-height:inherit}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text *{margin-bottom:0}#onetrust-banner-sdk.ot-iab-2 .onetrust-vendors-list-handler{display:block;margin-left:0;margin-top:5px;clear:both;margin-bottom:0;padding:0;border:0;height:auto;width:auto}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk.ot-close-btn-link{padding-top:25px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container{top:15px;transform:none;right:15px}#onetrust-banner-sdk.ot-close-btn-link #onetrust-close-btn-container button{padding:0;white-space:pre-wrap;border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em}#onetrust-banner-sdk #onetrust-policy-text,#onetrust-banner-sdk .ot-dpd-desc,#onetrust-banner-sdk .ot-b-addl-desc{font-size:.813em;line-height:1.5}#onetrust-banner-sdk .ot-dpd-desc{margin-bottom:10px}#onetrust-banner-sdk .ot-dpd-desc>.ot-b-addl-desc{margin-top:10px;margin-bottom:10px;font-size:1em}@media only screen and (max-width: 425px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:6px;right:2px}#onetrust-banner-sdk #onetrust-policy{margin-left:0;margin-top:3em}#onetrust-banner-sdk #onetrust-button-group{display:block}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{width:100%}#onetrust-banner-sdk .onetrust-close-btn-ui{top:auto;transform:none}#onetrust-banner-sdk #onetrust-policy-title{display:inline;float:none}#onetrust-banner-sdk #banner-options{margin:0;padding:0;width:100%}}@media only screen and (max-width: 550px){#onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler,#onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler{margin-right:0}#onetrust-banner-sdk .has-reject-all-button div#onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler,#onetrust-banner-sdk .has-reject-all-button div#onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button div#onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler{margin-right:0}}@media only screen and (min-width: 426px)and (max-width: 896px){#onetrust-banner-sdk #onetrust-close-btn-container{position:absolute;top:0;right:0}#onetrust-banner-sdk #onetrust-policy{margin-left:1em;margin-right:1em}#onetrust-banner-sdk .onetrust-close-btn-ui{top:10px;right:10px}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:95%}#onetrust-banner-sdk.ot-iab-2 #onetrust-group-container{width:100%}#onetrust-banner-sdk.ot-bnr-w-logo #onetrust-button-group-parent{padding-left:50px}#onetrust-banner-sdk #onetrust-button-group-parent{width:100%;position:relative;margin-left:0}#onetrust-banner-sdk #onetrust-button-group button{display:inline-block}#onetrust-banner-sdk #onetrust-button-group{margin-right:0;text-align:center}#onetrust-banner-sdk #onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler{width:auto}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container{display:inline-flex;flex-wrap:wrap}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container #onetrust-pc-btn-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container #onetrust-accept-btn-handler{float:none}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group.ot-button-order-container *[class*=ot-button-order-]:nth-of-type(1){margin-right:auto !important}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler{float:left}#onetrust-banner-sdk .has-reject-all-button #onetrust-reject-all-handler,#onetrust-banner-sdk .has-reject-all-button #onetrust-accept-btn-handler{float:right}#onetrust-banner-sdk .has-reject-all-button #onetrust-button-group{width:calc(100% - 2em);margin-right:0}#onetrust-banner-sdk .has-reject-all-button #onetrust-pc-btn-handler.cookie-setting-link{padding-left:0px;text-align:left}#onetrust-banner-sdk.ot-buttons-fw .ot-sdk-three button{width:100%;text-align:center}#onetrust-banner-sdk.ot-buttons-fw #onetrust-button-group-parent button{float:none}#onetrust-banner-sdk.ot-buttons-fw #onetrust-pc-btn-handler.cookie-setting-link{text-align:center}}@media only screen and (min-width: 550px){#onetrust-banner-sdk .banner-option:not(:first-child){border-left:1px solid #d8d8d8;padding-left:25px}}@media only screen and (min-width: 425px)and (max-width: 550px){#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group,#onetrust-banner-sdk.ot-iab-2 #onetrust-policy,#onetrust-banner-sdk.ot-iab-2 .banner-option{width:100%}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-accept-btn-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-reject-all-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-pc-btn-handler{width:100%}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-accept-btn-handler,#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group #onetrust-reject-all-handler{float:left}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group.ot-button-order-container{width:auto}}@media only screen and (min-width: 769px){#onetrust-banner-sdk #onetrust-button-group{margin-right:30%}#onetrust-banner-sdk #banner-options{margin-left:2em;margin-right:5em;margin-bottom:1.25em;width:calc(100% - 7em)}}@media only screen and (min-width: 897px)and (max-width: 1023px){#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:80%;transform:translateY(-50%)}#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;padding:0;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{position:relative;margin:0;right:-22px;top:2px}}@media only screen and (min-width: 1024px){#onetrust-banner-sdk #onetrust-close-btn-container{top:50%;margin:auto;transform:translate(-50%, -50%);position:absolute;right:0}#onetrust-banner-sdk #onetrust-close-btn-container button{right:-12px}#onetrust-banner-sdk #onetrust-policy{margin-left:2em}#onetrust-banner-sdk.vertical-align-content #onetrust-button-group-parent{position:absolute;top:50%;left:60%;transform:translateY(-50%)}#onetrust-banner-sdk .ot-optout-signal{width:50%}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-title{width:50%}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text,#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:1em;width:50%;border-right:1px solid #d8d8d8;padding-right:1rem}#onetrust-banner-sdk.ot-iab-2 #onetrust-policy-text{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 :not(.ot-dpd-desc)>.ot-b-addl-desc{margin-bottom:0;padding-bottom:1em}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-container{width:45%;padding-left:1rem;display:inline-block;float:none}#onetrust-banner-sdk.ot-iab-2 .ot-dpd-title{line-height:1.7}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group-parent{left:auto;right:4%;margin-left:0}#onetrust-banner-sdk.ot-iab-2 #onetrust-button-group button{display:block}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{margin:auto;width:30%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:60%}#onetrust-banner-sdk #onetrust-button-group{margin-right:auto}#onetrust-banner-sdk #onetrust-accept-btn-handler,#onetrust-banner-sdk #onetrust-reject-all-handler,#onetrust-banner-sdk #onetrust-pc-btn-handler{margin-top:1em}}@media only screen and (min-width: 890px){#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group-parent{padding-left:3%;padding-right:4%;margin-left:0}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group{margin-right:0;margin-top:1.25em;width:100%}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button{width:100%;margin-bottom:5px;margin-top:5px}#onetrust-banner-sdk.ot-buttons-fw:not(.ot-iab-2) #onetrust-button-group button:last-of-type{margin-bottom:20px}}@media only screen and (min-width: 1280px){#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-group-container{width:55%}#onetrust-banner-sdk:not(.ot-iab-2) #onetrust-button-group-parent{width:44%;padding-left:2%;padding-right:2%}#onetrust-banner-sdk:not(.ot-iab-2).vertical-align-content #onetrust-button-group-parent{position:absolute;left:55%}}\n        #onetrust-consent-sdk #onetrust-banner-sdk {background-color: #FFFFFF;}\n            #onetrust-consent-sdk #onetrust-policy-title,\n                    #onetrust-consent-sdk #onetrust-policy-text,\n                    #onetrust-consent-sdk .ot-b-addl-desc,\n                    #onetrust-consent-sdk .ot-dpd-desc,\n                    #onetrust-consent-sdk .ot-dpd-title,\n                    #onetrust-consent-sdk #onetrust-policy-text *:not(.onetrust-vendors-list-handler),\n                    #onetrust-consent-sdk .ot-dpd-desc *:not(.onetrust-vendors-list-handler),\n                    #onetrust-consent-sdk #onetrust-banner-sdk #banner-options *,\n                    #onetrust-banner-sdk .ot-cat-header,\n                    #onetrust-banner-sdk .ot-optout-signal\n                    {\n                        color: #696969;\n                    }\n            #onetrust-consent-sdk #onetrust-banner-sdk .banner-option-details {\n                    background-color: #E9E9E9;}\n             #onetrust-consent-sdk #onetrust-banner-sdk a[href],\n                    #onetrust-consent-sdk #onetrust-banner-sdk a[href] font,\n                    #onetrust-consent-sdk #onetrust-banner-sdk .ot-link-btn\n                        {\n                            color: #0B41CD;\n                        }#onetrust-consent-sdk #onetrust-accept-btn-handler,\n                         #onetrust-banner-sdk #onetrust-reject-all-handler {\n                            background-color: #0B41CD;border-color: #0B41CD;\n                color: #FFFFFF;\n            }\n            #onetrust-consent-sdk #onetrust-banner-sdk *:focus,\n            #onetrust-consent-sdk #onetrust-banner-sdk:focus {\n               outline-color: #000000;\n               outline-width: 1px;\n            }\n            #onetrust-consent-sdk #onetrust-pc-btn-handler,\n            #onetrust-consent-sdk #onetrust-pc-btn-handler.cookie-setting-link {\n                color: #0B41CD; border-color: #0B41CD;\n                background-color:\n                #FFFFFF;\n            }#onetrust-banner-sdk #onetrust-policy-text a.ot-cookie-policy-link,\n                         #onetrust-banner-sdk #onetrust-policy-text a.ot-imprint-link {\n                    margin-left: 5px;\n                }#onetrust-pc-sdk{position:fixed;width:730px;max-width:730px;height:610px;left:0;right:0;top:0;bottom:0;margin:auto;font-size:16px;z-index:2147483647;border-radius:2px;background-color:#fff;box-shadow:0 2px 4px 0 rgba(0,0,0,0),0 7px 14px 0 rgba(50,50,93,.1)}#onetrust-pc-sdk.otRelFont{font-size:1rem}#onetrust-pc-sdk *,#onetrust-pc-sdk ::after,#onetrust-pc-sdk ::before{box-sizing:content-box}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr,#onetrust-pc-sdk .ot-hide-tgl{visibility:hidden}#onetrust-pc-sdk #ot-addtl-venlst .ot-arw-cntr *,#onetrust-pc-sdk .ot-hide-tgl *{visibility:hidden}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk #ot-pc-lst{height:calc(100% - 185px)}#onetrust-pc-sdk li{list-style:none}#onetrust-pc-sdk ul,#onetrust-pc-sdk li{margin:0}#onetrust-pc-sdk ul li div:focus{margin:0px 2px !important}#onetrust-pc-sdk ul:focus-within{padding-top:2px !important}#onetrust-pc-sdk .ot-desc-cntr:focus{outline-offset:-1px !important}#onetrust-pc-sdk a{text-decoration:underline}#onetrust-pc-sdk .ot-link-btn{padding:0;margin-bottom:0;border:0;font-weight:normal;line-height:normal;width:auto;height:auto}#onetrust-pc-sdk .ot-grps-cntr *::-webkit-scrollbar,#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar{width:11px}#onetrust-pc-sdk .ot-grps-cntr *::-webkit-scrollbar-thumb,#onetrust-pc-sdk .ot-pc-scrollbar::-webkit-scrollbar-thumb{border-radius:10px;background:#c1c1c1}#onetrust-pc-sdk .ot-grps-cntr *,#onetrust-pc-sdk .ot-pc-scrollbar{scrollbar-arrow-color:#c1c1c1;scrollbar-darkshadow-color:#c1c1c1;scrollbar-face-color:#c1c1c1;scrollbar-shadow-color:#c1c1c1}#onetrust-pc-sdk .ot-pc-header{height:auto;padding:10px;display:block;width:calc(100% - 20px);min-height:52px;border-bottom:1px solid #d8d8d8;position:relative}#onetrust-pc-sdk .ot-pc-logo{vertical-align:middle;width:180px}#onetrust-pc-sdk .ot-pc-logo.ot-pc-logo{height:40px}#onetrust-pc-sdk .ot-title-cntr{position:relative;display:inline-block;vertical-align:middle;width:calc(100% - 190px);padding-left:10px}#onetrust-pc-sdk .ot-optout-signal{margin:.625rem .625rem .625rem 1.75rem}#onetrust-pc-sdk .ot-always-active{font-size:.813em;line-height:1.5;font-weight:700;color:#3860be}#onetrust-pc-sdk .ot-close-cntr{float:right;position:absolute;right:-9px;top:50%;transform:translateY(-50%)}#onetrust-pc-sdk #ot-pc-content{position:relative;overflow-y:auto;overflow-x:hidden}#onetrust-pc-sdk #ot-pc-content .ot-sdk-container{margin-left:0}#onetrust-pc-sdk .ot-grps-cntr,#onetrust-pc-sdk .ot-grps-cntr>*{height:100%;overflow-y:auto}#onetrust-pc-sdk .category-menu-switch-handler{cursor:pointer;border-left:10px solid rgba(0,0,0,0);background-color:#f4f4f4;border-bottom:1px solid #d7d7d7;padding-top:12px;padding-right:5px;padding-bottom:12px;padding-left:12px;overflow:hidden}#onetrust-pc-sdk .category-menu-switch-handler h3{float:left;text-align:left;margin:0;color:dimgray;line-height:1.4;font-size:.875em;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-active-menu{border-left:10px solid #68b631;background-color:#fff;border-bottom:none;position:relative}#onetrust-pc-sdk .ot-active-menu h3{color:#263238;font-weight:bold}#onetrust-pc-sdk .ot-desc-cntr{word-break:break-word;word-wrap:break-word;padding-top:20px;padding-right:16px;padding-bottom:15px}#onetrust-pc-sdk .ot-grp-desc{word-break:break-word;word-wrap:break-word;text-align:left;font-size:.813em;line-height:1.5;margin:0}#onetrust-pc-sdk .ot-grp-desc *{font-size:inherit;line-height:inherit}#onetrust-pc-sdk #ot-pc-desc a{color:#3860be;cursor:pointer;font-size:1em}#onetrust-pc-sdk #ot-pc-desc a.privacy-notice-link,#onetrust-pc-sdk #ot-pc-desc a.ot-imprint-handler{margin-right:8px}#onetrust-pc-sdk #ot-pc-desc a:hover{color:#1883fd}#onetrust-pc-sdk #ot-pc-desc button{margin-right:8px}#onetrust-pc-sdk #ot-pc-desc *{font-size:inherit}#onetrust-pc-sdk #ot-pc-desc ul li{padding:10px 0px;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk #ot-pc-desc+.ot-link-btn{display:none}#onetrust-pc-sdk .ot-btn-subcntr{float:right}#onetrust-pc-sdk .ot-close-icon{background-size:12px;background-repeat:no-repeat;background-position:center;height:44px;width:44px;display:inline-block}#onetrust-pc-sdk .ot-tgl{float:right;position:relative;z-index:1}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob{background-color:#468254;border:1px solid #fff}#onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob:before{-webkit-transform:translateX(21px);-ms-transform:translateX(21px);transform:translateX(21px);background-color:#fff}#onetrust-pc-sdk .ot-tgl input:focus+.ot-switch .ot-switch-nob{box-shadow:0 0 1px #2196f3;outline-style:auto !important;outline-width:1px !important}#onetrust-pc-sdk .ot-switch{position:relative;display:inline-block;width:45px;height:25px;margin-bottom:0}#onetrust-pc-sdk .ot-switch-nob{position:absolute;cursor:pointer;top:0;left:0;right:0;bottom:0;background-color:#767676;border:1px solid #ddd;transition:all .2s ease-in 0s;-moz-transition:all .2s ease-in 0s;-o-transition:all .2s ease-in 0s;-webkit-transition:all .2s ease-in 0s;border-radius:20px}#onetrust-pc-sdk .ot-switch-nob:before{position:absolute;content:\"\";height:18px;width:18px;bottom:3px;left:2px;background-color:#fff;-webkit-transition:.4s;transition:.4s;border-radius:20px}#onetrust-pc-sdk .ot-chkbox{z-index:1;position:relative;float:left}#onetrust-pc-sdk .ot-chkbox input{width:28px !important;height:28px !important}#onetrust-pc-sdk .ot-chkbox input:checked~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input+label::after{content:none;color:#fff}#onetrust-pc-sdk .ot-chkbox input:checked+label::after{content:\"\"}#onetrust-pc-sdk .ot-chkbox input:focus+label::before{outline-style:solid;outline-width:2px;outline-style:auto}#onetrust-pc-sdk .ot-chkbox input[aria-checked=mixed]~label::before{background-color:#3860be}#onetrust-pc-sdk .ot-chkbox input[aria-checked=mixed]+label::after{content:\"\"}#onetrust-pc-sdk .ot-chkbox label{position:relative;padding-left:30px;display:flex;align-items:center;cursor:pointer;min-height:28px !important}#onetrust-pc-sdk .ot-chkbox label::before,#onetrust-pc-sdk .ot-chkbox label::after{position:absolute;content:\"\";display:inline-block;border-radius:3px}#onetrust-pc-sdk .ot-chkbox label::before{height:18px;width:18px;border:1px solid #3860be;left:0px;left:4px;top:4px}#onetrust-pc-sdk .ot-chkbox label::after{height:5px;width:9px;border-left:3px solid;border-bottom:3px solid;transform:rotate(-45deg);-o-transform:rotate(-45deg);-ms-transform:rotate(-45deg);-webkit-transform:rotate(-45deg);left:8px;top:8px}#onetrust-pc-sdk .ot-label-txt{display:none}#onetrust-pc-sdk .ot-fltr-opt .ot-label-txt{display:inline-block}#onetrust-pc-sdk .ot-chkbox input,#onetrust-pc-sdk .ot-tgl input{position:absolute;opacity:0;width:0;height:0}#onetrust-pc-sdk .ot-arw-cntr{float:right;position:relative;pointer-events:none}#onetrust-pc-sdk .ot-arw{width:16px;height:16px;margin-left:5px;color:dimgray;display:inline-block;vertical-align:middle;-webkit-transition:all 150ms ease-in 0s;-moz-transition:all 150ms ease-in 0s;-o-transition:all 150ms ease-in 0s;transition:all 150ms ease-in 0s}#onetrust-pc-sdk input:checked~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk button[aria-expanded=true]~.ot-acc-hdr .ot-arw-cntr svg{transform:rotate(90deg);-o-transform:rotate(90deg);-ms-transform:rotate(90deg);-webkit-transform:rotate(90deg)}#onetrust-pc-sdk .ot-label-status{font-size:.75em;position:relative;top:2px;display:none;padding-right:5px;float:left}#onetrust-pc-sdk #ot-lst-cnt .ot-label-status{top:-6px}#onetrust-pc-sdk .ot-fltr-opts{min-height:35px}#onetrust-pc-sdk .ot-fltr-btns{margin:10px 15px 0 15px}#onetrust-pc-sdk .ot-fltr-btns button{padding:12px 30px}#onetrust-pc-sdk .ot-pc-footer{position:absolute;bottom:0px;width:100%;max-height:160px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-pc-footer button{margin-top:20px;margin-bottom:20px;font-weight:600;font-size:.813em;min-height:40px;height:auto;line-height:normal;padding:10px 30px}#onetrust-pc-sdk .ot-tab-desc{margin-left:3%}#onetrust-pc-sdk .ot-grp-hdr1{display:inline-block;width:100%;margin-bottom:10px}#onetrust-pc-sdk .ot-desc-cntr h4{color:#263238;display:inline-block;vertical-align:middle;margin:0;font-weight:bold;font-size:.875em;line-height:1.3;max-width:80%}#onetrust-pc-sdk .ot-subgrps .ot-subgrp h5{top:0;max-width:unset}#onetrust-pc-sdk #ot-pvcy-hdr{margin-bottom:10px}#onetrust-pc-sdk .ot-vlst-cntr{overflow:hidden}#onetrust-pc-sdk .category-vendors-list-handler,#onetrust-pc-sdk .category-host-list-handler,#onetrust-pc-sdk .category-vendors-list-handler+a{display:block;float:left;color:#3860be;font-size:.813em;font-weight:400;line-height:1.1;cursor:pointer;margin:5px 0px}#onetrust-pc-sdk .category-vendors-list-handler:hover,#onetrust-pc-sdk .category-host-list-handler:hover,#onetrust-pc-sdk .category-vendors-list-handler+a:hover{text-decoration-line:underline}#onetrust-pc-sdk .ot-vlst-cntr .ot-ext-lnk,#onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{display:inline-block;height:13px;width:13px;background-repeat:no-repeat;margin-left:1px;margin-top:6px;cursor:pointer}#onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{margin-bottom:-1px}#onetrust-pc-sdk .category-host-list-handler,#onetrust-pc-sdk .ot-vlst-cntr,#onetrust-pc-sdk #ot-pc-desc+.category-vendors-list-handler{margin-top:8px}#onetrust-pc-sdk .ot-grp-hdr1+.ot-vlst-cntr{margin-top:0px;margin-bottom:10px}#onetrust-pc-sdk .ot-always-active-group h3.ot-cat-header,#onetrust-pc-sdk .ot-subgrp.ot-always-active-group>h4{max-width:70%}#onetrust-pc-sdk .ot-always-active-group .ot-tgl-cntr{max-width:28%}#onetrust-pc-sdk .ot-grp-desc ul,#onetrust-pc-sdk li.ot-subgrp p ul{margin:0px;margin-left:15px;padding-bottom:8px}#onetrust-pc-sdk .ot-grp-desc ul li,#onetrust-pc-sdk li.ot-subgrp p ul li{font-size:inherit;padding-top:8px;display:list-item;list-style:disc}#onetrust-pc-sdk ul.ot-subgrps{margin:0;font-size:inherit}#onetrust-pc-sdk ul.ot-subgrps li{padding:0;border:none;position:relative}#onetrust-pc-sdk ul.ot-subgrps li h5,#onetrust-pc-sdk ul.ot-subgrps li p{font-size:.82em;line-height:1.4}#onetrust-pc-sdk ul.ot-subgrps li p{color:dimgray;clear:both;float:left;margin-top:10px;margin-bottom:0;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk ul.ot-subgrps li h5{color:#263238;font-weight:bold;margin-bottom:0;float:left;position:relative;top:3px}#onetrust-pc-sdk li.ot-subgrp{margin-left:30px;display:inline-block;width:calc(100% - 30px)}#onetrust-pc-sdk .ot-subgrp-tgl{float:right}#onetrust-pc-sdk .ot-subgrp-tgl.ot-always-active-subgroup{width:auto}#onetrust-pc-sdk .ot-pc-footer-logo{height:30px;width:100%;text-align:right;background:#f4f4f4;border-radius:0 0 2px 2px}#onetrust-pc-sdk .ot-pc-footer-logo a{display:inline-block;margin-top:5px;margin-right:10px}#onetrust-pc-sdk #accept-recommended-btn-handler{float:right;text-align:center}#onetrust-pc-sdk .save-preference-btn-handler{min-width:155px;background-color:#68b631;border-radius:2px;color:#fff;font-size:.9em;line-height:1.1;text-align:center;margin-left:15px;margin-right:15px}#onetrust-pc-sdk .ot-btn-subcntr button{margin-right:16px}#onetrust-pc-sdk.ot-ftr-stacked .save-preference-btn-handler,#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-subcntr{white-space:normal;text-align:center;min-width:40%}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-subcntr button{text-wrap:wrap;margin-left:auto;margin-right:auto;max-width:90%;width:90%}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-subcntr button:nth-child(2){margin-top:0}#onetrust-pc-sdk.ot-ftr-stacked #accept-recommended-btn-handler{float:none}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container{overflow:hidden}#onetrust-pc-sdk .ot-btn-container.ot-button-order-container{display:flex;flex-wrap:wrap;justify-content:flex-end}#onetrust-pc-sdk .ot-btn-container.ot-button-order-container .ot-pc-refuse-all-handler,#onetrust-pc-sdk .ot-btn-container.ot-button-order-container .ot-pc-refuse-all-handler,#onetrust-pc-sdk .ot-btn-container.ot-button-order-container .save-preference-btn-handler,#onetrust-pc-sdk .ot-btn-container.ot-button-order-container #accept-recommended-btn-handler{float:none}#onetrust-pc-sdk .ot-btn-container.ot-button-order-container *[class*=ot-button-order-]:nth-of-type(1){min-width:155px;margin-left:15px;margin-right:auto}#onetrust-pc-sdk .ot-btn-container.ot-button-order-container *[class*=ot-button-order-]:nth-of-type(2),#onetrust-pc-sdk .ot-btn-container.ot-button-order-container *[class*=ot-button-order-]:nth-of-type(3){margin-right:15px}#onetrust-pc-sdk #ot-pc-title{margin:0px;overflow:hidden;position:relative;line-height:1.2;max-height:2.4em;padding-right:1em;font-size:1.37em;text-overflow:ellipsis;white-space:nowrap;display:block;max-width:90%}#onetrust-pc-sdk #ot-pc-title.ot-pc-title-shrink{max-width:70%}#onetrust-pc-sdk #ot-pc-title-mobile{display:none !important}#onetrust-pc-sdk #ot-pc-lst{width:100%;position:relative}#onetrust-pc-sdk #ot-pc-lst .ot-acc-hdr{padding-top:17px;padding-right:15px;padding-bottom:17px;padding-left:20px;display:inline-block;width:calc(100% - 35px);vertical-align:middle}#onetrust-pc-sdk #ot-pc-lst .ot-acc-txt{padding-top:6px;padding-right:15px;padding-bottom:10px;padding-left:20px}#onetrust-pc-sdk .ot-lst-cntr{height:100%}#onetrust-pc-sdk #ot-pc-hdr{padding-top:15px;padding-right:30px;padding-bottom:15px;padding-left:20px;display:inline-block;width:calc(100% - 50px);height:20px;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk #ot-pc-hdr input{height:32px;width:100%;border-radius:50px;font-size:.8em;padding-right:35px;padding-left:15px;float:left}#onetrust-pc-sdk #ot-pc-hdr input::placeholder{color:#707070;font-style:italic}#onetrust-pc-sdk #ot-lst-cnt{height:calc(100% - 86px);padding-left:30px;padding-right:27px;padding-top:20px;margin-top:8px;margin-right:3px;margin-bottom:4px;margin-left:0;overflow-x:hidden;overflow-y:auto;transform:translate3d(0, 0, 0)}#onetrust-pc-sdk #ot-back-arw{height:12px;width:12px}#onetrust-pc-sdk #ot-lst-title{display:inline-block;font-size:1em}#onetrust-pc-sdk #ot-lst-title h3{color:dimgray;font-weight:bold;margin-left:10px;display:inline-block;font-size:1em}#onetrust-pc-sdk #ot-lst-title h3 *{font-size:inherit}#onetrust-pc-sdk .ot-lst-subhdr{float:right;position:relative;bottom:6px}#onetrust-pc-sdk #ot-search-cntr{display:inline-block;vertical-align:middle;position:relative;width:300px}#onetrust-pc-sdk #ot-search-cntr svg{position:absolute;right:0px;width:30px;height:30px;font-size:1em;line-height:1;top:2px}#onetrust-pc-sdk #ot-fltr-cntr{display:inline-block;position:relative;margin-left:20px;vertical-align:middle;font-size:0}#onetrust-pc-sdk #ot-filter-list-header{margin-top:15px;margin-bottom:10px;float:left;max-width:150px;text-decoration:none;color:#3860be;font-size:.9em;font-weight:bold;background-color:rgba(0,0,0,0);border-color:rgba(0,0,0,0);padding:1px 1px 1px 15px;overflow:hidden;text-overflow:ellipsis;white-space:nowrap}#onetrust-pc-sdk #filter-btn-handler{background-color:#3860be;border-radius:17px;-moz-transition:.1s ease;-o-transition:.1s ease;-webkit-transition:1s ease;transition:.1s ease;width:32px;height:32px;padding:0;margin:0;position:relative}#onetrust-pc-sdk #filter-btn-handler svg{cursor:pointer;width:15px;height:15px;position:absolute;left:50%;top:50%;transform:translate(-50%, -50%);padding-top:5px}#onetrust-pc-sdk #filter-btn-handler path{fill:#fff}#onetrust-pc-sdk #ot-sel-blk{min-width:200px;min-height:30px;padding-left:20px}#onetrust-pc-sdk #ot-selall-vencntr,#onetrust-pc-sdk #ot-selall-adtlvencntr{float:left;height:100%}#onetrust-pc-sdk #ot-selall-vencntr label,#onetrust-pc-sdk #ot-selall-adtlvencntr label{height:100%;padding-left:0}#onetrust-pc-sdk #ot-selall-hostcntr{width:21px;height:21px;position:relative;left:20px}#onetrust-pc-sdk #ot-selall-vencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-adtlvencntr.line-through label::after,#onetrust-pc-sdk #ot-selall-licntr.line-through label::after,#onetrust-pc-sdk #ot-selall-hostcntr.line-through label::after,#onetrust-pc-sdk #ot-selall-gnvencntr.line-through label::after{height:auto;border-left:0;left:9px;top:12px;transform:none;-o-transform:none;-ms-transform:none;-webkit-transform:none}#onetrust-pc-sdk .ot-ven-name,#onetrust-pc-sdk .ot-host-name{color:#2c3643;font-weight:bold;font-size:.813em;line-height:1.2;margin:0;height:auto;text-align:left;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-ven-name *,#onetrust-pc-sdk .ot-host-name *{font-size:inherit}#onetrust-pc-sdk .ot-host-desc{font-size:.69em;line-height:1.4;margin-top:5px;margin-bottom:5px;color:dimgray}#onetrust-pc-sdk .ot-host-name>a{text-decoration:underline;position:relative;z-index:2;margin-bottom:5px;font-weight:bold}#onetrust-pc-sdk .ot-host-hdr{float:left;width:calc(100% - 50px);pointer-events:none;position:relative;z-index:1}#onetrust-pc-sdk .ot-host-hdr .ot-host-name{pointer-events:none}#onetrust-pc-sdk .ot-host-hdr a{pointer-events:initial}#onetrust-pc-sdk .ot-host-hdr .ot-host-name~a{margin-top:5px;font-size:.813em;text-decoration:underline}#onetrust-pc-sdk .ot-ven-hdr{width:88%;float:right}#onetrust-pc-sdk input:focus+.ot-acc-hdr{outline:#000 solid 1px !important}#onetrust-pc-sdk #ot-selall-hostcntr input[type=checkbox],#onetrust-pc-sdk #ot-selall-vencntr input[type=checkbox],#onetrust-pc-sdk #ot-selall-adtlvencntr input[type=checkbox]{position:absolute}#onetrust-pc-sdk .ot-host-item .ot-chkbox{float:left}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all-hdr{right:38px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) #ot-sel-blk{background-color:#f9f9fc;border:1px solid #e2e2e2;width:auto;padding-bottom:5px;padding-top:5px}#onetrust-pc-sdk.ot-addtl-vendors #ot-lst-cnt:not(.ot-host-cnt) .ot-sel-all-chkbox{right:2px;width:auto}#onetrust-pc-sdk #ot-pc-lst .ot-acc-cntr{position:relative;border-left:1px solid #e2e2e2;border-right:1px solid #e2e2e2;border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk #ot-pc-lst .ot-acc-cntr input{z-index:1}#onetrust-pc-sdk #ot-pc-lst .ot-acc-cntr>.ot-acc-hdr{background:#f9f9fc;padding-top:10px;padding-bottom:10px;background-color:#f9f9fc}#onetrust-pc-sdk #ot-pc-lst .ot-acc-cntr>.ot-acc-hdr input{z-index:2}#onetrust-pc-sdk #ot-pc-lst .ot-acc-cntr>input[type=checkbox]:checked~.ot-acc-hdr{border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk #ot-pc-lst .ot-acc-cntr>input[type=checkbox][aria-checked=mixed]~.ot-acc-hdr{border-bottom:1px solid #e2e2e2}#onetrust-pc-sdk #ot-pc-lst .ot-acc-cntr .ot-addtl-venbox{display:none}#onetrust-pc-sdk #ot-addtl-venlst .ot-tgl-cntr{margin-right:13px}#onetrust-pc-sdk .ot-vensec-title{font-size:.813em;display:inline-block}#onetrust-pc-sdk .ot-ven-item>button:focus,#onetrust-pc-sdk .ot-host-item>button:focus,#onetrust-pc-sdk .ot-acc-cntr>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-ven-item>button,#onetrust-pc-sdk .ot-host-item>button,#onetrust-pc-sdk .ot-acc-cntr>button{position:absolute;cursor:pointer;width:100%;height:100%;border:0;opacity:0;margin:0;top:0;left:0}#onetrust-pc-sdk .ot-ven-item>button~.ot-acc-hdr,#onetrust-pc-sdk .ot-host-item>button~.ot-acc-hdr,#onetrust-pc-sdk .ot-acc-cntr>button~.ot-acc-hdr{cursor:pointer}#onetrust-pc-sdk .ot-ven-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-host-item>button[aria-expanded=false]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-ven-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-host-item>button[aria-expanded=true]~.ot-acc-txt,#onetrust-pc-sdk .ot-acc-cntr>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;display:block}#onetrust-pc-sdk .ot-ven-item ul{list-style:none inside;font-size:100%;margin:0}#onetrust-pc-sdk .ot-ven-item ul li{margin:0 !important;padding:0;border:none !important}#onetrust-pc-sdk .ot-hide-acc>button{pointer-events:none}#onetrust-pc-sdk .ot-hide-acc .ot-arw-cntr>*{visibility:hidden}#onetrust-pc-sdk #ot-ven-lst,#onetrust-pc-sdk #ot-host-lst,#onetrust-pc-sdk #ot-addtl-venlst,#onetrust-pc-sdk #ot-gn-venlst{width:100%}#onetrust-pc-sdk #ot-ven-lst li,#onetrust-pc-sdk #ot-host-lst li,#onetrust-pc-sdk #ot-addtl-venlst li,#onetrust-pc-sdk #ot-gn-venlst li{border:1px solid #d7d7d7;border-radius:2px;position:relative;margin-top:10px}#onetrust-pc-sdk #ot-gn-venlst li.ot-host-info{padding:.5rem;overflow-y:hidden}#onetrust-pc-sdk #ot-ven-lst .ot-tgl-cntr{width:65%}#onetrust-pc-sdk #ot-host-lst .ot-tgl-cntr{width:65%;float:left}#onetrust-pc-sdk label{margin-bottom:0}#onetrust-pc-sdk .ot-host-notice{float:right}#onetrust-pc-sdk .ot-ven-link,#onetrust-pc-sdk .ot-ven-legclaim-link,#onetrust-pc-sdk .ot-host-expand{color:dimgray;font-size:.75em;line-height:.9;display:inline-block}#onetrust-pc-sdk .ot-ven-link *,#onetrust-pc-sdk .ot-ven-legclaim-link *,#onetrust-pc-sdk .ot-host-expand *{font-size:inherit}#onetrust-pc-sdk .ot-ven-link,#onetrust-pc-sdk .ot-ven-legclaim-link{position:relative;z-index:2}#onetrust-pc-sdk .ot-ven-link:hover,#onetrust-pc-sdk .ot-ven-legclaim-link:hover{text-decoration:underline}#onetrust-pc-sdk .ot-ven-dets{border-radius:2px;background-color:#f8f8f8}#onetrust-pc-sdk .ot-ven-dets li:first-child p:first-child{border-top:none}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:not(:first-child){border-top:1px solid #ddd !important}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(odd){width:30%}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc:nth-child(n+3) p:nth-of-type(even){width:50%;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p,#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h5{padding-top:5px;padding-bottom:5px;display:block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc h5{display:inline-block}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p:nth-last-child(-n+1){padding-bottom:10px}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc p:nth-child(-n+2):not(.disc-pur){padding-top:10px}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur-cont{display:inline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur{position:relative;width:50% !important;word-break:break-word;word-wrap:break-word;left:calc(30% + 17px)}#onetrust-pc-sdk .ot-ven-dets .ot-ven-disc .disc-pur:nth-child(-n+1){position:static}#onetrust-pc-sdk .ot-ven-dets p,#onetrust-pc-sdk .ot-ven-dets h5,#onetrust-pc-sdk .ot-ven-dets span{font-size:.69em;text-align:left;vertical-align:middle;word-break:break-word;word-wrap:break-word;margin:0;padding-bottom:10px;padding-left:15px;color:#2e3644}#onetrust-pc-sdk .ot-ven-dets h5{padding-top:5px}#onetrust-pc-sdk .ot-ven-dets span{color:dimgray;padding:0;vertical-align:baseline}#onetrust-pc-sdk .ot-ven-dets .ot-ven-pur h5{border-top:1px solid #e9e9e9;border-bottom:1px solid #e9e9e9;padding-bottom:5px;margin-bottom:5px;font-weight:bold}#onetrust-pc-sdk .ot-host-opt{display:inline-block;width:100%;margin:0;font-size:inherit}#onetrust-pc-sdk .ot-host-opt li>div div{font-size:.81em;padding:5px 0}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(1){width:30%;float:left}#onetrust-pc-sdk .ot-host-opt li>div div:nth-child(2){width:70%;float:left;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk #ot-host-lst li.ot-host-info{border:none;font-size:.8em;color:dimgray;float:left;text-align:left;padding:10px;margin-bottom:10px;width:calc(100% - 10px);background-color:#f8f8f8}#onetrust-pc-sdk #ot-host-lst li.ot-host-info a{color:dimgray}#onetrust-pc-sdk #ot-host-lst li.ot-host-info>div{overflow:auto}#onetrust-pc-sdk #no-results{text-align:center;margin-top:30px}#onetrust-pc-sdk #no-results p{font-size:1em;color:#2e3644;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk #no-results p span{font-weight:bold}#onetrust-pc-sdk .ot-tgl-cntr{display:inline-block;vertical-align:middle}#onetrust-pc-sdk .ot-arw-cntr,#onetrust-pc-sdk .ot-tgl-cntr{float:right}#onetrust-pc-sdk .ot-desc-cntr{padding-top:0px;margin-top:20px;padding-right:0px;border-radius:3px;overflow:hidden;padding-bottom:10px}#onetrust-pc-sdk .ot-desc-cntr:focus,#onetrust-pc-sdk .ot-desc-cntr:active,#onetrust-pc-sdk .ot-desc-cntr:focus-visible{outline:2px solid #101010;border-radius:2px}#onetrust-pc-sdk .ot-leg-border-color{border:1px solid #e9e9e9}#onetrust-pc-sdk .ot-leg-border-color .ot-subgrp-cntr{border-top:1px solid #e9e9e9;padding-bottom:10px}#onetrust-pc-sdk .ot-category-desc{padding-bottom:10px}#onetrust-pc-sdk .ot-grp-hdr1{padding-left:10px;width:calc(100% - 20px);padding-top:10px;margin-bottom:0px;padding-bottom:8px}#onetrust-pc-sdk .ot-subgrp-cntr{padding-top:10px}#onetrust-pc-sdk .ot-desc-cntr>*:not(.ot-grp-hdr1){padding-left:10px;padding-right:10px}#onetrust-pc-sdk .ot-pli-hdr{overflow:hidden;padding-top:7.5px;padding-bottom:7.5px;background-color:#f8f8f8;border:none;border-bottom:1px solid #e9e9e9}#onetrust-pc-sdk .ot-pli-hdr span:first-child{text-align:left;max-width:80px;padding-right:5px}#onetrust-pc-sdk .ot-pli-hdr span:last-child{padding-right:20px;text-align:center}#onetrust-pc-sdk .ot-li-title{float:right;font-size:.813em}#onetrust-pc-sdk .ot-desc-cntr .ot-tgl-cntr:first-of-type,#onetrust-pc-sdk .ot-cat-header+.ot-tgl{padding-left:7px;padding-right:7px}#onetrust-pc-sdk .ot-always-active-group .ot-grp-hdr1 .ot-tgl-cntr:first-of-type{padding-left:0px}#onetrust-pc-sdk .ot-cat-header,#onetrust-pc-sdk .ot-subgrp h4{max-width:calc(100% - 133px)}#onetrust-pc-sdk #ot-lst-cnt #ot-sel-blk{width:100%;display:inline-block;padding:0}#onetrust-pc-sdk .ot-sel-all{display:inline-block;width:100%}#onetrust-pc-sdk .ot-sel-all-hdr,#onetrust-pc-sdk .ot-sel-all-chkbox{width:100%;float:right;position:relative}#onetrust-pc-sdk .ot-sel-all-chkbox{z-index:1}#onetrust-pc-sdk :not(.ot-hosts-ui) .ot-sel-all-hdr,#onetrust-pc-sdk :not(.ot-hosts-ui) .ot-sel-all-chkbox{right:23px;width:calc(100% - 23px)}#onetrust-pc-sdk .ot-consent-hdr,#onetrust-pc-sdk .ot-li-hdr{float:right;font-size:.813em;position:relative;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-hosts-ui .ot-consent-hdr{float:left;position:relative;left:5px}#onetrust-pc-sdk .ot-li-hdr{max-width:100px;margin-right:10px}#onetrust-pc-sdk .ot-consent-hdr{max-width:55px}#onetrust-pc-sdk .ot-ven-ctgl{margin-left:10px}#onetrust-pc-sdk .ot-ven-litgl{margin-right:55px}#onetrust-pc-sdk .ot-ven-litgl.ot-ven-litgl-only{margin-right:86px}#onetrust-pc-sdk .ot-ven-ctgl,#onetrust-pc-sdk .ot-ven-litgl,#onetrust-pc-sdk .ot-ven-gvctgl{float:left}#onetrust-pc-sdk .ot-ven-ctgl label,#onetrust-pc-sdk .ot-ven-litgl label,#onetrust-pc-sdk .ot-ven-gvctgl label{width:22px;padding:0}#onetrust-pc-sdk #ot-selall-licntr{display:block;width:21px;height:21px;position:relative;float:right;right:80px}#onetrust-pc-sdk #ot-selall-licntr input{position:absolute}#onetrust-pc-sdk #ot-selall-vencntr,#onetrust-pc-sdk #ot-selall-adtlvencntr,#onetrust-pc-sdk #ot-selall-gnvencntr{float:right;width:21px;height:21px;position:relative;right:15px}#onetrust-pc-sdk #ot-ven-lst .ot-tgl-cntr{float:right;width:auto}#onetrust-pc-sdk .ot-ven-hdr{float:left;width:60%}#onetrust-pc-sdk #vdr-lst-dsc{font-size:.812em;line-height:1.5;padding:10px 15px 5px 15px}#onetrust-pc-sdk #ot-anchor{border:12px solid rgba(0,0,0,0);display:none;position:absolute;z-index:2147483647;top:40px;right:35px;transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);-webkit-transform:rotate(45deg);background-color:#fff;-webkit-box-shadow:-3px -3px 5px -2px #c7c5c7;-moz-box-shadow:-3px -3px 5px -2px #c7c5c7;box-shadow:-3px -3px 5px -2px #c7c5c7}#onetrust-pc-sdk #ot-fltr-modal{width:300px;position:absolute;z-index:2147483646;top:46px;height:90%;max-height:350px;display:none;-moz-transition:.2s ease;-o-transition:.2s ease;-webkit-transition:2s ease;transition:.2s ease;opacity:1;right:0}#onetrust-pc-sdk #ot-fltr-modal button{max-width:200px;line-height:1;word-break:break-word;white-space:normal;height:auto;font-weight:bold}#onetrust-pc-sdk #ot-fltr-cnt{background-color:#fff;margin:5px;border-radius:3px;height:100%;margin-right:10px;padding-right:10px;-webkit-box-shadow:0px 0px 12px 2px #c7c5c7;-moz-box-shadow:0px 0px 12px 2px #c7c5c7;box-shadow:0px 0px 12px 2px #c7c5c7}#onetrust-pc-sdk .ot-fltr-scrlcnt{overflow-y:auto;overflow-x:hidden;clear:both;max-height:calc(100% - 60px)}#onetrust-pc-sdk .ot-fltr-opt{margin-bottom:5px;margin-left:15px;min-height:20px;clear:both}#onetrust-pc-sdk .ot-fltr-opt .ot-chkbox{float:none}#onetrust-pc-sdk .ot-fltr-opt span{cursor:pointer;color:dimgray;font-size:.8em;line-height:1.1;font-weight:normal}#onetrust-pc-sdk #clear-filters-handler{float:right;margin-top:15px;margin-bottom:10px;text-decoration:none;color:#3860be;font-size:.9em;border:none;padding:1px}#onetrust-pc-sdk #clear-filters-handler:hover{color:#1883fd}#onetrust-pc-sdk #clear-filters-handler:focus{outline:#000 solid 1px}#onetrust-pc-sdk #filter-apply-handler{margin-right:10px}#onetrust-pc-sdk .ot-grp-desc+.ot-leg-btn-container{margin-top:0}#onetrust-pc-sdk .ot-leg-btn-container{display:inline-block;width:100%;margin-top:10px}#onetrust-pc-sdk .ot-leg-btn-container button{height:auto;padding:6.5px 8px;margin-bottom:0;line-height:normal;letter-spacing:0}#onetrust-pc-sdk .ot-leg-btn-container svg{display:none;height:14px;width:14px;padding-right:5px;vertical-align:sub}#onetrust-pc-sdk .ot-active-leg-btn{cursor:default;pointer-events:none}#onetrust-pc-sdk .ot-active-leg-btn svg{display:inline-block}#onetrust-pc-sdk .ot-remove-objection-handler{border:none;text-decoration:underline;padding:0;font-size:.82em;font-weight:600;line-height:1.4;padding-left:10px}#onetrust-pc-sdk .ot-obj-leg-btn-handler span{font-weight:bold;text-align:center;font-size:.91em;line-height:1.5}#onetrust-pc-sdk.ot-close-btn-link #close-pc-btn-handler{border:none;height:auto;line-height:1.5;text-decoration:underline;font-size:.69em;background:none;width:auto}#onetrust-pc-sdk.ot-close-btn-link .ot-close-cntr{right:5px;top:5px;transform:none}#onetrust-pc-sdk .ot-grps-cntr{overflow-y:hidden}#onetrust-pc-sdk .ot-cat-header{float:left;font-weight:600;font-size:.875em;line-height:1.5;max-width:90%;vertical-align:middle}#onetrust-pc-sdk .ot-vnd-item>button:focus{outline:#000 solid 2px}#onetrust-pc-sdk .ot-vnd-item>button{position:absolute;cursor:pointer;width:100%;height:100%;margin:0;top:0;left:0;z-index:1;max-width:none;border:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=false]~.ot-acc-txt{margin-top:0;max-height:0;opacity:0;overflow:hidden;width:100%;transition:.25s ease-out;display:none}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-txt{transition:.1s ease-in;margin-top:10px;width:100%;overflow:auto;display:block}#onetrust-pc-sdk .ot-vnd-item>button[aria-expanded=true]~.ot-acc-grpcntr{width:auto;margin-top:0px;padding-bottom:10px}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item{position:relative;border-radius:2px;margin:0;padding:0;border:1px solid #d8d8d8;border-top:none;width:calc(100% - 2px);float:left}#onetrust-pc-sdk .ot-accordion-layout.ot-cat-item:first-of-type{margin-top:10px;border-top:1px solid #d8d8d8}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:first-child{margin-top:10px}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr:last-child,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr:last-child{margin-bottom:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{padding-top:11.5px;padding-bottom:11.5px;padding-left:20px;padding-right:20px;width:calc(100% - 40px);display:inline-block}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-txt{width:100%;padding:0}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp-cntr{padding-left:20px;padding-right:15px;padding-bottom:0;width:calc(100% - 35px)}#onetrust-pc-sdk .ot-accordion-layout .ot-subgrp{padding-right:5px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-grpcntr{z-index:1;position:relative}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr{position:absolute;top:50%;transform:translateY(-50%);right:20px;margin-top:-2px}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header+.ot-arw-cntr .ot-arw{width:15px;height:20px;margin-left:5px;color:dimgray}#onetrust-pc-sdk .ot-accordion-layout .ot-cat-header{float:none;color:#2e3644;margin:0;display:inline-block;height:auto;word-wrap:break-word;min-height:inherit}#onetrust-pc-sdk .ot-accordion-layout .ot-vlst-cntr,#onetrust-pc-sdk .ot-accordion-layout .ot-hlst-cntr{padding-left:20px;width:calc(100% - 20px);display:inline-block;margin-top:0;padding-bottom:2px}#onetrust-pc-sdk .ot-accordion-layout .ot-acc-hdr{position:relative;min-height:25px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl,#onetrust-pc-sdk .ot-accordion-layout h4~.ot-always-active{position:absolute;top:50%;transform:translateY(-50%);right:20px}#onetrust-pc-sdk .ot-accordion-layout h4~.ot-tgl+.ot-tgl{right:95px}#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler,#onetrust-pc-sdk .ot-accordion-layout .category-vendors-list-handler+a{margin-top:5px}#onetrust-pc-sdk #ot-lst-cnt{margin-top:1rem;max-height:calc(100% - 96px)}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 2rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list,#onetrust-pc-sdk .ot-vnd-serv{width:auto;padding:1rem 1.25rem;padding-bottom:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:600;font-size:.95em;line-height:2;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item{border:none;margin:0;padding:0}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button{outline:none;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item button[aria-expanded=true],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item button[aria-expanded=true]{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:first-child{margin-top:.25rem;border-top:unset}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child{margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item:last-child button,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item:last-child button{border-bottom:none}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info-cntr{border:1px solid #d8d8d8;padding:.75rem 1.75rem;padding-bottom:0;width:auto;margin-top:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info{margin-bottom:1rem;padding-left:.75rem;padding-right:.75rem;display:flex;flex-direction:column}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOEmail]{border-top:1px solid #d8d8d8;padding-top:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink],#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info[data-vnd-info-key*=DPOLink]{border-bottom:1px solid #d8d8d8;padding-bottom:1rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-lbl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-lbl{font-weight:bold;font-size:.85em;margin-bottom:.5rem}#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-vnd-info .ot-vnd-cnt,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info .ot-vnd-cnt{margin-left:.5rem;font-weight:500;font-size:.85rem}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt{padding-left:40px}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-size:.8em}#onetrust-pc-sdk .ot-vs-list.ot-vnd-subgrp-cnt .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv.ot-vnd-subgrp-cnt .ot-cat-header{font-size:.8em}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv{margin-bottom:1rem;padding:1rem .95rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr{padding-bottom:.75rem;border-bottom:1px solid #d8d8d8}#onetrust-pc-sdk .ot-subgrp-cntr .ot-vnd-serv .ot-vnd-serv-hdr-cntr .ot-vnd-serv-hdr{font-weight:700;font-size:.8em;line-height:20px;margin-left:.82rem}#onetrust-pc-sdk .ot-subgrp-cntr .ot-cat-header{font-weight:700;font-size:.8em;line-height:20px}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-vnd-serv .ot-vnd-lst-cont .ot-accordion-layout .ot-acc-hdr div.ot-chkbox{margin-left:.82rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr{padding:.7rem 0;margin:0;display:flex;width:100%;align-items:center;justify-content:space-between}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:first-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:first-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:first-child{margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr div:last-child,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr div:last-child,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr div:last-child{margin-right:.5rem;margin-left:.5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-always-active,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-always-active{position:relative;right:unset;top:unset;transform:unset}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-arw-cntr,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-arw-cntr{float:none;top:unset;right:unset;transform:unset;margin-top:-2px;position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-cat-header,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-cat-header{flex:1;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-tgl,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-tgl{position:relative;transform:none;right:0;top:0;float:none}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox{position:relative;margin:0 .5rem}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label{padding:0}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox label::before,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox label::before{position:relative}#onetrust-pc-sdk .ot-vs-config .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk #ot-pc-lst .ot-vs-list .ot-vnd-item .ot-acc-hdr .ot-chkbox input,#onetrust-pc-sdk .ot-accordion-layout.ot-checkbox-consent .ot-acc-hdr .ot-chkbox input{position:absolute;cursor:pointer;width:100%;height:100%;opacity:0;margin:0;top:0;left:0;z-index:1}#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h5.ot-cat-header,#onetrust-pc-sdk .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp .ot-acc-hdr h4.ot-cat-header{margin:0}#onetrust-pc-sdk .ot-vs-config .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp h5{top:0;line-height:20px}#onetrust-pc-sdk .ot-vs-list{display:flex;flex-direction:column;padding:0;margin:.5rem 4px}#onetrust-pc-sdk .ot-vs-selc-all{display:flex;padding:0;float:unset;align-items:center;justify-content:flex-start}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf{justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf.ot-caret-conf .ot-sel-all-chkbox{margin-right:48px}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf .ot-sel-all-chkbox{margin:0;padding:0;margin-right:14px;justify-content:flex-end}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-chkbox,#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr.ot-tgl{display:inline-block;right:unset;width:auto;height:auto;float:none}#onetrust-pc-sdk .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr label{width:45px;height:25px}#onetrust-pc-sdk .ot-vs-selc-all .ot-sel-all-chkbox{margin-right:11px;margin-left:.75rem;display:flex;align-items:center}#onetrust-pc-sdk .ot-vs-selc-all .sel-all-hdr{margin:0 1.25rem;font-size:.812em;line-height:normal;text-align:center;word-break:break-word;word-wrap:break-word}#onetrust-pc-sdk .ot-vnd-list-cnt #ot-selall-vencntr.ot-chkbox{float:unset;right:0}#onetrust-pc-sdk.otPcTab .ot-vs-selc-all.ot-toggle-conf.ot-caret-conf .ot-sel-all-chkbox{margin-right:50px}#onetrust-pc-sdk.otPcTab .ot-vs-selc-all.ot-toggle-conf #ot-selall-vencntr label{width:35px;height:10px}#onetrust-pc-sdk.otPcTab .ot-vs-selc-all.ot-toggle-conf .ot-sel-all-chkbox{justify-content:flex-end}#onetrust-pc-sdk.otPcTab .ot-vs-selc-all .ot-sel-all-chkbox{right:unset;display:flex;align-items:center}#onetrust-pc-sdk.otPcTab .ot-vs-selc-all .ot-sel-all-chkbox #ot-selall-vencntr.ot-chkbox{right:unset}#onetrust-pc-sdk.otPcTab .ot-vs-selc-all .ot-sel-all-chkbox{margin-left:12px}#onetrust-pc-sdk.otPcTab .ot-vs-selc-all .ot-sel-all-chkbox .sel-all-hdr{margin:0 1rem}#onetrust-pc-sdk .ot-pgph-link{font-size:.813em;margin-top:5px;position:relative}#onetrust-pc-sdk .ot-pgph-link.ot-pgph-link-subgroup{margin-bottom:1rem}#onetrust-pc-sdk .ot-pgph-contr{margin:0 2.5rem}#onetrust-pc-sdk .ot-pgph-title{font-size:1.18rem;margin-bottom:2rem}#onetrust-pc-sdk .ot-pgph-desc{font-size:1rem;font-weight:400;margin-bottom:2rem;line-height:1.5rem}#onetrust-pc-sdk .ot-pgph-desc:not(:last-child):after{content:\"\";width:96%;display:block;margin:0 auto;padding-bottom:2rem;border-bottom:1px solid #e9e9e9}#onetrust-pc-sdk.otPcTab[dir=rtl] input~.ot-acc-hdr .ot-arw,#onetrust-pc-sdk.otPcTab[dir=rtl] #ot-back-arw{transform:rotate(180deg);-o-transform:rotate(180deg);-ms-transform:rotate(180deg);-webkit-transform:rotate(180deg)}#onetrust-pc-sdk.otPcTab[dir=rtl] input:checked~.ot-acc-hdr .ot-arw{transform:rotate(270deg);-o-transform:rotate(270deg);-ms-transform:rotate(270deg);-webkit-transform:rotate(270deg)}#onetrust-pc-sdk.otPcTab[dir=rtl] #ot-search-cntr svg{right:15px}#onetrust-pc-sdk.otPcTab[dir=rtl] .ot-chkbox label::after{transform:rotate(45deg);-webkit-transform:rotate(45deg);-o-transform:rotate(45deg);-ms-transform:rotate(45deg);border-left:0;border-right:3px solid}#onetrust-pc-sdk #close-pc-btn-handler.ot-close-icon{padding:0;background-color:rgba(0,0,0,0);border:none;margin:0}@media(max-width: 767px){#onetrust-pc-sdk{width:100%;border:none}#onetrust-pc-sdk .ot-optout-signal{margin:.625rem}#onetrust-pc-sdk .ot-sdk-container,#onetrust-pc-sdk .ot-sdk-container{padding:0;margin:0}#onetrust-pc-sdk .ot-title-cntr{width:75%}#onetrust-pc-sdk .ot-title-cntr #ot-pc-title{white-space:break-spaces;font-size:20px;overflow-x:visible;margin-left:10px}#onetrust-pc-sdk .ot-pc-logo{width:15%}#onetrust-pc-sdk .ot-pc-logo img{max-height:100%;font-size:10px}#onetrust-pc-sdk .ot-desc-cntr{margin:0;padding-top:20px;padding-right:20px;padding-bottom:15px;padding-left:20px;position:relative;left:auto}#onetrust-pc-sdk .ot-desc-cntr{margin-top:20px;margin-left:20px;padding:0;padding-bottom:10px}#onetrust-pc-sdk .ot-grps-cntr{max-height:none;overflow:hidden}#onetrust-pc-sdk #accept-recommended-btn-handler{float:none}}@media(min-width: 768px){#onetrust-pc-sdk.ot-tgl-with-label .ot-label-status{display:inline}#onetrust-pc-sdk.ot-tgl-with-label #ot-pc-lst .ot-label-status{display:none}#onetrust-pc-sdk.ot-tgl-with-label.ot-leg-opt-out .ot-pli-hdr{padding-right:8%}#onetrust-pc-sdk.ot-tgl-with-label .ot-cat-header{max-width:60%}#onetrust-pc-sdk.ot-tgl-with-label .ot-subgrp h4{max-width:58%}#onetrust-pc-sdk.ot-tgl-with-label .ot-subgrp-cntr ul.ot-subgrps li.ot-subgrp>h6{max-width:50%}#onetrust-pc-sdk.ot-tgl-with-label .ot-desc-cntr .ot-tgl-cntr:first-of-type,#onetrust-pc-sdk.ot-tgl-with-label .ot-cat-header+.ot-tgl{padding-left:15px}}@media(max-width: 640px){#onetrust-pc-sdk{height:100%}#onetrust-pc-sdk .ot-optout-signal{margin:.625rem}#onetrust-pc-sdk .ot-pc-header{padding:10px;width:calc(100% - 20px)}#onetrust-pc-sdk #ot-pc-content{overflow:auto}#onetrust-pc-sdk .ot-sdk-row .ot-sdk-columns{width:100%}#onetrust-pc-sdk .ot-desc-cntr{margin:0;overflow:hidden}#onetrust-pc-sdk .ot-desc-cntr{margin-left:10px;width:calc(100% - 15px);margin-top:5px;margin-bottom:5px}#onetrust-pc-sdk .ot-ven-hdr{max-width:80%}#onetrust-pc-sdk #ot-lst-cnt{width:calc(100% - 18px);padding-top:13px;padding-right:5px;padding-left:10px}#onetrust-pc-sdk .ot-grps-cntr{width:100%}#onetrust-pc-sdk .ot-pc-footer{max-height:300px}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk #ot-pc-lst{height:calc(100% - 322px)}#onetrust-pc-sdk.ot-close-btn-link #close-pc-btn-handler{position:fixed;top:10px;right:15px}#onetrust-pc-sdk.ot-close-btn-link .ot-pc-header{padding-top:25px}#onetrust-pc-sdk.ot-close-btn-link #ot-pc-title{max-width:100%}#onetrust-pc-sdk .ot-btn-container.ot-button-order-container *[class*=ot-button-order-]:nth-of-type(1){margin-right:15px}#onetrust-pc-sdk #ot-pc-title-mobile{display:block !important;line-height:1.5;margin-bottom:10px;margin-top:10px;width:100%;padding-left:12px}#onetrust-pc-sdk #ot-pc-title{display:none !important}#onetrust-pc-sdk .ot-pc-logo{width:180px !important}#onetrust-pc-sdk .ot-title-cntr{float:right;width:auto !important}#onetrust-pc-sdk .ot-close-cntr{transform:translateY(0%)}}@media(max-width: 640px)and (orientation: portrait){#onetrust-pc-sdk #ot-pc-hdr{height:70px;padding:15px 0;width:100%}#onetrust-pc-sdk .ot-lst-subhdr{width:calc(100% - 15px);float:none;bottom:auto;display:inline-block;padding-top:8px;padding-left:15px}#onetrust-pc-sdk .ot-btn-subcntr{float:none}#onetrust-pc-sdk #ot-search-cntr{display:inline-block;width:calc(100% - 55px);position:relative}#onetrust-pc-sdk #ot-anchor{top:75px;right:30px}#onetrust-pc-sdk #ot-fltr-modal{top:81px}#onetrust-pc-sdk #ot-fltr-cntr{float:right;right:15px}#onetrust-pc-sdk #ot-lst-title{padding-left:15px}#onetrust-pc-sdk #ot-lst-cnt{height:auto;overflow:auto}#onetrust-pc-sdk .save-preference-btn-handler,#onetrust-pc-sdk #accept-recommended-btn-handler,#onetrust-pc-sdk .ot-pc-refuse-all-handler{width:calc(100% - 33px) !important}#onetrust-pc-sdk.ot-ftr-stacked .save-preference-btn-handler,#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-subcntr{max-width:none}#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-footer button{margin:15px}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-subcntr button{min-width:none;max-width:none}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-subcntr button:nth-child(2){margin-top:15px}#onetrust-pc-sdk.ot-ftr-stacked .ot-btn-container button:not(:last-child){margin-bottom:0}}@media(max-width: 425px){#onetrust-pc-sdk .ot-pc-header .ot-pc-logo{width:150px img;width-max-height:100%;width-font-size:10px}#onetrust-pc-sdk .ot-title-cntr{width:75%}#onetrust-pc-sdk #ot-pc-lst .ot-acc-txt{padding-top:6px;padding-bottom:10px}#onetrust-pc-sdk #ot-pc-lst .ot-host-notice{float:left;margin-left:30px}#onetrust-pc-sdk #ot-pc-lst .ot-arw-cntr{float:none;display:inline}#onetrust-pc-sdk #ot-pc-lst .ot-ven-hdr{float:left;width:100%;max-width:85%}#onetrust-pc-sdk.ot-addtl-vendors #ot-pc-lst .ot-acc-cntr .ot-arw-cntr:first-of-type{float:right}#onetrust-pc-sdk #ot-pc-title{max-width:100%;white-space:break-spaces;font-size:20px;overflow-x:visible}#onetrust-pc-sdk .ot-subgrp-cntr li.ot-subgrp{margin-left:10px;width:calc(100% - 10px)}#onetrust-pc-sdk #ot-ven-lst .ot-tgl-cntr{width:auto;float:right}#onetrust-pc-sdk #ot-ven-lst .ot-arw-cntr{float:right}#onetrust-pc-sdk .ot-ven-hdr{max-width:47%}#onetrust-pc-sdk .ot-always-active-group .ot-tgl-cntr:first-of-type{max-width:none;padding-left:20px}}@media only screen and (max-height: 425px)and (max-width: 896px)and (orientation: landscape){#onetrust-pc-sdk{height:100%;width:100%;max-width:none}#onetrust-pc-sdk .ot-always-active-group .ot-tgl-cntr{max-width:none}#onetrust-pc-sdk .ot-pc-header{padding:10px;width:calc(100% - 20px);height:auto;min-height:20px}#onetrust-pc-sdk .ot-pc-header .ot-pc-logo{max-height:20px;width:20%}#onetrust-pc-sdk .ot-pc-header .ot-pc-logo img{max-height:100%;font-size:10px}#onetrust-pc-sdk .ot-title-cntr{width:75%}#onetrust-pc-sdk .ot-title-cntr #ot-pc-title{white-space:break-spaces;font-size:20px;overflow-x:visible}#onetrust-pc-sdk .ot-pc-footer{max-height:52px;overflow-y:auto}#onetrust-pc-sdk #ot-pc-lst{overflow-y:auto}#onetrust-pc-sdk #ot-pc-lst #ot-pc-hdr{height:auto}#onetrust-pc-sdk #ot-pc-lst #ot-pc-hdr #ot-pc-title{max-height:20px}#onetrust-pc-sdk #ot-pc-lst #ot-pc-hdr .ot-lst-subhdr{padding:10px 5px;float:none}#onetrust-pc-sdk #ot-pc-lst #ot-pc-hdr .ot-lst-subhdr #ot-fltr-cntr{margin-top:5px}#onetrust-pc-sdk #ot-pc-lst #ot-lst-cnt{overflow:visible}#onetrust-pc-sdk #ot-lst-cnt{height:auto;overflow:auto}#onetrust-pc-sdk #accept-recommended-btn-handler{float:right}#onetrust-pc-sdk .save-preference-btn-handler,#onetrust-pc-sdk #accept-recommended-btn-handler,#onetrust-pc-sdk .ot-pc-refuse-all-handler{width:auto}#onetrust-pc-sdk.ot-ftr-stacked #accept-recommended-btn-handler,#onetrust-pc-sdk.ot-ftr-stacked .ot-pc-refuse-all-handler{width:90%}#onetrust-pc-sdk #ot-pc-content,#onetrust-pc-sdk #ot-pc-lst{height:calc(100% - 120px)}#onetrust-pc-sdk.ot-shw-fltr .ot-lst-cntr{overflow:hidden}#onetrust-pc-sdk.ot-shw-fltr #ot-pc-lst{position:static}#onetrust-pc-sdk.ot-shw-fltr #ot-fltr-modal{top:0;width:100%;height:100%;max-height:none}#onetrust-pc-sdk.ot-shw-fltr #ot-fltr-modal>div{margin:0;box-sizing:initial;height:100%;max-height:none}#onetrust-pc-sdk.ot-shw-fltr #clear-filters-handler{padding-right:20px}#onetrust-pc-sdk.ot-shw-fltr #ot-anchor{display:none !important}#onetrust-pc-sdk .ot-pc-footer button{margin:10px}}@media(max-width: 425px),(max-width: 896px)and (max-height: 425px)and (orientation: landscape){#onetrust-pc-sdk .ot-pc-header{padding-right:20px}#onetrust-pc-sdk .ot-pc-logo{margin-left:0px;margin-top:5px;width:150px}#onetrust-pc-sdk .ot-close-icon{width:44px;height:44px;background-size:12px}#onetrust-pc-sdk .ot-grp-hdr1{float:right;padding-right:10px}#onetrust-pc-sdk .ot-grp-hdr1+.ot-vlst-cntr{padding-top:10px}}@media only screen and (max-height: 610px){#onetrust-pc-sdk{max-height:100%}}@media(max-width: 425px)and (orientation: landscape){#onetrust-pc-sdk .ot-pc-header #ot-pc-title{font-size:10px}}\n            #onetrust-consent-sdk #onetrust-pc-sdk,\n                #onetrust-consent-sdk #ot-search-cntr,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-switch.ot-toggle,\n                #onetrust-consent-sdk #onetrust-pc-sdk ot-grp-hdr1 .checkbox,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title:after\n                ,#onetrust-consent-sdk #onetrust-pc-sdk #ot-sel-blk,\n                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-cnt,\n                        #onetrust-consent-sdk #onetrust-pc-sdk #ot-anchor {\n                    background-color: #FFFFFF;\n                }\n               \n            #onetrust-consent-sdk #onetrust-pc-sdk h3,\n                #onetrust-consent-sdk #onetrust-pc-sdk h4,\n                #onetrust-consent-sdk #onetrust-pc-sdk h5,\n                #onetrust-consent-sdk #onetrust-pc-sdk h6,\n                #onetrust-consent-sdk #onetrust-pc-sdk p,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-ven-lst .ot-ven-opts p,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-desc,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-title,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-li-title,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-sel-all-hdr span,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-fltr-modal #modal-header,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-checkbox label span,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-sel-blk p,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-lst-title h3,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .back-btn-handler p,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst .ot-ven-name,\n                #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-lst #ot-ven-lst .consent-category,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-label-status,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-chkbox label span,\n                #onetrust-consent-sdk #onetrust-pc-sdk #clear-filters-handler,\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-optout-signal\n                {\n                    color: #696969;\n                }\n             #onetrust-consent-sdk #onetrust-pc-sdk .privacy-notice-link,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-pgph-link,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler + a,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .category-host-list-handler,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-link,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-ven-legclaim-link,\n                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-name a,\n                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-acc-hdr .ot-host-expand,\n                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info a,\n                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-content #ot-pc-desc .ot-link-btn,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-vnd-serv .ot-vnd-item .ot-vnd-info a,\n                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-lst-cnt .ot-vnd-info a,\n                    #onetrust-consent-sdk #onetrust-pc-sdk #ot-pc-desc a\n                    {\n                        color: #3860BE;\n                    }\n            #onetrust-consent-sdk #onetrust-pc-sdk .category-vendors-list-handler:hover { text-decoration: underline;}\n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-grpcntr.ot-acc-txt,\n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-subgrp-tgl .ot-switch.ot-toggle\n             {\n                background-color: #F8F8F8;\n            }\n             #onetrust-consent-sdk #onetrust-pc-sdk #ot-host-lst .ot-host-info,\n                    #onetrust-consent-sdk #onetrust-pc-sdk .ot-acc-txt .ot-ven-dets\n                            {\n                                background-color: #F8F8F8;\n                            }\n        #onetrust-consent-sdk #onetrust-pc-sdk\n            button:not(#clear-filters-handler):not(.ot-close-icon):not(#filter-btn-handler):not(.ot-remove-objection-handler):not(.ot-obj-leg-btn-handler):not([aria-expanded]):not(.ot-link-btn),\n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-active-leg-btn {\n                background-color: #3860BE;border-color: #3860BE;\n                color: #FFFFFF;\n            }\n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu {\n                border-color: #3860BE;\n            }\n            \n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-remove-objection-handler{\n                background-color: transparent;\n                border: 1px solid transparent;\n            }\n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-leg-btn-container .ot-inactive-leg-btn {\n                background-color: #FFFFFF;\n                color: #4D4D4D; border-color: #4D4D4D;\n            }#onetrust-consent-sdk #onetrust-pc-sdk .ot-tgl input:checked+.ot-switch .ot-switch-nob {\n                background-color: #468254;\n            }\n                #onetrust-consent-sdk #onetrust-pc-sdk .ot-switch-nob {\n                    background-color: #767676;\n                }\n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-tgl input:focus + .ot-switch, .ot-switch .ot-switch-nob, .ot-switch .ot-switch-nob:before,\n            #onetrust-pc-sdk .ot-checkbox input[type=\"checkbox\"]:focus + label::before,\n            #onetrust-pc-sdk .ot-chkbox input[type=\"checkbox\"]:focus + label::before {\n                outline-color: #000000;\n                outline-width: 1px;\n                outline-offset: 1px;\n            }\n            #onetrust-pc-sdk .ot-host-item > button:focus, #onetrust-pc-sdk .ot-ven-item > button:focus {\n                border: 1px solid #000000;\n            }\n            #onetrust-consent-sdk #onetrust-pc-sdk *:focus,\n            #onetrust-consent-sdk #onetrust-pc-sdk .ot-vlst-cntr > a:focus {\n               outline: 1px solid #000000;\n               outline-offset: 1px;\n            }#onetrust-consent-sdk #onetrust-pc-sdk .category-menu-switch-handler {\n                    background-color: #F4F4F4\n                }#onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu {\n                    background-color: #FFFFFF\n                }#onetrust-consent-sdk #onetrust-pc-sdk .category-menu-switch-handler {\n                    background-color: #F4F4F4\n                }#onetrust-consent-sdk #onetrust-pc-sdk .ot-active-menu {\n                    background-color: #FFFFFF\n                }#onetrust-pc-sdk .ot-vlst-cntr .ot-ext-lnk,  #onetrust-pc-sdk .ot-ven-hdr .ot-ext-lnk{\n                    background-image: url('https://cdn.cookielaw.org/logos/static/ot_external_link.svg');\n                }\n            #onetrust-pc-sdk .ot-sdk-container {\n\n      margin-left: 0;\n\n}.ot-sdk-cookie-policy{font-family:inherit;font-size:16px}.ot-sdk-cookie-policy.otRelFont{font-size:1rem}.ot-sdk-cookie-policy h3,.ot-sdk-cookie-policy h4,.ot-sdk-cookie-policy h6,.ot-sdk-cookie-policy p,.ot-sdk-cookie-policy li,.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy th,.ot-sdk-cookie-policy #cookie-policy-description,.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}.ot-sdk-cookie-policy h4{font-size:1.2em}.ot-sdk-cookie-policy h6{font-size:1em;margin-top:2em}.ot-sdk-cookie-policy th{min-width:75px}.ot-sdk-cookie-policy a,.ot-sdk-cookie-policy a:hover{background:#fff}.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}.ot-sdk-cookie-policy .ot-mobile-border{display:none}.ot-sdk-cookie-policy section{margin-bottom:2em}.ot-sdk-cookie-policy table{border-collapse:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy{font-family:inherit;font-size:1rem}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h3,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h4,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title{color:dimgray}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup{margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group-desc,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-table-header,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td{font-size:.9em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td span,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td a{font-size:inherit}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group{font-size:1em;margin-bottom:.6em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-title{margin-bottom:1.2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy>section{margin-bottom:1em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th{min-width:75px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a:hover{background:#fff}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead{background-color:#f6f6f4;font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-mobile-border{display:none}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy section{margin-bottom:2em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li{list-style:disc;margin-left:1.5em}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-subgroup ul li h4{display:inline-block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{border-collapse:inherit;margin:auto;border:1px solid #d7d7d7;border-radius:5px;border-spacing:initial;width:100%;overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border-bottom:1px solid #d7d7d7;border-right:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr th:last-child,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr td:last-child{border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:25%}.ot-sdk-cookie-policy[dir=rtl]{text-align:left}#ot-sdk-cookie-policy h3{font-size:1.5em}@media only screen and (max-width: 530px){.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) table,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tbody,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) th,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td,.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{display:block}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) thead tr{position:absolute;top:-9999px;left:-9999px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr{margin:0 0 1em 0}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd),.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) tr:nth-child(odd) a{background:#f6f6f4}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td{border:none;border-bottom:1px solid #eee;position:relative;padding-left:50%}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{position:absolute;height:100%;left:6px;width:40%;padding-right:10px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) .ot-mobile-border{display:inline-block;background-color:#e4e4e4;position:absolute;height:100%;top:0;left:45%;width:2px}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) td:before{content:attr(data-label);font-weight:bold}.ot-sdk-cookie-policy:not(#ot-sdk-cookie-policy-v2) li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table{overflow:hidden}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table td{border:none;border-bottom:1px solid #d7d7d7}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tbody,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{display:block}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-host,#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table .ot-cookies-type{width:auto}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy tr{margin:0 0 1em 0}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{height:100%;width:40%;padding-right:10px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td:before{content:attr(data-label);font-weight:bold}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li{word-break:break-word;word-wrap:break-word}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy thead tr{position:absolute;top:-9999px;left:-9999px;z-index:-9999}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td{border-bottom:1px solid #d7d7d7;border-right:0px}#ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table tr:last-child td:last-child{border-bottom:0px}}\n                \n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h5,\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy h6,\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy li,\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy p,\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy a,\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy span,\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy td,\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-description {\n                        color: #696969;\n                    }\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy th {\n                        color: #696969;\n                    }\n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy .ot-sdk-cookie-policy-group {\n                        color: #696969;\n                    }\n                    \n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy #cookie-policy-title {\n                            color: #696969;\n                        }\n                    \n            \n                    #ot-sdk-cookie-policy-v2.ot-sdk-cookie-policy table th {\n                            background-color: #F8F8F8;\n                        }\n                    \n            .ot-floating-button__front{background-image:url('https://cdn.cookielaw.org/logos/d83b6e8f-2787-46e5-b85f-ad52b3a0acb6/0537bd7f-107d-432a-ac1b-fbcea3dc21f8/42782c75-355b-4909-9bbb-b7445eddfc25/wbg-YPCround.png')}\n        @keyframes slide-down-custom {\n            0% {\n                bottom: 945px !important;\n            }\n            100% {\n                bottom: 0px;\n            }\n        }\n        @-webkit-keyframes slide-down-custom {\n            0% {\n                bottom: 945px !important;\n            }\n            100% {\n                bottom: 0px;\n            }\n        }\n        @-moz-keyframes slide-down-custom {\n            0% {\n                bottom: 945px !important;\n            }\n            100% {\n                bottom: 0px;\n            }\n        }\n        #ot-sdk-btn-floating.ot-floating-button{position:fixed;bottom:10px;opacity:0;width:50px;height:50px;line-height:15px;cursor:pointer;background-color:rgba(0,0,0,0);transition:all 300ms ease;z-index:2147483646;animation:otFloatingBtnIntro 800ms ease 0ms 1 forwards}#ot-sdk-btn-floating.ot-floating-button.ot-hide{display:none}#ot-sdk-btn-floating.ot-floating-button::before,#ot-sdk-btn-floating.ot-floating-button::after{text-transform:none;line-height:1;user-select:none;pointer-events:none;position:absolute;transform:scale(0);opacity:0;transition:all 300ms ease;display:block;height:auto}#ot-sdk-btn-floating.ot-floating-button::before{content:\"\";border:5px solid rgba(0,0,0,0);z-index:1001;top:50%;border-left-width:0;border-right-color:#333;right:calc(0em - 5px);transform:translate(10px, -50%)}#ot-sdk-btn-floating.ot-floating-button::after{content:attr(data-title);position:absolute;text-align:center;top:50%;left:calc(100% + 5px);transform:translate(10px, -50%);font-size:.75rem;min-width:3em;max-width:21em;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;padding:5px;border-radius:.3ch;box-shadow:0 1em 2em -0.5em rgba(0,0,0,.35);background:#333;color:#fff;z-index:2147483645}#ot-sdk-btn-floating.ot-floating-button:hover::before,#ot-sdk-btn-floating.ot-floating-button:hover::after{opacity:1}#ot-sdk-btn-floating.ot-floating-button:hover::before{transform:translate(0.5em, -50%) scale(1)}#ot-sdk-btn-floating.ot-floating-button:hover::after{transform:translate(0.5em, -50%) scale(1)}#ot-sdk-btn-floating.ot-floating-button.ot-pc-open .ot-floating-button__front{transform:rotateY(-180deg)}#ot-sdk-btn-floating.ot-floating-button.ot-pc-open .ot-floating-button__back{transform:rotateY(0)}#ot-sdk-btn-floating .ot-floating-button__front,#ot-sdk-btn-floating .ot-floating-button__back{position:absolute;width:100%;height:100%;-webkit-backface-visibility:hidden;backface-visibility:hidden;background-color:#6aaae4;border-radius:10px;box-shadow:0 4px 8px 0 rgba(0,0,0,.2);transition:transform .6s;transform-style:preserve-3d}#ot-sdk-btn-floating .ot-floating-button__front{background-color:#6aaae4;transform:rotateY(0)}#ot-sdk-btn-floating .ot-floating-button__front.custom-persistent-icon{background-position:center center;background-repeat:no-repeat;background-size:100%;border-radius:100px}#ot-sdk-btn-floating .ot-floating-button__front svg:not(.ot-source-sprite){width:30px;height:37px}#ot-sdk-btn-floating .ot-floating-button__front svg.ot-source-sprite{width:50px;height:50px}#ot-sdk-btn-floating .ot-floating-button__back{background-color:#fff;transform:rotateY(-180deg)}#ot-sdk-btn-floating .ot-floating-button__back.custom-persistent-icon{background-position:center center;background-repeat:no-repeat;background-size:100%;border-radius:100px}#ot-sdk-btn-floating .ot-floating-button__back svg{width:24px;height:24px}#ot-sdk-btn-floating.ot-floating-button button{padding:0;background-color:rgba(0,0,0,0);border:0;width:100%;height:100%;cursor:pointer}#ot-sdk-btn-floating.ot-floating-button button>*{pointer-events:none}@keyframes otFloatingBtnIntro{0%{opacity:0;left:-75px}100%{opacity:1;left:1%}}@keyframes otFloatingBtnImageIntro{0%{opacity:0;transform:scale(0) rotate(-270deg)}100%{opacity:100%;transform:scale(0.95) rotate(0deg)}}</style><script src=\"https://assets.adobedtm.com/9215900255c9/17f1b4dd3439/6638f9da92c8/RC2cc0a09f4f244c6e97223b4120b341b6-source.min.js\" async=\"\"></script></head><body style=\"\"><roche-modal id=\"global-modal\" appearance=\"default\"></roche-modal><div id=\"___gatsby\"><div tabindex=\"-1\" id=\"gatsby-focus-wrapper\" style=\"outline: none;\"><div><div style=\"height: 100%; position: absolute; top: 0px; left: 0px;\"></div><roche-global-config data-all-space-locales=\"[&quot;en&quot;,&quot;de&quot;,&quot;fr&quot;,&quot;es&quot;]\" data-tag-page-url=\"/topic\" data-base-domain=\"roche\" data-brightcove-account-id=\"6205269558001\" data-brightcove-player-id=\"9bQkMnKAjA\" data-cludo-customer-id=\"473\" data-cludo-engine-id=\"13012\" data-cognito-userpool-client-id=\"4c8b744o367afv48n85cidkgt8\" data-cognito-userpool-id=\"eu-central-1_oUXROgnTJ\" data-forms-api-url=\"https://api-prod.roche.com/forms/v1/processing-requests\" data-header-icon-url=\"default\" data-locale=\"en\" data-page-id=\"storyblok:roche-com:live:34bc087b-3647-46f2-8023-db4b7ff47366\" data-recaptcha-key=\"6LfnSAoUAAAAAG49XsPZF3YJHzE3KiAuQuoivYZb\" data-translation-url=\"/translations/en.json?version=1762520514253\" data-tags-translation-url=\"/tags-translations/en.json?version=1762520514253\" data-popular-searches-translation-url=\"/popular-searches-translations/en.json?version=1762520514253\" data-twitter-handle=\"@roche\" data-website-name=\"roche-com\" data-white-listed-domains=\"[&quot;assets.roche.com&quot;,&quot;assets.cwp.roche.com&quot;,&quot;roche.com&quot;]\" data-is-share-hidden=\"false\" data-gapi-client-id=\"63339946847-k26jidt6gvpot2ekip4je2ic0bjfe4qh.apps.googleusercontent.com\" data-gapi-key=\"AIzaSyA9wwU3OfBHTOWZs_jrPLr6laHG6YQwvnc\" data-cludo-fuzziness=\"default\" data-storyblok-story-id=\"318940624\" data-component-library=\"https://component-library.roche.com/feat/monorepo\" data-website-domain=\"roche.com\"></roche-global-config><header class=\"header header--scrolled header--hidden\"><a class=\"header__skip-link\" href=\"#main-content\">Skip to main content</a><div class=\"header__first-row\"><a class=\"header__logo-link\" href=\"/\" aria-label=\"Home\"><span class=\"header__logo\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 72 40\" height=\"40px\" class=\"icon\" aria-hidden=\"true\"><path fill-rule=\"evenodd\" d=\"M16.2 39h39.7L72 19.5 55.9 0H16.2L0 19.5 16.2 39zM55 37H17L2.6 19.4 17.1 2H55l14.5 17.6L55 36.9zM17 19.1v6.9h-2.2V10.8h4.3c1.2 0 2 .3 2.8 1 .6.8 1 1.7 1 3a4 4 0 01-.6 2.2c-.3.6-.8 1-1.4 1.3.3.1.6.4.9.7l.4 1.5.6 5.5h-2.2l-.5-5.3c-.1-.5-.2-.9-.5-1.1-.2-.2-.5-.4-1-.4H17zm0-6.4v4.4H19c.5 0 1-.1 1.2-.5.4-.4.5-1 .5-1.7 0-.8-.2-1.3-.5-1.7-.2-.3-.7-.5-1.2-.5H17zm13 13c-.5.3-1.2.5-2 .5s-1.4-.2-2-.6c-.6-.3-1.1-.9-1.4-1.6-.4-.6-.5-1.5-.5-2.4v-2c0-1 .1-1.8.5-2.5A3.7 3.7 0 0128 15c.8 0 1.4.2 2 .6.6.4 1.1.9 1.4 1.6.4.7.5 1.5.5 2.4v2.1c0 1-.1 1.8-.5 2.4-.3.7-.8 1.3-1.4 1.6zm-3.4-2.1c.4.4.8.6 1.4.6.6 0 1-.2 1.4-.6.3-.5.5-1.1.5-2v-2.2a3 3 0 00-.5-1.9c-.4-.4-.8-.6-1.4-.6-.6 0-1 .2-1.4.6a3 3 0 00-.5 1.9v2.3c0 .8.2 1.4.5 1.9zm13.5 1.7c-.6.6-1.5 1-2.5 1-1.2 0-2.2-.5-2.9-1.3a5 5 0 01-1-3.4v-2a5 5 0 011-3.4c.8-.9 1.7-1.3 3-1.3 1 0 1.9.3 2.5 1 .6.5 1 1.4 1.2 2.5l-2 .5c-.2-1.4-.8-2-1.8-2-.6 0-1 .2-1.4.6-.3.5-.5 1.1-.5 1.9v2.3c0 .8.2 1.4.5 1.9.4.4.8.6 1.4.6.5 0 .9-.1 1.2-.5.3-.3.5-.8.6-1.5l2 .5c-.2 1.1-.6 2-1.3 2.6zm4.9-6.5V26h-2V10.8h2V16c.2-.3.5-.5 1-.8a3 3 0 011.4-.3c1 0 1.7.3 2.2 1 .5.5.8 1.4.8 2.5V26h-2v-7.2c0-.6-.2-1.1-.5-1.5-.3-.3-.7-.5-1.2-.5s-1 .2-1.2.5A2 2 0 0045 19zm13.6-2.7c.6.8 1 2 1 3.3V21H54v.9c0 .8.2 1.4.5 1.9.4.4.8.6 1.3.6s.9-.1 1.2-.5c.3-.3.5-.7.6-1.3l1.8.4c-.1 1-.5 1.8-1.1 2.4-.7.6-1.5.9-2.5.9-1.2 0-2-.4-2.8-1.3-.7-.8-1-2-1-3.4v-2c0-1 .1-1.7.5-2.5.3-.6.8-1.2 1.3-1.6.6-.3 1.3-.5 2-.5 1.2 0 2 .4 2.8 1.2zm-1.4 1.3c-.4-.5-.8-.7-1.4-.7-.5 0-1 .2-1.2.7-.4.4-.5 1-.5 1.8v.3h3.5v-.4a3 3 0 00-.4-1.7z\" clip-rule=\"evenodd\"></path></svg></span></span><span class=\"header__logo-mobile\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 72 40\" height=\"30px\" class=\"icon\" aria-hidden=\"true\"><path fill-rule=\"evenodd\" d=\"M16.2 39h39.7L72 19.5 55.9 0H16.2L0 19.5 16.2 39zM55 37H17L2.6 19.4 17.1 2H55l14.5 17.6L55 36.9zM17 19.1v6.9h-2.2V10.8h4.3c1.2 0 2 .3 2.8 1 .6.8 1 1.7 1 3a4 4 0 01-.6 2.2c-.3.6-.8 1-1.4 1.3.3.1.6.4.9.7l.4 1.5.6 5.5h-2.2l-.5-5.3c-.1-.5-.2-.9-.5-1.1-.2-.2-.5-.4-1-.4H17zm0-6.4v4.4H19c.5 0 1-.1 1.2-.5.4-.4.5-1 .5-1.7 0-.8-.2-1.3-.5-1.7-.2-.3-.7-.5-1.2-.5H17zm13 13c-.5.3-1.2.5-2 .5s-1.4-.2-2-.6c-.6-.3-1.1-.9-1.4-1.6-.4-.6-.5-1.5-.5-2.4v-2c0-1 .1-1.8.5-2.5A3.7 3.7 0 0128 15c.8 0 1.4.2 2 .6.6.4 1.1.9 1.4 1.6.4.7.5 1.5.5 2.4v2.1c0 1-.1 1.8-.5 2.4-.3.7-.8 1.3-1.4 1.6zm-3.4-2.1c.4.4.8.6 1.4.6.6 0 1-.2 1.4-.6.3-.5.5-1.1.5-2v-2.2a3 3 0 00-.5-1.9c-.4-.4-.8-.6-1.4-.6-.6 0-1 .2-1.4.6a3 3 0 00-.5 1.9v2.3c0 .8.2 1.4.5 1.9zm13.5 1.7c-.6.6-1.5 1-2.5 1-1.2 0-2.2-.5-2.9-1.3a5 5 0 01-1-3.4v-2a5 5 0 011-3.4c.8-.9 1.7-1.3 3-1.3 1 0 1.9.3 2.5 1 .6.5 1 1.4 1.2 2.5l-2 .5c-.2-1.4-.8-2-1.8-2-.6 0-1 .2-1.4.6-.3.5-.5 1.1-.5 1.9v2.3c0 .8.2 1.4.5 1.9.4.4.8.6 1.4.6.5 0 .9-.1 1.2-.5.3-.3.5-.8.6-1.5l2 .5c-.2 1.1-.6 2-1.3 2.6zm4.9-6.5V26h-2V10.8h2V16c.2-.3.5-.5 1-.8a3 3 0 011.4-.3c1 0 1.7.3 2.2 1 .5.5.8 1.4.8 2.5V26h-2v-7.2c0-.6-.2-1.1-.5-1.5-.3-.3-.7-.5-1.2-.5s-1 .2-1.2.5A2 2 0 0045 19zm13.6-2.7c.6.8 1 2 1 3.3V21H54v.9c0 .8.2 1.4.5 1.9.4.4.8.6 1.3.6s.9-.1 1.2-.5c.3-.3.5-.7.6-1.3l1.8.4c-.1 1-.5 1.8-1.1 2.4-.7.6-1.5.9-2.5.9-1.2 0-2-.4-2.8-1.3-.7-.8-1-2-1-3.4v-2c0-1 .1-1.7.5-2.5.3-.6.8-1.2 1.3-1.6.6-.3 1.3-.5 2-.5 1.2 0 2 .4 2.8 1.2zm-1.4 1.3c-.4-.5-.8-.7-1.4-.7-.5 0-1 .2-1.2.7-.4.4-.5 1-.5 1.8v.3h3.5v-.4a3 3 0 00-.4-1.7z\" clip-rule=\"evenodd\"></path></svg></span></span></a><div class=\"header__secondary-nav\"><nav class=\"meta-navigation\" aria-label=\"Secondary navigation\"><ul class=\"meta-navigation__items\"><li class=\"meta-navigation__item\"><a class=\"meta-navigation__item-link\" href=\"/stories\" aria-current=\"false\">Stories</a></li><li class=\"meta-navigation__item\"><a class=\"meta-navigation__item-link\" href=\"https://careers.roche.com\" aria-current=\"false\">Careers</a></li></ul><div class=\"meta-navigation__separator\"></div><a class=\"meta-navigation__item meta-navigation__item--icon\" href=\"/our-websites\" aria-label=\"Worldwide\" aria-current=\"false\"><span class=\"meta-navigation__item-icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"20px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 2a10 10 0 100 20 10 10 0 000-20zm8 9h-2.8c-.2-2.2-.8-4.3-1.8-6.2a8 8 0 014.5 6.2zm-7.5-7a13 13 0 012.7 7H9c.2-2.6 1-5 2.5-7h1zm-3.8.7c-1 2-1.6 4-1.7 6.3H4a8 8 0 014.7-6.3zM4 13h3c0 2.4.6 4.5 1.5 6.2A8 8 0 014.1 13zm7.3 7A12 12 0 019 13h6.2c-.3 2.8-1.2 5.2-2.6 7h-1.2zm4-.8c1-1.8 1.6-3.9 1.8-6.2h2.7a8 8 0 01-4.4 6.2z\"></path></svg></span></span></a><a class=\"meta-navigation__item meta-navigation__item--icon\" href=\"/search\" aria-label=\"Search\" aria-current=\"false\"><span class=\"meta-navigation__item-icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"20px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M10 18a8 8 0 004.9-1.7l4.4 4.4 1.4-1.4-4.4-4.4A8 8 0 1010 18zm0-14a6 6 0 110 12 6 6 0 010-12z\"></path></svg></span></span></a></nav></div><div class=\"header__actions\"><a href=\"/search\" class=\"header__search\" aria-label=\"Search\" aria-current=\"false\"><span class=\"header__search-icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 32 32\" height=\"32px\" class=\"icon\" aria-hidden=\"true\"><path fill-rule=\"evenodd\" d=\"M22.167 13.333a7.833 7.833 0 1 1-15.667 0 7.833 7.833 0 0 1 15.667 0Zm-2.568 7.708a9.333 9.333 0 1 1 1.168-.945l6.121 6.733-1.11 1.009L19.6 21.04Z\" clip-rule=\"evenodd\"></path></svg></span></span></a><button class=\"header__burger\" aria-label=\"Open navigation\" aria-controls=\"mobile-navigation\" aria-expanded=\"false\"><span class=\"header__burger-icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 32 32\" height=\"32px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M29 8.75H3v-1.5h26v1.5zm0 7.5H3v-1.5h26v1.5zm0 7.5H3v-1.5h26v1.5z\"></path></svg></span></span></button></div></div><div class=\"header__second-row\"><nav aria-label=\"Primary navigation\"><ul class=\"main-navigation\"><li class=\"main-navigation__item\"><button class=\"main-navigation__item-button\" aria-controls=\"/about\" aria-expanded=\"false\">About Roche</button><ul class=\"main-navigation__submenu\" id=\"/about\"><li><a class=\"main-navigation__submenu-link main-navigation__submenu-link--title\" href=\"/about\" aria-current=\"false\"><span>About Roche</span><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/about/strategy\" aria-current=\"false\">Strategy</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/about/business\" aria-current=\"false\">Business</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/about/sustainability\" aria-current=\"false\">Sustainability</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/about/leadership\" aria-current=\"false\">Leadership</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/about/governance\" aria-current=\"false\">Governance</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/about/history\" aria-current=\"false\">History</a></li></ul></li><li class=\"main-navigation__item\"><button class=\"main-navigation__item-button\" aria-controls=\"/solutions\" aria-expanded=\"false\">Solutions</button><ul class=\"main-navigation__submenu\" id=\"/solutions\"><li><a class=\"main-navigation__submenu-link main-navigation__submenu-link--title\" href=\"/solutions\" aria-current=\"false\"><span>Solutions</span><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/solutions/focus-areas\" aria-current=\"false\">Focus areas</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/solutions/pharma\" aria-current=\"false\">Pharma solutions</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/solutions/diagnostics\" aria-current=\"false\">Diagnostic solutions</a></li><li class=\"main-navigation__submenu-item--active\"><a class=\"main-navigation__submenu-link\" href=\"/solutions/pipeline\" aria-current=\"page\">Pipeline</a></li></ul></li><li class=\"main-navigation__item\"><button class=\"main-navigation__item-button\" aria-controls=\"/innovation\" aria-expanded=\"false\">Innovation</button><ul class=\"main-navigation__submenu\" id=\"/innovation\"><li><a class=\"main-navigation__submenu-link main-navigation__submenu-link--title\" href=\"/innovation\" aria-current=\"false\"><span>Innovation</span><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/innovation/structure\" aria-current=\"false\">Team &amp; structure</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/innovation/process\" aria-current=\"false\">Innovation process</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/innovation/ethical-standards\" aria-current=\"false\">Ethical standards</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/innovation/partnering\" aria-current=\"false\">Partnering</a></li></ul></li><li class=\"main-navigation__item main-navigation__item--separator\" aria-hidden=\"true\"></li><li class=\"main-navigation__item\"><button class=\"main-navigation__item-button\" aria-controls=\"/investors\" aria-expanded=\"false\">Investors</button><ul class=\"main-navigation__submenu\" id=\"/investors\"><li><a class=\"main-navigation__submenu-link main-navigation__submenu-link--title\" href=\"/investors\" aria-current=\"false\"><span>Investors</span><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/investors/updates\" aria-current=\"false\">Investor updates</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/investors/events\" aria-current=\"false\">Investor events</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/investors/reports\" aria-current=\"false\">Reporting</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/investors/rofis\" aria-current=\"false\">Finance Information Tool</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/investors/bonds\" aria-current=\"false\">Share and Bond information</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/investors/downloads\" aria-current=\"false\">Download center</a></li></ul></li><li class=\"main-navigation__item\"><button class=\"main-navigation__item-button\" aria-controls=\"/media\" aria-expanded=\"false\">Media</button><ul class=\"main-navigation__submenu\" id=\"/media\"><li><a class=\"main-navigation__submenu-link main-navigation__submenu-link--title\" href=\"/media\" aria-current=\"false\"><span>Media</span><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/media/releases\" aria-current=\"false\">Media releases</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/media/events\" aria-current=\"false\">Media events</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/media/statements\" aria-current=\"false\">Media statements</a></li><li class=\"\"><a class=\"main-navigation__submenu-link\" href=\"/media/library-images\" aria-current=\"false\">Media library</a></li></ul></li></ul></nav></div><div class=\"header__mobile-nav\"><nav class=\"mobile-navigation\"><dialog class=\"mobile-navigation__overlay\" id=\"mobile-navigation\" inert=\"\" aria-hidden=\"true\"><header class=\"mobile-navigation__header\"><a class=\"mobile-navigation__worldwide-link\" href=\"/our-websites\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 2a10 10 0 100 20 10 10 0 000-20zm8 9h-2.8c-.2-2.2-.8-4.3-1.8-6.2a8 8 0 014.5 6.2zm-7.5-7a13 13 0 012.7 7H9c.2-2.6 1-5 2.5-7h1zm-3.8.7c-1 2-1.6 4-1.7 6.3H4a8 8 0 014.7-6.3zM4 13h3c0 2.4.6 4.5 1.5 6.2A8 8 0 014.1 13zm7.3 7A12 12 0 019 13h6.2c-.3 2.8-1.2 5.2-2.6 7h-1.2zm4-.8c1-1.8 1.6-3.9 1.8-6.2h2.7a8 8 0 01-4.4 6.2z\"></path></svg></span>Worldwide</a><button class=\"mobile-navigation__close-button\" aria-label=\"Close navigation\" aria-controls=\"mobile-navigation\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 32 32\" height=\"32px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M15.132 16.192L6.47 24.854l1.06 1.061 8.662-8.662 8.663 8.662 1.06-1.06-8.662-8.663 8.662-8.662-1.06-1.06-8.663 8.662L7.53 6.47 6.47 7.53l8.662 8.662z\"></path></svg></span></button></header><ul class=\"mobile-navigation__list mobile-navigation__list--primary\"><li class=\"mobile-navigation__list-item\"><button class=\"mobile-navigation__list-item-button\" aria-controls=\"/about\" aria-expanded=\"false\">About Roche<span class=\"mobile-navigation__chevron\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 15.7l6-6-1.4-1.4-4.6 4.6-4.6-4.6L6 9.7l6 6z\"></path></svg></span></span></button><ul class=\"mobile-navigation__submenu-list\" aria-hidden=\"true\" style=\"max-height: 0px; opacity: 0;\"><li class=\"mobile-navigation__submenu-item-title\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/about\" aria-label=\"About Roche\" aria-current=\"false\">Explore<span class=\"mobile-navigation__submenu-item-arrow\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/about/strategy\" aria-current=\"false\">Strategy</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/about/business\" aria-current=\"false\">Business</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/about/sustainability\" aria-current=\"false\">Sustainability</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/about/leadership\" aria-current=\"false\">Leadership</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/about/governance\" aria-current=\"false\">Governance</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/about/history\" aria-current=\"false\">History</a></li></ul></li><li class=\"mobile-navigation__list-item mobile-navigation__list-item--open\"><button class=\"mobile-navigation__list-item-button\" aria-controls=\"/solutions\" aria-expanded=\"true\">Solutions<span class=\"mobile-navigation__chevron\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 15.7l6-6-1.4-1.4-4.6 4.6-4.6-4.6L6 9.7l6 6z\"></path></svg></span></span></button><ul class=\"mobile-navigation__submenu-list\" aria-hidden=\"false\" style=\"max-height: 0px; opacity: 1;\"><li class=\"mobile-navigation__submenu-item-title\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/solutions\" aria-label=\"Solutions\" aria-current=\"false\">Explore<span class=\"mobile-navigation__submenu-item-arrow\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/solutions/focus-areas\" aria-current=\"false\">Focus areas</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/solutions/pharma\" aria-current=\"false\">Pharma solutions</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/solutions/diagnostics\" aria-current=\"false\">Diagnostic solutions</a></li><li class=\"mobile-navigation__submenu-item mobile-navigation__submenu-item--active\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/solutions/pipeline\" aria-current=\"page\">Pipeline</a></li></ul></li><li class=\"mobile-navigation__list-item\"><button class=\"mobile-navigation__list-item-button\" aria-controls=\"/innovation\" aria-expanded=\"false\">Innovation<span class=\"mobile-navigation__chevron\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 15.7l6-6-1.4-1.4-4.6 4.6-4.6-4.6L6 9.7l6 6z\"></path></svg></span></span></button><ul class=\"mobile-navigation__submenu-list\" aria-hidden=\"true\" style=\"max-height: 0px; opacity: 0;\"><li class=\"mobile-navigation__submenu-item-title\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/innovation\" aria-label=\"Innovation\" aria-current=\"false\">Explore<span class=\"mobile-navigation__submenu-item-arrow\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/innovation/structure\" aria-current=\"false\">Team &amp; structure</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/innovation/process\" aria-current=\"false\">Innovation process</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/innovation/ethical-standards\" aria-current=\"false\">Ethical standards</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/innovation/partnering\" aria-current=\"false\">Partnering</a></li></ul></li><li class=\"mobile-navigation__list-item\"><button class=\"mobile-navigation__list-item-button\" aria-controls=\"/investors\" aria-expanded=\"false\">Investors<span class=\"mobile-navigation__chevron\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 15.7l6-6-1.4-1.4-4.6 4.6-4.6-4.6L6 9.7l6 6z\"></path></svg></span></span></button><ul class=\"mobile-navigation__submenu-list\" aria-hidden=\"true\" style=\"max-height: 0px; opacity: 0;\"><li class=\"mobile-navigation__submenu-item-title\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/investors\" aria-label=\"Investors\" aria-current=\"false\">Explore<span class=\"mobile-navigation__submenu-item-arrow\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/investors/updates\" aria-current=\"false\">Investor updates</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/investors/events\" aria-current=\"false\">Investor events</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/investors/reports\" aria-current=\"false\">Reporting</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/investors/rofis\" aria-current=\"false\">Finance Information Tool</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/investors/bonds\" aria-current=\"false\">Share and Bond information</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/investors/downloads\" aria-current=\"false\">Download center</a></li></ul></li><li class=\"mobile-navigation__list-item\"><button class=\"mobile-navigation__list-item-button\" aria-controls=\"/media\" aria-expanded=\"false\">Media<span class=\"mobile-navigation__chevron\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 15.7l6-6-1.4-1.4-4.6 4.6-4.6-4.6L6 9.7l6 6z\"></path></svg></span></span></button><ul class=\"mobile-navigation__submenu-list\" aria-hidden=\"true\" style=\"max-height: 0px; opacity: 0;\"><li class=\"mobile-navigation__submenu-item-title\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/media\" aria-label=\"Media\" aria-current=\"false\">Explore<span class=\"mobile-navigation__submenu-item-arrow\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/media/releases\" aria-current=\"false\">Media releases</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/media/events\" aria-current=\"false\">Media events</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/media/statements\" aria-current=\"false\">Media statements</a></li><li class=\"mobile-navigation__submenu-item\"><a class=\"mobile-navigation__submenu-item-link\" href=\"/media/library-images\" aria-current=\"false\">Media library</a></li></ul></li></ul><ul class=\"mobile-navigation__list\"><li class=\"mobile-navigation__list-item\"><a class=\"mobile-navigation__list-item-link\" href=\"/stories\">Stories</a></li><li class=\"mobile-navigation__list-item\"><a class=\"mobile-navigation__list-item-link\" href=\"https://careers.roche.com\">Careers</a></li></ul></dialog></nav></div></header><main id=\"main-content\"><div class=\"grid grid--no-padding grid--has-breadcrumbs grid--equal-columns\"><div class=\"container\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-12 is-offset-0\"><nav class=\"breadcrumbs\" aria-label=\"Breadcrumbs\" slot=\"full\"><ol class=\"breadcrumbs__item-list\"><li class=\"breadcrumbs__item\"><span class=\"text-link text-link--breadcrumbs\"><a class=\"text-link__link\" href=\"/solutions\" target=\"_self\"><span class=\"text-link__text\">Solutions</span></a></span></li></ol></nav></div></div></div></div><div class=\"grid grid--no-padding grid--has-staging-hero grid--move-to-back grid--equal-columns\"><div class=\"container container--colored\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-12 is-offset-0\"><section class=\"staging-hero hero--variant-b\" data-variant=\"hero--variant-b\" slot=\"full\"><div class=\"staging-hero__wrapper\"><div class=\"staging-hero__background\"></div><div class=\"staging-hero__content\"><div class=\"staging-hero__letter\"></div><h1 class=\"staging-hero__headline\">Product Development Portfolio</h1></div><div class=\"staging-hero__divider\"></div></div></section></div></div></div></div><div class=\"grid grid--equal-columns\"><div class=\"container container--colored\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-12 is-offset-0\"><div slot=\"full\" dir=\"ltr\" class=\"rich-text\"><div><p>Last update: 23rd of October 2025</p></div></div><div class=\"tabs\"><div class=\"tabs__tab-list-wrapper\"><div class=\"tabs__tab-list\" role=\"tablist\"><button class=\"tabs__tab tabs__tab--active\" id=\"81ad1b25-f415-4714-9450-45c188614658\" type=\"button\" role=\"tab\" aria-selected=\"true\" aria-controls=\"panel-81ad1b25-f415-4714-9450-45c188614658\" tabindex=\"0\"><span class=\"tabs__tab-label\">Pharma</span></button><button class=\"tabs__tab\" id=\"a0ee39d1-4024-4867-943c-60eb804c7ff0\" type=\"button\" role=\"tab\" aria-selected=\"false\" aria-controls=\"panel-a0ee39d1-4024-4867-943c-60eb804c7ff0\" tabindex=\"-1\"><span class=\"tabs__tab-label\">Diagnostics</span></button></div></div><div class=\"tabs__panel tabs__panel--active\" id=\"panel-81ad1b25-f415-4714-9450-45c188614658\" role=\"tabpanel\" aria-labelledby=\"81ad1b25-f415-4714-9450-45c188614658\" tabindex=\"0\"><div class=\"tabs\"><div class=\"tabs__tab-list-wrapper\"><div class=\"tabs__tab-list tabs__tab-list--filter tabs__tab-list--filter-gray\" role=\"tablist\"><button class=\"tabs__tab tabs__tab--active\" id=\"f24b5f67-0000-422b-b6a0-68b7d67a513d\" type=\"button\" role=\"tab\" aria-selected=\"true\" aria-controls=\"panel-f24b5f67-0000-422b-b6a0-68b7d67a513d\" tabindex=\"0\"><span class=\"tabs__tab-label\">Current Version</span></button><button class=\"tabs__tab\" id=\"2fed21d8-ce3e-4c4c-a9d0-519999c0984a\" type=\"button\" role=\"tab\" aria-selected=\"false\" aria-controls=\"panel-2fed21d8-ce3e-4c4c-a9d0-519999c0984a\" tabindex=\"-1\"><span class=\"tabs__tab-label\">See Changes</span></button></div></div><div class=\"tabs__panel tabs__panel--active\" id=\"panel-f24b5f67-0000-422b-b6a0-68b7d67a513d\" role=\"tabpanel\" aria-labelledby=\"f24b5f67-0000-422b-b6a0-68b7d67a513d\" tabindex=\"0\"><div><div class=\"grid grid--overflow-visible\"><div class=\"container container--full-width\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-8 is-offset-0\"><roche-pipeline-table is-small=\"false\" slot=\"left\" group-list-by=\"all\" content=\"[{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;indicationShort&quot;:&quot;macular edema secondary to central retinal vein occlusion (CRVO)&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;99&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;COMINO&quot;,&quot;description&quot;:&quot;Vabysmo (faricimab, RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;indicationShort&quot;:&quot;maintenance 1Lextensive stage-small cell lung cancer (1L maintenance ES-SCLC)&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2025&quot;,&quot;combination&quot;:&quot;plus lurbinectedin&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;63&quot;,&quot;partner&quot;:&quot;Jazz Pharma&quot;,&quot;comment&quot;:&quot;IMforte&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;geographic atrophy&quot;,&quot;name&quot;:&quot;RG6327&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;195&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q2 2025&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;indicationShort&quot;:&quot;systemic lupus erythematosus (SLE)&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;92&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Lunsumio (mosunetuzumab, anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Enspryng&quot;,&quot;indicationShort&quot;:&quot;myelin oligodendrocyte glycoprotein antibody disease (MOG-AD)&quot;,&quot;name&quot;:&quot;RG6168&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;satralizumab&quot;,&quot;Autogenerated&quot;:&quot;120&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added Q3 2022&quot;,&quot;description&quot;:&quot;Enspryng (satralizumab, RG6168) is a humanized monoclonal antibody to the interleukin-6 receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;systemic lupus erythematosus (SLE)&quot;,&quot;name&quot;:&quot;RG6382&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;CD19 x CD3&quot;,&quot;Autogenerated&quot;:&quot;168&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;Anti-CD19 CD3 TCB is a T cell-engaging bispecific antibody, designed to engage both CD19 on B cells and CD3 on T cells. It was specifically designed to mediate profound B cell depletion with low risk of systemic cytokine release for use in autoimmune conditions.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;uveitic macular edema (UME)&quot;,&quot;name&quot;:&quot;RG6179&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;vamikibart&quot;,&quot;Autogenerated&quot;:&quot;103&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;transitioned to late stage FY 2022&quot;,&quot;description&quot;:&quot;Vamikibart (RG6179) is a monoclonal antibody that potently binds interleukin-6 (IL-6) cytokine. Anti-IL-6  is evaluated for the treatment of UME (Phase III) and DME (Phase II).&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;1L ER-positive and HER2-positive breast cancer (1L ER+/HER2+ BC)&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;plus Phesgo&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;36&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at HY 2022; heredERA&quot;,&quot;description&quot;:&quot;Giredestrant (RG6171, GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation. Phesgo (RG6264) is the first fixed-dose combination of Perjeta and Herceptin administered via subcutaneous injection (SC), that shortens the administration time from hours to minutes.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;Anti-CTLA-4 Switch antibody (ROSE12)&quot;,&quot;Autogenerated&quot;:&quot;167&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added Q3 2023&quot;,&quot;description&quot;:&quot;Switch Antibody\u2122 technology, is expected to work selectively on tumor tissue.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;1L ER-positive and HER2-negative metastatic breast cancer (1L ER+/HER2- mBC)&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;plus palbociclib&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;33&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;SERD 3 added as a NME FY 2017 GDC-9545; persevERA&quot;,&quot;description&quot;:&quot;Giredestrant (RG6171, GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;HR+ HER2- breast cancer&quot;,&quot;name&quot;:&quot;RGXXXX (TBD)&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;CDK4/2i (RGT-419B)&quot;,&quot;Autogenerated&quot;:&quot;186&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q3 2024&quot;,&quot;description&quot;:&quot;Potent CDK4 inhibitor with increased activity on CDK2 addressing a key mechanism of resistance to existing therapies&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Hepatocellular carcinoma (HCC)&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;codrituzumab&quot;,&quot;Autogenerated&quot;:&quot;22&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Codrituzumab, a humanized monoclonal antibody created by Chugai, targets glypican-3 (GPC3), which is specifically expressed in hepatocellular carcinoma.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6468&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;172&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease (AD)&quot;,&quot;name&quot;:&quot;RG6289&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;nivegacetor (gamma-secretase modulator)&quot;,&quot;Autogenerated&quot;:&quot;139&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;Itovebi&quot;,&quot;indicationShort&quot;:&quot;1L HER2-positive PIK3CA-mutant metastatic breast cancer  (1L HER2+ PIK3CA-mut. mBC)&quot;,&quot;name&quot;:&quot;RG6114&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;plus Phesgo&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Inavolisib&quot;,&quot;Autogenerated&quot;:&quot;18&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;INAVO122, added Q3 2023&quot;,&quot;description&quot;:&quot;Inavolisib (RG6114, GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Huntington's disease&quot;,&quot;name&quot;:&quot;RG6662&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;HTT miRNA GT (SPK-10001)&quot;,&quot;Autogenerated&quot;:&quot;191&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q1 2025&quot;,&quot;description&quot;:&quot;SPK-10001 delivers microRNA and downregulates both mHtt and wild-type HTT (wHtt) in transduced neurons&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Crohn's disease&quot;,&quot;name&quot;:&quot;RG6631&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;afimkibart (anti-TL1A)&quot;,&quot;Autogenerated&quot;:&quot;174&quot;,&quot;partner&quot;:&quot;Telavant&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Xofluza&quot;,&quot;indicationShort&quot;:&quot;influenza, pediatric patients (0-1yr)&quot;,&quot;name&quot;:&quot;RG6152&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;baloxavir marboxil&quot;,&quot;Autogenerated&quot;:&quot;109&quot;,&quot;partner&quot;:&quot;Shionogi&quot;,&quot;comment&quot;:&quot;miniSTONE 1&quot;,&quot;description&quot;:&quot;Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;other&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Other&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;clesitamig (DLL3 trispecific)&quot;,&quot;Autogenerated&quot;:&quot;156&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added FY 2022&quot;,&quot;description&quot;:&quot;DLL3 trispecific is a trispecific antibody targeting DLL3, with bivalent CD3/CD137 binding.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Itovebi&quot;,&quot;indicationShort&quot;:&quot;1L metastatic ER-positive and HER2-negative breast cancer (1L HR+ PIK3CA-mut. mBC)&quot;,&quot;name&quot;:&quot;RG6114&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;combination&quot;:&quot;plus palbociclib plus fulvestrant&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Inavolisib&quot;,&quot;Autogenerated&quot;:&quot;16&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;INAVO120&quot;,&quot;description&quot;:&quot;Inavolisib (RG6114, GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;IgA-nephropathy&quot;,&quot;name&quot;:&quot;RG6299&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;sefaxersen (ASO factor B)&quot;,&quot;Autogenerated&quot;:&quot;90&quot;,&quot;partner&quot;:&quot;Ionis&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Sefaxersen (ASO factor B) is an antisense oligonucleotide that inhibits complement factor B gene expression by binding with factor B mRNA. ASO factor B is being studied for the treatment of IgA nephropathy as well as for the treatment of geographic atrophy.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Polivy&quot;,&quot;indicationShort&quot;:&quot;1L diffuse large B-cell lymphoma (1L DLBCL)&quot;,&quot;name&quot;:&quot;RG7596&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;polatuzumab vedotin&quot;,&quot;Autogenerated&quot;:&quot;2&quot;,&quot;partner&quot;:&quot;Seagen Inc.&quot;,&quot;comment&quot;:&quot;Phase III POLARIX NCT03274492 added FY 2017&quot;,&quot;description&quot;:&quot;Polivy (Polatuzumab vedotin, RG7596) is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody anti-CD79b, conjugated to a potent anti-cancer agent that is selectively delivered to tumor cells.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Tecentriq SC&quot;,&quot;indicationShort&quot;:&quot;subcutaneous formulation, all approved indications&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;13&quot;,&quot;partner&quot;:&quot;Halozyme&quot;,&quot;comment&quot;:&quot;IMscin001&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Enspryng&quot;,&quot;indicationShort&quot;:&quot;autoimmune encephalitis (AE)&quot;,&quot;name&quot;:&quot;RG6168&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;satralizumab&quot;,&quot;Autogenerated&quot;:&quot;121&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added Q3 2023&quot;,&quot;description&quot;:&quot;Enspryng (satralizumab, RG6168) is a humanized monoclonal antibody to the interleukin-6 receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;p40xTL1A bispecific antibody&quot;,&quot;name&quot;:&quot;RG6730&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;UC&quot;,&quot;Autogenerated&quot;:&quot;198&quot;,&quot;partner&quot;:&quot;Pfizer&quot;,&quot;comment&quot;:&quot;Added Q3 2025&quot;,&quot;description&quot;:&quot;Next generation anti-p40/TL1A bi-specific antibody designed to target p40 and TL1A&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6561&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;189&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added FY 2024&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Gazyva/Gazyvaro&quot;,&quot;indicationShort&quot;:&quot;pediatric nephrotic syndrome (PNS)&quot;,&quot;name&quot;:&quot;RG7159&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;Autogenerated&quot;:&quot;79&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;INShore&quot;,&quot;description&quot;:&quot;Gazyva/Gazyvaro (obinutuzumab, RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;indicationShort&quot;:&quot;hematologic tumors (heme tumors)&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;plus combinations&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;8&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Lunsumio (mosunetuzumab, anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;obesity +/- Type 2 diabetes (T2D)&quot;,&quot;name&quot;:&quot;RG6652&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;GLP-1 receptor agonist (CT-996)&quot;,&quot;Autogenerated&quot;:&quot;170&quot;,&quot;partner&quot;:&quot;Carmot Therapeutics&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;CT-996 is a once daily oral small molecule agonist of the GLP-1 receptor being developed for the treatment of obesity and type 2 diabetes. Unlike the endogenous GLP-1 hormone, CT-996 is specifically designed to be a biased agonist that activates cAMP signaling with minimal-to- no  beta-arrestin recruitment. These signaling properties are expected to lead to strong glycemic control, significant weight loss and good tolerability.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;Xofluza&quot;,&quot;indicationShort&quot;:&quot;influenza, pediatric patients (1-12yr)&quot;,&quot;name&quot;:&quot;RG6152&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;baloxavir marboxil&quot;,&quot;Autogenerated&quot;:&quot;108&quot;,&quot;partner&quot;:&quot;Shionogi&quot;,&quot;comment&quot;:&quot;miniSTONE 2&quot;,&quot;description&quot;:&quot;Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;other&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Other&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;obesity +/-T2D&quot;,&quot;name&quot;:&quot;RG6849&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;petrelintide.&quot;,&quot;Autogenerated&quot;:&quot;194&quot;,&quot;partner&quot;:&quot;Zealand&quot;,&quot;comment&quot;:&quot;Added Q2 2025&quot;,&quot;description&quot;:&quot;Petrelintide is a long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Acinetobacter baumannii infections (bacterial infections)&quot;,&quot;name&quot;:&quot;RG6006&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;zosurabalpin (Abx MCP)&quot;,&quot;Autogenerated&quot;:&quot;115&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Zosurabalpin (Abx MCP, RG6006) is a small molecule, novel chemical class antibiotic for the treatment of Acinetobacter baumannii infections.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;other&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Other&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease (AD)&quot;,&quot;name&quot;:&quot;RG6102&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;trontinemab&quot;,&quot;Autogenerated&quot;:&quot;131&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added Q3 2019&quot;,&quot;description&quot;:&quot;Trontinemab (RG6102) is a novel Brainshuttle\u2122 A\u03b2 antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with AD.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;hemophilia A&quot;,&quot;name&quot;:&quot;RG6512&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;anti-FIXa/FX (NXT007)&quot;,&quot;Autogenerated&quot;:&quot;142&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;Anti-FIXa/FX (NXT007, RG6512) is an optimized anti-FIXa/FX bispecific monoclonal antibody. NXT007 has an enhanced hemostatic activity and improved pharmacokinetics by antibody engineering technologies.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;indicationShort&quot;:&quot;2L+ Follicular Lymphoma (2L+ FL)&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;plus lenalidomide&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;9&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Lunsumio (mosunetuzumab, anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;neovascular age related macular degeneration (wAMD)&quot;,&quot;name&quot;:&quot;RG6120&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;zifibancimig (VEGF-Ang2 DutaFab)&quot;,&quot;Autogenerated&quot;:&quot;106&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Zifibancimig (VEGF-Ang2 DutaFab, RG6120) is a bispecific Fab molecule targeting vascular endothelial growth factor (VEGF) and Angiopoietin 2 (Ang-2). Built on the DutaFab platform, zifibancimig is specifically designed to be compatible with the Port Delivery Platform.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;obesity +/- Type 2 diabetes (T2D)&quot;,&quot;name&quot;:&quot;RG6640&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;GLP-1/GIP receptor agonist (CT-388)&quot;,&quot;Autogenerated&quot;:&quot;169&quot;,&quot;partner&quot;:&quot;Carmot Therapeutics&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). It was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no \u00df-arrestin recruitment on either receptor. This biased signaling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;Xofluza&quot;,&quot;indicationShort&quot;:&quot;influenza, direct transmission&quot;,&quot;name&quot;:&quot;RG6152&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;baloxavir marboxil&quot;,&quot;Autogenerated&quot;:&quot;110&quot;,&quot;partner&quot;:&quot;Shionogi&quot;,&quot;comment&quot;:&quot;CENTERSTONE&quot;,&quot;description&quot;:&quot;Xofluza (baloxavir marboxil, RG6152) is an oral cap-dependent endonuclease inhibitor with broad and potent antiviral activity against seasonal influenza A and B viruses.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Filed&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;other&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Other&quot;},{&quot;tradeName&quot;:&quot;Kadcyla&quot;,&quot;indicationShort&quot;:&quot;high risk patients with adjuvant HER2-positive breast cancer (HER-2+ eBC high-risk)&quot;,&quot;name&quot;:&quot;RG3502&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;plus Tecentriq&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;trastuzumab emtansine&quot;,&quot;Autogenerated&quot;:&quot;1&quot;,&quot;partner&quot;:&quot;ImmunoGen&quot;,&quot;comment&quot;:&quot;ASTEFANIA&quot;,&quot;description&quot;:&quot;Kadcyla (trastuzumab emtansine, RG3502) is a novel antibody-drug conjugate (ADC) that combines the therapeutic effect of trastuzumab (the active substance of Herceptin) with intracellular delivery of DM1, a highly potent chemotherapy agent, to specifically target HER2-positive tumors.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;multiple sclerosis (MS)&quot;,&quot;name&quot;:&quot;RG6182&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;MAGL inhibitor&quot;,&quot;Autogenerated&quot;:&quot;136&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;MAGL inhibitor (RG6182) has a unique and multimodal mechanism of action to target compartmentalized inflammation in the central nervous system. MAGLi has disease modifying potential to tackle the accumulation of persistent neurological disability in Multiple Sclerosis.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractory multiple myeloma (r/r MM)&quot;,&quot;name&quot;:&quot;RG6160&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;cevostamab&quot;,&quot;Autogenerated&quot;:&quot;31&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added as NME Q3 2017&quot;,&quot;description&quot;:&quot;Cevostamab (RG6160) is a first-of-its-kind FcRH5xCD3 T-cell engaging bispecific antibody, targeting Fc receptor-like protein 5 (FcRH5) on myeloma cells and CD3 on immune T-cells. Cevostamab is currently being evaluated in relapsed/refractory multiple myeloma.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Elevidys&quot;,&quot;indicationShort&quot;:&quot;0 to &lt;4 year old  Duchenne muscular dystrophy (DMD)&quot;,&quot;name&quot;:&quot;RG6356&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;delandistrogene moxeparvovec  (SRP-9001)&quot;,&quot;Autogenerated&quot;:&quot;133&quot;,&quot;partner&quot;:&quot;Sarepta&quot;,&quot;comment&quot;:&quot;added FY 2023, ENVOL&quot;,&quot;description&quot;:&quot;Delandistrogene moxeparvovec (SRP-9001; rAAVrh74.MHCK7.micro-dystrophin) is an investigational gene therapy aimed to deliver the micro-dystrophin-encoding transgene directly to the skeletal and cardiac muscle for the targeted production of the SRP-9001-dystrophin protein to enable a durable clinical response.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;Xolair&quot;,&quot;indicationShort&quot;:&quot;Food allergy&quot;,&quot;name&quot;:&quot;RG3648&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;omalizumab&quot;,&quot;Autogenerated&quot;:&quot;80&quot;,&quot;partner&quot;:&quot;Novartis&quot;,&quot;comment&quot;:&quot;food allergy added Q3 2019&quot;,&quot;description&quot;:&quot;Xolair (omalizumab, RG3648) is a monoclonal antibody that specifically targets the antibody IgE (immunoglobulin E).&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;indicationShort&quot;:&quot;ctDNA+ high risk muscle-invasive bladder cancer (ctDNA+ high-risk MIBC)&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2025&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;6&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMvigor011&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;SCLC&quot;,&quot;name&quot;:&quot;RG6810&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;DLL3 ADC&quot;,&quot;Autogenerated&quot;:&quot;187&quot;,&quot;partner&quot;:&quot;Innovent&quot;,&quot;comment&quot;:&quot;Added FY 2024&quot;,&quot;description&quot;:&quot;DLL3 targeted ADC with Topo1 isomerase payload&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Muco-obstructive respiratory disease&quot;,&quot;name&quot;:&quot;RG6421&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;TMEM16A potentiator&quot;,&quot;Autogenerated&quot;:&quot;155&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2022&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;r/r multiple myeloma (MM)&quot;,&quot;name&quot;:&quot;RG6538&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;P-BCMA-ALLO1&quot;,&quot;Autogenerated&quot;:&quot;151&quot;,&quot;partner&quot;:&quot;Poseida Therapeutics&quot;,&quot;comment&quot;:&quot;added Q3 2022&quot;,&quot;description&quot;:&quot;P-BCMA-ALLO1 (RG6538) is an off-the-shelf, donor derived, allogeneic anti-BCMA CAR T therapy with potent antitumor function for the treatment of multiple myeloma. P-BCMA-ALLO1 is designed to be fully allogeneic, with genetic edits to eliminate or reduce both host-vs-graft and graft-vs-host alloreactivity.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Actemra/RoACTEMRA&quot;,&quot;indicationShort&quot;:&quot;Covid-19 pneumonia&quot;,&quot;name&quot;:&quot;RG1569&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tocilizumab&quot;,&quot;Autogenerated&quot;:&quot;87&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Actemra/RoACTEMRA (tocilizumab, RG1569) is a humanised monoclonal antibody to the interleukin-6 receptor, inhibiting the activity of interleukin-6 and is being investigated in the treatment of Covid-19 pneumonia.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;relapsing multiple sclerosis (RMS)&quot;,&quot;name&quot;:&quot;RG7845&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;fenebrutinib&quot;,&quot;Autogenerated&quot;:&quot;75&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Fenebrutinib (GDC-0853, RG7845) is a novel Bruton\u2019s tyrosine kinase (BTK) inhibitor that helps block B cell proliferation. Fenebrutinib binds to BTK in a novel way that is believed to increase its effectiveness.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;Gazyva/Gazyvaro&quot;,&quot;indicationShort&quot;:&quot;lupus nephritis (LN)&quot;,&quot;name&quot;:&quot;RG7159&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;Autogenerated&quot;:&quot;76&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;NOBILITY, REGENCY&quot;,&quot;description&quot;:&quot;Gazyva/Gazyvaro (obinutuzumab, RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;indicationShort&quot;:&quot;neovascular age related macular degeneration (wAMD)&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;97&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;TENAYA, LUCERNE&quot;,&quot;description&quot;:&quot;Vabysmo (faricimab, RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;2L non small cell lung cancer (2L NSCLC)&quot;,&quot;name&quot;:&quot;RG6330&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;divarasib (KRAS G12C)&quot;,&quot;Autogenerated&quot;:&quot;60&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Divarasib (KRAS G12C, GDC-6036, RG6330) is an irreversible covalent inhibitor of the KRAS G12C mutant protein, resulting in a locked inactive conformation. KRAS is a frequently mutated oncogene, occurring in more than 25% of all cancers.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;hemophilia A&quot;,&quot;name&quot;:&quot;RG6797&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;SPARK&quot;,&quot;genericName&quot;:&quot;SPK-8011QQ&quot;,&quot;Autogenerated&quot;:&quot;143&quot;,&quot;partner&quot;:&quot;Spark Therapeutics&quot;,&quot;comment&quot;:&quot;added at FY 2024&quot;,&quot;description&quot;:&quot;SPK-8011QQ is an investigational AAV gene therapy incorporating an enhanced function FVIII variant with increased hemostatic activity into a well-described capsid and vector backbone from SPK-8011 for treatment of people with hemophilia A&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Hemlibra&quot;,&quot;indicationShort&quot;:&quot;Moderate hemophilia A, without FVIII inhibitors&quot;,&quot;name&quot;:&quot;RG6013&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;emicizumab&quot;,&quot;Autogenerated&quot;:&quot;144&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Hemlibra (emicizumab, RG6013, ACE910) is a bispecific antibody that mimics coagulation factor VIII, an essential blood clotting protein.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Ocrevus SC&quot;,&quot;indicationShort&quot;:&quot;relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)&quot;,&quot;name&quot;:&quot;RG1594&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;ocrelizumab&quot;,&quot;Autogenerated&quot;:&quot;148&quot;,&quot;partner&quot;:&quot;Halozyme, Biogen Idec&quot;,&quot;comment&quot;:&quot;added at HY 2022; Ocarina II&quot;,&quot;description&quot;:&quot;Ocrevus (ocrelizumab, RG1594) is a humanized monoclonal antibody targeting CD20-positive B cells which play a key role in MS. Ocrevus is the first therapy approved for both relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6330&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;plus combinations&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;divarasib (KRAS G12C)&quot;,&quot;Autogenerated&quot;:&quot;61&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Divarasib (KRAS G12C, GDC-6036, RG6330) is an irreversible covalent inhibitor of the KRAS G12C mutant protein, resulting in a locked inactive conformation. KRAS is a frequently mutated oncogene, occurring in more than 25% of all cancers.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;1L ET resistant ER-positive and HER2-negative breast cancer (1L ET resistant ER+/HER2- BC)&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;plus CDK4/6i&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;38&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2023, pionERA&quot;,&quot;description&quot;:&quot;Giredestrant (RG6171, GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Inflammation&quot;,&quot;name&quot;:&quot;RG6418&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;selnoflast (NLRP3 inhibitor)&quot;,&quot;Autogenerated&quot;:&quot;89&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Selnoflast (NLRP3i, RG6418) is a small molecule inhibitor of the NLRP3 inflammasome. NLRP3 is a cytosolic multiprotein complex of the innate immune system and its activation triggers inflammatory response leading to pyroptotic cell death. Selnoflast is developed in several disease areas, including Immunology and Neurology.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;REGEN-COV-2 (Ronapreve)&quot;,&quot;indicationShort&quot;:&quot;hospitalized adult patients with COVID-19&quot;,&quot;name&quot;:&quot;RG6412/RG6413&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Partner managed&quot;,&quot;genericName&quot;:&quot;casivirimab, imdevimab&quot;,&quot;Autogenerated&quot;:&quot;114&quot;,&quot;partner&quot;:&quot;Regeneron&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Filed&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;other&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Other&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;indicationShort&quot;:&quot;age-related macular degeneration (AMD) - 36 week refill interval&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;94&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;Velodrome&quot;,&quot;description&quot;:&quot;Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. Ranibizumab delivered via the ranibizumab port delivery system implant (Susvimo, PDS, RG6321) refilled every 36 weeks is evaluated for the treatment of patients with subfoveal neovascular age-related macular degeneration (nAMD).&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;indicationShort&quot;:&quot;macular edema secondary to branch retinal vein occlusion (BRVO)&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;98&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;BALATON&quot;,&quot;description&quot;:&quot;Vabysmo (faricimab, RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;MINT91&quot;,&quot;Autogenerated&quot;:&quot;192&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Added Q1 2025&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;spinal muscular atrophy (SMA)&quot;,&quot;name&quot;:&quot;RG6237&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;plus Evrysdi&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;emubrobart (GYM 329)&quot;,&quot;Autogenerated&quot;:&quot;130&quot;,&quot;partner&quot;:&quot;PTC Therapeutics, SMA Foundation&quot;,&quot;comment&quot;:&quot;added at HY 2022; new NME&quot;,&quot;description&quot;:&quot;Emubrobart (GYM 329) is a SMART-Ig* using recycling and sweeping antibody technologies that eliminates latent myostatin from plasma and tissues. Latent myostatin is an inactive form that is mainly secreted from muscle cells, and is activated by BMP-1 and other protein degrading enzymes. Activated myostatin inhibits muscle growth and hypertrophy, and by inhibiting latent myostatin, gym 329 is more targeted and expected to improve the various conditions associated with muscle atrophy and loss of muscular strength.\\n\\n* Sequential Monoclonal Antibody Recycling Technology - Immunoglobulin&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;PiaSky&quot;,&quot;indicationShort&quot;:&quot;atypical hemolytic uremic syndrome (aHUS)&quot;,&quot;name&quot;:&quot;RG6107&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;Autogenerated&quot;:&quot;82&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;COMMUTE-a, COMMUTE-p&quot;,&quot;description&quot;:&quot;PiaSky (crovalimab, RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology.  By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, it is planned to study the potential of this antibody in a broader range of complement-mediated diseases.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;multiple sclerosis (MS)&quot;,&quot;name&quot;:&quot;RG6035&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;Brainshuttle\u2122 CD20&quot;,&quot;Autogenerated&quot;:&quot;137&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;RG6035 (Brainshuttle\u2122 CD20) uses the brain shuttle technology to transfer Anti-CD20 antibodies across the blood brain barrier and increase the antibody concentrations in the brain/CNS.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;35&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Giredestrant (RG6171, GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Hemlibra&quot;,&quot;indicationShort&quot;:&quot;Type 3 VWD&quot;,&quot;name&quot;:&quot;RG6013&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;emicizumab&quot;,&quot;Autogenerated&quot;:&quot;145&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added Q3 2025&quot;,&quot;description&quot;:&quot;Hemlibra (emicizumab, RG6013, ACE910) is a bispecific antibody that mimics coagulation factor VIII, an essential blood clotting protein.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;geographic atrophy (GA)&quot;,&quot;name&quot;:&quot;RG6501&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Partner managed&quot;,&quot;genericName&quot;:&quot;OpRegen&quot;,&quot;Autogenerated&quot;:&quot;107&quot;,&quot;partner&quot;:&quot;Lineage Cell Therapeutics&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;OpRegen (RG6501) is a retinal pigment epithelium (RPE) cell therapy for the treatment of ocular disorders under development by Lineage Cell Therapeutics in collaboration with Roche.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;DME&quot;,&quot;name&quot;:&quot;RG6351&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;Tie2 agonist&quot;,&quot;Autogenerated&quot;:&quot;146&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at HY 2022&quot;,&quot;description&quot;:&quot;Tie2 agonist (RG6351) is a Fab-PEG-hexamer conjugate designed to directly activate Tie2.  Tie2 agonist is initially being combined with Vabysmo (RG7716) to treat patients with DME (Ph2)&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;heme tumors&quot;,&quot;name&quot;:&quot;RG6540&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;P-CD19 x CD20 - ALLO1&quot;,&quot;Autogenerated&quot;:&quot;179&quot;,&quot;partner&quot;:&quot;Poseida Therapeutics&quot;,&quot;comment&quot;:&quot;Added HY 2024&quot;,&quot;description&quot;:&quot;P-CD19xCD20-ALLO1 is an off-the-shelf, allogeneic CAR-T cell therapy product candidate being developed for relapsed or refractory B-cell malignancies in partnership with Poseida. P-CD19xCD20-ALLO1 expresses two fully functional CAR molecules to target cells that express either CD19 or CD20. The dual targeting approach employed in P-CD19xCD20-ALLO1 aims to overcome the antigen escape limitations of CD19-only targeted CAR-T therapies by simultaneously targeting both CD19 and CD20. In addition to the dual targeting, P-CD19xCD20-ALLO1 uses a novel CD19 binder that showed greater potency in in vivo preclinical models when compared to the canonical FMC63 Single-chain variable fragment (scFv) binder.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Type 1 diabetes (T1D) with BMI \u2265 25&quot;,&quot;name&quot;:&quot;RG6641&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;GLP-1/GIP receptor agonist (CT-868)&quot;,&quot;Autogenerated&quot;:&quot;171&quot;,&quot;partner&quot;:&quot;Carmot Therapeutics&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;CT-868 is a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed as an adjunct to insulin for the treatment of type 1 diabetes (T1D) with overweight or obesity. We designed CT-868 to exhibit signaling bias with no \u00df-arrestin recruitment to either GLP-1 or GIP receptors, minimizing receptor internalization and consequent desensitization. This signal biased dual GLP-1/GIP receptor agonism is expected to contribute to improved glycemic control, insulin sensitivity, and weight loss.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;Gazyva/Gazyvaro&quot;,&quot;indicationShort&quot;:&quot;systemic lupus erythematosus (SLE)&quot;,&quot;name&quot;:&quot;RG7159&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;Autogenerated&quot;:&quot;77&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;ALLEGORY&quot;,&quot;description&quot;:&quot;Gazyva/Gazyvaro (obinutuzumab, RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;chronic obstructive pulmonary disease (COPD)&quot;,&quot;name&quot;:&quot;RG6149&quot;,&quot;filingDate&quot;:&quot;2025&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;astegolimab (anti-ST2)&quot;,&quot;Autogenerated&quot;:&quot;91&quot;,&quot;partner&quot;:&quot;Amgen&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Astegolimab (anti-ST2, AMG 282, RG6149) is a fully human monoclonal antibody designed to inhibit binding of interleukin-33 (IL-33) to the ST2 receptor.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;PiaSky&quot;,&quot;indicationShort&quot;:&quot;paroxysmal nocturnal hemoglobinuria (PNH)&quot;,&quot;name&quot;:&quot;RG6107&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;Autogenerated&quot;:&quot;81&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Commodore 1,2,3&quot;,&quot;description&quot;:&quot;PiaSky (crovalimab, RG6107) is a humanised complement inhibitor C5 monoclonal antibody discovered by Chugai using recycling antibody technology.  By blocking the cleavage of C5 to C5a and C5b, it is expected to inhibit complement activation, which is the cause of a number of diseases. As the complement system is a key innate immune defense mechanism, it is planned to study the potential of this antibody in a broader range of complement-mediated diseases.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;ulcerative colitis&quot;,&quot;name&quot;:&quot;RG6631&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;afimkibart (anti-TL1A)&quot;,&quot;Autogenerated&quot;:&quot;173&quot;,&quot;partner&quot;:&quot;Telavant&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Columvi&quot;,&quot;indicationShort&quot;:&quot;relapsed or refractor mantle cell lymphoma (r/r MCL)&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;glofitamab&quot;,&quot;Autogenerated&quot;:&quot;27&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2023, GloBryte&quot;,&quot;description&quot;:&quot;Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;indicationShort&quot;:&quot;diabetic macular edema (DME)&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;96&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;Pagoda&quot;,&quot;description&quot;:&quot;Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. Ranibizumab delivered via the ranibizumab port delivery system implant (Susvimo, PDS, RG6321) refilled every 36 weeks is evaluated for the treatment of patients with diabetic macular edema (DME).&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Huntington's Disease&quot;,&quot;name&quot;:&quot;RG6042&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;tominersen&quot;,&quot;Autogenerated&quot;:&quot;128&quot;,&quot;partner&quot;:&quot;Ionis&quot;,&quot;comment&quot;:&quot;Moved back into Phase 2 FY 2022&quot;,&quot;description&quot;:&quot;Tominersen (ASO-HTT, RG6042) is an antisense drug in development for the treatment of Huntington's Disease. Tominersen is designed to reduce the production of all forms of the huntingtin (HTT) protein, which in its mutated variant (mHTT) is responsible for Huntington's Disease.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6344&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;mosperafenib (BRAF inhibitor (3))&quot;,&quot;Autogenerated&quot;:&quot;71&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Mosperafenib (BRAF inhibitor (3), RG6344) is a potent and selective  inhibitor of mtBRAFV600E and is currently investigated for the treatment of Braf-V600 mutation-positive solid tumors.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;HER2-positive breast cancer (HER-2+ BC)&quot;,&quot;name&quot;:&quot;RG6596&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;HER2 TKI&quot;,&quot;Autogenerated&quot;:&quot;165&quot;,&quot;partner&quot;:&quot;Zion Pharma&quot;,&quot;comment&quot;:&quot;added Q3 2023&quot;,&quot;description&quot;:&quot;HER2 TKI (ZN-A-1041, RG6596) is an orally administered selective tyrosine kinase inhibitor (TKI) that targets the human epidermal growth factor receptor 2 (HER2).&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;DME&quot;,&quot;name&quot;:&quot;RG6209&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;VEGF-IL6 DutaFab&quot;,&quot;Autogenerated&quot;:&quot;153&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2022&quot;,&quot;description&quot;:&quot;VEGF-IL6 DutaFab (RG6209) is a bispecific Fab molecule targeting vascular endothelial growth factor (VEGF) and Interleukin 6 (IL-6)&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;Tecentriq&quot;,&quot;indicationShort&quot;:&quot;periadjuvant non-small cell lung cancer (NSCLC periadj)&quot;,&quot;name&quot;:&quot;RG7446&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;plus platinum-based chemotherapy&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;Autogenerated&quot;:&quot;4&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;IMpower030&quot;,&quot;description&quot;:&quot;Cancer immunotherapy is the use of the immune system to fight cancer. Tecentriq (anti-PDL1, RG7446, atezolizumab) is an engineered monoclonal antibody that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;MASH&quot;,&quot;name&quot;:&quot;RG6631&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;afimkibart (anti-TL1A)&quot;,&quot;Autogenerated&quot;:&quot;175&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added Q1 2025&quot;,&quot;description&quot;:&quot;A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;CDH17 ADC&quot;,&quot;name&quot;:&quot;RGXXXX (TBD)&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;CRC&quot;,&quot;Autogenerated&quot;:&quot;200&quot;,&quot;partner&quot;:&quot;Hansoh Pharma&quot;,&quot;comment&quot;:&quot;Added Q3 2025&quot;,&quot;description&quot;:&quot;Novel potentially first-in-class antibody-drug conjugate composed of a humanized anti-CDH17 monoclonal antibody covalently conjugated to topoisomerase inhibitor (TOPOi) payload.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;indicationShort&quot;:&quot;diabetic retinopathy (DR)&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;95&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;Pavilion&quot;,&quot;description&quot;:&quot;Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. Ranibizumab delivered via the ranibizumab port delivery system implant (Susvimo, PDS, RG6321) refilled every 36 weeks is evaluated for the treatment of patients with diabetic retinopathy (DR).&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;ER+/HER2- BC&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2025&quot;,&quot;combination&quot;:&quot;plus everolimus&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;32&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Evera, Added FY 2024&quot;,&quot;description&quot;:&quot;Giredestrant (RG6171, GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;indicationShort&quot;:&quot;diabetic macular edema (DME)&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;100&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;YOSEMITE, RHINE&quot;,&quot;description&quot;:&quot;Vabysmo (faricimab, RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;Gazyva/Gazyvaro&quot;,&quot;indicationShort&quot;:&quot;membranous nephropathy&quot;,&quot;name&quot;:&quot;RG7159&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;Autogenerated&quot;:&quot;78&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;MAJESTY&quot;,&quot;description&quot;:&quot;Gazyva/Gazyvaro (obinutuzumab, RG7159, GA101) is the first glycoengineered, type II, humanised anti-CD20 monoclonal antibody. It has a distinct mode of action compared with other anti-CD20s, including MabThera/Rituxan, and was specifically designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;atopic dermatitis&quot;,&quot;name&quot;:&quot;RG6631&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;afimkibart (anti-TL1A)&quot;,&quot;Autogenerated&quot;:&quot;176&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added Q1 2025&quot;,&quot;description&quot;:&quot;A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;pan-KRAS inhibitor (AUBE00)&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;solid tumors&quot;,&quot;Autogenerated&quot;:&quot;199&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Added Q3 2025&quot;,&quot;description&quot;:&quot;Orally available cyclic peptide. Through its selective inhibitory activity based on binding to KRAS-GDP, it is expected to deliver anti-tumor effects with a favorable safety profile, and target a broad spectrum of KRAS gene mutations.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6620&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;KRAS G12D inhibitor&quot;,&quot;Autogenerated&quot;:&quot;188&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added FY 2024&quot;,&quot;description&quot;:&quot;GDC-7035 is selective for KRAS G12D, the most prevalent KRAS mutation, found in ~40% of PDAC, 15% of CRC, 4% of NSCLC&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;adjuvant ER+ breast cancer (ER+ BC, adj)&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;34&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;lidERA&quot;,&quot;description&quot;:&quot;Giredestrant (RG6171, GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Vabysmo&quot;,&quot;indicationShort&quot;:&quot;Myopic choriodial neovascularization  (CNV)&quot;,&quot;name&quot;:&quot;RG7716&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;faricimab&quot;,&quot;Autogenerated&quot;:&quot;101&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;POYANG&quot;,&quot;description&quot;:&quot;Vabysmo (faricimab, RG7716) is a bispecific antibody developed with CrossMab technology to tightly bind VEGF-A on one arm and angiopoietin (Ang)-2 on the other arm.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;Columvi&quot;,&quot;indicationShort&quot;:&quot;hematologic tumors (heme tumors)&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;plus combinations&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;glofitamab&quot;,&quot;Autogenerated&quot;:&quot;23&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q1 2017&quot;,&quot;description&quot;:&quot;Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6411&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;157&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added FY 2022&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6505&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;PanRAS inhibitor&quot;,&quot;Autogenerated&quot;:&quot;193&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q2 2025&quot;,&quot;description&quot;:&quot;A small molecule inhibitor covering a broad range of RAS mutations in solid tumors.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;obesity&quot;,&quot;name&quot;:&quot;RG6237&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;emubrobart (GYM 329)&quot;,&quot;Autogenerated&quot;:&quot;182&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added HY 2024&quot;,&quot;description&quot;:&quot;Emubrobart (GYM 329) is a SMART-Ig* using recycling and sweeping antibody technologies that eliminates latent myostatin from plasma and tissues. Latent myostatin is an inactive form that is mainly secreted from muscle cells, and is activated by BMP-1 and other protein degrading enzymes. Activated myostatin inhibits muscle growth and hypertrophy, and by inhibiting latent myostatin, gym 329 is more targeted and expected to improve the various conditions associated with muscle atrophy and loss of muscular strength.\\n\\n* Sequential Monoclonal Antibody Recycling Technology - Immunoglobulin&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;immunology&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;anti-C1s recycling antibody&quot;,&quot;Autogenerated&quot;:&quot;159&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added FY 2022&quot;,&quot;description&quot;:&quot;RAY121 is a therapeutic antibody that applies the recycling antibody\u00ae technology created by Chugai.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;acute diseases&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;REVN24&quot;,&quot;Autogenerated&quot;:&quot;178&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Added FY 2023&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;other&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Other&quot;},{&quot;tradeName&quot;:&quot;Itovebi&quot;,&quot;indicationShort&quot;:&quot;1L endocrine-sensitive PIK3CA-mut. HR+/HER2- advanced BC&quot;,&quot;name&quot;:&quot;RG6114&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;plus CDK4/6i plus letrozole&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Inavolisib&quot;,&quot;Autogenerated&quot;:&quot;19&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;INAVO123, added Q1 25 to portfolio&quot;,&quot;description&quot;:&quot;Inavolisib (RG6114, GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Idiopathic pulmonary fibrosis / Systemic sclerosis-associated interstitial lung disease (IPF &amp; SSc-ILD)&quot;,&quot;name&quot;:&quot;RG6536&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;vixarelimab&quot;,&quot;Autogenerated&quot;:&quot;150&quot;,&quot;partner&quot;:&quot;Kiniksa Pharmaceuticals&quot;,&quot;comment&quot;:&quot;added Q3 2022 transitioned to Phase 2 HY 2023&quot;,&quot;description&quot;:&quot;Vixarelimab (RG6536) is a selective OSMR\u03b2-targeting, fully human monoclonal antibody that blocks OSM and IL-31 signaling while preserving signaling through the LIFR pathway. Dysregulation of OSM and/or OSMR\u03b2 is observed in multiple human diseases and may drive fibrosis, inflammation, and other pathological processes in affected tissue. Vixarelimab is developed in several indications including Idiopathic pulmonary fibrosis / Systemic sclerosis-associated interstitial lung disease (IPF &amp; SSc-ILD) and Inflammatory bowel disease (IBD).&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;Columvi&quot;,&quot;indicationShort&quot;:&quot;1L diffuse large B-cell lymphoma (1L DLBCL)&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;2027&quot;,&quot;combination&quot;:&quot;plus Polivy + R-CHP&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;glofitamab&quot;,&quot;Autogenerated&quot;:&quot;26&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;SKYGLO, added Q3 2023&quot;,&quot;description&quot;:&quot;Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;celiac disease&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;anti-HLA-DQ2.5 x gluten peptides (DONQ52)&quot;,&quot;Autogenerated&quot;:&quot;158&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added FY 2022&quot;,&quot;description&quot;:&quot;DONQ52 is a bispecific antibody against complex of HLADQ2.5/gluten peptides. DONQ52 directly inhibits gluten dependent T cell activation by neutralizing interaction of T cell receptor (TCR) and complex of HLA-DQ2.5/gluten peptides. DONQ52 covers &gt;25 gluten derived peptides including all immunodominant gluten peptides for celiac disease.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6221&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;LTBR agonist&quot;,&quot;Autogenerated&quot;:&quot;184&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q3 2024&quot;,&quot;description&quot;:&quot;LTBR agonist is a novel tumour stroma modulator designed to increase tumour immune cell infiltration&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Lunsumio SC&quot;,&quot;indicationShort&quot;:&quot;3L+ Follicular Lymphoma (3L+ FL)&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;2024&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;11&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Lunsumio (mosunetuzumab, anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Filed&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Alecensa&quot;,&quot;indicationShort&quot;:&quot;adjuvant ALK-positive non-small cell lung cancer (ALK+ NSCLC adj)&quot;,&quot;name&quot;:&quot;RG7853&quot;,&quot;filingDate&quot;:&quot;2023&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;alectinib&quot;,&quot;Autogenerated&quot;:&quot;3&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added Q3 2018&quot;,&quot;description&quot;:&quot;Alecensa (Alectinib, RG7853) is a small molecule designed to selectively target ALK (anaplastic lymphoma kinase) and to penetrate and stay in the central nervous system. Alectinib binds ALK, inhibiting downstream malignant pathways that contribute to tumorigenesis and disease progression. Alecensa is evaluated for the treatment of adjuvant ALK-positive non-small cell lung cancer.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;chronic diseases&quot;,&quot;name&quot;:&quot;CHU&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;BRY10&quot;,&quot;Autogenerated&quot;:&quot;190&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;Added FY 2024&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;other&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Other&quot;},{&quot;tradeName&quot;:&quot;Enspryng&quot;,&quot;indicationShort&quot;:&quot;DMD&quot;,&quot;name&quot;:&quot;RG6168&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;satralizumab&quot;,&quot;Autogenerated&quot;:&quot;123&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added Q1 2025&quot;,&quot;description&quot;:&quot;Enspryng (satralizumab, RG6168) is a humanized monoclonal antibody to the interleukin-6 receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Parkinson's disease (PD)&quot;,&quot;name&quot;:&quot;RG7935&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;prasinezumab&quot;,&quot;Autogenerated&quot;:&quot;124&quot;,&quot;partner&quot;:&quot;Prothena&quot;,&quot;comment&quot;:&quot;Q3 2017: Filing date added.&quot;,&quot;description&quot;:&quot;Prasinezumab (RG7935) is a monoclonal antibody targeting alpha-synuclein, a protein that may misfold and be involved in the pathogenesis of Parkinson's disease. It has been tested in preclinical models of synuclein-related disease and has shown a reduction of neurodegeneration.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6648&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;cMET ADC&quot;,&quot;Autogenerated&quot;:&quot;181&quot;,&quot;partner&quot;:&quot;Medilink&quot;,&quot;comment&quot;:&quot;Added HY 2024&quot;,&quot;description&quot;:&quot;YL211 selectively targets the cognate cMET expressed on the surface of target cancer cells. After the internalization of the cMET-YL211 complex through the endosomal-lysosomal pathway, the active antitumor payload YL0010014 is released, arresting the cell cycle of tumor cells, and eventually leading to tumor cell apoptosis. YL211, with its anti- cMET specific antibody, the novel cytotoxin YL0010014, and advanced linker and conjugate methods, is designed to provide potent, targeted therapy against cancer cells that express cMET&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;primary progressive multiple sclerosis (PPMS)&quot;,&quot;name&quot;:&quot;RG7845&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;fenebrutinib&quot;,&quot;Autogenerated&quot;:&quot;74&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Fenebrutinib (GDC-0853, RG7845) is a novel Bruton\u2019s tyrosine kinase (BTK) inhibitor that helps block B cell proliferation. Fenebrutinib binds to BTK in a novel way that is believed to increase its effectiveness.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;endometrial cancer&quot;,&quot;name&quot;:&quot;RG6171&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;giredestrant&quot;,&quot;Autogenerated&quot;:&quot;37&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added HY 2023&quot;,&quot;description&quot;:&quot;Giredestrant (RG6171, GDC-9545) is a selective estrogen receptor degrader (SERD) that is designed to bind to the estrogen receptor to limit its function.  In addition, when SERDs bind to the estrogen receptor, they may be able to change the shape of the receptor in such a way that the cell eliminates it by degradation.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Susvimo&quot;,&quot;indicationShort&quot;:&quot;age-related macular degeneration (AMD)&quot;,&quot;name&quot;:&quot;RG6321&quot;,&quot;filingDate&quot;:&quot;2020&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;Autogenerated&quot;:&quot;93&quot;,&quot;partner&quot;:&quot;ForSight VISION4&quot;,&quot;comment&quot;:&quot;Archway&quot;,&quot;description&quot;:&quot;Ranibizumab, the active ingredient of Lucentis, is a monoclonal antibody fragment. It is designed to bind to and inhibit VEGF (vascular endothelial growth factor), a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. Ranibizumab delivered via the ranibizumab port delivery system implant (Susvimo, PDS, RG6321) is evaluated for the treatment of patients with subfoveal neovascular age-related macular degeneration (nAMD).&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Cardiac surgery associated acute kidney injury (CS-AKI)&quot;,&quot;name&quot;:&quot;RG6287&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;flizasertib&quot;,&quot;Autogenerated&quot;:&quot;86&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added at FY 2019&quot;,&quot;description&quot;:&quot;Flizasertib is an oral, highly potent and selective inhibitor of RIP1 that blocks RIP1-mediated cell death, inflammation, and tissue damage&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;name&quot;:&quot;RG6180&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;autogene cevumeran&quot;,&quot;Autogenerated&quot;:&quot;21&quot;,&quot;partner&quot;:&quot;BioNTech AG&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Autogene cevumeran (Individualised Neoantigen-Specific Therapy, iNeST (RG6180)) is a messenger RNA (mRNA)-based, individually tailored, personalized cancer vaccine. Each vaccine will be made using unique neoantigen signatures from an individual patient\u2019s tumor, which is expected to elicit an effective immune response against that patient\u2019s tumor.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Columvi&quot;,&quot;indicationShort&quot;:&quot;3L+ diffuse large B-cell lymphoma (3L+ DLBCL)&quot;,&quot;name&quot;:&quot;RG6026&quot;,&quot;filingDate&quot;:&quot;2022&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;glofitamab&quot;,&quot;Autogenerated&quot;:&quot;25&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Columvi (glofitamab, Anti-CD20 CD3 TCB, RG6026) is a 2:1 format T cell-engaging bispecific antibody, designed to engage both CD20 on B cells and CD3 on T cells. By engaging both targets simultaneously, the antibody activates the T cells to attack and eliminate the B cells, allowing treatment of B cell cancers such as non-Hodgkin\u2019s lymphoma.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Elevidys&quot;,&quot;indicationShort&quot;:&quot;amb. 8 to &lt;18y &amp; non amb.\\r\\nDMD&quot;,&quot;name&quot;:&quot;RG6356&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;delandistrogene moxeparvovec  (SRP-9001)&quot;,&quot;Autogenerated&quot;:&quot;134&quot;,&quot;partner&quot;:&quot;Sarepta&quot;,&quot;comment&quot;:&quot;added HY 2024, ENVISION&quot;,&quot;description&quot;:&quot;Delandistrogene moxeparvovec (SRP-9001; rAAVrh74.MHCK7.micro-dystrophin) is an investigational gene therapy aimed to deliver the micro-dystrophin-encoding transgene directly to the skeletal and cardiac muscle for the targeted production of the SRP-9001-dystrophin protein to enable a durable clinical response.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;Evrysdi&quot;,&quot;indicationShort&quot;:&quot;spinal muscular atrophy (SMA) pediatric &lt;2 months&quot;,&quot;name&quot;:&quot;RG7916&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;risdiplam&quot;,&quot;Autogenerated&quot;:&quot;125&quot;,&quot;partner&quot;:&quot;PTC Therapeutics, SMA Foundation&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Evrysdi (risdiplam, RG7916) is an investigational oral SMN2 splicing modifier being studied in the treatment of spinal muscular atrophy.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;neurodegenerative disorders&quot;,&quot;name&quot;:&quot;RG6434&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;185&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q3 2024&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;indicationShort&quot;:&quot;2L+ SCT ineligible diffuse large B-cell lymphoma (2L+ DLBCL)&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;2025&quot;,&quot;combination&quot;:&quot;plus Polivy&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;12&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;added at HY 2022, SUNMO&quot;,&quot;description&quot;:&quot;Lunsumio (mosunetuzumab, anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Itovebi&quot;,&quot;indicationShort&quot;:&quot;post CDKi HR-positive breast cancer (post CDKi HR+ PIK3CA-mut. BC)&quot;,&quot;name&quot;:&quot;RG6114&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;plus fulvestrant&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;Inavolisib&quot;,&quot;Autogenerated&quot;:&quot;17&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;INAVO121, added HY 2023&quot;,&quot;description&quot;:&quot;Inavolisib (RG6114, GDC-0077) is a small molecule PI3 kinase (PI3K) inhibitor. Dysregulation of PI3K signaling is implicated in a broad range of human cancers, and activating mutations in the PI3K alpha-isoform gene (PIK3CA) are common oncogenic drivers. The PI3K/Akt/mTOR pathway regulates cell growth and survival.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Lunsumio&quot;,&quot;indicationShort&quot;:&quot;3L+ Follicular Lymphoma (3L+ FL)&quot;,&quot;name&quot;:&quot;RG7828&quot;,&quot;filingDate&quot;:&quot;2021&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;mosunetuzumab&quot;,&quot;Autogenerated&quot;:&quot;10&quot;,&quot;partner&quot;:&quot;Biogen Idec&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Lunsumio (mosunetuzumab, anti-CD20/CD3 TDB, RG7828) is a humanized full-length T cell-dependent bispecific antibody designed to target both CD20 on B cells and CD3 on T cells. This dual-targeting antibody is designed to redirect T cells to attack cancer cells.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Approved&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;pegozafermin&quot;,&quot;name&quot;:&quot;RGXXXX (TBD)&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;MASH with fibrosis stage F2 or F3&quot;,&quot;Autogenerated&quot;:&quot;196&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q3 2025&quot;,&quot;description&quot;:&quot;Pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage)&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;pegozafermin&quot;,&quot;name&quot;:&quot;RGXXXX (TBD)&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;MASH with fibrosis stage F4&quot;,&quot;Autogenerated&quot;:&quot;197&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added Q3 2025&quot;,&quot;description&quot;:&quot;Pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage)&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;hypertension&quot;,&quot;name&quot;:&quot;RG6615&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Partner managed&quot;,&quot;genericName&quot;:&quot;zilebesiran&quot;,&quot;Autogenerated&quot;:&quot;166&quot;,&quot;partner&quot;:&quot;Alnylam Pharmaceuticals&quot;,&quot;comment&quot;:&quot;added Q3 2023&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;IBD&quot;,&quot;name&quot;:&quot;RG6377&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;NME&quot;,&quot;Autogenerated&quot;:&quot;183&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;Added HY 2024&quot;,&quot;description&quot;:&quot;&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;immunology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Immunology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;hematologic tumors (heme tumors)&quot;,&quot;name&quot;:&quot;RG6076&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;combinations&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;englumafusp alfa (CD19-4-1BBL)&quot;,&quot;Autogenerated&quot;:&quot;43&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added Q3 2019&quot;,&quot;description&quot;:&quot;Englumafusp alfa (CD19-4-1BBL, RG6076) is a fusion protein targeting the 4-1BB ligand to cells bearing CD19 acting as an NK- and T-cell co-stimulator.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;Enspryng&quot;,&quot;indicationShort&quot;:&quot;Thyroid eye disease (TED)&quot;,&quot;name&quot;:&quot;RG6168&quot;,&quot;filingDate&quot;:&quot;2026&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;managedBy&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;genericName&quot;:&quot;satralizumab&quot;,&quot;Autogenerated&quot;:&quot;122&quot;,&quot;partner&quot;:&quot;Chugai&quot;,&quot;comment&quot;:&quot;added FY 2023&quot;,&quot;description&quot;:&quot;Enspryng (satralizumab, RG6168) is a humanized monoclonal antibody to the interleukin-6 receptor.&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 3&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;ophthalmology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Ophthalmology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;metastatic castration-resistant prostate cancer (mCRPC)&quot;,&quot;name&quot;:&quot;RG6537&quot;,&quot;filingDate&quot;:&quot;&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;managedBy&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;genericName&quot;:&quot;AR degrader&quot;,&quot;Autogenerated&quot;:&quot;162&quot;,&quot;partner&quot;:&quot;Jemincare&quot;,&quot;comment&quot;:&quot;added HY 2023&quot;,&quot;description&quot;:&quot;AR degrader (RG6537, GDC-2992) is a small molecule, oral degrader of the androgen receptor, a disease driver in prostate cancer. GDC-2992 has the potential to treat patients with prostate cancer who have developed resistance to current therapies.&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 1&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;oncology/hematology&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Oncology/Hematology&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;Angelman syndrome&quot;,&quot;name&quot;:&quot;RG7816&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;genericName&quot;:&quot;alogabat (GABA-Aa5 PAM)&quot;,&quot;Autogenerated&quot;:&quot;127&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;added as NME in FY 2017&quot;,&quot;description&quot;:&quot;Alogabat (GABA-Aa5 PAM, RG7816) is a small molecule highly selective positive allosteric modulator of the GABAA \u03b15 receptor&quot;,&quot;projectType&quot;:&quot;nme&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;},{&quot;tradeName&quot;:&quot;&quot;,&quot;indicationShort&quot;:&quot;facioscapulohumeral muscular dystrophy (FSHD )&quot;,&quot;name&quot;:&quot;RG6237&quot;,&quot;filingDate&quot;:&quot;2028+&quot;,&quot;combination&quot;:&quot;&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;managedBy&quot;:&quot;Chugai&quot;,&quot;genericName&quot;:&quot;emubrobart (GYM 329)&quot;,&quot;Autogenerated&quot;:&quot;129&quot;,&quot;partner&quot;:&quot;&quot;,&quot;comment&quot;:&quot;&quot;,&quot;description&quot;:&quot;Emubrobart (GYM 329) is a SMART-Ig* using recycling and sweeping antibody technologies that eliminates latent myostatin from plasma and tissues. Latent myostatin is an inactive form that is mainly secreted from muscle cells, and is activated by BMP-1 and other protein degrading enzymes. Activated myostatin inhibits muscle growth and hypertrophy, and by inhibiting latent myostatin, gym 329 is more targeted and expected to improve the various conditions associated with muscle atrophy and loss of muscular strength.\\n\\n* Sequential Monoclonal Antibody Recycling Technology - Immunoglobulin&quot;,&quot;projectType&quot;:&quot;ai&quot;,&quot;originalPhase&quot;:&quot;Phase 2&quot;,&quot;therapeuticAreaFilterValue&quot;:&quot;neuroscience&quot;,&quot;therapeuticAreaGroupByValue&quot;:&quot;Neuroscience&quot;}]\"><div class=\"pipeline-table\"><roche-table-sort-header appearance=\"pipeline\"><div class=\"table__header\"><div class=\"table__headline table__headline--sortable\"><span class=\"table__headline--sortable__item\">compound<roche-icon data-sort-icon=\"chevron-down\" dir=\"ltr\"></roche-icon></span><span class=\"table__headline--sortable__item\">generic name<roche-icon data-sort-icon=\"chevron-down\" dir=\"ltr\"></roche-icon></span></div><div class=\"table__headline table__headline--sortable\"><span class=\"table__headline--sortable__item\">trade name<roche-icon data-sort-icon=\"chevron-down\" dir=\"ltr\"></roche-icon></span></div><div class=\"table__headline table__headline--sortable\"><span class=\"table__headline--sortable__item\">combination<roche-icon data-sort-icon=\"chevron-down\" dir=\"ltr\"></roche-icon></span></div><div class=\"table__headline table__headline--sortable\"><span class=\"table__headline--sortable__item\">indication<roche-icon data-sort-icon=\"chevron-down\" dir=\"ltr\"></roche-icon></span></div><div class=\"table__headline table__headline--sortable\"><span class=\"table__headline--sortable__item\">phase \n1 2 3 f<roche-icon data-sort-icon=\"chevron-down\" dir=\"ltr\"></roche-icon></span></div><div class=\"table__headline table__headline--sortable\"><span class=\"table__headline--sortable__item\">expected \nfiling<roche-icon data-sort-icon=\"chevron-down\" dir=\"ltr\"></roche-icon></span></div></div></roche-table-sort-header><roche-pipeline-table-row class=\"table__row\" trade-name=\"Vabysmo\" generic-name=\"faricimab\" indication-short=\"macular edema secondary to central retinal vein occlusion (CRVO)\" filing-date=\"2023\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Tecentriq\" generic-name=\"atezolizumab\" indication-short=\"maintenance 1Lextensive stage-small cell lung cancer (1L maintenance ES-SCLC)\" filing-date=\"2025\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"NME\" indication-short=\"geographic atrophy\" filing-date=\"\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Lunsumio\" generic-name=\"mosunetuzumab\" indication-short=\"systemic lupus erythematosus (SLE)\" filing-date=\"\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Enspryng\" generic-name=\"satralizumab\" indication-short=\"myelin oligodendrocyte glycoprotein antibody disease (MOG-AD)\" filing-date=\"2026\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"CD19 x CD3\" indication-short=\"systemic lupus erythematosus (SLE)\" filing-date=\"\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"vamikibart\" indication-short=\"uveitic macular edema (UME)\" filing-date=\"2026\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"giredestrant\" indication-short=\"1L ER-positive and HER2-positive breast cancer (1L ER+/HER2+ BC)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"Anti-CTLA-4 Switch antibody (ROSE12)\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"giredestrant\" indication-short=\"1L ER-positive and HER2-negative metastatic breast cancer (1L ER+/HER2- mBC)\" filing-date=\"2026\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"CDK4/2i (RGT-419B)\" indication-short=\"HR+ HER2- breast cancer\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"codrituzumab\" indication-short=\"Hepatocellular carcinoma (HCC)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"NME\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"nivegacetor (gamma-secretase modulator)\" indication-short=\"Alzheimer's disease (AD)\" filing-date=\"\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Itovebi\" generic-name=\"Inavolisib\" indication-short=\"1L HER2-positive PIK3CA-mutant metastatic breast cancer  (1L HER2+ PIK3CA-mut. mBC)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"HTT miRNA GT (SPK-10001)\" indication-short=\"Huntington's disease\" filing-date=\"\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"afimkibart (anti-TL1A)\" indication-short=\"Crohn's disease\" filing-date=\"2028+\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Xofluza\" generic-name=\"baloxavir marboxil\" indication-short=\"influenza, pediatric patients (0-1yr)\" filing-date=\"2024\" therapeutic-area=\"Other\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"clesitamig (DLL3 trispecific)\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Itovebi\" generic-name=\"Inavolisib\" indication-short=\"1L metastatic ER-positive and HER2-negative breast cancer (1L HR+ PIK3CA-mut. mBC)\" filing-date=\"2024\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"sefaxersen (ASO factor B)\" indication-short=\"IgA-nephropathy\" filing-date=\"2027\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Polivy\" generic-name=\"polatuzumab vedotin\" indication-short=\"1L diffuse large B-cell lymphoma (1L DLBCL)\" filing-date=\"2021\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Tecentriq SC\" generic-name=\"atezolizumab\" indication-short=\"subcutaneous formulation, all approved indications\" filing-date=\"2022\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Enspryng\" generic-name=\"satralizumab\" indication-short=\"autoimmune encephalitis (AE)\" filing-date=\"2026\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"UC\" indication-short=\"p40xTL1A bispecific antibody\" filing-date=\"2028+\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"NME\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Gazyva/Gazyvaro\" generic-name=\"obinutuzumab\" indication-short=\"pediatric nephrotic syndrome (PNS)\" filing-date=\"2026\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Lunsumio\" generic-name=\"mosunetuzumab\" indication-short=\"hematologic tumors (heme tumors)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"GLP-1 receptor agonist (CT-996)\" indication-short=\"obesity +/- Type 2 diabetes (T2D)\" filing-date=\"2028+\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Xofluza\" generic-name=\"baloxavir marboxil\" indication-short=\"influenza, pediatric patients (1-12yr)\" filing-date=\"2021\" therapeutic-area=\"Other\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"petrelintide.\" indication-short=\"obesity +/-T2D\" filing-date=\"\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"zosurabalpin (Abx MCP)\" indication-short=\"Acinetobacter baumannii infections (bacterial infections)\" filing-date=\"\" therapeutic-area=\"Other\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"trontinemab\" indication-short=\"Alzheimer's disease (AD)\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"anti-FIXa/FX (NXT007)\" indication-short=\"hemophilia A\" filing-date=\"2028+\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Lunsumio\" generic-name=\"mosunetuzumab\" indication-short=\"2L+ Follicular Lymphoma (2L+ FL)\" filing-date=\"2026\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"zifibancimig (VEGF-Ang2 DutaFab)\" indication-short=\"neovascular age related macular degeneration (wAMD)\" filing-date=\"\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"GLP-1/GIP receptor agonist (CT-388)\" indication-short=\"obesity +/- Type 2 diabetes (T2D)\" filing-date=\"2028+\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Xofluza\" generic-name=\"baloxavir marboxil\" indication-short=\"influenza, direct transmission\" filing-date=\"2024\" therapeutic-area=\"Other\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Kadcyla\" generic-name=\"trastuzumab emtansine\" indication-short=\"high risk patients with adjuvant HER2-positive breast cancer (HER-2+ eBC high-risk)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"MAGL inhibitor\" indication-short=\"multiple sclerosis (MS)\" filing-date=\"\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"cevostamab\" indication-short=\"relapsed or refractory multiple myeloma (r/r MM)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Elevidys\" generic-name=\"delandistrogene moxeparvovec  (SRP-9001)\" indication-short=\"0 to &lt;4 year old  Duchenne muscular dystrophy (DMD)\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Xolair\" generic-name=\"omalizumab\" indication-short=\"Food allergy\" filing-date=\"2023\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Tecentriq\" generic-name=\"atezolizumab\" indication-short=\"ctDNA+ high risk muscle-invasive bladder cancer (ctDNA+ high-risk MIBC)\" filing-date=\"2025\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"DLL3 ADC\" indication-short=\"SCLC\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"TMEM16A potentiator\" indication-short=\"Muco-obstructive respiratory disease\" filing-date=\"\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"P-BCMA-ALLO1\" indication-short=\"r/r multiple myeloma (MM)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Actemra/RoACTEMRA\" generic-name=\"tocilizumab\" indication-short=\"Covid-19 pneumonia\" filing-date=\"2021\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"fenebrutinib\" indication-short=\"relapsing multiple sclerosis (RMS)\" filing-date=\"2026\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Gazyva/Gazyvaro\" generic-name=\"obinutuzumab\" indication-short=\"lupus nephritis (LN)\" filing-date=\"2024\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Vabysmo\" generic-name=\"faricimab\" indication-short=\"neovascular age related macular degeneration (wAMD)\" filing-date=\"2021\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"divarasib (KRAS G12C)\" indication-short=\"2L non small cell lung cancer (2L NSCLC)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"SPK-8011QQ\" indication-short=\"hemophilia A\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"SPARK\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Hemlibra\" generic-name=\"emicizumab\" indication-short=\"Moderate hemophilia A, without FVIII inhibitors\" filing-date=\"2021\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Ocrevus SC\" generic-name=\"ocrelizumab\" indication-short=\"relapsing multiple sclerosis (RMS) &amp; primary progressive multiple sclerosis (PPMS)\" filing-date=\"2023\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"divarasib (KRAS G12C)\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"giredestrant\" indication-short=\"1L ET resistant ER-positive and HER2-negative breast cancer (1L ET resistant ER+/HER2- BC)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"selnoflast (NLRP3 inhibitor)\" indication-short=\"Inflammation\" filing-date=\"\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"REGEN-COV-2 (Ronapreve)\" generic-name=\"casivirimab, imdevimab\" indication-short=\"hospitalized adult patients with COVID-19\" filing-date=\"2021\" therapeutic-area=\"Other\" project-type=\"ai\" managed-by=\"Partner managed\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Susvimo\" generic-name=\"Port Delivery System with ranibizumab\" indication-short=\"age-related macular degeneration (AMD) - 36 week refill interval\" filing-date=\"2027\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Vabysmo\" generic-name=\"faricimab\" indication-short=\"macular edema secondary to branch retinal vein occlusion (BRVO)\" filing-date=\"2023\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"MINT91\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"emubrobart (GYM 329)\" indication-short=\"spinal muscular atrophy (SMA)\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"PiaSky\" generic-name=\"crovalimab\" indication-short=\"atypical hemolytic uremic syndrome (aHUS)\" filing-date=\"2026\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"Brainshuttle\u2122 CD20\" indication-short=\"multiple sclerosis (MS)\" filing-date=\"\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"giredestrant\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Hemlibra\" generic-name=\"emicizumab\" indication-short=\"Type 3 VWD\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"OpRegen\" indication-short=\"geographic atrophy (GA)\" filing-date=\"2028+\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Partner managed\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"Tie2 agonist\" indication-short=\"DME\" filing-date=\"2028+\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"P-CD19 x CD20 - ALLO1\" indication-short=\"heme tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"GLP-1/GIP receptor agonist (CT-868)\" indication-short=\"Type 1 diabetes (T1D) with BMI \u2265 25\" filing-date=\"2028+\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Gazyva/Gazyvaro\" generic-name=\"obinutuzumab\" indication-short=\"systemic lupus erythematosus (SLE)\" filing-date=\"2026\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"astegolimab (anti-ST2)\" indication-short=\"chronic obstructive pulmonary disease (COPD)\" filing-date=\"2025\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"PiaSky\" generic-name=\"crovalimab\" indication-short=\"paroxysmal nocturnal hemoglobinuria (PNH)\" filing-date=\"2022\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"afimkibart (anti-TL1A)\" indication-short=\"ulcerative colitis\" filing-date=\"2027\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Columvi\" generic-name=\"glofitamab\" indication-short=\"relapsed or refractor mantle cell lymphoma (r/r MCL)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Susvimo\" generic-name=\"Port Delivery System with ranibizumab\" indication-short=\"diabetic macular edema (DME)\" filing-date=\"2024\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"tominersen\" indication-short=\"Huntington's Disease\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"mosperafenib (BRAF inhibitor (3))\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"HER2 TKI\" indication-short=\"HER2-positive breast cancer (HER-2+ BC)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"VEGF-IL6 DutaFab\" indication-short=\"DME\" filing-date=\"\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Tecentriq\" generic-name=\"atezolizumab\" indication-short=\"periadjuvant non-small cell lung cancer (NSCLC periadj)\" filing-date=\"2026\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"afimkibart (anti-TL1A)\" indication-short=\"MASH\" filing-date=\"\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"CRC\" indication-short=\"CDH17 ADC\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Susvimo\" generic-name=\"Port Delivery System with ranibizumab\" indication-short=\"diabetic retinopathy (DR)\" filing-date=\"2024\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"giredestrant\" indication-short=\"ER+/HER2- BC\" filing-date=\"2025\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Vabysmo\" generic-name=\"faricimab\" indication-short=\"diabetic macular edema (DME)\" filing-date=\"2021\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Gazyva/Gazyvaro\" generic-name=\"obinutuzumab\" indication-short=\"membranous nephropathy\" filing-date=\"2026\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"afimkibart (anti-TL1A)\" indication-short=\"atopic dermatitis\" filing-date=\"2028+\" therapeutic-area=\"Immunology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"solid tumors\" indication-short=\"pan-KRAS inhibitor (AUBE00)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"KRAS G12D inhibitor\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"giredestrant\" indication-short=\"adjuvant ER+ breast cancer (ER+ BC, adj)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Vabysmo\" generic-name=\"faricimab\" indication-short=\"Myopic choriodial neovascularization  (CNV)\" filing-date=\"2027\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Columvi\" generic-name=\"glofitamab\" indication-short=\"hematologic tumors (heme tumors)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"NME\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"PanRAS inhibitor\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"emubrobart (GYM 329)\" indication-short=\"obesity\" filing-date=\"2028+\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"ai\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"anti-C1s recycling antibody\" indication-short=\"immunology\" filing-date=\"\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"REVN24\" indication-short=\"acute diseases\" filing-date=\"\" therapeutic-area=\"Other\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Itovebi\" generic-name=\"Inavolisib\" indication-short=\"1L endocrine-sensitive PIK3CA-mut. HR+/HER2- advanced BC\" filing-date=\"2028+\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"vixarelimab\" indication-short=\"Idiopathic pulmonary fibrosis / Systemic sclerosis-associated interstitial lung disease (IPF &amp; SSc-ILD)\" filing-date=\"2028+\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Columvi\" generic-name=\"glofitamab\" indication-short=\"1L diffuse large B-cell lymphoma (1L DLBCL)\" filing-date=\"2027\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"anti-HLA-DQ2.5 x gluten peptides (DONQ52)\" indication-short=\"celiac disease\" filing-date=\"\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"LTBR agonist\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Lunsumio SC\" generic-name=\"mosunetuzumab\" indication-short=\"3L+ Follicular Lymphoma (3L+ FL)\" filing-date=\"2024\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Alecensa\" generic-name=\"alectinib\" indication-short=\"adjuvant ALK-positive non-small cell lung cancer (ALK+ NSCLC adj)\" filing-date=\"2023\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"BRY10\" indication-short=\"chronic diseases\" filing-date=\"\" therapeutic-area=\"Other\" project-type=\"nme\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Enspryng\" generic-name=\"satralizumab\" indication-short=\"DMD\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"prasinezumab\" indication-short=\"Parkinson's disease (PD)\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"cMET ADC\" indication-short=\"solid tumors\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"fenebrutinib\" indication-short=\"primary progressive multiple sclerosis (PPMS)\" filing-date=\"2026\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"giredestrant\" indication-short=\"endometrial cancer\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Susvimo\" generic-name=\"Port Delivery System with ranibizumab\" indication-short=\"age-related macular degeneration (AMD)\" filing-date=\"2020\" therapeutic-area=\"Ophthalmology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"flizasertib\" indication-short=\"Cardiac surgery associated acute kidney injury (CS-AKI)\" filing-date=\"2028+\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"autogene cevumeran\" indication-short=\"solid tumors\" filing-date=\"2028+\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Columvi\" generic-name=\"glofitamab\" indication-short=\"3L+ diffuse large B-cell lymphoma (3L+ DLBCL)\" filing-date=\"2022\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Elevidys\" generic-name=\"delandistrogene moxeparvovec  (SRP-9001)\" indication-short=\"amb. 8 to &lt;18y &amp; non amb.\r\nDMD\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Evrysdi\" generic-name=\"risdiplam\" indication-short=\"spinal muscular atrophy (SMA) pediatric &lt;2 months\" filing-date=\"2021\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"NME\" indication-short=\"neurodegenerative disorders\" filing-date=\"\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Lunsumio\" generic-name=\"mosunetuzumab\" indication-short=\"2L+ SCT ineligible diffuse large B-cell lymphoma (2L+ DLBCL)\" filing-date=\"2025\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Itovebi\" generic-name=\"Inavolisib\" indication-short=\"post CDKi HR-positive breast cancer (post CDKi HR+ PIK3CA-mut. BC)\" filing-date=\"2026\" therapeutic-area=\"Oncology/Hematology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Lunsumio\" generic-name=\"mosunetuzumab\" indication-short=\"3L+ Follicular Lymphoma (3L+ FL)\" filing-date=\"2021\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"MASH with fibrosis stage F2 or F3\" indication-short=\"pegozafermin\" filing-date=\"2028+\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"nme\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"MASH with fibrosis stage F4\" indication-short=\"pegozafermin\" filing-date=\"2028+\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"zilebesiran\" indication-short=\"hypertension\" filing-date=\"2028+\" therapeutic-area=\"cardiovascular &amp; metabolism\" project-type=\"nme\" managed-by=\"Partner managed\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"NME\" indication-short=\"IBD\" filing-date=\"\" therapeutic-area=\"Immunology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"englumafusp alfa (CD19-4-1BBL)\" indication-short=\"hematologic tumors (heme tumors)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"Enspryng\" generic-name=\"satralizumab\" indication-short=\"Thyroid eye disease (TED)\" filing-date=\"2026\" therapeutic-area=\"Ophthalmology\" project-type=\"ai\" managed-by=\"Roche Late Stage Product Development\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"AR degrader\" indication-short=\"metastatic castration-resistant prostate cancer (mCRPC)\" filing-date=\"\" therapeutic-area=\"Oncology/Hematology\" project-type=\"nme\" managed-by=\"Genentech Research and Early Development (gRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"alogabat (GABA-Aa5 PAM)\" indication-short=\"Angelman syndrome\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"nme\" managed-by=\"Pharma Research and Early Development (pRED)\" dir=\"ltr\"></roche-pipeline-table-row><roche-pipeline-table-row class=\"table__row\" trade-name=\"\" generic-name=\"emubrobart (GYM 329)\" indication-short=\"facioscapulohumeral muscular dystrophy (FSHD )\" filing-date=\"2028+\" therapeutic-area=\"Neuroscience\" project-type=\"ai\" managed-by=\"Chugai\" dir=\"ltr\"></roche-pipeline-table-row></div></roche-pipeline-table></div><div class=\"grid__column column is-1 is-offset-0\"></div><div class=\"grid__column column is-3 is-offset-0\"><div slot=\"right\" style=\"position: sticky; top: 1rem; z-index: 100;\"><span class=\"text-link\"><button class=\"text-link__link\"><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M19 9h-4V3H9v6H5l7 7 7-7zm-8 2V5h2v6h1.2L12 13.2 9.8 11H11zm-6 7h14v2H5v-2z\"></path></svg></span></span><span class=\"text-link__text\">Download current view as CSV</span></button></span><roche-input name=\"search\" type=\"search\" label=\"Search\" value=\"\" required=\"true\" dir=\"ltr\"></roche-input><div class=\"roche-dropdown\"><div class=\"roche-dropdown__label-wrapper\"><label class=\"roche-dropdown__label\">Group list by</label></div><div class=\"roche-dropdown__container\"><select name=\"groupListBy\" class=\"roche-dropdown__select\" aria-invalid=\"false\"><option value=\"\" disabled=\"\"></option><option value=\"all\">All</option><option value=\"therapeuticAreaGroupByValue\">Therapeutic Area</option><option value=\"partner\">Partner</option><option value=\"phase\">Phase</option><option value=\"managedBy\">Managed By</option><option value=\"filingDate\">Expected Filing</option></select><div class=\"roche-dropdown__icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" width=\"16px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 15.7l6-6-1.4-1.4-4.6 4.6-4.6-4.6L6 9.7l6 6z\"></path></svg></span></div></div><div class=\"roche-dropdown__error\"></div></div><roche-accordion-tabs appearance=\"pipeline\" type=\"accordion\" no-margin=\"true\" dir=\"ltr\"><!----><ul class=\"tabs\"><li><button class=\"tabs__item\">Therapeutic Area</button></li><li><button class=\"tabs__item\">Project Type</button></li><li><button class=\"tabs__item\">Phase</button></li><li><button class=\"tabs__item\">Expected Filing Date</button></li><li><button class=\"tabs__item\">Managed By</button></li></ul><roche-accordion-tabs-item headline=\"Therapeutic Area\" appearance=\"pipeline\" is-overflow-y-scrollable=\"true\" type=\"accordion\" dir=\"ltr\"><roche-select label-wrapper=\"true\" select-all=\"true\" multi-select=\"true\" name=\"therapeuticAreaFilterValue\" options=\"[{&quot;group&quot;:&quot;therapeuticAreaFilterValue&quot;,&quot;label&quot;:&quot;Cardiovascular, Renal &amp; Metabolism&quot;,&quot;value&quot;:&quot;cardiovascular &amp; metabolism&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticAreaFilterValue&quot;,&quot;label&quot;:&quot;Immunology&quot;,&quot;value&quot;:&quot;immunology&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticAreaFilterValue&quot;,&quot;label&quot;:&quot;Neuroscience&quot;,&quot;value&quot;:&quot;neuroscience&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticAreaFilterValue&quot;,&quot;label&quot;:&quot;Oncology/Hematology&quot;,&quot;value&quot;:&quot;oncology/hematology&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticAreaFilterValue&quot;,&quot;label&quot;:&quot;Ophthalmology&quot;,&quot;value&quot;:&quot;ophthalmology&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;},{&quot;group&quot;:&quot;therapeuticAreaFilterValue&quot;,&quot;label&quot;:&quot;Other&quot;,&quot;value&quot;:&quot;other&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;color-indicator&quot;}]\" enable-scroll-into-view=\"true\" dir=\"ltr\"></roche-select></roche-accordion-tabs-item><roche-accordion-tabs-item headline=\"Project Type\" appearance=\"pipeline\" is-overflow-y-scrollable=\"false\" type=\"accordion\" dir=\"ltr\"><roche-select label-wrapper=\"true\" select-all=\"true\" multi-select=\"true\" name=\"projectType\" options=\"[{&quot;group&quot;:&quot;projectType&quot;,&quot;label&quot;:&quot;Additional Indication&quot;,&quot;value&quot;:&quot;ai&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;additional&quot;},{&quot;group&quot;:&quot;projectType&quot;,&quot;label&quot;:&quot;New Molecular Entity&quot;,&quot;value&quot;:&quot;nme&quot;,&quot;checked&quot;:false,&quot;icon&quot;:&quot;molecular-item&quot;}]\" enable-scroll-into-view=\"true\" dir=\"ltr\"></roche-select></roche-accordion-tabs-item><roche-accordion-tabs-item headline=\"Phase\" appearance=\"pipeline\" is-overflow-y-scrollable=\"true\" type=\"accordion\" dir=\"ltr\"><roche-select label-wrapper=\"true\" select-all=\"true\" multi-select=\"true\" name=\"phase\" options=\"[{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Filed&quot;,&quot;value&quot;:&quot;Filed&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Phase 1&quot;,&quot;value&quot;:&quot;Phase 1&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Phase 2&quot;,&quot;value&quot;:&quot;Phase 2&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;phase&quot;,&quot;label&quot;:&quot;Phase 3&quot;,&quot;value&quot;:&quot;Phase 3&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null}]\" enable-scroll-into-view=\"true\" dir=\"ltr\"></roche-select></roche-accordion-tabs-item><roche-accordion-tabs-item headline=\"Expected Filing Date\" appearance=\"pipeline\" is-overflow-y-scrollable=\"true\" type=\"accordion\" dir=\"ltr\"><roche-select label-wrapper=\"true\" select-all=\"true\" multi-select=\"true\" name=\"filingDate\" options=\"[{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2020&quot;,&quot;value&quot;:&quot;2020&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2021&quot;,&quot;value&quot;:&quot;2021&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2022&quot;,&quot;value&quot;:&quot;2022&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2023&quot;,&quot;value&quot;:&quot;2023&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2024&quot;,&quot;value&quot;:&quot;2024&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2025&quot;,&quot;value&quot;:&quot;2025&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2026&quot;,&quot;value&quot;:&quot;2026&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2027&quot;,&quot;value&quot;:&quot;2027&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;filingDate&quot;,&quot;label&quot;:&quot;2028+&quot;,&quot;value&quot;:&quot;2028+&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null}]\" enable-scroll-into-view=\"true\" dir=\"ltr\"></roche-select></roche-accordion-tabs-item><roche-accordion-tabs-item headline=\"Managed By\" appearance=\"pipeline\" is-overflow-y-scrollable=\"true\" type=\"accordion\" dir=\"ltr\"><roche-select label-wrapper=\"true\" select-all=\"true\" multi-select=\"true\" name=\"managedBy\" options=\"[{&quot;group&quot;:&quot;managedBy&quot;,&quot;label&quot;:&quot;Chugai&quot;,&quot;value&quot;:&quot;Chugai&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;managedBy&quot;,&quot;label&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;value&quot;:&quot;Genentech Research and Early Development (gRED)&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;managedBy&quot;,&quot;label&quot;:&quot;Partner managed&quot;,&quot;value&quot;:&quot;Partner managed&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;managedBy&quot;,&quot;label&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;value&quot;:&quot;Pharma Research and Early Development (pRED)&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;managedBy&quot;,&quot;label&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;value&quot;:&quot;Roche Late Stage Product Development&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null},{&quot;group&quot;:&quot;managedBy&quot;,&quot;label&quot;:&quot;SPARK&quot;,&quot;value&quot;:&quot;SPARK&quot;,&quot;checked&quot;:false,&quot;icon&quot;:null}]\" enable-scroll-into-view=\"true\" dir=\"ltr\"></roche-select></roche-accordion-tabs-item></roche-accordion-tabs></div></div></div></div></div></div></div><div class=\"tabs__panel\" id=\"panel-2fed21d8-ce3e-4c4c-a9d0-519999c0984a\" role=\"tabpanel\" aria-labelledby=\"2fed21d8-ce3e-4c4c-a9d0-519999c0984a\" hidden=\"\" tabindex=\"0\"><roche-pipeline-changes-table content=\"[{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;genericName&quot;:&quot;pan-KRAS inhibitor (AUBE00)&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;CRC&quot;,&quot;genericName&quot;:&quot;CDH17 ADC&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;UC&quot;,&quot;genericName&quot;:&quot;p40xTL1A bispecific antibody&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Cardiovascular &amp; Metabolism&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;obesity +/- Type 2 diabetes (T2D)&quot;,&quot;genericName&quot;:&quot;GLP-1 receptor agonist (CT-996)&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;Alzheimer's disease (AD)&quot;,&quot;genericName&quot;:&quot;trontinemab&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Cardiovascular &amp; Metabolism&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;MASH with fibrosis stage F2 or F3&quot;,&quot;genericName&quot;:&quot;pegozafermin&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Cardiovascular &amp; Metabolism&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;MASH with fibrosis stage F4&quot;,&quot;genericName&quot;:&quot;pegozafermin&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Cardiovascular &amp; Metabolism&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;hypertension&quot;,&quot;genericName&quot;:&quot;zilebesiran&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;Type 3 VWD&quot;,&quot;genericName&quot;:&quot;emicizumab&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;Hemlibra&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Filed&quot;,&quot;indicationShort&quot;:&quot;wAMD&quot;,&quot;genericName&quot;:&quot;Port Delivery System with ranibizumab&quot;,&quot;region&quot;:&quot;EU&quot;,&quot;name&quot;:&quot;Susvimo&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Approved&quot;,&quot;indicationShort&quot;:&quot;maintenance 1Lextensive stage-small cell lung cancer (1L maintenance ES-SCLC)&quot;,&quot;genericName&quot;:&quot;atezolizumab plus lurbinectedin&quot;,&quot;region&quot;:&quot;US&quot;,&quot;name&quot;:&quot;Tecentriq plus lurbinectedin&quot;},{&quot;projectStatus&quot;:&quot;Active&quot;,&quot;therapeuticArea&quot;:&quot;Immunology&quot;,&quot;phase&quot;:&quot;Approved&quot;,&quot;indicationShort&quot;:&quot;lupus nephritis (LN)&quot;,&quot;genericName&quot;:&quot;obinutuzumab&quot;,&quot;region&quot;:&quot;US&quot;,&quot;name&quot;:&quot;Gazyva/Gazyvaro&quot;},{},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;genericName&quot;:&quot;CD137 agonist switch antibody&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;genericName&quot;:&quot;Anti-latent TGF-\u03b21 (SOF10)&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;solid tumors&quot;,&quot;genericName&quot;:&quot;paluratide (RAS inhibitor)&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;CLDN6+ solid tumors&quot;,&quot;genericName&quot;:&quot;anti-CLDN6 trispecific (SAIL66)&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Phase 1&quot;,&quot;indicationShort&quot;:&quot;complicated urinary tract infection&quot;,&quot;genericName&quot;:&quot;LepB inhibitor&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Other&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;endometriosis&quot;,&quot;genericName&quot;:&quot;anti-IL-8 (AMY109)&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;sickle cell disease (SCD)&quot;,&quot;genericName&quot;:&quot;crovalimab&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;PiaSky&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Ophthalmology&quot;,&quot;phase&quot;:&quot;Phase 2&quot;,&quot;indicationShort&quot;:&quot;diabetic macular edema (DME)&quot;,&quot;genericName&quot;:&quot;vamikibart&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Neuroscience&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;Primary progressive multiple sclerosis (PPMS)&quot;,&quot;genericName&quot;:&quot;ocrelizumab&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;Ocrevus higher dose&quot;},{&quot;projectStatus&quot;:&quot;Removed&quot;,&quot;therapeuticArea&quot;:&quot;Oncology/Hematology&quot;,&quot;phase&quot;:&quot;Phase 3&quot;,&quot;indicationShort&quot;:&quot;high risk non-muscle-invasive bladder cancer (NMIBC, high-risk)&quot;,&quot;genericName&quot;:&quot;atezolizumab&quot;,&quot;comment&quot;:&quot;Removed Q3 2025&quot;,&quot;region&quot;:&quot;&quot;,&quot;name&quot;:&quot;Tecentriq plus BCG induction and maintenance&quot;}]\" dir=\"ltr\"></roche-pipeline-changes-table></div></div></div><div class=\"tabs__panel\" id=\"panel-a0ee39d1-4024-4867-943c-60eb804c7ff0\" role=\"tabpanel\" aria-labelledby=\"a0ee39d1-4024-4867-943c-60eb804c7ff0\" hidden=\"\" tabindex=\"0\"><div><roche-pipeline-diagnostics content=\"[{&quot;area&quot;:&quot;Tests planned for 2023&quot;,&quot;description&quot;:&quot;Neuropathology Immunohistochemistry (IHC) solution supporting the detection of tumor cells with the IDH1 R132H mutation aiding pathologists to render a diagnosis of gliomas&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;IDH1 R132H (IDH Glioma)&quot;},{&quot;area&quot;:&quot;Tests planned for 2023&quot;,&quot;description&quot;:&quot;Anti-HEV IgM: Immunoassay aiding in the diagnosis of acute HEV infection in clinical settings; Anti-HEV IgG: Immunoassay aiding in the detection of a recent or past HEV infection and enabling accurate seroprevalence determinations. The two assays expand the hepatitis panel (HAV, HBV, HCV, HEV) on the same analytical platform&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Anti-HEV IgG and Anti-HEV IgM&quot;},{&quot;area&quot;:&quot;Tests planned for 2023&quot;,&quot;description&quot;:&quot;Immunoassay aiding in diagnosis, monitoring and predicting treatment response for patients with hepatitis B viral infection&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;HBeAg Quant&quot;},{&quot;area&quot;:&quot;Tests planned for 2023&quot;,&quot;description&quot;:&quot;Only immunoassay available on the market with dedicated claim and supporting evidence aiding in diagnosis of sepsis in neonates, with potential to reduce newborn mortality&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;IL-6 Neonatal sepsis (claim extension)&quot;},{&quot;area&quot;:&quot;Tests planned for 2023&quot;,&quot;description&quot;:&quot;Two qualitative immunoassays measuring the phosphorylated Tau 181 protein and apolipoprotein E4 in human plasma for research use only&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;RUO Amyloid Plasma Assays (pTau181 &amp; ApoE4)&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2023&quot;,&quot;description&quot;:&quot;Digital pathology algorithm aiding pathologists in scoring PD-L1 (SP142) breast samples, ensuring a standardized approach and an adjunctive tool to augment diagnostic confidence for research use only&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;RUO Digital Pathology Algorithm: PD-L1 SP142&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2023&quot;,&quot;description&quot;:&quot;Digital solution providing access to an open library of certified IVD-based clinical algorithms&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;navify Algorithm Suite&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2023&quot;,&quot;description&quot;:&quot;Certified clinical algorithms for oncology applications such as colon and liver cancers&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;Menu for navify Algorithm Suite&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2023&quot;,&quot;description&quot;:&quot;Next-generation lab middleware enabling ecosystem of cloud-based solutions for quality control and instrument maintenance&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;cobas infinity lab 3.05&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2023&quot;,&quot;description&quot;:&quot;Digital marketplace offering lab customers full range of innovative applications (from Roche and third parties)&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;navify Marketplace&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2023&quot;,&quot;description&quot;:&quot;Open digital solution offering sample tracking beyond the lab setting (from IVD-sample creation to lab reception) to improve testing traceability and quality&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;navify Sample Tracking&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with enhanced software capabilities, workflow and testing efficiency&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;BenchMark ULTRA PLUS&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;High capacity pathology slide scanner for high volume digitization applications&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;DP600&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Serum work area analyzer for low-to-medium sized labs&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae pure integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Real-time PCR molecular testing for low volume labs&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae 5800&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Novel digital PCR platform for lab developed tests (LDTs) and in-vitro diagnostics labs&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;Digital LightCycler&quot;},{&quot;area&quot;:&quot;Instruments planned for 2022&quot;,&quot;description&quot;:&quot;Handheld device combining professional Glucose Meter and a digital platform to host Roche owned and 3rd party digital clinical decision support applications&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;POC&quot;,&quot;productName&quot;:&quot;cobas\u00ae pulse&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Assay for diagnosis of HER2 low expression breast cancer&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;HER2 Low Breast&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;First immunohistochemistry assay for differential diagnosis of benign from malignant melanocytic lesions in skin cancer&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;PRAME&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Self sample collection device for patients at home to collect sample for cervical cancer testing&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;HPV Self Sampling&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Antigen/antibody combined assay for faster diagnosis of hepatitis C&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae HCV Duo&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Detect amyloid disease and enable a broader availability of testing for patients suspected of Alzheimer\u2019s Disease&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys pTau/AB42 ratio Gen2 (CSF)&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Automated RT-PCR assay for use on the cobas\u00ae 6800/8800 systems&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; OUS&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae SARS-CoV-2 DUO&quot;},{&quot;area&quot;:&quot;Tests planned for 2022&quot;,&quot;description&quot;:&quot;Assays to test for SARS-CoV-2, chlamydia trachomatis (CT)/neisseria gonorrhoeae (NG) and cytomegalovirus (CMV)&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae 5800 Menu Expansion&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Digital solution (mobile app and dashboard) providing insights for chronic kidney disease patient management&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;Chronic Kidney Disease InSight&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Digital solution (mobile app and workflow) improving the management of screening programs for cervical cancer&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;Cervical Cancer Screening&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Portfolio of digital products to support decentralization of testing and data, to launch commercially with an open ecosystem&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;cobas\u00ae infinity edge suite&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Data integration platform for laboratory customers across disciplines&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Lab Insights&quot;,&quot;productName&quot;:&quot;Lab Insights Platform&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Diabetic population dashboard for healthcare professional administrators and payers&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;OUS3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Payer Dashboard&quot;},{&quot;area&quot;:&quot;Digital solutions planned for 2022&quot;,&quot;description&quot;:&quot;Module providing basal rate data and expanded smartphone compatibility for all Android and iPhone users&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;OUS3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;mySugar Pump V2.0&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Low-to-medium volume SWA&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae pure integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;New high throughput configurations of the cobas pro instrument&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae pro integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Successor of Accu-Chek\u00ae Inform II&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Point of Care&quot;,&quot;productName&quot;:&quot;cobas\u00ae pulse&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Fully automated low throughput PCR system&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas\u00ae 5800&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;Automated sequencing library preparation and target enrichment instrument&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;AVENIO Edge System&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2021&quot;,&quot;description&quot;:&quot;New features for the Instant meter to increase performance and user experience&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Accu-Chek Instant Forward&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2023&quot;,&quot;description&quot;:&quot;Modular transportation system, integrated into the existing cobas connection modules, allowing for overhead sample transportation over different work areas or different floors enabling effective use of lab space&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;CCM Vertical&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2023&quot;,&quot;description&quot;:&quot;Scalable and modular serum work area analyzer for mid to high volume clinical chemistry and immunochemistry testing&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;China&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas pro integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2023&quot;,&quot;description&quot;:&quot;Serum work area analyzer for low to mid volume clinical chemistry and immunochemistry testing on a footprint of two square meter&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;China&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas pure integrated solutions&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2023&quot;,&quot;description&quot;:&quot;Flexible real-time PCR instrument with dual IVD and research mode as well as enhanced system features&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE3&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;LightCycler Pro&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2023&quot;,&quot;description&quot;:&quot;Handheld device combining professional glucose meter and a digital platform to host digital clinical decision support applications (from Roche and third parties&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;POC&quot;,&quot;productName&quot;:&quot;cobas pulse&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;Automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae SARS-CoV-2 Antigen&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;A set of 5 intended use extensions in the Coronary Arterial Disease, Atrial Fibrillation and Heart Failure Space&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae NT-proBNP IU&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;A set of 5 intended use extensions in the Coronary Arterial Disease, Atrial Fibrillation and Heart Failure Space&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae TnT\u2013hs 3 claim extensions in Coronary Arterial Disease&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;Decentralized kit of the FoundationOne test&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;AVENIO FoundationOne kit (RUO)&quot;},{&quot;area&quot;:&quot;Tests planned for 2021&quot;,&quot;description&quot;:&quot;New targeted sequencing portfolio using primer extension for small targets&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;KAPA HyperPETE kit&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;First IVD release and version of Open API of the clinical pathologist workflow module for NAVIFY Digital Pathology &amp; on-premise uPath&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;uPath 2.0&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Whole slide image analysis algorithms (ER (SP1), Ki-67 (30-9), and PR (1E2))&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;RUO Algorithms&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Modular Oncology decision support solution&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Insights&quot;,&quot;productName&quot;:&quot;NAVIFY Oncology 1.0&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Solution for providers to communicate SARS-CoV-2 rapid antigen test results to a mobile app&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; CE3&quot;,&quot;title&quot;:&quot;Insights&quot;,&quot;productName&quot;:&quot;NAVIFY Pass 1.0&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Algorithm for early detection of HCC in patients with chronic liver disease&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae GAAD Algorithm&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Module within RDCP that enables remote Health Care Professional - Patient with Diabetes interaction, including a patient dashboard, check-in and chat functionality&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Remote Patient Monitoring&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2021&quot;,&quot;description&quot;:&quot;Meter-free blood glucose testing using a smartphone and app&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;OUS3&quot;,&quot;title&quot;:&quot;Diabetes Care&quot;,&quot;productName&quot;:&quot;Accu-Chek SugarView&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2024&quot;,&quot;description&quot;:&quot;Launch of an unique total solution for clinical mass spectrometry testing: fully automated, integrated and IVD-compliant&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;i601 mass spectrometry system&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2024&quot;,&quot;description&quot;:&quot;Introducing high-throughput clinical chemistry testing to cobas pro integrated solutions&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas c703&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2024&quot;,&quot;description&quot;:&quot;Introducing high-throughput ISE testing to cobas pro integrated solutions&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas ISE neo&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2024&quot;,&quot;description&quot;:&quot;Launch of Roche\u2019s first generation Continuous Glucose Monitoring (CGM) solution&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Near Patient Care&quot;,&quot;productName&quot;:&quot;Accu-Chek SmartGuide (Continuous Glucose Monitoring)&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2024&quot;,&quot;description&quot;:&quot;Upgraded system with increased flexibility, higher throughput and greater automation to enable broader test menu. Retrofittable with existing cobas 6800/8800 installed base&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas 6800/8800 v2.0&quot;},{&quot;area&quot;:&quot;Instruments/devices planned for 2024&quot;,&quot;description&quot;:&quot;FDA 510k Primary Diagnosis clearance on DP600 scanner as a critical step to advance Digital Pathology&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;Primary Diagnosis Claim on DP600 US&quot;},{&quot;area&quot;:&quot;Tests planned for 2024&quot;,&quot;description&quot;:&quot;FDA approval of our serology Roche Blood Safety Solution (RBSS) for the US donor screening market (largest donor screening market globally)&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;cobas pro serology solution (blood screening)&quot;},{&quot;area&quot;:&quot;Tests planned for 2024&quot;,&quot;description&quot;:&quot;Detection and differentiation of four respiratory targets:&nbsp; SARS-CoV-2, Influenza A, Influenza B &amp;&nbsp; respiratory syncytial virus&nbsp; (RSV)&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;US &amp; EUA&quot;,&quot;title&quot;:&quot;Near Patient Care&quot;,&quot;productName&quot;:&quot;cobas Liat Respiratory Panel\\r\\n(SARS-CoV-2, Flu A/B &amp; RSV&quot;},{&quot;area&quot;:&quot;Tests planned for 2024&quot;,&quot;description&quot;:&quot;Using novel Temperature Assisted Generation of Signal (TAGS\u00ae) Multiplex technology &amp; digital reflex approach, enables strategic efficiency with flexible testing for cobas x800 Systems&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE &amp; US&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas Respiratory flex&quot;},{&quot;area&quot;:&quot;Tests planned for 2024&quot;,&quot;description&quot;:&quot;RT qualitative PCR test on the cobas\u00ae x800 systems detecting all five plasmodium species that occur in humans. Utilized for malaria screening of&nbsp; blood donors, blood products, organs, and tissues&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE &amp; US&quot;,&quot;title&quot;:&quot;Molecular Lab&quot;,&quot;productName&quot;:&quot;cobas Malaria (blood screening)&quot;},{&quot;area&quot;:&quot;Tests planned for 2024&quot;,&quot;description&quot;:&quot;Aid in diagnosis of B-cell lymphomas and plasma cell neoplasms&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;CE &amp; US&quot;,&quot;title&quot;:&quot;Pathology Lab&quot;,&quot;productName&quot;:&quot;VENTANA Kappa Lambda Dual ISH mRNA Probe Cocktail&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2024&quot;,&quot;description&quot;:&quot;Supports lab directors/managers to track, review, identify trends/challenges and optimize operations. Has four apps tailored to Core, Pathology, Molecular Labs and Point of Care&quot;,&quot;color&quot;:&quot;Brown&quot;,&quot;market&quot;:&quot;WW&quot;,&quot;title&quot;:&quot;Diagnostics Insights&quot;,&quot;productName&quot;:&quot;navify Analytics family&quot;},{&quot;area&quot;:&quot;Tests planned for 2025&quot;,&quot;comment&quot;:&quot;CE mark July 2025&quot;,&quot;description&quot;:&quot;Non-invasive blood-based biomarker to enable earlier detection and rule out amyloid pathology&quot;,&quot;color&quot;:&quot;&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae pTau181&quot;},{&quot;area&quot;:&quot;Tests planned for 2025&quot;,&quot;comment&quot;:&quot;CE mark September 30th&quot;,&quot;description&quot;:&quot;High-sensitive test with greater precision at lower measurement ranges, enabling HCPs to confidently diagnose acute myocardial infarction&quot;,&quot;color&quot;:&quot;&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae high-sensitivity Troponin-T Generation 6&quot;},{&quot;area&quot;:&quot;Tests planned for 2025&quot;,&quot;comment&quot;:&quot;Launch May 6th/ approval April 2025&quot;,&quot;description&quot;:&quot;Solution to identify the severity of liver fibrosis in patients with MASLD/MASH&quot;,&quot;color&quot;:&quot;&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae Pro-C3 ADAPT&quot;},{&quot;area&quot;:&quot;Tests planned for 2025&quot;,&quot;comment&quot;:&quot;Regulatory approval in China in May 2025&quot;,&quot;description&quot;:&quot;Tests to identify individuals with advanced atrophic gastritis who are at increased risk for gastric cancer&quot;,&quot;color&quot;:&quot;&quot;,&quot;market&quot;:&quot;CN&quot;,&quot;title&quot;:&quot;Core Lab&quot;,&quot;productName&quot;:&quot;Elecsys\u00ae Pepsinogen 1 and 2&quot;},{&quot;area&quot;:&quot;Tests planned for 2025&quot;,&quot;description&quot;:&quot;Rapid test for the differential diagnosis of Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG)&quot;,&quot;color&quot;:&quot;&quot;,&quot;market&quot;:&quot;US&quot;,&quot;title&quot;:&quot;Near Patient Care&quot;,&quot;productName&quot;:&quot;cobas\u00ae liat CT/NG&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2025&quot;,&quot;description&quot;:&quot;Algorithm to triage chest pain patients in the emergency department&quot;,&quot;color&quot;:&quot;&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Healthcare Insights&quot;,&quot;productName&quot;:&quot;Chest Pain Triage algorithm&quot;},{&quot;area&quot;:&quot;Digital Solutions planned for 2025&quot;,&quot;comment&quot;:&quot;CE Mark Oct. 6th&quot;,&quot;description&quot;:&quot;Algorithm to assess the likelihood of reaching end-stage renal disease&quot;,&quot;color&quot;:&quot;&quot;,&quot;market&quot;:&quot;CE&quot;,&quot;title&quot;:&quot;Healthcare Insights&quot;,&quot;productName&quot;:&quot;Kidney Klinrisk algorithm&quot;}]\" is-mobile=\"false\"><div class=\"pipeline-table\"><roche-table-sort-header appearance=\"diagnostics\"><div class=\"table__header\"><div class=\"table__headline\"><span class=\"table__headline--sortable__item\">area</span></div><div class=\"table__headline\"><span class=\"table__headline--sortable__item\">product name</span></div><div class=\"table__headline\"><span class=\"table__headline--sortable__item\">description</span></div><div class=\"table__headline\"><span class=\"table__headline--sortable__item\">market</span></div></div></roche-table-sort-header><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Digital Solutions planned for 2021</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae GAAD Algorithm\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Diabetes Care\" product-name=\"Accu-Chek SugarView\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Diabetes Care\" product-name=\"Remote Patient Monitoring\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Insights\" product-name=\"NAVIFY Pass 1.0\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Insights\" product-name=\"NAVIFY Oncology 1.0\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"RUO Algorithms\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"uPath 2.0\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Digital solutions planned for 2022</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Diabetes Care\" product-name=\"mySugar Pump V2.0\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Diabetes Care\" product-name=\"Payer Dashboard\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Lab Insights\" product-name=\"Lab Insights Platform\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Lab Insights\" product-name=\"cobas\u00ae infinity edge suite\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Lab Insights\" product-name=\"Cervical Cancer Screening\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Lab Insights\" product-name=\"Chronic Kidney Disease InSight\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Digital Solutions planned for 2023</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Lab Insights\" product-name=\"navify Sample Tracking\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Lab Insights\" product-name=\"navify Marketplace\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Lab Insights\" product-name=\"cobas infinity lab 3.05\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"Menu for navify Algorithm Suite\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"navify Algorithm Suite\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"RUO Digital Pathology Algorithm: PD-L1 SP142\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Digital Solutions planned for 2024</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Diagnostics Insights\" product-name=\"navify Analytics family\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Digital Solutions planned for 2025</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Healthcare Insights\" product-name=\"Kidney Klinrisk algorithm\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Healthcare Insights\" product-name=\"Chest Pain Triage algorithm\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Instruments planned for 2022</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas\u00ae pure integrated solutions\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"Digital LightCycler\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"cobas\u00ae 5800\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"DP600\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"BenchMark ULTRA PLUS\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"POC\" product-name=\"cobas\u00ae pulse\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Instruments/devices planned for 2021</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas\u00ae pro integrated solutions\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas\u00ae pure integrated solutions\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Diabetes Care\" product-name=\"Accu-Chek Instant Forward\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"AVENIO Edge System\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"cobas\u00ae 5800\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Point of Care\" product-name=\"cobas\u00ae pulse\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Instruments/devices planned for 2023</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas pure integrated solutions\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas pro integrated solutions\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"CCM Vertical\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"LightCycler Pro\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"POC\" product-name=\"cobas pulse\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Instruments/devices planned for 2024</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas ISE neo\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas c703\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"i601 mass spectrometry system\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"cobas 6800/8800 v2.0\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Near Patient Care\" product-name=\"Accu-Chek SmartGuide (Continuous Glucose Monitoring)\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"Primary Diagnosis Claim on DP600 US\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Tests planned for 2021</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae TnT\u2013hs 3 claim extensions in Coronary Arterial Disease\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae NT-proBNP IU\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae SARS-CoV-2 Antigen\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"KAPA HyperPETE kit\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"AVENIO FoundationOne kit (RUO)\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Tests planned for 2022</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys pTau/AB42 ratio Gen2 (CSF)\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas\u00ae HCV Duo\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"cobas\u00ae 5800 Menu Expansion\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"cobas\u00ae SARS-CoV-2 DUO\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"HPV Self Sampling\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"PRAME\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"HER2 Low Breast\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Tests planned for 2023</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"RUO Amyloid Plasma Assays (pTau181 &amp; ApoE4)\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"IL-6 Neonatal sepsis (claim extension)\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"HBeAg Quant\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Anti-HEV IgG and Anti-HEV IgM\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"IDH1 R132H (IDH Glioma)\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Tests planned for 2024</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"cobas pro serology solution (blood screening)\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"cobas Malaria (blood screening)\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Molecular Lab\" product-name=\"cobas Respiratory flex\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Near Patient Care\" product-name=\"cobas Liat Respiratory Panel\r\n(SARS-CoV-2, Flu A/B &amp; RSV\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Pathology Lab\" product-name=\"VENTANA Kappa Lambda Dual ISH mRNA Probe Cocktail\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-headline appearance=\"pipeline\" level=\"6\" dir=\"ltr\"><!----><h6>Tests planned for 2025</h6></roche-headline><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae Pepsinogen 1 and 2\" is-title-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae Pro-C3 ADAPT\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae high-sensitivity Troponin-T Generation 6\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Core Lab\" product-name=\"Elecsys\u00ae pTau181\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row><roche-pipeline-diagnostics-row class=\"table__row\" diagnostic-title=\"Near Patient Care\" product-name=\"cobas\u00ae liat CT/NG\" is-title-visible=\"\" is-border-visible=\"\" dir=\"ltr\"></roche-pipeline-diagnostics-row></div><roche-pipeline-caption caption-string=\"[{&quot;abbreviation&quot;:&quot;CE - &quot;,&quot;description&quot;:&quot;European Conformity;&quot;},{&quot;abbreviation&quot;:&quot;US - &quot;,&quot;description&quot;:&quot;FDA Approval;&quot;},{&quot;abbreviation&quot;:&quot;WW - &quot;,&quot;description&quot;:&quot;Worldwide including CE, US and China;&quot;},{&quot;sup&quot;:&quot;1 &quot;,&quot;abbreviation&quot;:&quot;OUS - &quot;,&quot;description&quot;:&quot;Outside the US; PCR:  Polymerase Chain Reaction; RT: Real Time;&quot;},{&quot;sup&quot;:&quot;2 &quot;,&quot;abbreviation&quot;:&quot;EUA - &quot;,&quot;description&quot;:&quot;Emergency Use Authorization;&quot;},{&quot;sup&quot;:&quot;3 &quot;,&quot;description&quot;:&quot;Only selected countries&quot;}]\" dir=\"ltr\"></roche-pipeline-caption></roche-pipeline-diagnostics></div></div></div></div></div></div></div><div class=\"grid grid--equal-columns\"><div class=\"container container--colored\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-6 is-offset-0\"><h2 slot=\"left\" class=\"headline headline--2\">Downloads</h2></div><div class=\"grid__column column is-6 is-offset-0\"><div slot=\"right\" class=\"teaser\"><a target=\"_self\" href=\"https://assets.roche.com/f/176343/x/69dee621d8/pharmaq325.pdf\" aria-label=\"Download Roche Group Pharmaceuticals pipeline\" class=\"teaser__link-wrapper\"><h3 class=\"teaser__heading\"><span class=\"teaser__title teaser__title--small\">Roche Group Pharmaceuticals pipeline<span class=\"teaser__icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"1.5rem\" class=\"icon\" aria-hidden=\"true\"><path d=\"M19 9h-4V3H9v6H5l7 7 7-7zm-8 2V5h2v6h1.2L12 13.2 9.8 11H11zm-6 7h14v2H5v-2z\"></path></svg></span></span></span></h3><p class=\"teaser__description\">PDF</p><div class=\"teaser__border\"></div></a></div><div slot=\"right\" class=\"teaser\"><a target=\"_self\" href=\"https://assets.roche.com/f/176343/x/75547970e6/diaq325.pdf\" aria-label=\"Download Roche Group Diagnostics pipeline\" class=\"teaser__link-wrapper\"><h3 class=\"teaser__heading\"><span class=\"teaser__title teaser__title--small\">Roche Group Diagnostics pipeline<span class=\"teaser__icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"1.5rem\" class=\"icon\" aria-hidden=\"true\"><path d=\"M19 9h-4V3H9v6H5l7 7 7-7zm-8 2V5h2v6h1.2L12 13.2 9.8 11H11zm-6 7h14v2H5v-2z\"></path></svg></span></span></span></h3><p class=\"teaser__description\">PDF</p><div class=\"teaser__border\"></div></a></div></div></div></div></div><div class=\"grid grid--equal-columns\"><div class=\"container container--colored container--theme-aware\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-12 is-offset-0\"><div class=\"side-by-side side-by-side--top\"><h2 class=\"headline headline--2\">Discover more</h2></div><roche-teaser-wall can-load-more=\"false\" is-fetching=\"true\" slot=\"full\"><div slot=\"teasers\" class=\"teaser\" style=\"margin-top: 0px;\"><a target=\"_self\" href=\"/innovation/process/clinical-trials/\" aria-label=\"Clinical trials\" class=\"teaser__link-wrapper\"><h3 class=\"teaser__heading\"><span class=\"teaser__title\">Clinical trials<span class=\"teaser__icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"1.5rem\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></span><span class=\"teaser__overline\">Innovation</span></h3><p class=\"teaser__description\">Clinical trials are essential to determine whether new drugs or diagnostics are safe and effective when used to diagnose or treat people. </p><div class=\"teaser__border\"></div></a></div><div slot=\"teasers\" class=\"teaser\" style=\"margin-top: 0px;\"><a target=\"_self\" href=\"/innovation/partnering/\" aria-label=\"Partnering\" class=\"teaser__link-wrapper\"><h3 class=\"teaser__heading\"><span class=\"teaser__title\">Partnering<span class=\"teaser__icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"1.5rem\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></span><span class=\"teaser__overline\">Innovation</span></h3><p class=\"teaser__description\">At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients.</p><div class=\"teaser__border\"></div></a></div><div slot=\"teasers\" class=\"teaser\" style=\"margin-top: 0px;\"><a target=\"_self\" href=\"/investors/reports/\" aria-label=\"Reporting\" class=\"teaser__link-wrapper\"><h3 class=\"teaser__heading\"><span class=\"teaser__title\">Reporting<span class=\"teaser__icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"1.5rem\" class=\"icon\" aria-hidden=\"true\"><path d=\"M2.6 13h14.6l-5.3 5.3 1.4 1.4L21 12l-7.7-7.7-1.4 1.4 5.3 5.3H2.6v2z\"></path></svg></span></span></span><span class=\"teaser__overline\">Investors</span></h3><p class=\"teaser__description\">Access Roche's financial and non-financial reports for the latest updates on Roche's performance. </p><div class=\"teaser__border\"></div></a></div><div slot=\"teasers\" class=\"teaser\" style=\"margin-top: 0px;\"><a target=\"_blank\" href=\"https://www.gene.com/medical-professionals/pipeline\" aria-label=\"Genentech Pipeline\" class=\"teaser__link-wrapper\"><h3 class=\"teaser__heading\"><span class=\"teaser__title\">Genentech Pipeline<span class=\"teaser__icon\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"1.5rem\" class=\"icon\" aria-hidden=\"true\"><path d=\"M10 6v2H5v11h11v-5h2v6a1 1 0 01-1 1H4a1 1 0 01-1-1V7a1 1 0 011-1h6zm11-3v8h-2V6.4l-7.8 7.8-1.4-1.4L17.6 5H13V3h8z\"></path></svg></span></span></span></h3><p class=\"teaser__description\">Our R&amp;D activities are focused on applying excellent science to discover and develop potential new medicines with the goal of becoming first-in-class or best-in-class therapeutics.</p><div class=\"teaser__border\"></div></a></div></roche-teaser-wall></div></div></div></div></main><footer class=\"footer footer--with-extra-columns\"><div class=\"grid grid--no-padding grid--equal-columns\"><div class=\"container\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-12 is-offset-0\"><div class=\"footer__first-row\" slot=\"full\"><div class=\"grid\"><div class=\"container container--full-width\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-3 is-offset-0\"><nav class=\"footer__quick-links-nav\" aria-label=\"quick links\" slot=\"left\"><ul class=\"footer__quick-links\"><li><span class=\"text-link text-link--footer-quick\"><a class=\"text-link__link\" href=\"/contact\" target=\"_self\"><span class=\"text-link__text\">Contact</span><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M15.7 12l-6-6-1.4 1.4 4.6 4.6-4.6 4.6L9.7 18l6-6z\"></path></svg></span></span></a></span></li><li><span class=\"text-link text-link--footer-quick\"><a class=\"text-link__link\" href=\"/locations\" target=\"_self\"><span class=\"text-link__text\">Locations</span><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M15.7 12l-6-6-1.4 1.4 4.6 4.6-4.6 4.6L9.7 18l6-6z\"></path></svg></span></span></a></span></li></ul></nav></div><div class=\"grid__column column is-1 is-offset-0\"><div slot=\"center\"></div></div><div class=\"grid__column column is-8 is-offset-0\"><div class=\"footer__columns-container\" slot=\"right\"><div class=\"grid grid--equal-columns\"><div class=\"container container--full-width\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-4 is-offset-0\"><nav aria-labelledby=\"helpful-links\" slot=\"left\"><h3 class=\"footer__column-title\" id=\"helpful-links\">Helpful links</h3><ul><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"/solutions/pharma\" target=\"_self\"><span class=\"text-link__text\">Pharma solutions</span></a></span></li><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"/investors/events\" target=\"_self\"><span class=\"text-link__text\">Upcoming events</span></a></span></li><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"/investors/annualreport24\" target=\"_self\"><span class=\"text-link__text\">Annual Report 2024</span></a></span></li><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"/contact\" target=\"_self\"><span class=\"text-link__text\">Report a potential side effect</span></a></span></li></ul></nav></div><div class=\"grid__column column is-4 is-offset-0\"><nav aria-labelledby=\"roche-websites\" slot=\"center\"><h3 class=\"footer__column-title\" id=\"roche-websites\">Roche websites</h3><ul><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"https://diagnostics.roche.com\" target=\"_self\"><span class=\"text-link__text\">Diagnostics portal</span></a></span></li><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"https://suppliers.roche.com\" target=\"_self\"><span class=\"text-link__text\">Suppliers information</span></a></span></li><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"/our-websites\" target=\"_self\"><span class=\"text-link__text\">Roche around the world</span></a></span></li><li><span class=\"text-link text-link--footer-column\"><a class=\"text-link__link\" href=\"https://forpatients.roche.com/\" target=\"_self\"><span class=\"text-link__text\">Patients and clinical trials platform</span></a></span></li></ul></nav></div><div class=\"grid__column column is-4 is-offset-0\"><div class=\"footer__stock-price\" slot=\"right\"><div><a class=\"stock-price\" href=\"/investors/bonds\"><h3 class=\"stock-price__heading\">Share price</h3><div class=\"stock-price__price\"><span class=\"stock-price__value\">268.40</span><span class=\"stock-price__currency\">CHF</span></div><div class=\"stock-price__daily-change\"><span class=\"stock-price__icon stock-price__icon--up\" aria-hidden=\"true\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 32 32\" height=\"32px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M26 10h-4.5V8h8v8h-2v-4.6l-10.3 9.3-.7.7-.7-.7-5.3-5.3-7.8 7.3-1.4-1.4 8.5-8 .7-.7.7.7 5.3 5.3L26 10Z\" clip-rule=\"evenodd\"></path></svg></span></span><span class=\"stock-price__difference\"><span class=\"stock-price__price-difference\">+ 3.20</span><span class=\"stock-price__relative-difference\">(+1.21%)</span></span><span>Today</span></div></a></div></div></div></div></div></div></div></div></div></div></div></div><div class=\"footer__second-row\" slot=\"full\"><div class=\"grid\"><div class=\"container container--full-width\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-4 is-offset-0\"><nav class=\"footer__social-links-nav\" aria-label=\"Social links\" slot=\"left\"><ul class=\"footer__social-links\"><li><span class=\"text-link text-link--footer-social\"><a class=\"text-link__link\" href=\"https://www.linkedin.com/company/roche?trk=hb_tab_compy_id_1602\" target=\"_blank\" aria-label=\"LinkedIn\"><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M19.3 4H4.7c-.4 0-.7.3-.7.7v14.7c0 .3.3.6.7.6h14.7c.4 0 .7-.3.7-.7V4.7c-.1-.4-.4-.7-.8-.7zM8.7 17.6H6.4V10h2.4v7.6h-.1zM7.6 9c-.8 0-1.4-.7-1.4-1.4 0-.8.6-1.4 1.4-1.4.8 0 1.4.6 1.4 1.4-.1.7-.7 1.4-1.4 1.4zm10 8.6h-2.4v-3.7c0-.9 0-2-1.2-2s-1.4 1-1.4 2v3.8h-2.4V10h2.3v1c.3-.6 1.1-1.2 2.2-1.2 2.4 0 2.8 1.6 2.8 3.6v4.2h.1z\"></path></svg></span></span><span class=\"text-link__text\"> linkedin</span></a></span></li><li><span class=\"text-link text-link--footer-social\"><a class=\"text-link__link\" href=\"https://www.facebook.com/roche\" target=\"_blank\" aria-label=\"Facebook\"><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M10.02 20L10 13H7v-3h3V8c0-2.7 1.67-4 4.08-4 1.15 0 2.14.09 2.43.12v2.83h-1.67c-1.3 0-1.56.62-1.56 1.53V10H17l-1 3h-2.72v7h-3.26z\"></path></svg></span></span><span class=\"text-link__text\"> facebook</span></a></span></li><li><span class=\"text-link text-link--footer-social\"><a class=\"text-link__link\" href=\"https://twitter.com/roche\" target=\"_blank\" aria-label=\"X\"><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M17.1761 4H19.9362L13.9061 10.7774L21 20H15.4456L11.0951 14.4066L6.11723 20H3.35544L9.80517 12.7508L3 4H8.69545L12.6279 9.11262L17.1761 4ZM16.2073 18.3754H17.7368L7.86441 5.53928H6.2232L16.2073 18.3754Z\"></path></svg></span></span><span class=\"text-link__text\"> twitter</span></a></span></li><li><span class=\"text-link text-link--footer-social\"><a class=\"text-link__link\" href=\"https://www.instagram.com/roche/\" target=\"_blank\" aria-label=\"Instagram\"><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M12 5.44c2.14 0 2.39.01 3.23.05.51 0 1.01.1 1.49.27.35.13.66.34.92.6.26.26.47.58.6.92.17.48.27.98.27 1.49.04.84.05 1.1.05 3.23s0 2.4-.05 3.23c0 .51-.1 1.01-.27 1.49a2.64 2.64 0 01-1.52 1.52c-.48.17-.98.27-1.48.27-.85.04-1.1.05-3.24.05-2.13 0-2.39 0-3.23-.05-.5 0-1.01-.1-1.49-.27a2.47 2.47 0 01-.92-.6 2.47 2.47 0 01-.6-.92 4.42 4.42 0 01-.27-1.49c-.04-.84-.05-1.1-.05-3.23s.01-2.39.05-3.23c0-.51.1-1.01.27-1.49.13-.35.34-.66.6-.92.26-.26.58-.47.92-.6.48-.17.98-.27 1.49-.27.84-.04 1.1-.05 3.23-.05zM12 4c-2.17 0-2.45 0-3.3.05-.66.01-1.32.14-1.94.37a3.9 3.9 0 00-1.42.92c-.4.4-.72.89-.92 1.42a5.87 5.87 0 00-.37 1.94C4 9.56 4 9.83 4 12s0 2.45.05 3.3c.01.66.14 1.32.37 1.94.2.53.52 1.02.92 1.42.4.4.89.72 1.42.92.62.23 1.28.36 1.94.37.86.04 1.13.05 3.3.05s2.45 0 3.3-.05a5.87 5.87 0 001.94-.37 4.1 4.1 0 002.34-2.34c.24-.62.36-1.28.37-1.94.04-.86.05-1.13.05-3.3 0-2.18 0-2.45-.05-3.3a5.87 5.87 0 00-.37-1.94 3.9 3.9 0 00-.92-1.42 3.9 3.9 0 00-1.42-.92 5.87 5.87 0 00-1.94-.37C14.44 4 14.17 4 12 4zm0 3.9a4.1 4.1 0 100 8.2 4.1 4.1 0 000-8.2zm0 6.77a2.67 2.67 0 110-5.34 2.67 2.67 0 010 5.34zm5.23-6.94a.96.96 0 11-1.92 0 .96.96 0 011.92 0z\" clip-rule=\"evenodd\"></path></svg></span></span><span class=\"text-link__text\"> instagram</span></a></span></li><li><span class=\"text-link text-link--footer-social\"><a class=\"text-link__link\" href=\"https://www.youtube.com/roche\" target=\"_blank\" aria-label=\"YouTube\"><span class=\"text-link__icon-container\"><span class=\"icon-container\"><svg xmlns=\"http://www.w3.org/2000/svg\" viewBox=\"0 0 24 24\" height=\"24px\" class=\"icon\" aria-hidden=\"true\"><path d=\"M20.85 8.7s-.15-1.27-.75-1.8c-.68-.75-1.43-.75-1.8-.75C15.75 6 12 6 12 6s-3.75 0-6.3.15c-.38.07-1.13.07-1.8.75-.52.52-.75 1.8-.75 1.8S3 10.13 3 11.63v1.34a34 34 0 00.15 2.93s.15 1.28.75 1.8c.68.75 1.57.68 1.95.75 1.43.15 6.15.15 6.15.15s3.75 0 6.3-.23c.38-.07 1.13-.07 1.8-.75.52-.52.75-1.8.75-1.8S21 14.4 21 12.9v-1.35c0-1.43-.15-2.85-.15-2.85zm-10.73 5.93V9.6L15 12.15l-4.88 2.47z\"></path></svg></span></span><span class=\"text-link__text\"> youtube</span></a></span></li></ul></nav></div><div class=\"grid__column column is-8 is-offset-0\"><nav aria-label=\"Service links\" slot=\"right\"><ul class=\"footer__service-links\"><li><span class=\"text-link text-link--footer-service\"><a class=\"text-link__link\" href=\"/privacy-policy\" target=\"_self\"><span class=\"text-link__text\">Privacy notice</span></a></span></li><li><span class=\"text-link text-link--footer-service\"><a class=\"text-link__link\" href=\"/legal-statement\" target=\"_self\"><span class=\"text-link__text\">Legal statement</span></a></span></li><li><span class=\"text-link text-link--footer-service\"><a class=\"text-link__link\" href=\"/accessibility-statement\" target=\"_self\"><span class=\"text-link__text\">Accessibility statement</span></a></span></li><li><span class=\"text-link text-link--footer-service\"><button class=\"text-link__link\"><span class=\"text-link__text\">Cookies</span></button></span></li></ul></nav></div></div></div></div></div><div class=\"footer__third-row\" slot=\"full\"><div class=\"grid\"><div class=\"container container--full-width\"><div class=\"container__gradient-helper\"></div><div class=\"grid__columns columns is-centered is-variable is-0-mobile is-3-tablet is-4-desktop\"><div class=\"grid__column column is-4 is-offset-0\"><div class=\"footer__copyright\" slot=\"left\">\u00a9 <time>2025</time> &nbsp;F. Hoffmann-La Roche Ltd &nbsp;<time>11/7/2025</time></div></div><div class=\"grid__column column is-8 is-offset-0\"><div class=\"footer__legal-text\" slot=\"right\"><div dir=\"ltr\" class=\"rich-text rich-text--is-footer-type\"><div><p>This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.</p></div></div></div></div></div></div></div></div></div></div></div></div></footer></div></div><div id=\"gatsby-announcer\" aria-live=\"assertive\" aria-atomic=\"true\" style=\"position: absolute; top: 0px; width: 1px; height: 1px; padding: 0px; overflow: hidden; clip: rect(0px, 0px, 0px, 0px); white-space: nowrap; border: 0px;\"></div></div><script>\nwindow.dataLayer = window.dataLayer || [];\n\nfunction gtag() {\n    dataLayer.push(arguments);\n}\n</script><script>\n// Setup the initial data layers\nwindow.oneDataLayer = window.oneDataLayer || [];\nwindow.oneDataLayerComputed = window.oneDataLayerComputed || [];\n\n// Deep merge function to handle nested objects\nfunction deepMerge(target, source) {\n  Object.keys(source).forEach(key => {\n    if (source[key] && typeof source[key] === 'object' && source[key].constructor === Object) {\n      if (!target[key]) target[key] = {};\n      deepMerge(target[key], source[key]);\n    } else {\n      target[key] = source[key];\n    }\n  });\n  return target; // return the merged object\n}\n\n// Function to handle new data pushed to oneDataLayer\nfunction handleDataLayerPush(obj) {\n  // Start with a deep copy of the last item in oneDataLayerComputed, if it exists\n  var newState = {};\n  if (window.oneDataLayerComputed.length > 0) {\n    deepMerge(newState, window.oneDataLayerComputed[window.oneDataLayerComputed.length - 1]);\n  }\n  deepMerge(newState, obj);\n  window.oneDataLayerComputed.push(newState); // Push the newly merged state\n}\n\n// Override the push method of oneDataLayer to intercept data pushes\n(function() {\n  var originalPush = window.oneDataLayer.push;\n  window.oneDataLayer.push = function() {\n    for (var i = 0; i < arguments.length; i++) {\n      handleDataLayerPush(arguments[i]); // Handle the new data with deep merge\n      originalPush.call(window.oneDataLayer, arguments[i]); // Continue normal push operation\n    }\n  };\n})();\n\n// Function to initialize oneDataLayerComputed with existing data in oneDataLayer\nfunction initializeComputedDataLayer() {\n  window.oneDataLayer.forEach(data => {\n    handleDataLayerPush(data);\n  });\n}\n\n// Initialize oneDataLayerComputed after existing data has been loaded\ninitializeComputedDataLayer();\n</script><script>\n/******************************************* BEGIN CODE TO DEPLOY *******************************************/\n/* Adobe Consulting Plugin: apl (appendToList) v4.0 */\nfunction apl(lv,va,d1,d2,cc){var b=lv,d=va,e=d1,c=d2,g=cc;if(\"-v\"===b)return{plugin:\"apl\",version:\"4.0\"};var h=function(){if(\"undefined\"!==typeof window.s_c_il)for(var k=0,b;k<window.s_c_il.length;k++)if(b=window.s_c_il[k],b._c&&\"s_c\"===b._c)return b}();\"undefined\"!==typeof h&&(h.contextData.apl=\"4.0\");window.inList=window.inList||function(b,d,c,e){if(\"string\"!==typeof d)return!1;if(\"string\"===typeof b)b=b.split(c||\",\");else if(\"object\"!==typeof b)return!1;c=0;for(a=b.length;c<a;c++)if(1==e&&d===b[c]||d.toLowerCase()===b[c].toLowerCase())return!0;return!1};if(!b||\"string\"===typeof b){if(\"string\"!==typeof d||\"\"===d)return b;e=e||\",\";c=c||e;1==c&&(c=e,g||(g=1));2==c&&1!=g&&(c=e);d=d.split(\",\");h=d.length;for(var f=0;f<h;f++)window.inList(b,d[f],e,g)||(b=b?b+c+d[f]:d[f])}return b};\n/******************************************** END CODE TO DEPLOY ********************************************/\n\n</script><script>_satellite[\"_runScript1\"](function(event, target, Promise) {\nlet scroll25 = false;\nlet scroll50 = false;\nlet scroll75 = false;\nlet scroll100 = false;\n\nwindow.addEventListener('scroll', function() {\n    const scrollableHeight = document.documentElement.scrollHeight - window.innerHeight;\n    \n    const scrolled = (window.scrollY / scrollableHeight) * 100;\n\n    if (!scroll25 && scrolled >= 25) {\n        _satellite.track(\"25_percent_scrolled\");\n        scroll25 = true;\n    }\n\n    if (!scroll50 && scrolled >= 50) {\n        _satellite.track(\"50_percent_scrolled\");\n        scroll50 = true;\n    }\n\n    if (!scroll75 && scrolled >= 75) {\n        _satellite.track(\"75_percent_scrolled\");\n        scroll75 = true;\n    }\n\n    if (!scroll100 && scrolled >= 100) {\n        _satellite.track(\"100_percent_scrolled\");\n        scroll100 = true;\n    }\n});\n\n});</script><script type=\"text/plain\" id=\"content-square\" class=\"optanon-category-C0002\">(function (w, d) { piiObject={\n    PIISelectors: ['div.dropdown-container > select'], // DOM elements to be masked\n    };\n    w._uxa = w._uxa || [];\n    w._uxa.push(['setPIISelectors', piiObject]);\n    try {\n        if (typeof w.oneDataLayer !== 'undefined') {\n            // https://docs.contentsquare.com/en/web/sending-custom-vars/\n            w._uxa.push(['setCustomVariable', 1, 'Site Name', (w.oneDataLayer.find(e => e.event === 'defaultPageView')\n            || { page: { siteName: 'unknown'}}).page.siteName, 2]);\n        }\n    } catch(e){ console.warn('[CSQ] error setting custom vars!', e); }\n    if (typeof w.CS_CONF === 'undefined') {\n        w._uxa.push(['setPath', w.location.pathname+w.location.hash.replace('#','?__')]);\n        var mt = d.createElement('script'); mt.type = 'text/javascript'; mt.async = true;\n        mt.src = '//t.contentsquare.net/uxa/79ba3fbe68270.js';\n        d.getElementsByTagName('head')[0].appendChild(mt);\n    }\n    else {\n        w._uxa.push(['trackPageview', w.location.pathname+w.location.hash.replace('#','?__')]);\n    }\n    })(window, document);</script><script id=\"gatsby-script-loader\">window.pagePath=\"/solutions/pipeline\"</script><script id=\"gatsby-chunk-mapping\">window.___chunkMapping='{\"app\":[\"/app-e99c033018200821bbb6.js\"],\"component---src-pages-editor-tsx\":[\"/component---src-pages-editor-tsx-e0966222ec60c1d59d9c.js\"],\"component---src-pages-preview-login-wall-tsx\":[\"/component---src-pages-preview-login-wall-tsx-b5d9474ebf7dd420d67a.js\"],\"component---src-templates-default-tsx\":[\"/component---src-templates-default-tsx-fe474c8aadad1dba0266.js\"]}'</script><script>window.___webpackCompilationHash=\"b6d5eb9401a10b4afebb\"</script><script src=\"/webpack-runtime-1e4f2b5e5c2c342ef722.js\" async=\"\"></script><script src=\"/10e4eb51-bea9c9fcef60e5b4f9b9.js\" async=\"\"></script><script src=\"/e43edeba-715616f0cfcec3c14932.js\" async=\"\"></script><script src=\"/817fd6bd-3f7d52922491e0fdaf7e.js\" async=\"\"></script><script src=\"/app-e99c033018200821bbb6.js\" async=\"\"></script><script>_satellite[\"_runScript2\"](function(event, target, Promise) {\n_satellite.setVar(\"MultiSync defaultPageView\",\"true\"),_satellite.track(\"MultiSync Initial Page View\");\n});</script><script>_satellite[\"_runScript3\"](function(event, target, Promise) {\nadobe.optIn.deny(\"aa\",!0),adobe.optIn.deny(\"ecid\",!0),adobe.optIn.complete();\n});</script><div id=\"onetrust-consent-sdk\" data-nosnippet=\"true\"><div class=\"onetrust-pc-dark-filter ot-fade-in\" style=\"z-index:2147483645;\"></div><div id=\"onetrust-banner-sdk\" class=\"otFlat bottom vertical-align-content\" tabindex=\"0\" role=\"region\" aria-label=\"Cookie banner\" style=\"bottom: 0px;\"><div role=\"dialog\" aria-modal=\"true\" aria-label=\"Cookie banner\"><div class=\"ot-sdk-container\"><div class=\"ot-sdk-row\"><div id=\"onetrust-group-container\" class=\"ot-sdk-eight ot-sdk-columns\"><div class=\"banner_logo\"></div><div id=\"onetrust-policy\"><h2 id=\"onetrust-policy-title\">Cookie banner</h2><div id=\"onetrust-policy-text\">We would like to collect your personal information, some of which may be considered sensitive personal information, such as health data, through cookies and similar technologies in order to support our marketing efforts, personalize the site, and improve its performance. By clicking \u201cAccept All\u201d, you confirm that we have your consent to collect and process your personal information in accordance with our <a href=\"https://www.roche.com/us-privacy-policy\">Privacy Policy</a>, which may include online targeted and social media advertising. You can personalize your specific preferences by clicking \u201cYour Privacy Choices\u201d, or, by clicking \u201cReject All\u201d, you can reject all cookies except for Strictly Necessary Cookies. </div></div></div><div id=\"onetrust-button-group-parent\" class=\"ot-sdk-three ot-sdk-columns has-reject-all-button\"><div id=\"onetrust-button-group\"><button id=\"onetrust-pc-btn-handler\" aria-label=\"Your Privacy Choices, Opens the preference center dialog\" class=\"cookie-setting-link\">Your Privacy Choices</button> <button id=\"onetrust-reject-all-handler\">Reject All</button> <button id=\"onetrust-accept-btn-handler\">Accept All</button></div></div></div></div><!-- Close Button --><div id=\"onetrust-close-btn-container\"></div><!-- Close Button END--></div></div><div id=\"onetrust-pc-sdk\" class=\"otPcTab ot-hide ot-fade-in\" lang=\"en-US\" aria-label=\"Preference center\" role=\"region\"><div role=\"dialog\" aria-modal=\"true\" style=\"height: 100%;\" aria-label=\"Preference center\"><!-- pc header --><div class=\"ot-pc-header\" role=\"presentation\"><!-- Header logo --><div class=\"ot-pc-logo\" role=\"img\" aria-label=\"Company Logo\"><img alt=\"Company Logo\" src=\"https://cdn.cookielaw.org/logos/d83b6e8f-2787-46e5-b85f-ad52b3a0acb6/d724b17a-cb92-470d-bb53-4d0ed1294eb1/3542aaea-b7b2-408d-aa22-d683a0ca32fe/Roche_Logo_800px_Blue_RGB_Roche_Logo_RGB_(1).png\"></div><div class=\"ot-title-cntr\"><h2 id=\"ot-pc-title\" aria-hidden=\"false\">Preference center</h2><div class=\"ot-close-cntr\"></div></div></div><!-- content --><!-- Groups / Sub groups with cookies --><div id=\"ot-pc-content\" class=\"ot-pc-scrollbar ot-sdk-row\"><div class=\"ot-optout-signal ot-hide\"><div class=\"ot-optout-icon\"><svg xmlns=\"http://www.w3.org/2000/svg\" aria-hidden=\"true\"><path class=\"ot-floating-button__svg-fill\" d=\"M14.588 0l.445.328c1.807 1.303 3.961 2.533 6.461 3.688 2.015.93 4.576 1.746 7.682 2.446 0 14.178-4.73 24.133-14.19 29.864l-.398.236C4.863 30.87 0 20.837 0 6.462c3.107-.7 5.668-1.516 7.682-2.446 2.709-1.251 5.01-2.59 6.906-4.016zm5.87 13.88a.75.75 0 00-.974.159l-5.475 6.625-3.005-2.997-.077-.067a.75.75 0 00-.983 1.13l4.172 4.16 6.525-7.895.06-.083a.75.75 0 00-.16-.973z\" fill=\"#FFF\" fill-rule=\"evenodd\"></path></svg></div><span>The Global Privacy Signal that you have set in your devices browser has been recognized.</span></div><div class=\"ot-sdk-container ot-grps-cntr ot-sdk-column\"><div class=\"ot-sdk-four ot-sdk-columns ot-tab-list\" aria-label=\"Cookie Categories\"><h2 id=\"ot-pc-title-mobile\" aria-hidden=\"true\">Preference center</h2><ul class=\"ot-cat-grp\" role=\"tablist\" aria-orientation=\"vertical\"><li class=\"ot-abt-tab\" role=\"presentation\"><!-- About Privacy container --><div class=\"ot-active-menu category-menu-switch-handler\" role=\"tab\" tabindex=\"0\" aria-selected=\"true\" aria-controls=\"ot-tab-desc\"><h3 id=\"ot-pvcy-txt\">Your Privacy Choices</h3></div></li><li class=\"ot-cat-item ot-vs-config\" role=\"presentation\" data-optanongroupid=\"BG2130\"><div class=\"category-menu-switch-handler\" role=\"tab\" tabindex=\"-1\" aria-selected=\"false\" aria-controls=\"ot-desc-id-BG2130\"><h3 id=\"ot-header-id-BG2130\">Targeting &amp; Social Media Cookies</h3></div></li><li class=\"ot-cat-item ot-always-active-group ot-vs-config\" role=\"presentation\" data-optanongroupid=\"C0001\"><div class=\"category-menu-switch-handler\" role=\"tab\" tabindex=\"-1\" aria-selected=\"false\" aria-controls=\"ot-desc-id-C0001\"><h3 id=\"ot-header-id-C0001\">Strictly Necessary Cookies</h3></div></li><li class=\"ot-cat-item ot-vs-config\" role=\"presentation\" data-optanongroupid=\"C0003\"><div class=\"category-menu-switch-handler\" role=\"tab\" tabindex=\"-1\" aria-selected=\"false\" aria-controls=\"ot-desc-id-C0003\"><h3 id=\"ot-header-id-C0003\">Functional Cookies</h3></div></li><li class=\"ot-cat-item ot-vs-config\" role=\"presentation\" data-optanongroupid=\"C0002\"><div class=\"category-menu-switch-handler\" role=\"tab\" tabindex=\"-1\" aria-selected=\"false\" aria-controls=\"ot-desc-id-C0002\"><h3 id=\"ot-header-id-C0002\">Performance Cookies</h3></div></li></ul></div><div class=\"ot-tab-desc ot-sdk-eight ot-sdk-columns\"><div class=\"ot-desc-cntr\" id=\"ot-tab-desc\" tabindex=\"0\" role=\"tabpanel\" aria-labelledby=\"ot-pvcy-hdr\"><h4 id=\"ot-pvcy-hdr\">Your Privacy Choices</h4><p id=\"ot-pc-desc\" class=\"ot-grp-desc\"><p>\nThis website may use cookies as described in the categories on this page. By default, all cookie categories are \u2018off\u2019 except Strictly Necessary which is \u2018on\u2019. You may alter your cookie preferences for this website using the \u2018on/off\u2019 toggles and confirming your choices, or by using the buttons on the bottom of this page. Additional information about the company\u2019s privacy practices can be found here <a href=\"https://www.roche.com/us-privacy-policy\">Privacy Policy</a>.\n</p>\n<p>\nTo exercise other rights as may be allowed by state laws, please complete the form found here  <a href=\"https://docs.google.com/forms/d/e/1FAIpQLSc2sQpjdUdhjXRdj4qR1DvAifOMZqacJ5vlOIsqJiiga3xaAA/viewform\">Data Subject Request Form</a>.\n</p>\n            <br><a href=\"https://cookiepedia.co.uk/giving-consent-to-cookies\" class=\"privacy-notice-link\" rel=\"noopener\" target=\"_blank\" aria-label=\"More information about your privacy, opens in a new tab\"> </a></p></div><div class=\"ot-desc-cntr ot-hide\" role=\"tabpanel\" tabindex=\"0\" id=\"ot-desc-id-BG2130\"><div class=\"ot-grp-hdr1\"><h4 class=\"ot-cat-header\">Targeting &amp; Social Media Cookies</h4><div class=\"ot-tgl\"><input type=\"checkbox\" name=\"ot-group-id-BG2130\" id=\"ot-group-id-BG2130\" role=\"switch\" class=\"category-switch-handler\" data-optanongroupid=\"BG2130\" aria-labelledby=\"ot-header-id-BG2130\"> <label class=\"ot-switch\" for=\"ot-group-id-BG2130\"><span class=\"ot-switch-nob\"></span> <span class=\"ot-label-txt\">Targeting &amp; Social Media Cookies</span></label> </div><div class=\"ot-tgl-cntr\"></div></div><p class=\"ot-grp-desc ot-category-desc\">To personalize your specific preferences, use the toggle to turn the cookies \"on\" or \"off\".</p><div class=\"ot-subgrp-cntr\"><ul class=\"ot-subgrps\"><li class=\"ot-subgrp\" data-optanongroupid=\"C0004\"><h5>Targeting Cookies</h5><div class=\"ot-tgl-cntr ot-subgrp-tgl\"><div class=\"ot-tgl ot-hide-tgl\"><input type=\"checkbox\" name=\"switch\" id=\"ot-sub-group-id-C0004\" role=\"switch\" data-optanongroupid=\"C0004\" class=\"cookie-subgroup-handler\" aria-label=\"Targeting Cookies\" aria-hidden=\"true\"> <label class=\"ot-switch\" for=\"ot-sub-group-id-C0004\"><span class=\"ot-switch-nob\"></span> <span class=\"ot-label-txt\">Switch Label</span></label> <span class=\"ot-label-status\">label</span></div></div><p class=\"ot-subgrp-desc\">These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant advertisements on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.</p></li></ul></div><div class=\"ot-subgrp-cntr\"><ul class=\"ot-subgrps\"><li class=\"ot-subgrp\" data-optanongroupid=\"C0005\"><h5>Social Media Cookies</h5><div class=\"ot-tgl-cntr ot-subgrp-tgl\"><div class=\"ot-tgl ot-hide-tgl\"><input type=\"checkbox\" name=\"switch\" id=\"ot-sub-group-id-C0005\" role=\"switch\" data-optanongroupid=\"C0005\" class=\"cookie-subgroup-handler\" aria-label=\"Social Media Cookies\" aria-hidden=\"true\"> <label class=\"ot-switch\" for=\"ot-sub-group-id-C0005\"><span class=\"ot-switch-nob\"></span> <span class=\"ot-label-txt\">Switch Label</span></label> <span class=\"ot-label-status\">label</span></div></div><p class=\"ot-subgrp-desc\">These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks (such as Facebook, Twitter, LinkedIn). They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.</p></li></ul></div></div><div class=\"ot-desc-cntr ot-hide ot-always-active-group\" role=\"tabpanel\" tabindex=\"0\" id=\"ot-desc-id-C0001\"><div class=\"ot-grp-hdr1\"><h4 class=\"ot-cat-header\">Strictly Necessary Cookies</h4><div class=\"ot-tgl-cntr\"><div class=\"ot-always-active\">Always Active</div></div></div><p class=\"ot-grp-desc ot-category-desc\">These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you that amount to a request for services, such as setting your privacy preferences, logging in, or filling in forms. You can set your browser to block or alert you about these cookies, but blocking these cookies will prevent the site from working. These cookies do not store any personal information.</p></div><div class=\"ot-desc-cntr ot-hide\" role=\"tabpanel\" tabindex=\"0\" id=\"ot-desc-id-C0003\"><div class=\"ot-grp-hdr1\"><h4 class=\"ot-cat-header\">Functional Cookies</h4><div class=\"ot-tgl\"><input type=\"checkbox\" name=\"ot-group-id-C0003\" id=\"ot-group-id-C0003\" role=\"switch\" class=\"category-switch-handler\" data-optanongroupid=\"C0003\" aria-labelledby=\"ot-header-id-C0003\"> <label class=\"ot-switch\" for=\"ot-group-id-C0003\"><span class=\"ot-switch-nob\"></span> <span class=\"ot-label-txt\">Functional Cookies</span></label> </div><div class=\"ot-tgl-cntr\"></div></div><p class=\"ot-grp-desc ot-category-desc\">These cookies enable our websites to provide enhanced functionality and personalization. They may be set by us or by third party service providers whose services we have added to our pages. If you reject these cookies, then some or all of these services may not function properly.\n\n</p></div><div class=\"ot-desc-cntr ot-hide\" role=\"tabpanel\" tabindex=\"0\" id=\"ot-desc-id-C0002\"><div class=\"ot-grp-hdr1\"><h4 class=\"ot-cat-header\">Performance Cookies</h4><div class=\"ot-tgl\"><input type=\"checkbox\" name=\"ot-group-id-C0002\" id=\"ot-group-id-C0002\" role=\"switch\" class=\"category-switch-handler\" data-optanongroupid=\"C0002\" aria-labelledby=\"ot-header-id-C0002\"> <label class=\"ot-switch\" for=\"ot-group-id-C0002\"><span class=\"ot-switch-nob\"></span> <span class=\"ot-label-txt\">Performance Cookies</span></label> </div><div class=\"ot-tgl-cntr\"></div></div><p class=\"ot-grp-desc ot-category-desc\"> These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. We may collect your session ID, IP address, device identifiers, and your activity with the website. We may provide these cookies to third party service providers to help us run these analytics. If you block or opt out of these cookies, we will not know when you have visited our site, and will not be able to monitor its performance.\n<p>\nIf you are located in Europe, the personal data may be sent to a country (e.g. United States) that has not been deemed to provide an adequate level of data protection or appropriate safeguards. By accepting these cookies, you consent to the data processing for analytics purposes and to the transfer of your personal data to the United States each time you visit our site.\n</p> </p></div></div></div></div><!-- Vendors / Hosts --><section id=\"ot-pc-lst\" class=\"ot-hide ot-pc-scrollbar ot-enbl-chr\"><div class=\"ot-lst-cntr ot-pc-scrollbar\"><div id=\"ot-pc-hdr\"><div id=\"ot-lst-title\"><button class=\"ot-link-btn back-btn-handler\" aria-label=\"Back\"><svg id=\"ot-back-arw\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" x=\"0px\" y=\"0px\" viewBox=\"0 0 444.531 444.531\" xml:space=\"preserve\"><title>Back Button</title><g><path fill=\"#656565\" d=\"M213.13,222.409L351.88,83.653c7.05-7.043,10.567-15.657,10.567-25.841c0-10.183-3.518-18.793-10.567-25.835\n                  l-21.409-21.416C323.432,3.521,314.817,0,304.637,0s-18.791,3.521-25.841,10.561L92.649,196.425\n                  c-7.044,7.043-10.566,15.656-10.566,25.841s3.521,18.791,10.566,25.837l186.146,185.864c7.05,7.043,15.66,10.564,25.841,10.564\n                  s18.795-3.521,25.834-10.564l21.409-21.412c7.05-7.039,10.567-15.604,10.567-25.697c0-10.085-3.518-18.746-10.567-25.978\n                  L213.13,222.409z\"></path></g></svg></button><h3>Cookie List</h3></div><div class=\"ot-lst-subhdr\"><div id=\"ot-search-cntr\"><p role=\"status\" class=\"ot-scrn-rdr\"></p><input id=\"vendor-search-handler\" type=\"text\" name=\"vendor-search-handler\" placeholder=\"Search\u2026\" aria-label=\"Cookie list search\"> <svg xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" x=\"0px\" y=\"0px\" viewBox=\"0 -30 110 110\" aria-hidden=\"true\"><path fill=\"#2e3644\" d=\"M55.146,51.887L41.588,37.786c3.486-4.144,5.396-9.358,5.396-14.786c0-12.682-10.318-23-23-23s-23,10.318-23,23\n              s10.318,23,23,23c4.761,0,9.298-1.436,13.177-4.162l13.661,14.208c0.571,0.593,1.339,0.92,2.162,0.92\n              c0.779,0,1.518-0.297,2.079-0.837C56.255,54.982,56.293,53.08,55.146,51.887z M23.984,6c9.374,0,17,7.626,17,17s-7.626,17-17,17\n              s-17-7.626-17-17S14.61,6,23.984,6z\"></path></svg></div><div id=\"ot-fltr-cntr\"><button id=\"filter-btn-handler\" aria-label=\"Filter Cookie List\" aria-haspopup=\"true\"><svg role=\"presentation\" aria-hidden=\"true\" xmlns=\"http://www.w3.org/2000/svg\" xmlns:xlink=\"http://www.w3.org/1999/xlink\" x=\"0px\" y=\"0px\" viewBox=\"0 0 402.577 402.577\" xml:space=\"preserve\"><title>Filter Button</title><g><path fill=\"#2c3643\" d=\"M400.858,11.427c-3.241-7.421-8.85-11.132-16.854-11.136H18.564c-7.993,0-13.61,3.715-16.846,11.136\n                            c-3.234,7.801-1.903,14.467,3.999,19.985l140.757,140.753v138.755c0,4.955,1.809,9.232,5.424,12.854l73.085,73.083\n                            c3.429,3.614,7.71,5.428,12.851,5.428c2.282,0,4.66-0.479,7.135-1.43c7.426-3.238,11.14-8.851,11.14-16.845V172.166L396.861,31.413\n                            C402.765,25.895,404.093,19.231,400.858,11.427z\"></path></g></svg></button></div></div></div><section id=\"ot-lst-cnt\" class=\"ot-pc-scrollbar\"><div class=\"ot-sdk-row\"><div class=\"ot-sdk-column\"><div id=\"ot-sel-blk\"><div class=\"ot-sel-all\"><div class=\"ot-sel-all-hdr\"><span class=\"ot-consent-hdr\">Consent</span> <span class=\"ot-li-hdr\">Leg.Interest</span></div><div class=\"ot-sel-all-chkbox\"><div class=\"ot-chkbox\" id=\"ot-selall-hostcntr\"><input id=\"select-all-hosts-groups-handler\" type=\"checkbox\"> <label for=\"select-all-hosts-groups-handler\"><span class=\"ot-label-txt\">checkbox label</span></label> <span class=\"ot-label-status\">label</span></div><div class=\"ot-chkbox\" id=\"ot-selall-vencntr\"><input id=\"select-all-vendor-groups-handler\" type=\"checkbox\"> <label for=\"select-all-vendor-groups-handler\"><span class=\"ot-label-txt\">checkbox label</span></label> <span class=\"ot-label-status\">label</span></div><div class=\"ot-chkbox\" id=\"ot-selall-licntr\"><input id=\"select-all-vendor-leg-handler\" type=\"checkbox\"> <label for=\"select-all-vendor-leg-handler\"><span class=\"ot-label-txt\">checkbox label</span></label> <span class=\"ot-label-status\">label</span></div></div></div></div></div></div></section></div><div id=\"ot-anchor\"></div><section id=\"ot-fltr-modal\"><div id=\"ot-fltr-cnt\"><div id=\"ot-filter-list-header\"></div><button id=\"clear-filters-handler\">Clear</button><div class=\"ot-fltr-scrlcnt ot-pc-scrollbar\"><ul class=\"ot-fltr-opts\"><li class=\"ot-fltr-opt\"><div class=\"ot-chkbox\"><input id=\"chkbox-id\" type=\"checkbox\" class=\"category-filter-handler\"> <label for=\"chkbox-id\"><span class=\"ot-label-txt\">checkbox label</span></label> <span class=\"ot-label-status\">label</span></div></li></ul><div class=\"ot-fltr-btns\"><button id=\"filter-apply-handler\">Apply</button> <button id=\"filter-cancel-handler\">Cancel</button></div></div></div></section></section><!-- Footer buttons and logo --><div class=\"ot-pc-footer ot-pc-scrollbar\"><div class=\"ot-btn-container\"><button class=\"save-preference-btn-handler onetrust-close-btn-handler\" ot-button-order=\"0\">Confirm My Cookie Choices</button><div class=\"ot-btn-subcntr\"><button class=\"ot-pc-refuse-all-handler\" ot-button-order=\"1\">Reject All Cookies</button> <button id=\"accept-recommended-btn-handler\" ot-button-order=\"2\">Allow All Cookies</button></div></div><div class=\"ot-pc-footer-logo\"><a href=\"https://www.onetrust.com/products/cookie-consent/\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Powered by OneTrust Opens in a new Tab\"><img alt=\"Powered by Onetrust\" src=\"https://cdn.cookielaw.org/logos/static/powered_by_logo.svg\" title=\"Powered by OneTrust Opens in a new Tab\"></a></div></div><!-- Cookie subgroup container --><!-- Vendor list link --><!-- Cookie lost link --><!-- Toggle HTML element --><!-- Checkbox HTML --><!-- Arrow SVG element --><!-- Accordion basic element --><span class=\"ot-scrn-rdr\" aria-atomic=\"true\" aria-live=\"polite\"></span><!-- Vendor Service container and item template --></div><iframe class=\"ot-text-resize\" sandbox=\"allow-same-origin\" title=\"onetrust-text-resize\" style=\"position: absolute; top: -50000px; width: 100em;\" aria-hidden=\"true\"></iframe></div><div id=\"ot-sdk-btn-floating\" class=\"ot-floating-button ot-hide\" data-title=\"Your Privacy Choices\"><div class=\"ot-floating-button__front custom-persistent-icon\"><button type=\"button\" class=\"ot-floating-button__open\" aria-label=\"Your Privacy Choices\"></button></div><div class=\"ot-floating-button__back custom-persistent-icon\"><button type=\"button\" class=\"ot-floating-button__close\" aria-label=\"Close Preferences\" aria-hidden=\"true\" style=\"display: none;\"><!--?xml version=\"1.0\" encoding=\"UTF-8\"?--> <svg role=\"presentation\" tabindex=\"-1\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http://www.w3.org/2000/svg\"><g id=\"Page-1\" stroke=\"none\" stroke-width=\"1\" fill=\"none\" fill-rule=\"evenodd\"><g id=\"Banner_02\" class=\"ot-floating-button__svg-fill\" transform=\"translate(-318.000000, -725.000000)\" fill=\"#292B2E\" fill-rule=\"nonzero\"><g id=\"Group-2\" transform=\"translate(305.000000, 712.000000)\"><g id=\"icon/16px/white/close\"><polygon id=\"Line1\" points=\"13.3333333 14.9176256 35.0823744 36.6666667 36.6666667 35.0823744 14.9176256 13.3333333\"></polygon><polygon id=\"Line2\" transform=\"translate(25.000000, 25.000000) scale(-1, 1) translate(-25.000000, -25.000000) \" points=\"13.3333333 14.9176256 35.0823744 36.6666667 36.6666667 35.0823744 14.9176256 13.3333333\"></polygon></g></g></g></g></svg></button></div></div></div><script>_satellite[\"_runScript4\"](function(event, target, Promise) {\nvar OTAG=_satellite.getVar(\"OnetrustActiveGroups\");OTAG.includes(\",C0001,\")&&_satellite.setVar(\"MultiSync OneTrust Strictly Necessary Cookies\",\"true\"),OTAG.includes(\",C0002,\")&&_satellite.setVar(\"MultiSync OneTrust Performance Cookies\",\"true\"),OTAG.includes(\",C0003,\")&&_satellite.setVar(\"MultiSync OneTrust Functional Cookies\",\"true\"),OTAG.includes(\",C0004,\")&&_satellite.setVar(\"MultiSync OneTrust Targeting Cookies\",\"true\"),OTAG.includes(\",C0005,\")&&_satellite.setVar(\"MultiSync OneTrust Social Media Cookies\",\"true\"),_satellite.track(\"MultiSync Initial Page View\");\n});</script><script>_satellite[\"_runScript5\"](function(event, target, Promise) {\nadobe.optIn.deny(\"target\",!0),adobe.optIn.complete(),_satellite.logger.warn(\"OneTrust Functional Consent missing\");\n});</script></body></html>",
    "actions": [
        {
            "action": "scrollBottom",
            "elapsedTime": 5.314,
            "status": "success"
        },
        {
            "action": "waitForTimeout",
            "elapsedTime": 15,
            "status": "success"
        }
    ]
}